
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_NPTX_neuropathix.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001615999 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001615999</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0286" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0287" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0299" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0300" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0301" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0303" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0306" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0307" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0310" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0315" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0316" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0319" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0324" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0325" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0328" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0333" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0334" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0335" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0337" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0340" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0341" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0342" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0343" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0347" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0348" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0360" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0361" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0362" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0367" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0368" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0371" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0376" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0377" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0380" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0385" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0386" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0389" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0394" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0395" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0398" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0403" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0404" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0407" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0412" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0413" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0414" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0416" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0419" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0420" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0421" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0422" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0426" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0427" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0515" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0547" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="nptx-20211231.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesBPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesBPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesBPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesBPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SeriesBPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesBPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesBPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesBPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:SeriesBPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">NPTX:Phase2STTRStudyGrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember_custom_YearOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">NPTX:Phase2STTRStudyGrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">NPTX:YearOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember_custom_YearTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">NPTX:Phase2STTRStudyGrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">NPTX:YearTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember_custom_YearThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">NPTX:Phase2STTRStudyGrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">NPTX:YearThreeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesAandBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">NPTX:SeriesAandBPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SeriesAandBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">NPTX:SeriesAandBPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_WarrantsConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:WarrantsConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_WarrantsConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:WarrantsConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotePayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleNotePayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotePayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel12And3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel12And3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_srt_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LoansPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LoansPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LoansPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LoansPayableOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LoansPayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LoansPayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LoansPayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LoansPayableTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableTwoMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_LoansPayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableThreeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_LoansPayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableThreeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LoansPayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableThreeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LoansPayableThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoansPayableThreeMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_RelatedPartyPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:RelatedPartyPromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RelatedPartyPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:RelatedPartyPromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-09-01</xbrli:startdate>
        <xbrli:enddate>2019-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-022021-03-31_custom_ThermoFisherScientific2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NPTX:ThermoFisherScientific2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-03-02</xbrli:startdate>
        <xbrli:enddate>2021-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ThermoFisherScientific2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NPTX:ThermoFisherScientific2Member</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-24_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-26_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-12-012019-12-31_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-12-01</xbrli:startdate>
        <xbrli:enddate>2019-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-12_custom_N8NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N8NotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-12_custom_N8NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N8NotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-03-01</xbrli:startdate>
        <xbrli:enddate>2020-03-12</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_N8NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N8NotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-08_custom_N12NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N12NotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-08_custom_N12NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N12NotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-06-01</xbrli:startdate>
        <xbrli:enddate>2020-06-08</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-23_custom_N12ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N12ConvertiblePromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-23_custom_N12ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N12ConvertiblePromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-06-01</xbrli:startdate>
        <xbrli:enddate>2020-06-23</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_N12ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N12ConvertiblePromissoryNoteMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_SecuritiesPurchaseAgreementMember_custom_KettnerInvestmentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NPTX:KettnerInvestmentsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-02-01</xbrli:startdate>
        <xbrli:enddate>2020-02-29</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesPayableRelatedPartyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_ConvertibleNotesPayableRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesPayableRelatedPartyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesPayableRelatedPartyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesPayableRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesPayableRelatedPartyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_LoansPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:LoanPayableRelatedPartyMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-17_custom_IPPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:IPPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-17</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-17_custom_IPPurchaseAgreementMember_custom_RestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:IPPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">NPTX:RestrictedCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-12-01</xbrli:startdate>
        <xbrli:enddate>2020-12-17</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-17_custom_IPPurchaseAgreementMember_custom_RestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:IPPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">NPTX:RestrictedCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-17_custom_IPPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:IPPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-17_custom_IPPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:IPPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-17_custom_IPPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:IPPurchaseAgreementMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_RestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">NPTX:RestrictedCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-17_custom_RestrictedCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">NPTX:RestrictedCommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">NPTX:ConvertibleNotesMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-04-01_custom_OfficeSpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OtherCommitmentsAxis">NPTX:OfficeSpaceMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-04-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-07-02_custom_OfficeSpaceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:OtherCommitmentsAxis">NPTX:OfficeSpaceMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-07-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">NPTX:CommonStockOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-01-31_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-01-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-02-01</xbrli:startdate>
        <xbrli:enddate>2020-02-29</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-08_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-06-01</xbrli:startdate>
        <xbrli:enddate>2020-06-08</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-23_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-06-01</xbrli:startdate>
        <xbrli:enddate>2020-06-23</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-23_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:SecuritiesPurchaseAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_N10NotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">NPTX:N10NotesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-10_custom_LetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:LetterAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-10_us-gaap_CommonStockMember_custom_LetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:LetterAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-02-10</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-10_custom_LetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">NPTX:LetterAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-02-10</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2019-01-01</xbrli:startdate>
        <xbrli:enddate>2019-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-282021-03-12_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-02-28</xbrli:startdate>
        <xbrli:enddate>2021-03-12</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-12_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-152021-07-28_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-07-15</xbrli:startdate>
        <xbrli:enddate>2021-07-28</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-28_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-01_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-21_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001615999</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromrefs="Fact000719" torefs="Footnote000758"></ix:relationship>
  <ix:relationship fromrefs="Fact000721" torefs="Footnote000758"></ix:relationship>
  <ix:relationship fromrefs="Fact000731" torefs="Footnote000758"></ix:relationship>
  <ix:relationship fromrefs="Fact000733" torefs="Footnote000758"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20210101__20211231_zcbaWXwiFuni"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentType" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_90B_edei--DocumentAnnualReport_c20210101__20211231_zfXMnzy6ER7h"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="false" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></b></span><b>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>For the fiscal year ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20210101__20211231_zszHGZR7oZd4"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="false" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span id="xdx_905_edei--CurrentFiscalYearEndDate_c20210101__20211231_zUcsJpOCA2Ff"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" inside-table="false" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span></span>, 2021</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif"><b><span id="xdx_90E_edei--DocumentTransitionReport_c20210101__20211231_zXFA27HjR0ag"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="false" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></b></span><b>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">For the transition period from ___________ to ___________</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Commission file number: <span id="xdx_900_edei--EntityFileNumber_c20210101__20211231_zcalMenQ8KPl"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">000-55657</ix:nonnumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20210101__20211231_zQRGKaZOJ2ed"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName" inside-table="false" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NEUROPATHIX, INC.</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zr9hPQ6d8itl"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20210101__20211231_zIqAwZt9qUpl"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46-2645343</ix:nonnumeric></span></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressAddressLine1_c20210101__20211231_zdT4zNNTQCA3"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3805 Old Easton Road</ix:nonnumeric></span></span> <span id="xdx_902_edei--EntityAddressCityOrTown_c20210101__20211231_zb7M8saJkxxk"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Doylestown</ix:nonnumeric></span></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20210101__20211231_zlDCUdqIeRI8"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">PA</ix:nonnumeric></span></span></span></b></p></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_908_edei--EntityAddressPostalZipCode_c20210101__20211231_ztd2u9XuB2kk"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18902</ix:nonnumeric></span></span></span></b></p></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--CityAreaCode_c20210101__20211231_zs0BhXaes5Ge"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:CityAreaCode" inside-table="false" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">(858)</ix:nonnumeric></span></span> <span id="xdx_90F_edei--LocalPhoneNumber_c20210101__20211231_z4LO1cyvNdwc"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber" inside-table="false" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">883-2642</ix:nonnumeric></span></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrants telephone
number, including area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration: underline">KANNALIFE, INC.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal">(Former
Name, former address and former fiscal year, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-style: normal; font-weight: normal"></span><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Securities registered pursuant to Section&nbsp;12(b)
of the Act: </b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 43%; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-bottom: black 1pt solid; width: 2%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 16%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center">Trading</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center">Symbol(s)</p></td>
    <td style="border-bottom: black 1pt solid; width: 1%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 38%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center">Name of each exchange</p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center">on which registered</p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>N/A</b></span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>N/A</b></span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>N/A</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Securities registered pursuant to Section&nbsp;12(g)
of the Act:</b></p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 100%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--Security12gTitle_c20210101__20211231_ziE8ty68IvE"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:Security12gTitle" inside-table="true" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock, par value $0.0001 per share</ix:nonnumeric></span></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">(Title of class)</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right">Yes <span style="font-family: Segoe UI Symbol,sans-serif"></span>
&nbsp;<span id="xdx_907_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231_zizi0MBmbDfg"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="font-family: Segoe UI Symbol,sans-serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right">Yes <span style="font-family: Segoe UI Symbol,sans-serif"></span>
<span id="xdx_907_edei--EntityVoluntaryFilers_c20210101__20211231_zeyDXrx1c3c2"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="font-family: Segoe UI Symbol,sans-serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_edei--EntityCurrentReportingStatus_c20210101__20211231_zTqSQ50g4WSj"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> <span style="font-family: Segoe UI Symbol,sans-serif"></span>
&nbsp;No <span style="font-family: Segoe UI Symbol,sans-serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20210101__20211231_znTNN3xcV4Z3"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> <span style="font-family: Segoe UI Symbol,sans-serif"></span>
&nbsp;No <span style="font-family: Segoe UI Symbol,sans-serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of large accelerated filer, accelerated filer, smaller reporting company
and emerging growth company in Rule 12b-2 of the Exchange Act.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-size: 10pt">Large accelerated filer <span style="font-family: Segoe UI Symbol,sans-serif"></span></span></td>
    <td style="width: 50%"><span style="font-size: 10pt">Accelerated filer <span style="font-family: Segoe UI Symbol,sans-serif"></span></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20210101__20211231_zeooNdFMOdsi"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="true" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span> <span style="font-family: Segoe UI Symbol,sans-serif"></span></span></td>
    <td><span style="font-size: 10pt">Smaller reporting company <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90C_edei--EntitySmallBusiness_c20210101__20211231_zriN5fyUW4Z5"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="true" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Emerging growth company <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_903_edei--EntityEmergingGrowthCompany_c20210101__20211231_zCYs05vxdh03"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" inside-table="true" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></span></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_901_edei--EntityExTransitionPeriod_c20210101__20211231_zxbdXgeaW38e"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" inside-table="false" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate by check mark whether the registrant
has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
audit report. <span style="font-family: Segoe UI Symbol,sans-serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right">Yes <span style="font-family: Segoe UI Symbol,sans-serif"></span>
&nbsp;<span id="xdx_901_edei--EntityShellCompany_c20210101__20211231_zWbcUuLBIySb"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="font-family: Segoe UI Symbol,sans-serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">State the aggregate market value of the voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the
average bid and asked price of such common equity, as of the last business day of the registrants most recently completed second
fiscal quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate market value of the registrant's
common stock held by non-affiliates as of June 30, 2021, based upon the closing price of the registrant's common stock as reported by
the OTCQB Marketplace on such date, was approximately $<span id="xdx_90C_edei--EntityPublicFloat_iI_c20210630_zNSDcF6t1UW2"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,478,542</ix:nonfraction></span></span>. This calculation does not reflect a determination that persons are
affiliates for any other purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indicate the number of shares outstanding of each
of the issuers classes of common stock, as of the latest practicable date. As of April 15, 2022, there were <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20220415_zXVtLKXREk9"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2022-04-15" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93,374,531</ix:nonfraction></span></span> shares of
common stock outstanding, par value $0.0001.</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NEUROPATHIX, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM 10-K</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>TABLE OF CONTENTS</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>INDEX</b></span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 95%"><span style="font-size: 10pt"><b>PART I</b></span></td>
    <td style="width: 5%; text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 1. Business.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 1A. Risk Factors.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 1B. Unresolved Staff Comments.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 2. Properties.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">84</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 3. Legal Proceedings.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 4. Mine Safety Disclosures.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">85</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><b>PART II</b></span></td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 6. Selected Financial Data.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">86</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">87</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">103</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 8. Financial Statements and Supplementary Data.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">103</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">103</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 9A. Controls and Procedures.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">103</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 9B. Other Information.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">104</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>ITEM 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</td>
    <td style="text-align: right">104</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><b>PART III</b></span></td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 10. Directors, Executive Officers and Corporate Governance.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">105</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 11. Executive Compensation</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">112</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 13. Certain Relationships and Related Transactions, and Director Independence.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 14. Principal Accountant Fees and Services.</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt"><b>PART IV</b></span></td>
    <td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">ITEM 15. Exhibit and Financial Statement Schedules</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">ITEM 16. Form 10-K Summary</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Signatures</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">139</span></td></tr>
  </tbody></table>

<p>&nbsp;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>FORWARD LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This Annual Report on Form 10-K, the other reports,
statements, and information that the Company has previously filed with or furnished to, or that we may subsequently file with or furnish
to, the SEC and public announcements that we have previously made or may subsequently make include, may include, or may incorporate by
reference certain statements that may be deemed to be forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended, and that are intended to enjoy the protection of the safe harbor for forward-looking statements
provided by that Act. To the extent that any statements made in this report contain information that is not historical, these statements
are essentially forward-looking. Forward-looking statements can be identified by the use of words such as anticipate, estimate,
plan, project, continuing, ongoing, expect, believe,
intend, may, will, should, could, and other words of similar meaning.
These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation,
marketability of our products; legal and regulatory risks associated with trading publicly; our ability to raise additional capital to
finance our activities; the future trading of our common stock; our ability to operate as a public company; our ability to protect our
proprietary information; general economic and business conditions; the volatility of our operating results and financial condition; our
ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed from time
to time in our filings with the SEC, or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Information regarding market and industry statistics
contained in this report is included based on information available to us that we believe is accurate. It is generally based on industry
and other publications that are not produced for purposes of securities offerings or economic analysis. Forecasts and other forward-looking
information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates
of future market size, revenue and market acceptance of products and services. We do not undertake any obligation to publicly update any
forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b><span id="PARTI"></span>&nbsp;PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><span id="ITEM1"></span>ITEM 1. BUSINESS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Corporate History</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company was originally incorporated in the
State of Delaware on March 25, 2013 under the name TYG Solutions Corp. Our original business plan was to develop iPhone and Android smartphone
apps for companies who need an app for their internal and external operations. We subsequently expanded our operations to offering corporate
website design services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On July 25, 2018, the Company entered into a Share
Exchange Agreement with Kannalife Sciences, Inc., a Delaware corporation (Kannalife Sciences), and certain stockholders
of Kannalife Sciences (the Kannalife Sciences Stockholders). Pursuant to the terms of the Share Exchange Agreement, the
Company acquired substantially all of the issued and outstanding shares of Kannalife Sciences by means of a share exchange with the Kannalife
Sciences Stockholders in exchange for newly issued shares of the common stock of the Company (the Share Exchange). As a
result of the Share Exchange, Kannalife Sciences became a 99.7% owned subsidiary of the Company. The business operations of the Company
regarding iPhone and Android smartphone apps was reduced significantly to focus efforts on target therapeutics and drug discovery, and
accordingly, by virtue of the Share Exchange, the Company acquired the business of Kannalife Sciences including all of its assets. The
Share Exchange was accounted for as a reverse acquisition and change in reporting entity, whereby Kannalife Sciences was the accounting
acquirer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kannalife Sciences was incorporated in the State
of Delaware on August 11, 2010. Kannalife Sciences is a developmental stage phyto-medical/pharmaceutical and drug discovery company that
specializes in the research, development of cannabinoid and cannabinoid-based therapeutic products derived from synthetic and botanical
sources, including the Cannabis<i>&nbsp;</i>taxa<i></i>&nbsp;(the word taxa is the plural of taxon,
which defines a group of one or more populations of an organism or organisms to form a unit). On November 9, 2018, the Company filed an
amendment to its certificate of incorporation with the Delaware Secretary of State to change its name to Kannalife, Inc. The Company concurrently
submitted a request to FINRA for approval of the name change as well as a ticker symbol change to KLFE, and such action
went effective on January 17, 2019. &nbsp;Kannalife Sciences remains a wholly owned operational subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On November 4, 2020, the Company filed an amendment
to its certificate of incorporation with the Delaware Secretary of State to change its name to Neuropathix, Inc. The Company
concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change from KLFE to
NPTX. The Companys name change and ticker symbol change was reviewed and processed by FINRA, and went effective November
6, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 16, 2021, the Company established and
incorporated a new wholly owned subsidiary named Dermique Incorporated (Dermique). Dermique was established by the Company
to hold, operate and commercialize all intellectual property associated with Kannalife Sciences previous research and development
efforts to create and commercialize novel therapeutic topical over-the-counter cosmeceutical compounds to treat a variety of skin disorders,
including but not limited to atopic dermatitis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from our proprietary synthetic cannabinoid derivatives platform potentially
useful for a broad range of inflammatory and neuropathic pain related diseases. In our eleven (11) years of operations, dating back to
August 2010 under the name Kannalife Sciences, Inc. we have been principally involved in the research and development of new chemical
entities (NCEs) such as KLS-13019; KLS-13022 (linoneyldihydroxybenzyl ethoxycarbonyl azetidine or LEA<span style="font-family: Symbol"></span>);
its related molecules; and synthetic cannabidiol (CBD) therapeutics through pre-clinical drug discovery and development
processes. We have developed our own intellectual property portfolio and established relationships with third parties who are considered
leaders in active pharmaceutical (APIC) contract manufacturing, formulation; and contract bulk drug manufacturing. Most all
of the operations of the Company to date at Kannalife Sciences have been in the pre-clinical stage of drug discovery. In 2019 the Company
began commercialization efforts for over-the-counter cosmeceutical uses of LEA<span style="font-family: Symbol"></span>, the Companys
lead compound designed to address topical skin disorders.</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company anticipates that
all proposed and ongoing preclinical studies for LEA<span style="font-family: Symbol"></span> will be completed by April 2022. Preclinical
studies for LEA<span style="font-family: Symbol"></span> completed to date include, include in vitro efficacy, testing of irritants
under human repeat insult patch testing (HRIPT) and other predictive skin irritant and eye studies, completed formulation
of a finished white label skin cream product containing LEA<span style="font-family: Symbol"></span>, and stability studies of LEA<span style="font-family: Symbol"></span>
with only the completion of a three month stability study due for completion in March 2022. Upon the completion of the remaining stability
study, the Company intends to move forward in marketing LEA<span style="font-family: Symbol"></span> as an over-the-counter active
pharmaceutical ingredient (API) for bulk sales, white label opportunities, and branded product opportunities in the cosmeceutical
market. The results in preclinical testing for LEA<span style="font-family: Symbol"></span> indicate better results than cannabidiol
(CBD) and tacrolimus in addressing symptoms such as pain, itch and burning sensations in target therapeutic areas such as
eczema, psoriasis, radiation dermatitis and excess UVB radiation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our early research and development
efforts began under an exclusive license with National Institutes of Health  Office of Technology Transfer (NIH-OTT)
for the use of the U.S. Government Patent 6,630,507  Cannabinoids as Antioxidants and Neuroprotectants (the 507
Patent). Through the use of the 507 Patent, we centered our initial research into the use of CBD for use in a variety of
neurodegenerative and oxidative stress related diseases.&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our core businesses are comprised
of the following:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">A drug development company focused on the research and development
(R&amp;D) of non-opioid based synthetic and chemical-medical products from:</span></td>
</tr></tbody></table>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 72px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td><span style="font-size: 10pt">naturally recurring sources, including but not limited to cannabis, hemp, and other similar species of plantae;&nbsp;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 72px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td><span style="font-size: 10pt">semi-synthetic sources; and&nbsp;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 72px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td><span style="font-size: 10pt">synthetic and bio-synthetic sources.&nbsp;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Drug discovery platform to evaluate and potentially treat neurological
and oxidative stress related disorders such as overt hepatic encephalopathy (OHE), Chronic Traumatic Encephalopathy (CTE)
and Chemotherapy Induced Peripheral Neuropathy (CIPN) with high quality assured, quality-controlled cGMP pharmaceutical
grade semi-synthetic and synthetic cannabinoids, CBD, and cannabidiol-like molecules.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Topical skincare pre-clinical program designed to some of our
patented, proprietary cannabidiol-derived NCEs, for use as topical solutions, ointments, and creams for disorders such as diabetic neuropathies,
diabetic ulcers, and for use as an anti-pruritic. Anti-pruritics are known as anti-itch drugs and medications that inhibit the itching
often associated with a variety of disorders and diseases.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phyto Cannabinoids are a class of molecules derived
from Cannabis plants. The two primary cannabinoids contained in Cannabis are CBD and D9-tetrahydrocannabinol, or THC. Clinical and preclinical
data suggest that CBD has positive effects on treating refractory epilepsy, FXS and arthritis, and THC has positive effects on treating
pain. Interest in cannabinoid therapeutics has increased significantly over the past several years as preclinical and clinical data has
emerged highlighting the potential efficacy and safety benefits of cannabinoid therapeutics. The cannabinoid therapeutics market is expected
to grow significantly due to the potential benefits these products may provide over existing therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">CBD was discovered in 1940 and is known to exhibit
neuroprotective properties in many experimental systems. However, our early research and development efforts revealed that there could
be obstacles for CBD as a drug. The FDA approval of Epidiolex, a CBD based drug manufactured by GW Pharmaceuticals Ltd. for the
treatment of Dravet Syndrome and Lennox-Gastaut Syndrome, has indicated that there are certain safety issues. We also believe that the
development of CBD as a drug has been confounded by the following: (i) low potency; (ii) a large number of molecular targets; (iii) marginal
pharmacokinetic properties; and (iv) designation as a Schedule 1 controlled substance under the Controlled Substances Act.</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">KLS-13019 versus CBD</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our preclinical efforts to
evaluate CBD indicate that there are pharmacological challenges and limitation of CBD. Our preclinical studies have shown that three major
concerns were the low potency at 10 <span style="font-family: Symbol">m</span>M to achieve high efficacy; complex pharmacology as it hits
too many molecular targets; and low oral bioavailability and poor brain penetration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">Comparisons between CBD and KLS-13019</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Comparisons between CBD and
KLS-13019 have been published in peer reviewed articles in ACS Medicinal Chemistry Letters (2016, 7, 424-428) and two publications in
the Journal of Molecular Neuroscience (August 14, 2018, and May 10, 2019). The studies and science referenced in these articles were performed
by Advanced Neural Dynamics (AND), a third party provider of preclinical pharmacology services and Iteramed (Iteramed),
a third party provider of medicinal chemistry consulting and synthesis. Both AND and Iteramed are operated by Douglas Brenneman, Ph.D
and William A. Kinney Ph.D, respectively. Both Mr. Brenneman and Mr. Kinney are shareholders of the Company, co-inventors in our intellectual
property underlying U.S. Patents 9,611,213 and 10,004,722, and with respect to Mr. Kinney, is our Chief Scientific Officer. Mr. Brenneman
is a member of our scientific advisory board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">While results of the Companys
preclinical studies on KLS-13019 have shown preclinical efficacy via&nbsp;<i>in vitro</i>&nbsp;studies in CIPN and HE, KLS-13019 will
require human clinical trials to determine both safety and efficacy and such matters are subject to clinical trial endpoints and FDA review,
with ultimate approval coming at the end of a successful human clinical trial study and new drug application (NDA).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our peer reviewed, preclinical studies published in ACS Medicinal
Chemistry Letters, Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability
have shown that our lead drug candidate, KLS-13019 has better pharmacokinetics than CBD and lasts longer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_001.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_001.jpg"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;<img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_002.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_002.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;<img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_003.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_003.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the ACS abstract and paper,
notably, KLS-13019 was found to be 50-fold more potent and &gt;400-fold safer than CBD and exhibited an in vitro profile consistent with
improved oral bioavailability. In 2018 Journal of Molecular Neuroscience abstract and paper, the protective responses of CBD and KLS-13019
were compared in dissociated rat hippocampal cultures co-treated with toxic levels of ethanol and ammonium acetate. This comparison revealed
that KLS-13019 was 31-fold more potent than CBD in preventing neuronal toxicity from the combined toxin treatment, while both compounds
exhibited protective efficacy back to control values.</p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition to the ACS publication,
our research and development efforts with KLS-13019 were also the subject of peer reviewed, preclinical studies published in April 2021
in the British Journal of Pharmacology, Behavioural and Pharmacological Effects of Cannabidiol (CBD) and the Cannabidiol Analogue
KLS-13019 in Mouse Models of Pain and Reinforcement reported the following key results:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">Like CBD, KLS-13019 prevented the development
of mechanical sensitivity associated with paclitaxel administration.</span></td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">In contrast to CBD, KLS-13019 was also
effective at reversing established mechanical sensitivity.</span></td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">KLS-13019 significantly attenuated
acetic acid-induced stretching and produced modest effects in the hot plate assay.</span></td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">KLS-13019 was devoid of activity at
-, - or -opioid receptors. Lastly, KLS-13019, but not CBD, attenuated the reinforcing effects of palatable food or
morphine.</span></td>
</tr></tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following chart indicates opioid inhibition percentages
for both CBD and KLS-13019</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_004.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_004.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The study also reported the following conclusions
and Implications:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">KLS-13019 like CBD, prevented the development
of CIPN, while KLS-13019 uniquely attenuated established CIPN. Because KLS-13019 binds to fewer biological targets, this will help to
identifying molecular mechanisms shared by these two compounds and those unique to KLS-13019. Lastly, KLS-13019 may possess the ability
to attenuate reinforced behaviour, an effect not observed in the present study with CBD.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="color: #1C1D1E; background-color: white">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">Epidiolex<span style="font-family: Symbol">,
</span>a CBD based FDA Approved Drug to Treat Lennox-Gastaut Syndrome and Dravet Syndrome</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To date there has been only
one cannabidiol based medicament, Epidiolex<span style="font-family: Symbol"></span>,&nbsp;approved for use in humans by the FDA.
The drug, Epidiolex<span style="font-family: Symbol"></span>, is used&nbsp;to treat&nbsp;seizures&nbsp;due to certain medical conditions
(such as&nbsp;Lennox-Gastaut syndrome and&nbsp;Dravet syndrome). It is not known how this medication works for these&nbsp;seizures. CBD
belongs to a class of drugs known as cannabinoids.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additionally, the FDAs
Office of Orphan Products Development (OOPD) has designated cannabidiol twenty six times since 2013 for a multitude of diseases
ranging from rare forms of epilepsy to prevention of reperfusion injury due to organ transplantation to glioblastoma multiforme to autoimmune
hepatitis. While our primary indications of OHE and CIPN have not, heretofore, been targeted by CBD-based or CBD-derived drugs and cleared
by the FDA or other foreign regulatory agency, neither have the aforementioned twenty six orphan designated indications targeted by CBD.&nbsp;</p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">CBD is the active ingredient
in Epidiolex<span style="font-family: Symbol">. </span>The Warnings and Precautions on the Highlights of Prescribing information
for Epidiolex<span style="font-family: Symbol"> </span>states among other things:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Symbol"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Hepatocellular Injury. Epidiolex<span style="font-family: Symbol"> </span>causes dose-related
elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]).</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Symbol"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Transaminase elevations are dose-related. Overall ALT elevations greater than 3 times the
upper limit of normal (ULN) were reported in 17% of patients taking Epidiolex<span style="font-family: Symbol"> </span>20 mg/kg/day
compared with 1% in patients taking Epidiolex<span style="font-family: Symbol"> </span>10 mg/kg/day.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Symbol"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Somnolence and Sedation. Epidiolex<span style="font-family: Symbol"> </span>can cause
somnolence and sedation. In controlled studies for Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS), the incidence of somnolence
and sedation (including lethargy) was 32% in Epidiolex<span style="font-family: Symbol"> </span>treated patients, compared with
11% in patients on placebo and was dose-related (34% of patients taking Epidiolex<span style="font-family: Symbol"> </span>20 mg/kg/day,
compared with 27% in patients taking Epidiolex<span style="font-family: Symbol"> 10 </span>mg/kg/day.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Symbol"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Epidiolex<span style="font-family: Symbol"> </span>can cause hypersensitivity reactions.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Symbol"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Epidiolex<span style="font-family: Symbol"> </span>has drug interaction effects. Coadministration
of Epidiolex<span style="font-family: Symbol"> </span>with Clobazam produces a 3-fold increase in plasma concentrations of N-desmethylclobazam,
the active metabolite of clobazam (a substrate of CYP2C19).</td>
</tr></tbody></table>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Symbol"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Concomitant use of Epidiolex<span style="font-family: Symbol"> </span>and valproate
increases the incidence of liver enzume elevations.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Symbol"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Concomitant use of Epidiolex<span style="font-family: Symbol"> </span>with other central
nervous system (CNS) depressants may increase the risk of sedation and somnolence.</td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In Juvenile Animal Studies,
administration of cannabidiol (subcutaneous doses of 0 or 15 mg/kg on Postnatal Days (PNDs) 4  6, followed by oral administration
of 0, 100, 150, or 250 mg/kg on PNDs 7  77) to juvenile rats for 10 weeks resulted in increased body weight, delayed male sexual
maturation, neurobehavioral effects (decreased locomotor activity and auditory startle habituation), increased bone mineral density, and
liver hepatocyte vacuolation. A no-effect dose was not established. The lowest dose causing developmental toxicity in juvenile rats (15
sc/100 po mg/kg) was associated with cannabidiol exposures approximately 30 times that in humans at the recommended dose of 20 mg/kg/day.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">Neuropathix Research and Development in Chemotherapy
Induced Peripheral Neuropathy (CIPN)</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the past three years, our most recent research
and development efforts have been centered on the use of KLS-13019 as a neuroprotectant and therapeutic agent to treat chronic and neuropathic
pain. There is currently no FDA approved drug to treat CIPN. Our preclinical efforts in the research and development of treating CIPN
with our lead compound KLS-13019 have been fostered by a successful study grant from National Institutes of Health  National Institute
on Drug Abuse (NIH-NIDA) that compared KLS-13019 to CBD in the prevention and reversal of neuropathic pain in animal models.
As a result of the outcome of this and other preclinical studies, we believe there is strong evidence to support the use of KLS-13019
as a non-opioid solution to chronic and neuropathic pain in human clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our current focus is centered around advancing
KLS-13019 as a novel, non-opioid solution for the treatment of chronic and neuropathic pain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our present work involves comparing the properties
of CBD with our patented novel cannabidiol derived molecule, KLS-13019, that has structural similarities to CBD. The design strategy for
KLS-13019 was to increase hydrophilicity while optimizing neuroprotective potency against oxidative stress toxicity relevant to oxidative
stress related diseases and neuro-inflammatory disorders. In early pre-clinical studies, the responses of CBD and KLS-13019 were compared
in dissociated rat hippocampal cultures in a pre-clinical model for OHE and also CIPN.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">CIPN, is a progressive, enduring and often irreversible
condition featuring pain, numbness, tingling and sensitivity to cold in the hands and free (sometimes progressing to the arms and legs)
that affects between 30% and 40% of patients undergoing chemotherapy. CIPN often causes termination of chemotherapy in cancer patients
and presents a two-fold problem, both in the ongoing chemotherapy treatment regimen&nbsp;and the abundant use of opioids and gabapentinoids
as the most widely used products to treat CIPN.</p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">$2.97 Million Grant Award from National Institutes
of Health (NIH)  National Institute of Neurological Disorders and Stroke (NINDS) under the HEAL Initiative
(Helping to End Addiction Long-term)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 28, 2021, the
Company received a notice of award for a $2.97 million Phase 2 STTR Study Grant from the National Institutes of Health  National
Institute of Neurological Disorders and Stroke under the HEAL Initiative (the NIH-NINDS Study Grant Award). The NIH-NINDS
Study Grant Award is funded through the NIH HEAL Initiative (Helping End Addiction Long-Term) for Development of Therapies
and Technologies Directed at Enhanced Pain Management. This NIH-NINDS Study Grant Award provides funding specifically in the further development
of KLS-13019 for the treatment of chemotherapy induced neuropathic pain (CIPN). The grant award of $2.97 million sets forth
the funding allocation of $977,054 in year 1; $991,944 in year 2; and $1,001,774 in year 3 and collectively budgets investigational new
drug (IND) application enabling studies. IND enabling studies to be performed, include but are not limited to animal toxicity
studies and drug compound scale up studies under chemistry manufacturing and controls. The NIH-NINDS Study Grant Award budget includes
studies to be performed at Temple University; the University of Illinois; and Purisys (formerly, Noramco).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Of significant collateral
importance is the current epidemic of opioid addiction and abuse by patients in the United States and around the globe. Adding to the
equation is the off-label use of opioids and gabapentinoids for chronic and neuropathic pain as a result of the unmet medical need and
no FDA approved non-opioid drug to treat chronic and neuropathic pain, specifically CIPN.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In December 2019, the Companys
wholly owned subsidiary, Kannalife Sciences, Inc. completed an NIH-NINDS phase 1 STTR study grant with Temple University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Key preclinical animal testing
findings of this study were as follows. KLS-13019 has excellent oral bioavailability (F%) 67% was observed in mice. In rat PK, F% was
16% in females and 8% in males. Further PK work in the rat will be done following formulation optimization. The Cmax and half-life of
KLS-13019 is adequate in both mice and rats for twice a day treatment. In a separate mouse study, brain and plasma concentrations were
equivalent after oral administration, boding well for in vivo efficacy after oral administration. Under the Phase 1 award, the efficacy
of KLS-13019 was tested in a mouse model of CIPN as well as a mouse model of opioid reinforcement. It was determined that KLS-13019 was
as potent as CBD in preventing the development of paclitaxel induced mechanical sensitivity and superior to CBD in its ability to reverse
an established CIPN (Foss et al., 2020). Moreover, KLS13019 was also effective at preventing paclitaxelinduced mechanical sensitivity
following oral administration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To generate CIPN, male
C57Bl/6 mice are injected with 8.0 mg/kg paclitaxel IP on alternating days for a total of 4 injections. For prevention studies, test compounds
are administered 15 min prior to each paclitaxel injection. For reversal studies, test compounds are administered 2 weeks following paclitaxel
administration, after mechanical sensitivity has developed. Mechanical sensitivity is determined by testing with von Frey filaments as
described in Ward et al 2011. It was also determined that pretreatment with KLS-13019, but not CBD, attenuated motivated responding to
receive infusions of morphine in mice trained to self-administer morphine under an operant procedure called progressive ratio responding.
Taken together our results suggest that KLS-13019 may be effective in either preventing or reversing CIPN while having the added benefit
of reducing the rewarding effects of prescription opioids.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In April 2021, a peer reviewed
scientific research paper was published in the British Journal of Pharmacology (6 April 2021) titled Behavioural and Pharmacological
Effects of Cannabidiol (CBD) and the Cannabidiol Analogue KLS-13019 in Mouse Models of Pain and Reinforcement. As indicated in
the research paper, The overarching goal of the experiments reported here was to determine the behavioural effects of KLS-13019,
a structural analogue of CBD. Specifically, we aimed to determine whether KLS-13019 was as potent and effective as CBD at mitigating mechanical
allodynia associated with paclitaxel treatment and whether it was efficacious following oral administration.</p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Key findings in the report
included the following:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">CBD analogue KLS-13019 shows efficacy in an <i>in vitro</i> model of chemotherapy-induced
peripheral neuropathy (CIPN).</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">KLS-13019 has the potentially to be a more potent, effective, orally bioavailable option
to CBD.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">In the present study, KLS-13019 reversed established CIPN at a minimal effective dose of
2.5 mg/kg<sup>-1</sup> i.p. and p.o. These results indicate that in addition to the neuroprotective mechanisms of CBD and KLS-13019,
such as regulation of mitochondrial Ca<sup>2+</sup> handling (Brenneman et al., 2019), KLS-13019 may work through an additional, unique
mechanism.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Based on the present opioid receptor binding data for KLS-13019 showing no appreciable ginding
at <span style="font-family: Symbol">m-, d- </span>or <span style="font-family: Symbol">k- </span>opioid receptors at 10 <span style="font-family: Symbol">mM,
</span>it is unlikely that these reversal effects were opioid receptor mediated.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">In conclusion, these studies demonstrate that like CBD, KLS-13019 can prevent the development
of mechanical sensitivity following paclitaxel administration in mice, including following oral administration.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">While prevention of CIPN represents a significant unmet medical need, so does the treatment
of existing CIPN for thousands of cancer survivors. The present results highlight the additional potential benefit of KLS-13019 in its
ability to also reverse established paclitaxel-induced mechanical sensitivity, by extension underscoring the conclusion that KLS-13019
may work through unique mechanisms as compared with CBD in this model.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Lastly, KLS-13019 may possess the ability to attenuate reinforced behavior, an effect not
observed in the present study with CBD.</td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">Results from the Preclinical Screening Platform
for Pain (PSPP)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In April 2020, the companys
wholly owned subsidiary, Kannalife Sciences, Inc. entered into an Agreement for Submitting Your Asset to the Preclinical Screening
Platform for Pain (PSPP) of the National Institute of Neurological Disorders and Stroke (the PSPP Agreement). Critical
resources on exploring the mechanism of action and assessment of drug-like actions of KLS-13019 have been provided to Kannalife by the
Preclinical Screening Platform for Pain (PSPP) within NINDS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">With NIH HEAL (Helping to
End Addiction Long-Term) Initiative support, NINDS has developed a Preclinical Screening Platform for Pain (PSPP) program to facilitate
the identification of potential non-addictive treatments (small molecules, biologics, devices, or natural products) for acute and chronic
pain conditions. The overall goal of the PSPP is to provide pain researchers from the academic and industry community with an efficient,
rigorous one-stop <i>in vivo</i> screening resource to accelerate efficacy profiling and identification of alternatives to opioid analgesics.
PSPP conducts an assessment of <i>in vitro</i> and pharmacokinetic profiles, side effect profiles, abuse liability, and efficacy in models
relevant to human pain conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A summary of the tier 1 PSPP study included a
screen of targets related to pain are as follows. Results from the early tier 1 studies of KLS-13019 under the PSPP has provided valuable
data from their screening of 78 pain-related targets. This screening was not only valuable in identifying potential targets, insight into
potential sides effects also were obtained, including all of the opiate receptors. The results of this screen indicated KLS-13019 was
a remarkably <i>clean</i> compound in that none of the 78 targets exhibited high affinity functional activity (EC50 &lt;
100 nM). Low affinity responses (EC50 10-50 M) were observed for 5HT-3A, COX1 and COX2. KLS-13019 showed a weak activity at the
GABA-A 1/2/2 subtype, producing a 14 and 62% increase in the response to an EC20 of GABA at 1 and 10 M, respectively.
KLS-13019 was tested in the positive allosteric mode for the delta, kappa and mu opioid receptors in the presence of an EC20 of agonist.
KLS-13019 exhibited only low potency, with EC50 values between 24 and 38 M for the opiate receptors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">Neuropathix Novel Drug Compounds</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our lead target drug candidate,
KLS-13019, is part of an estate of new chemical entities (NCEs) underlying U.S. Patent 9,611,213 titled Functionalized
1,3 Benzene-diols and their Method of Use for the Treatment of Hepatic Encephalopathy. This patent is part of a divisional patent
application by the Company to the United States Patent and Trademark Office (USPTO) whereby we sought claims for composition
of matter, covered in Pat. 9,611,213, and separate claims for method for treatment, covered by U.S. Patent 10,004,722 titled Method
for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediate Stress and Oxidative Stress with Novel Functionalized
1,3 Benzene-diols.</p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">KLS-13019 and its related
molecules under the aforementioned patents describe novel functionalized 1,3-benzenediols (Cannabidiol Derived Molecules)
and methods that may be useful and have potential for the treatment of HE and related conditions. The present invention further describes
(i) a novel chemotype that may be useful and have potential for the treatment of diseases associated with HE, and (ii) a novel chemotype
that may be useful and have potential as neuroprotective agents. The Cannabidiol Derived Molecules under the present invention may be
useful and have potential for treating and preventing diseases associated with free radical mediated stress and oxidative stress including,
for example, HE, Parkinsons disease, Alzheimers, Huntingtons disease, traumatic head injury, stroke, epilepsy, neuropathic
pain, CTE, Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, and Epileptic Encephalopathy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We intend to study KLS-13019
in patients with chemotherapy induced neuropathic pain. We believe that the claims made in the Pat. 9,611,213 and Pat. 10,004,722 sufficiently
cover the use of the novel molecule KLS-13019 in the treatment of neuropathic pain, which is broadly defined and includes chemotherapy
induced neuropathic pain (a/k/a: chemotherapy induced peripheral neuropathy).&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To date, we have synthesized,
pre-clinically tested and patented our proprietary CBD like NCEs, including KLS-13019, and also formulated a new CBD based molecule, KLS-13023.
KLS-13023 is a target drug candidate that includes a synthetic CBD formulated in a gel capsule designed for potential use in humans, which
is intended to enable more effective delivery of CBD. The formulation of this product is proprietary and currently held as a trade secret
of the Company. CBD is the primary non-psychoactive component of cannabis. KLS-13023 has undergone a manufacturing feasibility study to
improve some of the limitations associated with CBD, including but not limited to CBDs low bioavailability and limited drug like
properties and improvement of the delivery of CBD through the first pass in the gut and into the circulatory system. We intend to study
KLS-13023 in patients with mild traumatic brain injury. In addition, we expect that KLS-13023 will be classified by the FDA as an NCE.
In our preclinical animal studies, KLS-13023 demonstrated effective intervention of neurodegeneration in the OHE disease state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><span style="text-decoration: underline">Acquisition of AND
Compounds</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On
November 17, 2020, the Company signed a binding letter of intent to acquire certain technology described in a patent estate PCT WO2012/074784
A2  Novel Fluorinated Sulfamides Exhibiting Neuroprotective Action and Their Method of Use; and US Patent 8,609,849
 Novel Hydroxylated Sulfamides Exhibiting Neuroprotective Action and Their Method of Use (the AND Compounds).
On December 18, 2020, the Company completed the acquisition of the AND Compounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The
AND Compounds, specifically AND-302, are novel potent neuroprotective sulfamide based drug candidates that have been shown in advanced
preclinical discovery efforts to protect against glutamate toxicity, prevent the accumulation of reactive oxygen species (ROS), have a
high therapeutic index in a refractory epilepsy test at 6 Hz and show neuroprotective efficacy in the sub-nanomolar range, approximately
1,000 times more potent than current standard of care anti-epileptic drugs (carbamazepine, lamotrigine and topiramate).</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt">Comparative and Distinguishing Characteristics</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; vertical-align: bottom">AND-302</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; vertical-align: bottom">Standard of Care AEDs*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Potent Neuroprotection against Glutamate Toxicity</td>
    <td style="font-size: 10pt; text-align: right">0.1-1 nM</td>
    <td style="text-align: right; font-size: 10pt; vertical-align: bottom">100 mM-1 mM</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Prevention of Reactive Oxygen Species Accumulation</td>
    <td style="font-size: 10pt; text-align: right">0.1 nM</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: right">None reported</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; font-size: 10pt; text-align: left; padding-left: 3.15pt">High Therapeutic Index in a Refractory Epilepsy test (6-Hz)</td>
    <td style="width: 25%; font-size: 10pt; text-align: right">12</td>
    <td style="text-align: right; width: 25%; font-size: 10pt; vertical-align: bottom">0-.5</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 3.15pt">Disease-modifying Potential</td>
    <td style="font-size: 10pt; text-align: right">Yes</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: right">None reported</td></tr>
  </tbody></table>

<p style="font: 10pt Sans-Serif; background-color: white; color: Red"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Sans-Serif; background-color: white; color: Red">&nbsp;</p>

<p style="font: 10pt Sans-Serif; text-align: center; background-color: white; color: Red"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_005.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_005.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Key
highlights underlying the AND Compounds include:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Validated in Phase 1 NIH SBIR Study Grant</td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Over $1.5 million invested to date</td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Patented technology</td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Wide therapeutic index</td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Better dose response curve than AEDs*</td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Non ion channel blocking </td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">
</span>unlike gabapentinoids  Gabitril<sup></sup> (tiagabine)</p>





<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">High potential in refractory epilepsy model </td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">
</span>hippocampal kindling validated</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Non dopamine (no dopaminergic effects </td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify"><span style="font-family: Arial, Helvetica, Sans-Serif">
</span>no dopey feel  Topamax<sup></sup> (topiramate)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We
believe these product candidates will provide new treatment options for patients, as well as additional treatment options for patients
not currently receiving adequate relief from current treatment regimens.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are still conducting pre-clinical
studies and have not yet commenced our clinical program or tested KLS-13019 or KLS-13023 in humans. For KLS-13019, we plan to conduct
Phase 1, and possibly Phase 2, clinical trials in either the U.S. or Australia, subject to applicable regulatory approval. We plan to
conduct our Phase 1 clinical trials for KLS-13023 in either the U.S. or Australia, subject to applicable regulatory approval. We plan
to submit New Drug Applications (NDAs) for KLS-13019 and KLS-13023 to the FDA upon completion of Phase 3 clinical trials,
regardless of where the Company conducts Phase 1 and Phase 2 clinical trials.. We expect to initiate clinical trials for KLS-13019 and
KLS-13023 in the first half of 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We plan to conduct our Phase
1, and possibly Phase 2, clinical trials for KLS-13019 in the U.S. or Australia, subject to applicable regulatory approval, and do not
expect at this time to file an investigational new drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, prior
to the commencement of those clinical trials. We must file an IND with the FDA and receive approval from the U.S. Drug Enforcement Agency,
or DEA, prior to commencement of any clinical trials in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In preclinical studies performed
pursuant to a small business technology transfers (STTR) agreement between us, and Temple University, funded by the National
Institutes of Health &nbsp;National Institute on Drug Abuse (NIH-NIDA), our research and results are the subject
of two peer reviewed scientific publications in the Journal of Molecular Neuroscience, and one peer reviewed scientific publication in
the British Journal of Pharmacology. These peer reviewed publications have described how KLS-13019, is superior to CBD and morphine in
the potential to prevent and reverse neuropathic pain caused by paclitaxel, a chemotherapeutic agent used to treat breast, ovarian and
non-small cell lung cancer. (See: Business &nbsp;Preclinical Studies for more information).</p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company is currently in
the midst of performing certain IND enabling studies, that include but are not limited to:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">Process Development, Analytical Method Development and Scale Up Production of Non-GMP KLS-13019 from 25
grams to 400 grams.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">Animal models of drug discrimination.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">HPLC method development and validation for formulations.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">LC-MS/MS Method development and validation for rat and dog toxicology.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">Non-GLP rat acute and 7-day repeated oral dose toxicity and toxicokinetics.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">GLP rat 28-day repeat oral dosing in with TK, NCS safety, and histopathology.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">Non-GLP acute 7-day toxicokinetic dog study.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">Formulatin development, analytical, and stability studies.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">In house biomarker evaluation, chemical development and reference standard synthesis.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">GLP cardiac and respiratory safety pharmacology in dogs.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">GLP Dog 28-day repead dose oral toxicity and toxicokinetics.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">Non-GMP preparation of three formulations, stability, and PK evaluation in rats.</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Upon completion of all requisite
preclinical studies, we expect to open an Investigational New Drug Application, or IND, to pursue a clinical development program with
either the U.S. Food and Drug Administration (FDA) in the U.S. or the&nbsp;Therapeutic Goods Administration (TGA),
the&nbsp;regulatory body&nbsp;for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in&nbsp;Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">OTC Solutions for Topical Use</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In mid 2019, we began screening
and conducting preliminary research and development of some of our patented, proprietary cannabidiol-derived NCEs for use as active pharmaceutical
ingredients (APIs) in topical solutions, ointments, and creams for various skin disorders such as eczema, psoriasis, radiation dermatitis
and excessive UVB radiation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These disorders general</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">ly lead to symptoms including
neuropathies, inflammation and itch. The Company believes that successful development of its topical APIs can be useful as anti-pruritics,
also known as anti-itch drugs and medications that inhibit the itching often associated with a variety of disorders and diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are considering commercialization
routes that include, but are not limited to, filing an FDA Monograph and/or pursing a path to the marketplace through International Nomenclature
of Cosmetic Ingredients (INCI) certification and registration with the Personal Care Products Council (PCPC).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In preclinical testing, KLS-13022,
a molecules covered under Pat. 9,611,213 was screened for neuroprotection and may have the potential mechanism of action for reducing
inflammation, neuropathic pain and itch. This molecule indicated that it is more soluble than CBD, also deemed a neuroprotectant with
potential anti-inflammatory properties. A molecule that is potentially more water soluble than CBD in this regard may be good candidate(s)
for use in topical applications.&nbsp;</p>


<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">OTC Cosmetic Skin Care  KLS-13022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since mid 2019, the Company
has been screening and conducting preliminary research and development of some of its patented, proprietary cannabidiol-derived new chemical
entities (NCEs), for use as topical solutions, ointments, and creams for disorders such as diabetic neuropathies, diabetic
ulcers, and for use as an anti-pruritic. (see: Business &nbsp;Neuropathix Intellectual Properties)&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In
preclinical testing, certain molecules under Patent 9,611,213 were screened for neuroprotection and may have the potential mechanism of
action for reducing inflammation and neuropathic pain. These molecules indicate that they are more soluble than cannabidiol, also deemed
a neuroprotectant with potential anti-inflammatory properties. A molecule that is potentially more water soluble than cannabidiol in this
regard may be good candidate(s) for use in topical applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has completed
the following relating to KLS-13022:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">Preclinical screening for consumer OTC cosmetic use under CFR 21.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></td><td style="text-align: justify"><span style="font-size: 10pt">Application to International Nomenclature of Cosmetic Ingredients (INCI)
completed to receive a compound nomenclature for KLS-13022 - Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (LEA</span><span style="font-family: Symbol"></span><span style="font-size: 10pt">).</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></span></td><td style="text-align: justify"><span style="font-size: 10pt">Received a registered trademark from the U.S. Patent and Trademark Office
(USPTO) for Atopidine</span><span style="font-family: Symbol"></span><span style="font-size: 10pt">, to be used as
a branded product as a relief cream, containing LEA, to treat inflammatory disorders like eczema, psoriasis, radiation dermatitis and
excessive UVB radiation (post sun burn).</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on preclinical testing of LEA<span style="font-family: Symbol">
</span>versus CBD (cannabidiol) in cultured human epidermal keratinocytes:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">LEA<span style="font-family: Symbol"></span> provided better anti-inflammatory activity compared
to CBD for TNFa, IL-6 and significantly more potent that CBD for IL-1b inhibition in UVB irradiation induced inflammation.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">LEA<span style="font-family: Symbol"></span> decreased CXCL5 levels by 100% after UVB irradiation
with IC50 of 0.05 mM. (CXCL5 is a small cytokine belonging to the chemokine family known as epithelial-derived neutrophil-activating peptide
78 (ENA-78). It is produced following the stimulation of cells with the inflammatory cytokines TNFa and IL-1b.)</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">LEA<span style="font-family: Symbol"></span> decreases levels of four (4) inflammatory mediators
at concentrations &gt; 65 times less than toxic levels.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="text-align: justify">LEA<span style="font-family: Symbol"></span> is an antioxidant that does not exhibit cellular irritation
and is locally restricted in its action (antioxidant activity of EC50 at 25 mM).</td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has completed
formulation of a topical relief cream for use as an OTC cosmetic skin care product to be marketed under the trade name of Atopidine<span style="font-family: Symbol"></span>
and LEA<span style="font-family: Symbol"></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 16, 2021, the Company
established and incorporated a new wholly owned subsidiary named Dermique Incorporated (Dermique). Dermique was established
by the Company to hold, operate and commercialize all intellectual property associated with Kannalife Sciences previous research
and development efforts to create and commercialize novel therapeutic topical over-the-counter cosmeceutical compounds to treat a variety
of skin disorders, including but not limited to atopic dermatitis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-decoration: underline">Hepatic Encephalopathy (HE)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">HE is a neuropsychiatric disorder
that includes learning deficits and impairment of long-term memory. OHE it is a sub-set of HE. HE is caused by accumulation of toxic substances
in the bloodstream that are normally removed by the liver as a result of liver failure. If left unchecked, HE can progress to hepatic
coma (also referred to as coma hepaticum) and ultimately death (Cordoba, 2011). The pathogenesis of HE includes damage to the prelimbic
cortex, striatum and the hippocampus (Aria et al., 2013). The hippocampus, is a major component of the brains of humans and other vertebrates.
The hippocampus belongs to the limbic system and plays important roles in the consolidation of information from short-term memory to long-term
memory, and in spatial memory that enables navigation.</p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">It has been previously demonstrated
that impaired liver function and liver disease is associated with the production of free radical and oxidative stress (Bailey and Cunningham,
1998). The accumulation of these free radicals and oxidative stress contribute to cognitive impairment, learning deficits, memory impairment,
as well as damage and death of neuronal tissue. <span style="background-color: white">Cognitive impairment is when a person has trouble
remembering, learning new things, concentrating, or making decisions that affect their everyday life. Cognitive impairment resulting from
H ranges from mild to severe. </span>There is a long felt need for neuroprotective agents that are both disease-modifying and effective
in treating patients that are experiencing HE. Onset of HE symptoms may be gradual or sudden.<sup>&nbsp;</sup>Other symptoms may include
movement problems, changes in mood, or changes in personality. In the advanced stages, HE can result in a coma.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Opioid Crisis in America</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">The
Centers for Disease Control released a report on November 17, 2021 that indicate there were and estimated 100,306 drug overdose deaths
in the United States during 12-month perioed ending in April 2021, an increase of 28.5% from 78,056 deaths during the same period the
year before (CDC/NCHS, National Vital Statistics System, Mortality 2021).&nbsp;The misuse of and addiction to opioidsincluding&nbsp;<span style="text-decoration: underline">prescription
pain relievers</span>,&nbsp;<span style="text-decoration: underline">heroin</span>, and synthetic opioids such as&nbsp;<span style="text-decoration: underline">fentanyl</span>  is a serious national crisis that affects
public health as well as social and economic welfare. The Centers for Disease Control and Prevention estimates that the total economic
burden&nbsp;of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost
productivity, addiction treatment, and criminal justice involvement. (Med Care 2016; 54(10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;<span style="background-color: white"><span style="text-decoration: underline">Opioids
and Pain  Pain and Addiction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">According
to a February 2018 research report from BIO, The State of Innocation in Highly Prevalent Chronic Diseases  Volume II: Pain
and Addiction Therapeutics, the report states that: </span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="background-color: white">Chronic pain affects as many as 100 million people
in the U.S. alone (Medical Expenditure Panel Survey  MEPS 2008).</span></td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="background-color: white">Total economic and direct healthcare costs for treating
pain in the U.S. have been estimated to be as high as $635 billion annually, higher than the costs for cancer, Alzheimers, or
cardiovascular disease (Relieving Pain in America: A Blueprint for Transforming Prevention Care, education and Research, 2011).</span></td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="background-color: white">Addiction to drugs and alcohol affects more than 23
million Americans and continues to rise, in part due to abuses of pain medications (Defining The Addiction Treatment Gap 2020).</span></td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="background-color: white">Total economic and direct healthcare costs for substance
abuse is an alarming $700 billion per year (Drugabuse.gov).</span></td>
</tr></tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Key
Takeaways from the BIO research report include:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="background-color: white">There have been only two novel chemical entities FDA
approved to treat pain over the past decade.</span></td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="background-color: white">Private company investment, as measured by venture
capital into U.S. companies with lead stage programs in pain, is 3.6% of total drug development venture funding. For venture funding
of novel R&amp;D. pain has received 17 times less venture capital than oncology over the last decade.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="background-color: white">Venture investment for addiction drug R&amp;D is nearly
non-existent.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="background-color: white">&nbsp;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"><span style="text-decoration: underline">Research
and Development Efforts Funded Through NIH-NINDS Under The HEAL Initiative</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Since
February 2020, the Companys lead compound, KLS-13019 has been in the preclinical screening program for pain (PSPP) at the National
Institutes of Health  National Institute of Neurological Disorders and Stroke (NIH-NINDS). This program is part of the NIH HEAL
(Helping to End Addiction Long-term) Initiative. With NIH-HEAL support, NINDS has developed the PSPP program to facilitate the identification
of potential non-addictive treatments (small molecules, biologics, devices, or natural products) for acute and chronic pain conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Research
offered by the PSPP will be a key step in transitioning HEAL preclinical programs into clinical programs, directly aligned with the HEAL
Initiative goal of accelerating the discovery and pre-clinical development of non-addictive pain treatments (NINDS  Preclinical
Screening Platform for Pain  ninds.nih.gov).</span></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">The
Companys lead compound, KLS-13019, has already gone through Tier 1 evaluation under the PSPP which, among other things, assesses
targets and pharmacokinetics (PK) of KLS-13019  compared against morphine and diazepam. Certain results from the Tier 1 screening
report under the PSPP indicate that KLS-13019 has a low abuse potential and acceptable PK to move to Tier 2 studies for animal model assessment
in pain and guardian behavior; wound healing and ability to recover; and Irwin testing for CNS toxicity. Tier 2 studies remain ongoing
for KLS-13019 under the PSPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 28, 2021, the
Company received a notice of award for a $2.97 million Phase 2 STTR Study Grant from the National Institutes of Health  National
Institute of Neurological Disorders and Stroke under the HEAL Initiative (the NIH-NINDS Study Grant Award). The NIH-NINDS
Study Grant Award is funded through the NIH HEAL Initiative (Helping End Addiction Long-Term) for Development of Therapies
and Technologies Directed at Enhanced Pain Management. This NIH-NINDS Study Grant Award provides funding specifically in the further development
of KLS-13019 for the treatment of chemotherapy induced neuropathic pain (CIPN). The grant award of $2.97 million sets forth
the funding allocation of $977,054 in year 1; $991,944 in year 2; and $1,001,774 in year 3 and collectively budgets investigational new
drug (IND) application enabling studies. IND enabling studies to be performed, include but are not limited to animal toxicity
studies and drug compound scale up studies under chemistry manufacturing and controls. The NIH-NINDS Study Grant Award budget includes
studies to be performed at Temple University; the University of Illinois; and Purisys (formerly, Noramco).</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Corporate Strengths and Weaknesses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We believe that we offer the
following key distinguishing characteristics:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We believe we are the first commercial drug discovery company
in the cannabinoid therapeutics space to successfully synthesize CBD derived new chemical entities and pre-clinically test lead NCEs
for potential treatment of oxidative stress related diseases, including OHE and CIPN.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We were the only commercial drug discovery company in the cannabinoid
therapeutics space to license the 507 Patent, prior to its expiration, from NIH on two separate occasions.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We have completed pharmacokinetic and pharmacodynamic pre-clinical
studies with high purity scale, pharmaceutical grade CBD and KLS-13019 for potential treatment of oxidative stress related disease &nbsp;OHE
and CIPN.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We anticipate commencing a Phase 1a trial in CIPN sometime
in the 2<sup>nd</sup> quarter of 2024.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We anticipate commencing a Phase 1a trial in OHE sometime in
the 3<sup>rd</sup> quarter of 2024.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We anticipate commencing a Phase 1a trial in Mild Traumatic
Brain Injury in the 1<sup>st</sup> quarter of 2025.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We have a firm understanding of the mechanism of action of
CBD and KLS-13019 in certain oxidative stress related disorders.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We believe we have a strong next generation intellectual property
estate on cannabidiol derived NCEs. On this basis, we believe we can expand the approved indications KLS-13019 and develop additional
cannabinoid therapeutic agents to add to our IP portfolio.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We believe that our pre-clinical drug development program points
to a significant opportunity in cancer pain, a large market.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We believe that our pre-clinical drug development program points
to a significant opportunity in opioid replacement / reduction market.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have not moved beyond pre-clinical
studies of our drug candidates to date, and there can be no assurances that we will do so in the near future, if ever. While we believe
that we are well positioned to be competitive in advancing non-opioid solutions for chronic and neuropathic pain, as well as the cannabinoid
like therapeutics space, we also believe that we will face significant challenges in successfully completing one or more clinical trials.
In addition, there is a competitive landscape that exists in the market for the Companys target indications of OHE and CIPN. The
competitive landscape is challenging. Competition in the OHE and CIPN spaces is well established, and many companies have significantly
greater resources than we do, some of which are viewed as leaders in the current standard of care for these diseases.</p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">With respect to competitive
landscape for CIPN,&nbsp;nearly a dozen agents have been studied in randomized controlled trials for the treatment of CIPN, but there
has been limited success. The characteristics and results of these studies are summarized in the study and abstract Management
of Chemotherapy Induced Peripheral Neuropathy (Physicians Education Resource LLC, Meghna S. Trivedi, MD; Dawn L. Hershman,
MD, MS;&nbsp;Katherine D. Crew, MD, MS). Clinical trials of the antiepileptic agents gabapentin&nbsp;and lamotrigine&nbsp;and the antidepressants
nortriptyline&nbsp;and amitriptyline&nbsp;have all been negative<span style="background-color: white">.&nbsp;</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Additionally,
there have been several small placebo-controlled trials which have shown that intravenous administration of glutathione with platinum-based
chemotherapy regimens can decrease the incidence of neurotoxicity without diminishing the effect of chemotherapy.&nbsp;A North Central
Cancer Treatment Group / Alliance trial conducted in 2014 studied the use of glutathione with carboplatin and paclitaxel for treatment
of CIPN, and found no improvement in neurotoxicity symptoms, suggesting that glutathione may not help in taxane-induced CIPN.</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Furthermore,
the continuous use of opiates in the current standard of care to treat CIPN have resulted in mixed results, addiction problems and dose
tolerance problems.&nbsp;</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">We
believe that, while the current standard of care is well positioned in the market, there is an unmet need for the treatment of CIPN in
the reduction of use of opiates. We believe that this presents us with an opportunity to participate in the market with a novel therapeutic
agent to treat CIPN.</span>&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The current standard of care
for patients suffering with OHE is 550mg of Xifaxan, originally an antibiotic useful in treating travelers diarrhea and irritable
bowel syndrome. Its exact mechanism of action is not known; however, it is theorized that Xifaxan&nbsp;clinical activity may be attributed
to effects on metabolic function of gut microbiota, rather than a change in the relative bacterial abundance. Currently, there is no drug
in the market for OHE that is being used to treat the toxic effects on the hippocampus, the cognitive and behavioral dysfunction associated
with OHE, and the action of neuroprotection from ammonia and ethanol toxicity.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Given the competitive landscape
in OHE, we believe we can participate in the OHE market with primary and adjunctive therapeutics currently under pre-clinical development,
and potentially obtain orphan drug designation for one or more of our target therapeutic agents.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Clinical Timelines</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As a result of the unprecedented
effects of COVID-19, we have updated our clinical timelines to give effect to the significant interruption to business and financial operations
worldwide as a result of the COVID-19 crisis. We will continue to monitor the progress of the shutdowns currently in effect, and revise
our clinical timelines accordingly.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 11%"><p style="font: 10pt Times New Roman, Times, Serif"><b>Product Candidate</b></p></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Target Indication</b></span></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Delivery Method</b></span></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; width: 13%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Current Development Status</b></p></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 22%; text-align: center"><span style="font-size: 10pt"><b>Expected Next Steps</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">KLS-13019</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Chemotherapy Induced</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">2Q24: Initiate Phase 1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Peripheral Neuropathy</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Mild Traumatic Brain Injury</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">1Q25: Initiate Phase 1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">KLS-13023</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Overt Hepatic Encephalopathy</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">3Q24: Initiate Phase 1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Mild Traumatic Brain Injury</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">1Q25: Initiate Phase 1</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">With respect to certain other
proprietary compounds underlying Pat. 9,611,213, we plan on pursuing topical solutions as potential relief creams and/or ointments for
neuropathic pain, anti-inflammation, anti-pruritic and skin ulcers. We are considering commercialization routes that include, but are
not limited to, filing and FDA Monograph and have already pursued and completed a commercialization path to the marketplace having received
INCI certification and registration with the PCPC for LEA<span style="font-family: Symbol"></span>.</p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In preclinical testing, certain
molecules under Pat. 9,611,213 were screened for neuroprotection and may have the potential mechanism of action for reducing inflammation
and neuropathic pain. These molecules indicate that they are more soluble than CBD, also deemed a neuroprotectant with potential anti-inflammatory
properties. A molecule that is potentially more water soluble than CBD in this regard may be good candidate(s) for use in topical applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We believe that we will be
able to raise sufficient capital to proceed forth with a Phase 1a human safety trial for the treatment of Chemotherapy Induced Peripheral
Neuropathy. All preclinical work in this indication, including animal toxicity studies, are expected to be completed before the end of
the third quarter 2023. We plan on entering into clinical trials sometime in the second quarter 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additionally, we believe that
we will be able to raise sufficient capital to proceed forth with a Phase 1a human safety trial for the treatment of Overt Hepatic Encephalopathy.
All preclinical work in this indication, including animal toxicity studies, are expected to be completed before the end of the first quarter
2024.&nbsp;We plan on entering into clinical trials sometime in the third quarter 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We intend to seek additional
capital to proceed with our business plan regarding additional drug pipeline opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We believe that our current relationships with
Purisys, LLC (formerly known as Noramco) (Purisys), a supplier of bulk active pharmaceutical ingredients (APIs), specifically
pharmaceutical grade CBD, and Catalent Pharma Solutions (Catalent), a manufacturer of formulated and packaged pharmaceuticals,
will enable us to meet our objectives in the production of target drug candidates that can be used in clinical trials and, beyond successful
clinical trials, meet patient demand in commercial sales for each of our target disease indications.<span style="text-decoration: underline">Estimated Costs for CIPN Clinical
Trials  Phase 1a through Phase 2b</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have estimated that the
cost of a Phase 1a and 1b trials, limited to 40 patients in each trial will will cost approximately $1,050,000 and $1,2500,000, respectively.
The Company anticipates that a Phase 2a trial limited to 180 patients will cost approximately $3,000,000, with a Phase 2b trial estimated
at $4,500,000 for 180 patients. As part of our plans to initiate Phase 1 clinical trials in the U.S. or Australia. The benefit of commencing
Phase 1 clinical trials in Australia is that the Australian government has provided incentives that provide for research and development
rebates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research &amp; Development
tax incentives offered by the government actively encourage overseas sponsors to conduct research in Australia. These incentives have
also made it attractive for global companies to access Australian research facilities, as holding the intellectual property within Australia
is not mandatory. Sponsors wishing to be eligible for this benefit can either establish an affiliate company in Australia (which may take
from 1 week to 1 month) or choose a Contract Research Organization (CRO) to act on their behalf.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Controlled Substances Laws and Regulations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our
drug candidates contain controlled substances as defined in the Controlled Substances Act (CSA). Controlled substances that
are pharmaceutical products are subject to a high degree of regulation under the CSA, which establishes, among other things, certain registration,
manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements administered by the DEA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Despite
recent approvals by the FDA and DEA for a newly approved medication that contains CBD, the scheduling of these substances, many of which
are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market KLS-13019 or KLS-13023.
Moreover, because our business is almost entirely dependent upon these two product candidates, any such setback in our pursuit of regulatory
approval would have a material adverse effect on our business and prospects. See our full description of the impact-controlled substances
laws and regulations have on our business in the Risk Factors section of this annual report.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">KLS-13019 does not contain
CBD and is a new chemical entity that would not fall under the CSA or be deemed a Schedule 1 controlled substance. <span style="background-color: white">A
new chemical entity (NCE) is a molecule developed by the innovator company in the early drug discovery stage, which, after
undergoing clinical trials, could translate into a drug that could be a treatment for some disease. Under the Food and Drug Administration
Amendments Act of 2007, all NCEs must first be reviewed by an advisory committee before the FDA can approve these products.</span></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">KLS-13023 is a formulation
that does contain CBD. At present, CBD is deemed a Schedule 1 controlled substance by the U.S. Drug Enforcement Agency (DEA)
under the CSA. Like the drug molecule Epidiolex<span style="font-family: Symbol"></span>, which was recently approved by the FDA
for marketing and sale for use in treating Dravet Syndrome and Lennox-Gasteau Syndrome (forms of child epilepsy), KLS-13023 would need
to follow the guidance set forth by the CSA, complete a successful human clinical trial, and apply for rescheduling, as was the case with
Epidiolex<span style="font-family: Symbol"></span>, now a Schedule 5 drug, before it can be sold and marketed to the public.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 14, 2019, we received
written notice from the DEA and Chemical Evaluation Section, as follows: Please be advised that your material meets the definition
of Hemp and is not regulated under the CSA, as long as it consists of high purity Cannabidiol (CBD) that contains approximately
0.1% delta-9- THC. (However, if it contains more than 0.3% delta-9 THC, it is considered Marihuana and would be in Schedule
1 of the CSA). While this notice is an official notice from the DEA regarding the scheduling of high purity CBD, we will continue
to abide by the CSA in all respects with regards to its treatment and handling of CBD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The
active pharmaceutical ingredient (API) found in KLS-13023 is highly purified pharmaceutical grade synthetic CBD produced
by Purisys and currently under drug master file with the FDA. Purisys (formerly, Noramco) has been manufacturing cannabidiol since 2016
(DMF33223). Today, through our partnership with Purisys, we have the ability to produce on the largest commercial scale. Purisys
ultra-high purity CBD (Purisys CBD) is attractive for drug development projects and falls significantly below the 0.3% THC
limits set in the 2018 Farm Bill for use in consumer products.&nbsp;Purisys patent-protected manufacturing process produces a consistently
odorless, tasteless white powder highest-purity form of CBD that exhibits:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No heavy metals (e.g. lead) from soil;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No pesticide residues;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No environmental influences on quality such as rain, sunlight
&amp; soil nutrients;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No plant impurities to remove;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No microbial or mold proliferation; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No structural (or stereo chemical) differences exist between
an active cannabinoid ingredient manufactured by Purisys and those that are chemically extracted and isolated from plants. They are,
in effect, nature-identical.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Purisys
currently has a drug master file (DMF) for its ultra-high purity CBD with the FDA. In November 2019, Purisys received advise
notice from the DEA that the Purisys CBD has been removed from Schedule 1 of the CSA.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>U.S. Food and Drug Administration (FDA)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The FDA is responsible for
advancing the public health by helping to speed innovations that make medicines safer and more effective and by helping the public get
the accurate, science-based information it needs to use medicines to maintain and improve public health. In 2004, the FDA provided a guidance
document for innovations, challenges, and solutions for new drug products that examine the critical path needed to bring therapeutic products
to completion, and how the FDA can collaborate in the process, from laboratory to production to end use, to make medical breakthroughs
available to those in need as quickly as possible.&nbsp;</p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>FDA Approval &nbsp;What It Means</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">FDA approval of a drug means
that data on the drugs effects have been reviewed by the Center for Drug Evaluation and Research, and the drug is determined to
provide benefits that outweigh its known and potential risks for the intended population. The drug approval process takes place within
a structured framework that includes:&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><i>Analysis of the target condition and available treatments</i>FDA
reviewers analyze the condition or illness for which the drug is intended and evaluate the current treatment landscape, which provide
the context for weighing the drugs risks and benefits. For example, a drug intended to treat patients with a life-threatening
disease for which no other therapy exists may be considered to have benefits that outweigh the risks even if those risks would be considered
unacceptable for a condition that is not life threatening.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><i>Assessment of benefits and risks from clinical data</i>FDA
reviewers evaluate clinical benefit and risk information submitted by the drug maker, taking into account any uncertainties that may
result from imperfect or incomplete data. Generally, the agency expects that the drug maker will submit results from two well-designed
clinical trials, to be sure that the findings from the first trial are not the result of chance or bias. In certain cases, especially
if the disease is rare and multiple trials may not be feasible, convincing evidence from one clinical trial may be enough. Evidence that
the drug will benefit the target population should outweigh any risks and uncertainties.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><i>Strategies for managing risks</i>All drugs have risks.
Risk management strategies include an FDA-approved drug label, which clearly describes the drugs benefits and risks, and how the
risks can be detected and managed. Sometimes, more effort is needed to manage risks. In these cases, a drug maker may need to implement
a Risk Management and Mitigation Strategy (REMS).</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Although many of the FDAs
risk-benefit assessments and decisions are straightforward, sometimes the benefits and risks are uncertain and may be difficult to interpret
or predict. The agency and the drug maker may reach different conclusions after analyzing the same data, or there may be differences of
opinion among members of the FDAs review team. As a science-led organization, the FDA uses the best scientific and technological
information available to make decisions through a deliberative process.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Accelerated Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In some cases, the approval
of a new drug is expedited. Accelerated Approval can be applied to promising therapies that treat a serious or life-threatening condition
and provide therapeutic benefit over available therapies. This approach allows for the approval of a drug that demonstrates an effect
on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that occurs earlier
but may not be as robust as the standard endpoint used for approval. This approval pathway is especially useful when the drug is meant
to treat a disease whose course is long, and an extended period of time is needed to measure its effect. After the drug enters the market,
the drug maker is required to conduct post-marketing clinical trials to verify and describe the drugs benefit. If further trials
fail to verify the predicted clinical benefit, FDA may withdraw approval.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since the Accelerated Approval
pathway was established in 1992, many drugs that treat life-threatening diseases have successfully been brought to market this way and
have made a significant impact on disease course. For example, many antiretroviral drugs used to treat HIV/AIDS entered the market via
accelerated approval, and subsequently altered the treatment paradigm. A number of targeted cancer-fighting drugs also have&nbsp;come
onto the market through this pathway.&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Drug Development Designations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The FDA also employs several
approaches to encourage the development of certain drugs, especially drugs that may represent the first available treatment for an illness,
or ones that have a significant benefit over existing drugs. These approaches, or designations, are meant to address specific needs, and
a new drug application may receive more than one designation, if applicable. Each designation helps ensure that therapies for serious
conditions are made available to patients as soon as reviewers can conclude that their benefits justify their risks.&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 20px; text-align: right"><span style="font-size: 10pt"></span></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Fast Track</b>&nbsp;is a process designed to facilitate the development and advance the review of drugs that treat serious conditions, and fill an unmet medical need, based on promising animal or human data. Fast tracking can get important new drugs to the patient earlier. The drug company must request the Fast Track process. </span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 20px; text-align: right"><span style="font-size: 10pt"></span></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Breakthrough Therapy</b>&nbsp;designation expedites the development and review of drugs that are intended to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. A drug with Breakthrough Therapy designation is also eligible for the Fast Track process. The drug company must request a Breakthrough Therapy designation. </span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 20px; text-align: right"><span style="font-size: 10pt"></span></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Priority Review</b>&nbsp;means that FDA aims to take action on an application within six months, compared to 10 months under standard review. A Priority Review designation directs attention and resources to evaluate drugs that would significantly improve the treatment, diagnosis, or prevention of serious conditions. More information about Priority Review is&nbsp;here.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>FDA Human Clinical Trials</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase I&nbsp;studies assess
the safety of a drug or device. This initial phase of testing, which can take several months to complete, usually includes a small number
of healthy volunteers (20 to 100), who are generally paid for participating in the study. The study is designed to determine the effects
of the drug or device on humans including how it is absorbed, metabolized, and excreted. This phase also investigates the side effects
that occur as dosage levels are increased. About 70% of experimental drugs pass this phase of testing.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase II&nbsp;studies test
the efficacy of a drug or device. This second phase of testing can last from several months to two years, and involves up to several hundred
patients. Most Phase II studies are randomized trials where one group of patients receives the experimental drug, while a second control
group receives a standard treatment or placebo. Often these studies are blinded, which means that neither the patients nor
the researchers know who has received the experimental drug. This allows investigators to provide the pharmaceutical company and the FDA
with comparative information about the relative safety and effectiveness of the new drug. Approximately one-third of experimental drugs
successfully complete both Phase I and Phase II studies.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase III&nbsp;studies involve
randomized and blind testing in several hundred to several thousand patients. This large-scale testing, which can last several years,
provides the pharmaceutical company and the FDA with a more thorough understanding of the effectiveness of the drug or device, the benefits
and the range of possible adverse reactions. Approximately 70% to 90% of drugs that enter Phase III studies successfully complete this
phase of testing. Once Phase III is complete, a pharmaceutical company can request FDA approval for marketing the drug.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase IV&nbsp;studies, often
called Post Marketing Surveillance Trials, are conducted after a drug or device has been approved for consumer sale. Pharmaceutical companies
have several objectives at this stage: (1) to compare a drug with other drugs already in the market; (2) to monitor a drugs long-term
effectiveness and impact on a patients quality of life; and (3) to determine the cost-effectiveness of a drug therapy relative
to other traditional and new therapies. Phase IV studies can result in a drug or device being taken off the market or restrictions of
use could be placed on the product depending on the findings in the study.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Therapeutic Goods Administration (TGA)
&nbsp;Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trials conducted
in Australia are subject to various regulatory controls to ensure the safety of participants. The TGA regulates the use of therapeutic
goods supplied in clinical trials in Australia under the therapeutic goods legislation.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trial sponsors must
be aware of the requirements to import, export, manufacture and supply therapeutic goods in Australia. The following avenues provide for
the importation into and/or supply in Australia of unapproved therapeutic goods for use in a clinical trial:&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Clinical Trial Notification (CTN) scheme; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Clinical Trial Exemption (CTX) scheme.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">The
CTN Scheme is a notification process involving the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The Australian clinical trial sponsor must notify the TGA of
the intent to sponsor a clinical trial involving an unapproved therapeutic good. This must take place before starting to
use the goods. The notification form must be submitted online and accompanied by the relevant fee.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The TGA may give the sponsor of the trial written notice to
provide specified information relating to goods notified in the CTN form.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The TGA does not evaluate any data relating to the clinical
trial at the time of submission. The Human Research Ethics Committee (HREC) reviews the scientific validity of the trial
design, the balance of risk versus harm of the therapeutic good, the ethical acceptability of the trial process, and approves the trial
protocol. The HREC is also responsible for monitoring the conduct of the trial.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The institution or organization at which the trial will be
conducted, referred to as the Approving Authority, gives the final approval for the conduct of the trial at the site, having
due regard to advice from the HREC.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">It is the responsibility of the sponsor to ensure that all
relevant approvals are in place before supplying the unapproved therapeutic goods in the clinical trial.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The CTX Scheme is an&nbsp;approval&nbsp;process
involving the following:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 20px; text-align: right"><span style="font-size: 10pt"></span></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">A sponsor submits an application to the TGA seeking approval to supply unapproved therapeutic goods in a clinical trial. The application must be accompanied by the relevant fee.</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 20px; text-align: right"><span style="font-size: 10pt"></span></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The TGA evaluates summary information about the product including relevant, but limited, scientific data (which may be preclinical and early clinical data) prior to the start of a trial.</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 20px; text-align: right"><span style="font-size: 10pt"></span></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The HREC is responsible for considering the scientific and ethical issues of the proposed trial protocol.</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 20px; text-align: right"><span style="font-size: 10pt"></span></td>
    <td style="width: 7px">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The sponsor must notify us of each trial conducted using the unapproved therapeutic good(s) approved in the CTX application.</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trials that do not
involve unapproved therapeutic goods are not subject to requirements of the CTN or CTX schemes. It is the responsibility
of the Australian clinical trial sponsor to determine whether a product is considered an unapproved therapeutic good.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trials that do not
involve unapproved therapeutic goods are not subject to requirements of the CTN or CTX schemes. It is the responsibility
of the Australian clinical trial sponsor to determine whether a product is considered an unapproved therapeutic good.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In Australia, in 2014, the
Advisory Council on Medicines Scheduling recommended rescheduling CBD from a prohibited substance to being a prescription medicine because,
according to the Advisory Council on Medicines Scheduling, there is a low risk of misuse or abuse as cannabidiol does not possess
psychoactive properties. The TGA accepted this recommendation, and the decision took effect in July 2015.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">CBD is one of the cannabinoids
which may be extracted as a therapeutic good from cannabis. From June 1, 2015, CBD has been included under Schedule 4 (S4) Prescription
Only Medicine of the Poisons Standard when preparations for therapeutic use contain 2% or less of other cannabinoids found in cannabis.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In February 2016, the Australian
Federal Government passed legislation that amended the Narcotic Drugs Act, allowing the supply of suitable medicinal cannabis products
for the management of painful and chronic conditions. This legislation does not relate to the decriminalization of cannabis for general
cultivation or recreational use and it does not include the provision of medicinal grade herbal cannabis, but rather only covers processed,
non-smokable medicinal grade products<sup>.</sup>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Much of the detail remains
unclear. For example, the legislation does not specify which products will be covered under the amendment, and it does not specify which
particular conditions or symptoms will be eligible for treatment with cannabis-based products. Before products can be prescribed, they
must be registered with the TGA or, in rare circumstances, receive special approval from the TGA. The registration process requires evidence
of testing and efficacy and it is therefore unlikely Australia will see a TGA registered medicinal cannabis product that GPs can prescribe
any time soon.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Whilst there are currently no cannabis-based products that are lawfully
produced in Australia, the medicinal use of pharmaceutical products containing cannabinoids is not prohibited, as long as authorization
for prescribing is granted from the Commonwealth Therapeutic Goods Administration and at this point in time, NSW Health.</p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Neuropathix Intellectual Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Neuropathix PCT Patent &nbsp;PCT/US2015/010827</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 13, 2014, we filed for a provisional
patent with the USPTO for our Novel Functionalized 1, 3-Benzene-diols and Their Treatment of Hepatic Encephalopathy, under
application number 61/926,869.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 9, 2015, we filed a non-provisional
patent application Patent Cooperation Treaty (PCT) Application under application number PCT/US2015/010827 titled, Novel
Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy (the PCT Patent).
Under the PCT Patent, the present invention describes novel functionalized 1,3-benzenediols (Cannabidiol Derived Molecules)
and methods that may be useful and have potential for the treatment of HE and related conditions. The present invention further describes
a novel chemotype that may be useful and have potential for the treatment of diseases associated with HE. The present invention further
describes a novel chemotype that may be useful and have potential as neuroprotective agents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We believe that the Cannabidiol Derived Molecules
under the present invention have potential for treating and preventing diseases associated with free radical mediated stress and oxidative
stress including, for example, HE, Parkinsons disease, Alzheimers, Huntingtons disease, traumatic head injury, stroke,
epilepsy, neuropathic pain, traumatic head injury, stroke, CTE, Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, and Epileptic Encephalopathy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The present invention addresses the need to prevent
free radical mediated stress and oxidative stress, as well as to prevent the neural damage associated with HE. The present invention further
addresses the need to prevent cognitive impairment, learning deficits, memory impairment, as well as damage and death of neuronal tissue
associated with HE.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On November 29, 2016, as part of our patent cooperation
treaty global patent application, the USPTO granted allowance on the composition of matter portion, covering claims 1 through 14 of the
Companys PCT Patent covering claims of our novel cannabidiol derived molecule.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In January 2017, we filed a divisional application
with the USPTO to cover the method claims, which were originally covered in claims 15 through 22 of the original PCT Patent. We currently
hold a valid allowance in the United States on the composition of matter for a new cannabidiol derived molecules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On April 4, 2017, we were awarded U.S. Patent
9,611,213 titled Functionalized 1,3 Benzene-diols and their Method of Use for the Treatment of Hepatic Encephalopathy. This
patent is part of a divisional patent application by the Company to the USPTO whereby we sought separate claims for composition of matter,
covered in Pat. 9,611,213, and separate claims for method for treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On June 26, 2018, we were awarded U.S. Patent
10,004,722 titled Method for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediate Stress and Oxidative
Stress with Novel Functionalized 1,3 Benzene-diols.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have patent pending status of the same PCT
Patent in Canada, the European Union, Brazil, Russia, India, China, Japan and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>National Institutes of Health &nbsp;Office of Technology
Transfer (NIH-OTT) &nbsp;Patent 6,630,507</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On June 12, 2010, we filed an application for
an exclusive license with the NIH-OTT for the development and commercialization of a target drug candidate to be used in the treatment
of patients suffering with HE. The application for exclusive license was made for the license and use of U.S. patent 6,630,507 Cannabinoids
as Antioxidants and Neuroprotectants, 507 Patent.&nbsp;</p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On November 17, 2011, we received notice of publication
in the Federal Register of NIH-OTTs Prospective Grant of Exclusive License &nbsp;Development of<span style="background-color: white">&nbsp;Cannabinoid(s)
and Cannabidiol(s) Based Therapeutics to treat hepatic encephalopathy in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">On June
12, 2012, we</span> entered into an exclusive license with NIH-OTT for the use of the 507 Patent in the commercialization of one
or more cannabinoid therapeutics to treat HE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition to the exclusive use of the 507
Patent for the treatment of hepatic encephalopathy, on July 16, 2014, we formally entered into a second license agreement with NIH-OTT
for the non-exclusive license of the 507 Patent for the treatment of CTE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prior to the expiration of the 507 Patent,
we were the only company that had use of the 507 Patent and corresponding licenses from NIH-OTT. The jurisdictions in which the
507 Patent<span style="background-color: white">&nbsp;is valid are: the U.S., the U.K., Ireland, the E.U., and Australia. The patent
life in these jurisdictions expired on April 21, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Although we properly maintained and paid all of
the minimum annual royalties and past prosecution fees underlying our two licenses of the 507 Patent during its lifetime and met
the additional financial benchmarks set forth in the NIH licenses L-113-2012/0 and L-302-2014/0, we were not able to secure the necessary
funds to advance our drug discovery efforts into human clinical trials. Our financial obligations to NIH-OTT terminated in 2019, effective
upon expiration of the 507 Patent.</p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A summary of the Companys patents and status
to each such patent is as set forth below:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="border: Black 1pt solid; text-align: center; width: 25%; vertical-align: bottom"><span style="font-size: 10pt"><b>TITLE</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 12%; vertical-align: bottom"><span style="font-size: 10pt"><b>COUNTRY</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 11%; vertical-align: bottom"><span style="font-size: 10pt"><b>STATUS</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 15%; vertical-align: bottom"><span style="font-size: 10pt"><b>APPLICATION NUMBER</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 13%; vertical-align: bottom"><span style="font-size: 10pt"><b>DATE FILED</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 11%; vertical-align: bottom"><span style="font-size: 10pt"><b>PATENT NUMBER</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; width: 13%; vertical-align: bottom"><span style="font-size: 10pt"><b>GRANT DATE</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF INFLAMMATION AND PAIN</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Pending</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT/US2022/014557</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">31-Jan-2022</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Pending</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">17/622,861</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">26-Dec-2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF INFLAMMATION AND PAIN</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Completed</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">63/144,471</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">1-Feb-2021</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF RADIATION DERMATITIS AND OTHER SKIN DISORDERS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Published</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT/US2020/060587</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">13-Nov-2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Brazil</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Abandoned</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">BR 11 2021 026514 7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">26-Jun-2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Canada</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Pending</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">26-Jun-2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">China</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Abandoned</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">26-Jun-2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Japan</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Abandoned</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2021-578018</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">26-Jun-2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Published</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT/US2020/039860</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">26-Jun-2020</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF RADIATION DERMATITIS AND OTHER SKIN DISORDERS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Completed</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">62/934,861</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">13-Nov-2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">USE OF CERTAIN PHOSPHATIDYLCHOLINES CONTAINING LONG CHAIN POLYUNSATURATED FATTY ACIDS AS NEUROPROTECTIVE AGENTS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Completed</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">62/866,938</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">26-Jun-2019</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">METHOD FOR TREATING HEPATIC ENCEPHALOPATHY OR A DISEASE ASSOCIATED WITH FREE RADICAL MEDIATE STRESS AND OXIDATIVE STRESS WITH NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15/436,956</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">20-Feb-2017</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">10004722</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Jun 26, 2018 </span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">14/781,081</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">29-Sep-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9611213</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Apr 04, 2017 </span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Australia</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2015204609</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2015204609</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 20,2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Belgium</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Brazil</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Pending</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">BR112016016138-6</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Canada</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2,936,506</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2936506</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 23, 2021 </span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">FUNCTIONALIZED 1, 3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">China</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">201580013646.6</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">ZL201580013646.6</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Dec 03, 2019</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Denmark</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">European Patent Office</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">France</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Germany</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">India</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">201617027528</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">382465</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Nov 24, 2021</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Ireland</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Italy</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Japan</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2016-547058</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">6486950</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Mar 01, 2019</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Macao</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Pending</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">J/4044</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Netherlands</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Closed</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">PCT/US15/10827</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Russian Federation</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2016133213</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">2676475</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Dec 29, 2018</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Spain</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Sweden</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Switzerland</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Turkey</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">United Kingdom</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Issued</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">15734870.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">9-Jan-2015</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">3094318</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Feb 19, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Expired</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">61/926,869</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">13-Jan-2014</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">NOVEL FUNCTIONALIZED 1,3-BENZENE DIOLS AND THEIR METHOD OF USE FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Colombia</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Unfiled</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">PROCESS FOR SYNTHESIZING CANNABINOIDS AND DERIVATIVES THEREOF</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Unfiled</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><span style="font-size: 10pt">METHOD FOR TREATING PERIPHERAL NEUROPATHIC PAIN</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">US</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top"><span style="font-size: 10pt">Unfiled</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; vertical-align: top">&nbsp;</td></tr>
  </tbody></table>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>PRE-CLINICAL DRUG DISCOVERY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since inception in 2010, our primary drug discovery
plans have revolved around neuroprotection and the use of CBD as well as the development of proprietary CBD-derived molecules as target
drug candidates to treat neurodegenerative and oxidative stress related diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Historical Pre-clinical Discovery Efforts</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our research and development
efforts at the Pennsylvania Biotechnology Center were originally centered on the creation of novel synthetic cannabinoid and cannabinoid-like
molecules, the pre-clinical and&nbsp;<i>in vitro</i>&nbsp;efficacy of CBD, a non-psychotropic molecule, and the testing and control of
our lead target drug candidates alongside CBD for the treatment of OHE and CTE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Conceptual Drug Discovery of Cannabidiol Derived
Molecules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An emerging concept is that blockade of free radical
mediated stress and oxidative stress will prevent the neural damage associated with HE and prevent cognitive impairment, learning deficits,
memory impairment, as well as damage and death of neuronal tissue associated with HE. Cannabidiol Derived Molecules may have the potential
of acting as neuroprotective agents by blocking the damage caused by free radicals and oxidative stress, may prevent the neural damage
associated with HE, and may also prevent cognitive impairment, learning deficits, memory impairment, as well as damage and death of neuronal
tissue associated with HE.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Around 1900, Moses Gomberg, a chemistry professor,
discovered that prevention of free radical mediated stress and oxidative stress can prevent damage and death of neuronal tissue, as well
as prevent cognitive impairment, learning deficits, and memory impairment associated with damage and death of neuronal tissue. Without
wishing to be limited by theory, it is believed that the neuroprotective agents of the disclosure can ameliorate, abate, and otherwise
cause to be controlled, diseases associated free radical mediated stress and oxidative stress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Free radical mediated stress and oxidative stress
is also known to contribute to additional pathological conditions including, but not limited to, epilepsy, neuropathic pain, traumatic
head injury, stroke, CTE, Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases
such as Parkinsons disease, Alzheimers, Huntingtons disease, and amyotrophic lateral sclerosis (ALS).
Under the present invention, these Cannabidiol Derived Molecules may be capable of acting as neuroprotective agents, and may be useful
for the treatment of epilepsy, neuropathic pain, traumatic head injury, stroke, CTE, Post Cardiac Arrest Hypoxic Ischemic Encephalopathy,
Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinsons disease, Alzheimers, Huntingtons disease,
and ALS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of October 2013, we had performed six distinct
pre-clinical studies on murine specimens, including functional assay screens on twenty-four viable analogues and pre-clinical studies
against CBD as a therapeutic control. Analogues are compounds or molecules having a structure similar to that of another compound or molecule,
but differing from it in respect to a certain component.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As a result of the screening process, we found
that there were four target candidates along with CBD that were screened for final pre-clinical in vitro testing for pharmacokinetics
(PK), CACO permeability, lethal dose (LD), EC50 and IC90 testing. PK relate to the branch of pharmacology
concerned with the movement of drugs within the body. Factors in PK studies include CACO permeability, which relates to assays that measure
the ability of a drug to be absorbed from the gastrointestinal tract and thereby to evaluate whether the drug can be suitably dosed via
an oral route. EC50 and IC90 relate to&nbsp;<span style="background-color: white">the concentration of a drug, antibody or toxicant which
induces a response halfway between the baseline and maximum after a specified exposure time. It is commonly used as a measure of a drugs
potency (EC50), and&nbsp;</span>the concentration of a medication in the blood that will inhibit the replication of a specified percentage
of microorganisms (IC90)<span style="background-color: white">.</span></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our lead target drug candidate was then analyzed
using a mouse model to determine, among other things, blood brain barrier xs, tissue and organ distribution, bioavailability, administration
(IV vs. Oral), spinal fluid concentration, and blood plasma concentration.&nbsp;<span style="background-color: white">A route of administration
in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Bioavailability
is a subcategory of absorption and relates to a fraction of an administered dose of a drug that reaches systemic circulation in the body.
Blood plasma concentration, otherwise known as volume of distribution,&nbsp;</span>is a theoretic concept that relates the
amount of drug in the body (dose) to the concentration (C) of drug that is measured (in blood, plasma, and unbound in tissue water).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In May 2014, we commissioned the first of two
animal behavioral studies via research pact with Temple University. The aim of the study was to test the effects of CBD and KLS-13019
on cognitive function in a mouse model of OHE in support of the identification of molecules with in vivo efficacy. An established model
of OHE, the thioacetamide model (TAA, 200 mg/kg i.p.), was used to assess the effect of CBD (5.0 mg/kg i.p.) and KLS-13019 (0.5 &nbsp;5.0
mg/kg i.p.) on learning and memory in male C57Bl6 mice. The autoshaping procedure, an operant learning and memory assay that rapidly assesses
acquisition and retention of a simple task, was the primary cognitive assay used. The task is an operant conditioning task wherein food
restricted mice are placed in experimental chambers and must learn how to make a behavioral response to gain access to food rewards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In summary, thioacetamide
induced a robust, but variable, toxicity associated with cognitive impairment, morbidity, and mortality. KLS-13019, administered in the
absence of thioacetamide, produced no negative behavioral or general health effects, and actually appeared to improve cognitive functioning
in the behavioral task. The 5.0 mg/kg dose of KLS-13019 also significantly prevented thioacetamide-induced cognitive performance deficit,
and the lower dose of 1.0 mg/kg showed a trend in this direction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Pharmacokinetic and Pharmacodynamic Comparison
Between KLS-13019 and CBD</b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Results from PK and PD studies performed in evaluating CBD versus
KLS-13019 (molecule name 16), has shown KLS-13019 to be superior in aqueous solubility (potential for drug absorption after oral administration);
Log P (ratio which measures difference in solubility in two phases); bioavailability (proportion of the drug that enters the circulation);
and C max at 10 mg/kg, p.o. (peak serum concentration).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;<img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_006.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_006.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Results from our pre-clinical efforts in the potential treatment
of OHE and the potential treatment of CIPN have shown a marked improvement over 99.7% pure pharmaceutical grade synthetic CBD in side
by side pre-clinical comparison. In a pre-clinical comparison for neuroprotection between CBD and KLS-13019, results indicated increased
potency for the new molecule (KLS-13019) as determined by six assays, while both molecules exhibited efficacy in preventing oxidative
stress-related toxicities back to control values. Treatment with KLS-13019 alone, however, was 5-fold less toxic than CBD. Previous studies
suggested that CBD targeted the Na<sup>+&nbsp;</sup>Ca<sup>2+</sup>&nbsp;(sodium-calcium) exchanger in mitochondria to regulate intracellular
calcium levels, an important determinant of neuronal survival. After treatment with an inhibitor, the mNCX inhibitor (CGP-37157),
no detectable neuroprotection from ethanol toxicity was observed for either CBD or KLS-13019. Furthermore, AM630 (a CB2 antagonist) significantly
attenuated CBD-mediated neuroprotection, while having no detectable effect on KLS-13019 neuroprotection. Our studies indicated KLS-13019
was more potent and less toxic than CBD. Both molecules can act through mNCX. Based on these results, amongst other things, we believe
that KLS-13019 may provide an alternative to CBD as a therapeutic candidate to treat disease associated with oxidative stress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_007.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_007.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_008.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_008.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As previously noted, comparisons between CBD and KLS-13019 have been
published in peer reviewed articles in ACS Medicinal Chemistry Letters (2016, 7, 424-428) and Journal of Molecular Neuroscience (14 August
2018).</p>


<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additional follow on studies recently published
on May 10, 2019 in the&nbsp;<i>Journal of Molecular Neuroscience</i>&nbsp;have further advanced our studies on the mechanism of action
for CBD and KLS-13019 in pre-clinical testing for the treatment of CIPN.&nbsp;The mechanism of action for CBD-and KLS-13019-mediated protection
now has been explored with dissociated dorsal root ganglion (DRG) cultures using small interfering RNA (siRNA) to the mitochondrial
Na+ Ca2+ exchanger-1 (mNCX-1). Treatment with this siRNA produced a 5055% decrease in the immunoreactive (IR)
area for mNCX-1 in neuronal cell bodies and a 7280% decrease in neuritic IR area as determined with high-content image analysis.
After treatment with 100 nM KLS-13019 and siRNA, DRG cultures exhibited a 75 5% decrease in protection from paclitaxel-induced
toxicity, whereas siRNA studies with 10 M CBD produced a 74 3% decrease in protection. Treatment with mNCX-1 siRNA alone did
not produce toxicity. The protective action of cannabidiol and KLS-13019 against paclitaxel-induced toxicity during a 5-h test period
was significantly attenuated after a 4-day knockdown of mNCX-1 that was not attributable to toxicity. This data indicates that decreases
in neuritic mNCX-1 corresponded closely with decreased protection after siRNA treatment. Pharmacological blockade of mNCX-1 with CGP-37157
produced complete inhibition of cannabinoid-mediated protection from paclitaxel in DRG cultures, supporting the observed siRNA effects
on mechanism.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><span style="background-color: white">Sodium-Calcium
Exchanger (NCX)&nbsp;</span>(often denoted Na<sup>+</sup>/Ca<sup>2+</sup>&nbsp;exchanger, NCX, or exchange protein) is an
antiporter membrane protein that removes calcium from cells. The exchanger exists in many different cell types and animal species. The
NCX is considered to be one of the most important cellular mechanisms for removing Ca<sup>2+</sup>&nbsp;(calcium ions) from cells. The
exchanger is usually found in the plasma membranes and the mitochondria and endoplasmic reticulum of excitable cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mitochondria&nbsp;<span style="background-color: white">is
a double-</span>membrane<span style="background-color: white">-bound&nbsp;</span>organelle<span style="background-color: white">&nbsp;found
in most&nbsp;</span>eukaryotic<span style="background-color: white">&nbsp;organisms. Mitochondria generate most of the cells supply
of&nbsp;</span>adenosine triphosphate<span style="background-color: white">&nbsp;(ATP), used as a source of&nbsp;</span>chemical
energy<span style="background-color: white">. ATP is a complex organic chemical that provides energy to drive many processes in living
cells, including muscle contractions, nerve impulse propagation and chemical synthesis.&nbsp;</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">According to Fallon, et al. in the March/April
2006 edition of Clinical Medicine, pain is uncontrolled with opioid treatments in approximately 20% of patients with advanced cancer,
or 420,000 people in the United States. There are currently no FDA approved non-opioid treatments for patients who do not respond to,
or experience negative side effects with, opioid medications. We believe that KLS-13019 has the potential to address a significant unmet
need in this large market by treating patients with a product that employs a differentiated non-opioid mechanism of action, and offers
the prospect of pain relief without increasing opioid-related adverse side effects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Neuropathix Early Studies on CBD</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In March 2013, we began our pre-clinical research
and discovery efforts at the Pennsylvania Biotechnology Center/Baruch Blumberg Institute in Doylestown, PA. We began the research and
development, and pre-clinical work focused on the identification, synthesis and/or extraction of novel Cannabis-derived molecules for
the treatment of impairments associated with oxidative stress in OHE. Prior research (published on April 16, 2011, in the British Journal
of Pharmacology under the title Cannabidiol Improves Brain and Liver Function in a Fulminant Hepatic Failure Induced Model of Hepatic
Encephalopathy in Mice) produced substantial behavioral and histochemical evidence demonstrating the effectiveness of certain Cannabis-derived
molecules, such as CBD, in the improvement of brain and liver function in fulminant hepatic failure. Findings from the above referenced
study include reversal of locomotors and cognitive pathologies, reversal of structural changes, such as Alzheimers Type II astrogliosis,
and reversal of increases in ammonia levels.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In 2014, we published an abstract on our completed
studies regarding CBD at the 24th Annual International Cannabinoid Research Society symposium, titled Cannabidiol Provides Protection
from Ethanol and Ammonium Toxicity in a Hippocampal Model of Hepatic Encephalopathy. In the present study, an in vitro model of
HE has been utilized to evaluate the protective properties of CBD, a substance with demonstrated protective properties against oxidative
stress in pre-clinical studies targeting the OHE range of neuronal toxicity.</p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">OHE is a known oxidative stress
related disorder.&nbsp;<span style="background-color: white">Although ammonia is considered the main factor involved in the pathogenesis
of OHE, it correlates well with the severity of OHE in acute liver failure, but not in chronic liver disease. Oxidative stress is another
factor believed to play a role in the pathogenesis of this syndrome; it represents an imbalance between the production and neutralization
of reactive oxygen species, which leads to cellular dysfunction (Oxidative Stress: A Systemic Factor Implicated in the Pathogenisis
of Hepatic Encephalopathy, Metabolic Brain Disease, 28 June 2013, 175-178).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As part of our research and
development efforts, we have sought to establish the pre-clinical efficacy of CBD, which, along with our novel and proprietary lead target
molecules, have shown to have neuroprotective properties. From 2013 through 2019 we conducted preclinical evaluations and formulation
of our CBD based target drug candidate, KLS-13023. These efforts involved a feasibility study with Catalent Pharma Solutions (Catalent)
utilizing a highly purified pharmaceutical grade synthetic CBD produced by Purisys (formerly, Noramco) and currently under drug master
file with the FDA. While we have evaluated CBD on its own, in a highly purified form, we plan on bringing a CBD based target drug therapeutic
revolve around a formulated product in oral dose administration capsule (KLS-13023) and supported with additional intellectual property
created by the Company. &nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 22, 2015, we signed an agreement with
Catalent Pharma Solutions LLC (Catalent), a $3.9 billion pharmaceutical manufacturer, for the performance of a feasibility
study named Solution for Cannabidiol Softgel Feasibility (the CBD OTC Feasibility Study). Catalent has over
eight years of experience in capsule and softgel manufacturing capabilities and experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The purpose of the CBD OTC Feasibility Study with
Catalent is to advance our plans to submit one or more products for FDA clinical trials to treat certain oxidative stress related and
neurodegenerative related diseases such as Traumatic Brain Injury (TBI).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">TBI,&nbsp;<span style="background-color: white">also
known as intracranial injury, occurs when an external force injures the brain. TBI can be classified based on severity, mechanism (closed
or penetrating head injury), or other features (e.g., occurring in a specific location or over a widespread area). Head injury is a broader
category that may involve damage to other structures, such as the scalp and skull. TBI can result in physical, cognitive, social, emotional,
and behavioral symptoms, and outcomes can range from complete recovery to permanent disability or death.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Centers for Disease Control and Prevention (the CDC)
has compiled statistics on TBI, which occurs more with children and older adults. According to the CDC, total combined rates for TBI-related
emergency department (ED) visits, hospitalizations and deaths have increased over the past decade. In 2014, there were approximately
2.5 million TBI-related ED visits in the U.S., including over 812,000 among children. Unintentional falls, being unintentionally struck
by or against an object, and motor vehicle crashes were the most common mechanisms of injury contributing to a TBI diagnosis in the ED.
These three principal mechanisms of injury accounted for 47.9%, 17.1%, and 13.2%, respectively, of all TBI-related ED visits. Rates of
TBI-related ED visits per 100,000 population were highest among older adults aged  75 years (1,682.0), young children aged 0-4 years
(1,618.6), and individuals 15-24 years (1,010.1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 4, 2015, the Company and Catalent commenced
the feasibility study named Solution for Cannabidiol Softgel Feasibility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 16, 2015, we received notice from Catalent
that the DEA advised them that the CBD drug code 7360 had been added to Catalents Schedule 1 registration and that a quota for
a certain quantum of CBD was successfully submitted for the importation of 150 grams of 99.7% pure synthetic cannabidiol from Purisys
(formerly, Noramco).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additionally, on July 13, 2018, we received notice
from the DEA that were approved for our own Schedule 1 Controlled Substance license for the purpose of research activity. The addition
of this license will further assist the Company in the bailment and delivery of CBD to and from research collaborators like Catalent and
Temple University, as well as others.</p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our relationship with Catalent was founded on
our efforts to produce a formulated version of a CBD based gel capsule, herein referred to as KLS-13023, for further advancements in the
treatment of oxidative stress related disorders, such as OHE. Catalent does not share in any royalties or ownership of intellectual property
that we provide to Catalent or that is developed under the feasibility study with Catalent described herein. The current feasibility study
being performed is for our efforts to create a high quality controlled and assured pharmaceutical grade product for use in an FDA clinical
trial to treat patients suffering with OHE. Catalents efforts in this instance is as a contract manufacturer involved in the advancement
of our intellectual property and for Catalent to be a third party contract manufacturer for the commercial production of KLS-13023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In late 2019, this novel formulation
and feasibility study was completed at Catalent and also validated through repeated in vitro viability assays and pharmacology tests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are satisfied by the successful
completion of the feasibility study with Catalent, and plan to perform additional research and development and further pre-clinical evaluation
of KLS-13023 in mild traumatic brain injury (mTBI) animal models and move towards animal toxicity studies. Thereafter we plan on filing
an IND application for KLS-13023 with the FDA. We have only committed to completing the feasibility study with Catalent, and are under
no obligation to enter into a commercial drug manufacturing agreement with Catalent. After the completion of our feasibility study with
Catalent, we currently believe that the logical next step in our commercial development plans for KLS-13023 is to engage with Purisys
(formerly, Noramco) for the API supply of their highly purified pharmaceutical grade CBD and with Catalent as our contract drug manufacturer
for KLS-13023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>CBD Reclassified by DEA for Epidiolex</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;On September 27, 2018,&nbsp;in
a significant decision relating to the classification of CBD, currently classified as a Schedule I narcotic by the DEA under the Controlled
Substances Act, <span style="background-color: white">the Department of Justice and the DEA announced that Epidiolex<span style="font-family: Symbol"></span>,
the recently approved medication by the FDA, was being placed in Schedule V of the Controlled Substances Act, the least restrictive schedule
of the CSA.</span>&nbsp;On June 26,<span style="background-color: white">&nbsp;2018, the FDA announced it approved Epidiolex<span style="font-family: Symbol"></span>
for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients
two years of age and older.</span>&nbsp;<span style="background-color: white">Epidiolex<span style="font-family: Symbol"></span>
contains CBD. The CBD in Epidiolex<span style="font-family: Symbol"></span> is extracted from the cannabis plant and is the first
FDA-approved drug to contain a purified extract from the plant. Schedule V drugs represent the least potential for abuse.&nbsp;</span>Schedule
V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing
limited quantities of certain narcotics. &nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We believe this was a significant
reclassification that validates our efforts in the research and development of ethical pharmaceuticals containing CBD as an active pharmaceutical
ingredient and reduces the regulatory and market risks associated with the use of CBD, still a Schedule I narcotic.&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have maintained since inception that the only clear path to reclassification
is to follow the regulatory path of proving medical purpose through traditional Phase 1 through Phase 3 clinical trials. We believe that
the approval of Epidiolex<span style="font-family: Symbol"></span> by the FDA on June 26, 2018 and reclassification of CBD as it
relates to Epidiolex<span style="font-family: Symbol"></span> by the DEA on September 27, 2018, is clear evidence of the need to
follow the regulatory path in order to meet the requirements of reclassification of a Schedule I controlled substance.&nbsp;</p>


<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif"><b>Neuropathix Strategic Third Party Business Relationships, Licenses
and Joint Ventures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"><i>Natural
Products Discovery Institute &nbsp;Pennsylvania Biotechnology Center</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In December 2013, we entered into a Materials
Transfer and Testing Agreement (MTTA) with the Institute for Hepatitis and Virus Research and their division, the Natural
Products Discovery Institute (NPDI), located at Pennsylvania Biotechnology Center in Doylestown, PA. The purpose of the
MTTA, is, among other things, the research of original material made up of plants, plant matter, and plant extracts (the Plant
Materials) to identify bioactive molecules contained in these Plant Materials which may lead to the commercial production of bioactive
molecules. To date, we have screened one plant source and have fractionated extracts to determine its neuroprotective activity. This plant
source and extracted material has shown a high degree of neuroprotectant factor in the face of ethanol and ammonium toxicity in neuronal
cell cultures. We plan on furthering the commercial development of this material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On April 2, 2020, we entered into an Intellectual
Property Rights Purchase and Transfer Agreement with the BSBI to purchase all of the rights, titles, and interests that would otherwise
belong to the BASBI solely under the MTTA Agreement. The purchase price for the acquisition of these rights was twenty five thousand shares
of the Companys restricted common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Subsequent to this transaction with the BSBI,
we filed for patent protection on this discovery, which patent describes claims on the process, method and use of this material in the
treatment of neurodegenerative diseases. (see: Neuropathix Intellectual Properties)&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Temple University &nbsp;Animal Behavioral/Pre-Clinical
Model</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On May 1, 2014, we signed a Research Services
Agreement with Temple University to test the effects of CBD and CBD-like molecules in an HE model of cognitive impairment in support of
the identification of molecules with&nbsp;<i>in vivo</i>&nbsp;efficacy. The tests were performed by Temple University in the pre-clinical
model for HE, and involved a mouse model of OHE and administration of CBD and KLS-13019 conducted by Dr. Sara Jane Ward and Dr. Ronald
Tuma, with the study titled &nbsp;Cognitive, neurological, and motor function in a mouse model of hepatic encephalopathy:
effects of CBD and CBD analogues (KLS-13019). The results of this study showed that KLS-13019 is superior to CBD in the intervention
of cognitive impairment from associated neurotoxicity in the OHE model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 4, 2017, we applied for a Phase 1 Small
Business Technology Transfer (STTR) grant from the National Institutes of Health  National Institute on Drug Abuse
(NIH-NIDA). This grant application was made in collaboration with Temple University and titled Development of KLS-13019
for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence. In December 2017, we were informed that the Phase 1 grant was
awarded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following is a summary outline of the aims
proposed in the aforementioned grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Chemotherapy-induced peripheral neuropathy (CIPN)
can be a chronic, severely debilitating consequence of cancer therapy for which there are no effective management strategies. Moreover,
upwards of 80% of CIPN patients reported using prescription opioids for pain management, despite the fact that there is only weak evidence
that the long-term continuation of opioids provides clinically significant pain relief in these patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mitochondrial dysfunction, oxidative stress, and
inflammation have all been implicated in its etiology. We have shown that the non-psychoactive cannabinoid CBD prevents the development
of CIPN in a mouse model of paclitaxel-induced cold and mechanical allodynia. This target, allodynia, refers to central pain sensitization
(increased response of neurons) following normally non-painful, often repetitive stimulation. It can lead to the triggering of pain response
from stimuli that normally do not provoke pain.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In vitro, we observe that paclitaxel increases
microglial expression of several putative mediators of neuropathic pain, and that this effect can be blocked by CBD in a mitochondrial
Na+/Ca2+ exchanger (mNCX)- dependent manner. We have also shown that a more potent, hydrophilic analogue of CBD, KLS-13019, protects against
paclitaxel-induced oxidative stress in cultured dorsal root ganglia neurons, and that the mechanism underlying this neuroprotection is
also regulation of intracellular calcium via the mNCX. Preliminary results demonstrate that KLS-13019 can attenuate mechanical sensitivity
associated with CIPN while also reducing microglial activation and T cell infiltration into the spinal cord.</p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dorsal root ganglia (DRG) is a cluster
of neurons (a ganglion) in the dorsal root of a spinal nerve. The cell bodies of sensory neurons known as the first-order neurons are
located in the dorsal root ganglia.&nbsp;<span style="background-color: white">Even though dorsal root ganglia are a part of the system
of peripheral nerves, they lie very close to the spine, and therefore to the central nervous system. That makes them an important connection
between the two systems. These nerve clusters help transmit messages toward the brain and play a key role in neuropathic pain development
and maintenance. Peripheral nerve injury-induced neuropathic pain is one of major clinical disorders characterized by spontaneous ongoing
or intermittent burning pain, sensory abnormalities (dysesthesia), an increased response to painful stimuli (hyperalgesia), and pain in
response to normally innocuous stimuli (allodynia).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our central hypothesis is that administration
of CBD or KLS-13019 helps preserve Ca2+ homeostasis by promoting activity of the mNCX, which in turn protects from both mitochondrial
dysfunction and microglial activation to prevent the neuronal and glial changes associated with the development and maintenance of paclitaxel-induced
neuropathic pain. We believe that results from experiments in AIM 1 will demonstrate that the neuroprotective properties of CBD and KLS-13019
can be reduced by pharmacological or gene knockdown of the mNCX in a statistically significant manner. We believe that results from experiments
in AIM 2 will further confirm the i.p. and p.o. efficacy of KLS-13019 vs CBD to prevent or reverse mechanical sensitivity and neuroinflammation
in a mouse model of paclitaxel-induced neuropathic pain and that repeated administration of these molecules does not lead to analgesic
tolerance. Remarkably, the non-psychoactive CBD has also been shown to inhibit cue-induced heroin-seeking and neurochemical correlates
thereof in a rat model of relapse and decrease heroin craving in a small human study. Experiments in AIM 3 are designed to test the hypothesis
that KLS-13019 and CBD will attenuate reinstatement of morphine seeking behavior in a rat model of opioid relapse. The overall impact
of the results from the proposed research will be significant advancements into (i) identification of specific mechanisms that induce
CIPN, (ii) application of this knowledge to facilitate design of novel treatment strategies for neuropathic pain, and (iii) novel treatment
strategies to reduce or replace prescription opioid use and decrease prescription opioid abuse.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Chemotherapy-induced peripheral neuropathy (CIPN)
can be a chronic, severely debilitating consequence of cancer therapy for which there are no effective management strategies. Moreover,
upwards of 80% of CIPN patients reported using prescription opioids for pain management, despite the weak evidence of their efficacy and
the risks of long term dependence (Hirayama, ESMO Open 2016). Mitochondrial dysfunction, calcium dysregulation, oxidative stress, and
inflammation have all been implicated in its etiology. In pre-clinical studies, CBD, a non-psychoactive component of cannabis sativa,
has shown evidence in a murine model to be a potentially effective treatment for CIPN and relieving opiate dependence currently experienced
by certain patients undergoing current therapeutic chemotherapy and pain management regimens in cancer treatment. However, CBD has severe
limitations in terms of potency, safety, oral bioavailability, and regulatory restrictions. KLS-13019 is a novel new chemical entity that,
as per pre-clinical testing, may be able to target these problems. In the NIH-NIDA Phase 1 STTR Study Grant completed in December 2019,
our research efforts with Temple University demonstrated the efficacy of KLS- 13019 in models of CIPN and opiate dependence, and also
further elucidated its mechanism of action in regulation of calcium levels and inflammatory sequelae.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have completed all of our work related to the
aforementioned grant and are currently in a peer review submission of our research results to the Journal of Molecular Neuroscience. Temple
University has completed two of the three aims outlined in the grant proposal, and is currently in the process of completing the third
and final aim, morphine reinstatement. We believe that the grant study will be completed on or about June 2019 and the results will be
published by Temple University.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 31, 2019, we, together with Temple
University, filed a completion report with NIH-NIDA regarding the Phase 1 STTR grant. The results of this study were promising and have
set forth our plans to file for a Phase 2 grant due for filing on or before April 7, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In April 2020, the Company and Temple University
filed for a Phase 2 SBIR Grant with National Institutes of Health  National Institute of Neurological Disorders and Stroke (NIH-NINDS).
Our application provided strong support to further the research and development of our treatment for CIPN. &nbsp;<span style="background-color: white">Phase
2&nbsp;is focused on the development, demonstration and delivery of the innovation. </span></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In June 2020, the Company was informed that its
Phase 2 SBIR grant application received an impact/priority score of 47. Generally speaking, impact/priority scores of 10 to 30 are most
likely to be funded. Scores between 31 and 45 might be funded; scores greater than 46 are rarely funded. The Company believed that there
were elements of its initial Phase 2 SBIR grant application that were misunderstood and believed it still had a very strong application.
After making several critical changes to the original application, in January 2021, the Company resubmitted its Phase 2 SBIR grant application
with NIH-NINDS and currently awaits response from NIH-NINDS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 10, 2021, we were notified that our resubmitted
application received a summary review and impact/priority score of 20, which is considered by many to be exceptional and rare. This impact/priority
score and summary attests to the novelty and advancement of our scientific discovery with KLS-13019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 28, 2021, the Company received a
notice of award for a $2.97 million Phase 2 STTR Study Grant from the National Institutes of Health  National Institute of Neurological
Disorders and Stroke under the HEAL Initiative (the NIH-NINDS Study Grant Award). The NIH-NINDS Study Grant Award is funded
through the NIH HEAL Initiative (Helping End Addiction Long-Term) for Development of Therapies and Technologies Directed
at Enhanced Pain Management. This NIH-NINDS Study Grant Award provides funding specifically in the further development of KLS-13019 for
the treatment of chemotherapy induced neuropathic pain (CIPN). The grant award of $2.97 million sets forth the funding allocation
of $977,054 in year 1; $991,944 in year 2; and $1,001,774 in year 3 and collectively budgets investigational new drug (IND)
application enabling studies. IND enabling studies to be performed, include but are not limited to animal toxicity studies and drug compound
scale up studies under chemistry manufacturing and controls. The NIH-NINDS Study Grant Award budget includes studies to be performed at
Temple University; the University of Illinois; and Purisys (formerly, Noramco).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Proposed Study for Traumatic Brain Injury</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To investigate the mechanisms of action through which CBD and
a cannabinoid analogue (KLS-13019) provide neuroprotection form neurotoxicity factors (glutamate and CCL11) relevant to TBI. Neural damage
associated with TBI has been associated with multiple processes including excitotoxicity, oxidative stress and neuroinflammation. Because
of the recognized protective effects of cannabinoids on all of these toxic processes, we have chosen to explore the effects and mechanism
of action of two molecules: (i) CBD, a substance found in cannabis; and (ii) KLS-13019, a novel CBD-like analogue that has been shown
to protect against various toxicity associated with oxidative stress (Kinney et al., 2016). In this proposal, we intend to investigate
the protective mechanisms related to the attenuation of CCL11 for both molecules in disease-relevant in vitro test systems that utilized
glutatmate as a relevant toxin and then explore their effectiveness in animal models of TBI.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Catalent Pharma Solutions</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">In December
2014, we signed a feasibility study contract with Catalent Pharma Solutions (Catalent), to, among other things, </span>commence
a feasibility study on a dose controlled soft-gel containing CBD as the main active pharmaceutical ingredient (the CBD Feasibility
Study). The purpose of the CBD Feasibility Study with Catalent is to enable us to develop a proprietary drug product formulation
using CBD that has suitable solubility and stability characteristics for IND, enabling pre-clinical studies in animals and clinical studies
in humans, as part of our ongoing research and development of a cannabinoid therapeutic for the treatment of neurodegenerative diseases,
including CTE and OHE. Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs,
biologics, consumer health and animal health products. With over 80 years serving the industry, Catalent has proven expertise in bringing
more customer products to<span style="background-color: white">&nbsp;market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs approximately 13,900 people, including over 1,000 scientists, at 53 facilities
across 4 continents, and in fiscal 2020 generated approximately $3.09 billion in annual revenue. Catalent is headquartered in Somerset,
N.J.</span>&nbsp;</p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Purisys, LLC (formerly, Noramco, Inc.)&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Noramco, Inc. (Noramco) was formed
in 1979 to provide a secure source of Codeine Phosphate. On October 1, 2019, Noramco spun off its cannabinoid related business into a
separate affiliated company, Purisys, LLC (Purisys). With Noramcos acquisition of Tasmanian Alkaloids and addition
of their Athens, Georgia site in 1982, and continuous expansions over the past three decades at both of its U.S. facilities, Noramco and
Purisys, together, now contribute to billion dollar affiliate franchises, as well as to significant third-party generic and branded pharmaceutical
products worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Noramco is a world leader in specialty active
pharmaceutical ingredients, with a particular focus in controlled substances. Purisys is the leader in manufacturing ultra-high purity
cannabinoid ingredients. Purisys headquarters and primary production facility is located in Athens, GA, with additional sites in
Wilmington, DE and Schaffhausen Switzerland.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">In April
2015, we entered into discussions with </span>Purisys <span style="background-color: white">(then, Noramco), for, among other things,
the long term supply of high purity,&nbsp;</span>pharmaceutical grade, synthetic cannabidiol for the purpose of delivering CBD as an active
pharmaceutical ingredient to Catalent in connection with our CBD Feasibility Study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition to the procurement of CBD through
Purisys, the Company and Purisys have discussed an additional feasibility study for the scale-up and commercial production of KLS-13019.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">SK Capital Partners (SK Capital)
acquired Noramco from Johnson &amp; Johnson in July 2016.&nbsp;<span style="background-color: white">SK Capital is a private investment
firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors.</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>PRIMARY TARGETS FOR DRUG DISCOVER AND MARKET SIZE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Target 1: Hepatic Encephalopathy &nbsp;$2+ Billion Market
in the U.S.&nbsp;</b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">HE is one
of the most important clinical manifestations in decompensated liver cirrhosis. Accepted concepts regarding the pathophysiology of HE
are that the endogenous neurotoxic substances, including ammonia: (i) escape from catabolism by the liver due both to the impaired function
of the cirrhotic liver and also to the presence of portal systemic shunting; (ii) circulate at elevated concentrations in the systemic
blood flow; (iii) reach the brain through the blood-brain barrier; and (iv) impair cerebral function leading to disturbances of consciousness.
See&nbsp;<i>Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability.</i>&nbsp;William
A. Kinney, Mark E. McDonnell, Hua Marlon Zhong, Chaomin Liu, Lanyi Yang, Wei Ling, Tao Qian, Yu Chen, Zhijie Cai, Dean Petkanas, and Douglas
E. Brenneman &nbsp;ACS Med. Chem. Lett., 2016, 7 (4), pp 424428.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">The majority
of these toxins are produced in the intestine by the bacterial flora, and are absorbed into the portal venous flow. In spite of improved
therapeutic options for encephalopathy, the long-term survival is still low. Thus, HE remains a serious complication of liver cirrhosis.
We believe that the establishment of truly effective prevention modalities and broader application of liver transplantation will help
rescue patients suffering from this complication of liver cirrhosis in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">According to an article
published in the British Journal of Pharmacology Research, studies conducted over the past decade has produced substantial behavioral
and histochemical evidence demonstrating the effectiveness of certain Cannabis-derived molecules such as CBD in the improvement of brain
and liver function in fulminant hepatic failure. Findings include reversal of locomotors and cognitive pathologies, reversal of structural
changes such as Alzheimers Type II astrogliosis, and reversal of increases in ammonia levels. Beyond the supportive preclinical
evidence, multiple factors provide reasons for enthusiasm in the pursuit of the HE indication:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><b>New mechanism of action</b>: Cannabinoids, if shown effective
in clinical trials, would provide a new mechanism of action, and thus be an incremental clinical tool to combine with existing treatments.
This combination of mechanisms of action could lead to additive or synergistic effects. Existing treatment methods, such as lactulose,
Rifaximin and others under study (e.g., AST-120), manage symptoms by reducing ammonia uptake in the digestive system. However, once blood
ammonia levels have increased, they putatively provide limited benefits. Cannabinoids, instead, act in the central nervous system ameliorating
the downstream pathological effects of ammonia.</span></td>
</tr></tbody></table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Multiple preventive benefits:</b>&nbsp;According to National
Institute of Health, pre-clinical studies have shown that CBD, the major constituent in our intended lead target drug molecule and candidate,
may provide benefits in the secondary prevention of HE.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 72px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Steatosis:&nbsp;<i>In vitro</i>&nbsp;studies have shown CBD to reverse the histopathology associated with steatosis or fatty liver syndrome. This is particularly relevant because fatty liver is a major cause of liver cirrhosis, and has no current drug-based treatment. In addition, multiple currently marketed drugs are known to induce steatosis. These include steroids (e.g., triamcinolone, cortisone, prednisone), the anti-cancer drug Tamoxifen (a breast cancer drug), HIV anti-retrovirals and anti-arrythmic drug Amiodarone.&nbsp;</span></td></tr>
  </tbody></table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 72px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">o</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fibrogenesis: Animal studies have shown that endocannabinoids are involved in the regulation of fibrogenesis in the liver. CB2 -/- mice show increased fibrogenesis in response to CCl4 injection, whereas CB1 -/- mice have decreased hepatic fibrogenesis. This suggests an opportunity to modulate fibrogenesis, a critical intermediate step in liver cirrhosis, through a proper selection of cannabinoid antagonists. &nbsp;</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">HE is a
neuropsychiatric disorder that includes learning deficits and impairment of long-term memory. HE can be caused by chronic and excessive
ethanol ingestion along with the accumulation of toxic substances that are normally removed by the liver. The pathogenesis of HE in the
central nervous system includes damage to the pre-limbic cortex, striatum and the hippocampus, and this pathology is believed to be mediated
by the accumulation of free radicals and oxidative stress. HE has primary epidemiological precursors in cirrhosis, hepatitis B, hepatitis
C, and portal hypertension. The incidence rate of HE among alcohol induced cirrhosis patients is as high as 45%, making HE a leading opportunistic</span>&nbsp;disease
stemming from alcoholism. If left unchecked, HE can progress to hepatic&nbsp;<span style="background-color: white">coma and ultimately
death. The pathogenesis of HE includes damage to the prelimbic cortex, striatum, and the hippocampus. HE is caused by accumulation of
toxic substances in the bloodstream that are normally removed by the liver.</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">It has been
previously demonstrated that impairment of hepatocytes by ethanol is associated with the production of free radical and oxidative stress.
The accumulation of these free radicals and oxidative stress contribute to cognitive impairment, learning deficits, memory impairment,
as well as damage and death of neuronal tissue. An emerging concept is that blockade of free radical mediated stress and oxidative stress
will prevent the neural damage associated with hepatic encephalopathy and prevent cognitive impairment, learning deficits, memory impairment,
as well as damage and death of neuronal tissue associated with OHE.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Currently
in the United States, there are over 1.5 million sufferers of HE across four stages, including approximately 121,000 patients hospitalized
each year from the </span>OHE stage of the disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Cannabidiol (CBD) vs. KLS-13019 in Overt Hepatic
Encephalopathy </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In a publication in American Chemical Society&nbsp;<span style="background-color: white">Medicinal
Chemistry Letters on February 10, 2016, our abstract read as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Cannabidiol
is the nonpsychoactive natural component of C. sativa (cannabis sativa) that has been shown to be neuroprotective in multiple animal models.
Our interest is to advance a therapeutic candidate for the orphan indication overt hepatic encephalopathy (OHE). OHE is a serious neurological
disorder that occurs in patients with cirrhosis or liver failure. Although cannabidiol&nbsp;</span>has shown evidence in a murine model
to be a potentially effective treatment for OHE<span style="background-color: white">, it has limitations in terms of safety and oral
bioavailability. Herein, we describe a series of side chain modified resorcinols that were designed for greater hydrophilicity and drug
likeness, while varying hydrogen bond donors, acceptors, architecture, basicity, neutrality, acidity, and polar surface area within
the pendent group. Our primary screen evaluated the ability of the test agents to prevent damage to hippocampal neurons induced by ammonium
acetate and ethanol at clinically relevant concentrations. Notably, KLS-13019 was 50-fold more potent and &gt;400-fold safer than cannabidiol
and exhibited an in vitro profile consistent with improved oral bioavailability.</span>&nbsp;&nbsp;</p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">CBD has
been shown to be neuroprotective by blocking the damage caused by free radicals and oxidative stress. This effect was independent of cannabinoid
receptors because it could not be blocked by a cannabinoid antagonist. CBD&nbsp;</span>has shown evidence in two murine models to be a
potentially effective treatment for HE,<span style="background-color: white">&nbsp;thioacetamide induced and bile duct ligation induced
liver damage, at a dose of 5 mg/kg IP (intraperitoneal injection). Importantly, CBD treated animals in the first study exhibited improvements
in both liver and brain function as compared to untreated control animals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Free radical
mediated stress and oxidative stress are also known to contribute to additional pathological conditions including epilepsy, neuropathic
pain, traumatic head injury, stroke, CTE, and neurodegenerative diseases such as Parkinsons disease, Alzheimers disease,
Huntingtons disease, and ALS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Other examples
of neuroprotection by CBD include use in hypoxia-ischemia and stroke models. A wide range of possible mechanisms have been attributed
to CBDs neuroprotective effects including antioxidant, anti-inflammatory, adenosine signaling, cannabinoid receptor GPR55 (G Protein-coupled
receptor 55), and serotonin mediated pathways; however, mitochondrial calcium modulation is fundamental. The GPR55 receptor is a G protein
receptor in humans that is encoded by the GPR55 gene. The GPR55 receptor has been identified as a novel cannabinoid receptor. Receptors
are sensing molecules which communicate signals between cells to illicit physiological changes in the body. To hedge our bets, we chose
to interrogate the hippocampal neuron, as a phenotypic screen that will measure neuroprotection independent of a mechanism.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Target 2: Chronic Traumatic Encephalopathy
(CTE) &nbsp;$2+ Billion Market in the U.S.&nbsp;</b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Not unlike OHE, CTE is a neuro-degenerative disease
of the brain and is associated with repeated head traumas like concussions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">CTE is a form of encephalopathy that is a progressive
neuro-degenerative disease, which can only be definitively diagnosed postmortem, in individuals with a history of multiple concussions
and other forms of head injury. The disease was previously called dementia pugilistica (DP), as it was initially found in
those with a history of boxing. CTE has been most commonly found in professional athletes participating in American football, ice hockey,
professional wrestling and other contact sports who have experienced repetitive brain trauma.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">It has also been found in soldiers exposed to
a blast or a concussive injury, in both cases resulting in characteristic degeneration of brain tissue and the accumulation of tau protein.
Individuals with CTE may show symptoms of dementia, such as memory loss, aggression, confusion and depression, which generally appear
years or many decades after the trauma. Repeated concussions and injuries less serious than concussions (sub-concussions)
incurred during the play of contact sports over a long period can result in CTE. In the case of blast injury, a single exposure to a blast
and the subsequent violent movement of the head in the blast wind can cause the condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The primary physical manifestations of CTE include
a reduction in brain weight, associated with atrophy of the frontal and temporal cortices and medial temporal lobe. The lateral ventricles
and the third ventricle are often enlarged, with rare instances of dilation of the fourth ventricle.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other physical manifestations of CTE include pallor
of the substantia nigra and locus ceruleus, and atrophy of the olfactory bulbs, thalamus, mammillary bodies, brainstem and cerebellum.
As CTE progresses, there may be marked atrophy of the hippocampus, entorhinal cortex, and amygdala.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On a microscopic scale, the pathology includes
neuronal loss, tau deposition, TAR DNA- binding Protein 43 (TDP 43) beta-amyloid deposition, white matter changes, and other abnormalities.
The tau deposition occurs as dense neurofibrillary tangles (NFT), neurites, and glial tangles, which are made up of astrocytes
and other glial cells Beta-amyloid deposition is relatively uncommon feature of CTE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A small group of individuals with CTE have chronic
traumatic encephalo-myopathy (CTEM), characterized by motor neuron disease symptoms, which mimics ALS, also known as Lou
Gehrigs disease. Progressive muscle weakness and balance and gait problems seem to be early signs of CTEM.</p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Target 3: Chemotherapy Induced Peripheral Neuropathy
(CIPN) &nbsp;$3+ Billion Market in U.S.</b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In December 2016, as part of a Small Business
Technology Transfer (STTR) program, we, together with Temple University, filed an STTR grant proposal with the National
Cancer Institute (NCI) to demonstrate improved in vivo efficacy of an orally administered KLS-13019, our lead target drug
candidate, in a head-to-head comparison to intraperitoneal injection (IP Injection) of CBD in a model of chemotherapy-induced
peripheral neuropathy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">At the conclusion of Phase I STTR application,
we hope to demonstrate that KLS-13019 (Per os &nbsp;taken through the mouth) can control mechanical sensitivity and inflammation
associated with CIPN in the absence of tolerance development, and also reduce opioid craving behavior with comparable efficacy to CBD
(intraperitoneal injection). In Phase II STTR, we will investigate a back-up series and will execute the CMC, pharmacokinetic, safety
pharmacology, and toxicology assessments required for IND filing on KLS-13019.&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A visual image of the chemical structure of cannabidiol
and KLS-13019 can be seen as follows, along with selected data describing EC<sub>50</sub>&nbsp;(the concentration of a drug that give
half-maximum response), Safety Margin (pre-clinical toxicity), and Bioavailability (seen as F):</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_009.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_009.jpg"></b></span></td>
    <td style="width: 50%; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_010.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_010.jpg"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b></b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">KLS-13019 does not contain
CBD and is a new chemical entity that would not fall under the CSA be deemed a Schedule 1 controlled substance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">KLS-13023 is a formulation
that does contain CBD. At present, CBD is deemed a Schedule 1 controlled substance by the DEA under the Controlled Substances Act. Like
the drug molecule Epidiolex, which was recently approved by the FDA for marketing and sale for use in treating Dravets
Syndrome and Lennox-Gasteau Syndrome (forms of child epilepsy), KLS-13023 would need to follow the guidance set forth by the CSA, complete
a successful human clinical trial and apply for rescheduling, as was the case with Epidiolex, now a Schedule 5 drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We currently plan on using KLS-13019 as our lead
target drug candidate for the treatment of CIPN.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The treatment of CIPN is a priority therapeutic
opportunity because, to date, no one drug or drug class is considered to be safe and effective in this disabling disease. Tricyclic antidepressants
are often the first choice in most patients, but are associated with significant side effects including sedation and cardiovascular complications
as well as marginal efficacy (Wolf et al 2008). Anticonvulsants, despite their efficacy in animal models of CIPN, are only partially effective
in the majority of patients (Bosnjak et al 2002).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Even more problematic, upwards of 80% of CIPN
patients report using prescription opioids for pain management despite lacking strong evidence for efficacy and increasing safety concerns
in the face of the current devastating opioid epidemic. The exact mechanism of CIPN has not been fully elucidated and can differ across
classes of chemotherapeutic agents. It is therefore necessary to identify novel therapies to prevent or treat CIPN that target one or
more of these putative mechanisms. Recently, there has been a resurgence in interest in the potential medical utility of the cannabis
plant and its constituents, and mechanism-based basic research is warranted to develop safe and effective cannabinoid-based pain treatments.
CBD is a non-psychoactive component of Cannabis sativa that is neuroprotective, independent of cannabinoid receptors (Hampson 1998).</p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prior studies at Temple University revealed that
CBD prevents the development of paclitaxel-induced mechanical sensitivity in mice in vivo (Ward et al 2011, 2014). Additionally, CBD attenuates
morphine reward and heroin seeking behavior in animal models (Ren, Whittard et al. 2009; Katsidoni, Anagnostou et al. 2013) and a small
trial in humans suggests attenuation of heroin craving in humans (Hurd, Yoon et al. 2015). However, CBD has limitations in terms of potency,
safety, and oral bioavailability. We believe that we may be able to address these problems in our fully owned series of side chain modified
derivatives, which have been protected in a non-provisional patent application WO2015/106108A2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">One of the molecules covered by the patent is
KLS-13019, which in pre-clinical studies, including PK studies, has shown evidence of improved in vitro efficacy, improved safety, and
improved oral bioavailability over CBD in side by side preclinical evaluation, and is not a controlled substance. (Pharmacological Comparisons
Between Cannabidiol and KLS-13019, Journal of Molecular Neuroscience, 14 August 2018)</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Preliminary Effects of KLS-13019 in CIPN model:&nbsp;</b>In
a preliminary study, we treated eight mice with saline and sixteen mice with paclitaxel (Days 1, 3, 5, and 7, 8.0 mg/kg IP). Half of
the paclitaxel-treated mice were pretreated with KLS-13019 (2.5 mg/kg IP) and half were pretreated with its vehicle alone. On days 9,
14, and 21 post initiation of injections, mechanical sensitivity was tested using von Frey filaments and compared with baseline sensitivities
prior to treatment (Fig. 3). One-way ANOVA revealed a significant effect of KLS-13019 on Day 14 to prevent the development of paclitaxel-induced
mechanical sensitivity [F<sub>(2, 21)</sub>&nbsp;= 4.67, p&lt;0.05]. Dunnetts multiple comparisons test revealed a significant
difference between the saline and paclitaxel treated groups, but not between the saline and KLS-13019+paclitaxel treated groups. Preliminary
flow cytometry results with pooled cords from three mice in each group revealed that paclitaxel-treated mice had increased numbers of
CD4+ T cells and microglia in the whole spinal cord, and that this increase is prevented by KLS-13019 treatment.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>E1. Aim 1. Research Plan. Determine target
for the neuroprotective actions of CBD and KLS-13019.&nbsp;</b>As mentioned above, DRG neurons are a primary cytotoxic target of chemotherapeutic
agents. In addition, spinal microglia have been heavily implicated in the development and maintenance of neuropathic pain and have shown
to become activated in animal models of CIPN.&nbsp;<i>At the conclusion of Aim 1, we intend to demonstrate that the neuroprotective properties
can be reduced by pharmacological or gene knock-down of a relevant target in a statically significant manner.</i>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>E2. Aim 2. Assess KLS-13019, CBD, and morphine
against paclitaxel-induced peripheral neuropathy.&nbsp;</b><i>At the conclusion of Aim 2, we intend to have demonstrated that KLS-13019
performs as well as CBD (ip and po) against CIPN and CNS inflammation and shows no antinociceptive tolerance as compared to morphine.&nbsp;</i>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>CIPN procedure:&nbsp;</b>Experiments are designed
to test the efficacy of novel CBD analogues in attenuating established mechanical sensitivity and inflammation associated with CIPN. Dr.
Wards laboratory has been using the CIPN procedure for ten years and has demonstrated that CBD treatment can both prevent the development
of (Ward et al 2011, 2014) and reverse established (King et al in revision,&nbsp;<i>British Journal of Pharmacology</i>) CIPN in mouse
models. CBD and KLS-13019 and their vehicle controls will be tested in groups of mice treated with paclitaxel (8.0 mg/kg IP, days 1, 3,
5 and 7). Testing of each dose for each molecule will require a final sample size of eight. Molecules will be administered daily for three
weeks, starting on Day 11 when peak mechanical allodynia has already been achieved. In the initial study, CBD (0.05 - 5 mg/kg ip) will
be compared with three doses of KLS-13019 (e.g., 0.05, 0.5 and 5 mg/kg ip) and three doses of morphine (1.0 &nbsp;10 mg/kg ip;
Neelakantan et al 2016). This will be followed by a study in which KLS-13019 will be assessed at three oral doses. In preliminary studies,
we have dosed the mice with KLS-13019 (2.5 - 5 mg/kg ip) with no adverse effects. In addition, KLS-13019 was shown to produce no impairment
in the mouse rotorod test at 100 mg/kg po in studies conducted at the Anticonvulsant Screening Program (NIH).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Neuroinflammation assessment:&nbsp;</b>Immunohistochemistry
and flow cytometry will run in the PIs laboratory to evaluate markers of pain and inflammation associated with neuropathic pain, including
astrocytic and microglial activation, CGRP, and T cell infiltration. Given the fact that we are observing CNS infiltration of T cells
that is reversed by treatment with KLS-13019, cranial windows will be surgically implanted (as described in Ni, Tuma et al 2004) in additional
groups of vehicle or KLS-13019 + paclitaxel treated mice prior to treatment to longitudinally assess the effect of paclitaxel with or
without cannabinoid treatment on leukocyte rolling and adhesion across the development of CIPN.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>E2. Aim 3.Assess KLS-13019 and CBD against reinstatement
of morphine seeking.&nbsp;</b><i>At the conclusion of Aim 3, we intend to have demonstrated that KLS-13019 attenuates opioid-seeking
behavior as well as CBD.</i></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Morphine Reinstatement:&nbsp;</b>The Principal
Investigator has 20 years of experience with behavioral assays with specific expertise in rodent models of substance abuse, including
opioid self-administration. A standard rat model of morphine seeking will be used (Vassoler et al 2017) wherein rats make lever presses
to receive infusions of morphine. Rats will be surgically implanted with chronically indwelling jugular catheters and trained to self-administer
morphine (0.75 mg/kg/inf) in the presence of auditory and visual cues daily for 20 days, followed by 10 days of extinction wherein the
morphine is replaced with saline and the conditioned cues are eliminated. During the last three days of extinction, rats will be treated
with vehicle, CBD (5.0 mg/kg IP), or KLS-13019 (0.5 &nbsp;5.0 mg/kg IP). The following day rats will be exposed to a single reinstatement
session wherein lever presses are again paired with auditory and visual cues but saline is delivered instead of morphine. This experimental
design is based on Ren et al 2009 results with CBD on cue-induced reinstatement of heroin seeking in rats.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Status of Phase 1 STTR Grant Research</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 4, 2017, we applied for a Phase 1 Small
Business Technology Transfer (STTR) grant from the NIH-NIDA. This grant application was made in collaboration with Temple
University and titled Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence. In December
2017, we were informed that the Phase 1 grant was awarded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have completed all of our work related to the aforementioned
grant and are currently in a peer review submission of our research results to the Journal of Molecular Neuroscience. Temple University
has completed all three aims outlined in the grant proposal.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 31, 2019, we, together with Temple
University, filed a completion report with NIH-NIDA regarding the Phase 1 STTR grant. The results of this study were promising and have
set forth our plans to file for a Phase 2 grant due for filing on or before April 7, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In April 2020, the Company and Temple University
filed for a Phase 2 SBIR Grant with National Institutes of Health  National Institute of Neurological Disorders and Stroke (NIH-NINDS).
Our application provided strong support to further the research and development of our treatment for CIPN. &nbsp;<span style="background-color: white">Phase
2&nbsp;is focused on the development, demonstration and delivery of the innovation. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In June 2020, the Company was informed that its
Phase 2 SBIR grant application received an impact/priority score of 47. Generally speaking, impact/priority scores of 10 to 30 are most
likely to be funded. Scores between 31 and 45 might be funded; scores greater than 46 are rarely funded. The Company believed that there
were elements of its initial Phase 2 SBIR grant application that were misunderstood and believed it still had a very strong application.
After making several critical changes to the original application, in January 2021, the Company resubmitted its Phase 2 SBIR grant application
with NIH-NINDS and currently awaits response from NIH-NINDS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 10, 2021, we were
notified that our resubmitted application received a summary review and impact/priority score of 20, which is considered by many to be
exceptional and rare. This impact/priority score and summary attests to the novelty and advancement of our scientific discovery with KLS-13019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 28, 2021, the Company received a
notice of award for a $2.97 million Phase 2 STTR Study Grant from the National Institutes of Health  National Institute of Neurological
Disorders and Stroke under the HEAL Initiative (the NIH-NINDS Study Grant Award). The NIH-NINDS Study Grant Award is funded
through the NIH HEAL Initiative (Helping End Addiction Long-Term) for Development of Therapies and Technologies Directed
at Enhanced Pain Management. This NIH-NINDS Study Grant Award provides funding specifically in the further development of KLS-13019 for
the treatment of chemotherapy induced neuropathic pain (CIPN). The grant award of $2.97 million sets forth the funding allocation
of $977,054 in year 1; $991,944 in year 2; and $1,001,774 in year 3 and collectively budgets investigational new drug (IND)
application enabling studies. IND enabling studies to be performed, include but are not limited to animal toxicity studies and drug compound
scale up studies under chemistry manufacturing and controls. The NIH-NINDS Study Grant Award budget includes studies to be performed at
Temple University; the University of Illinois; and Purisys (formerly, Noramco).</p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Reduction in Addiction Based Opiate Dependency
 HEAL</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">According to statistics compiled by the National
Institutes of Health for the HEAL Initiative (Helping End Addiction Long-term), <span style="background-color: white">the public health
crisis of opioid misuse and addiction in America is rapidly evolving. More than 47,000 Americans died of opioid overdose in 2017,and
more than 2 million Americans live with addiction to opioids. Moreover, more than 50 million Americans suffer from chronic pain, and&nbsp;of
those, 25 million live with daily chronic painand lack effective and safe non-opioid options for pain management. The widespread
use of opioids to treat acute and chronic pain contributed to the approximately 10.3 million people aged 12 years and older in the United
States in 2018 who misused opioids,&nbsp;including heroin.&nbsp;These staggering numbers are likely underestimates. They fail to capture
the full extent of the damage of the opioid crisis, which reaches across every domain of family and community life  from lost productivity
and economic opportunity,&nbsp;to intergenerational and childhood trauma,&nbsp;to extreme strain on community resources, including first
responders, emergency rooms, hospitals, and treatment centers. With the full support of the administration, NIH launched the&nbsp;Helping
to End Addiction Long-term&nbsp;Initiative, or&nbsp;NIH HEAL Initiative, to provide scientific solutions to theopioid crisis and
offer new hope for individuals, families, and communities affected by this devastating crisis.&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>NIH-NINDS HEAL Initiative</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Launched in April 2018,
the&nbsp;<span style="text-decoration: underline">NIH</span>&nbsp;Helping to End Addiction Long-term (HEAL) Initiative is an aggressive, trans-agency effort to speed scientific
solutions to stem the national opioid public health crisis.&nbsp;The Initiative will advance research to reduce the risks of opioid use
and misuse and improve pain management, thereby reducing reliance on opioids. NINDS is the lead Institute for pain research at NIH and
leads the Executive Committee of the&nbsp;<span style="text-decoration: underline">NIH Pain Consortium</span>,&nbsp;which includes 23 Institutes and Centers. The NIH Pain Consortiums
mission includes improving the treatment of a variety of pain conditions. NINDS will focus efforts in the&nbsp;<span style="text-decoration: underline">NIH HEAL Initiative</span>&nbsp;in
developing non-addictive pain treatments that may displace the need for opioids, and importantly, serve as effective treatments for acute
and chronic pain conditions for which opioids are not effective. This work will be informed by partners from the government, industry,
academia, and patients suffering from pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>Research on Pain and
Next Generation Analgesics</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Although opioid medications effectively
treat acute pain and help relieve chronic pain for some patients, their addiction risk presents a dilemma for healthcare providers who
seek to relieve suffering while preventing drug abuse and addiction. Little is yet known about the risk for addiction among those being
treated for chronic pain or about how basic pain mechanisms interact with prescription opioids to influence addiction potential. To better
understand this, NIDA launched a research initiative on Prescription Opioid Use and Abuse in the Treatment of Pain. This
initiative encourages a multidisciplinary approach using both human and animal studies to examine factors (including pain itself) that
predispose or protect against opioid abuse and addiction. Funded grants cover clinical neurobiology, genetics, molecular biology, prevention,
treatment, and services research. This type of information will help develop screening and diagnostic tools that physicians can use to
assess the potential for prescription drug abuse in their patients. Because opioid medications are prescribed for all ages and populations,
NIDA is also encouraging research that assesses the effects of prescription opioid abuse by pregnant women, children, and adolescents,
and how such abuse in these vulnerable populations might increase the lifetime risk of substance abuse and addiction.&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>PRIMARY TARGETS FOR TOPICAL MEDICAMENTS AND
MARKET SIZE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has completed
formulation of a topical relief cream containing LEA<span style="font-family: Symbol"></span> as the active pharmaceutical ingredient
for use as an OTC cosmetic skin care product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since mid 2019, the Company has been screening
and conducting preliminary research and development of some of its patented, proprietary cannabidiol-derived new chemical entities (NCEs),
for use as topical solutions, ointments, and creams for disorders such as diabetic neuropathies, diabetic ulcers, and for use as an anti-pruritic.
(see: Business &nbsp;Neuropathix Intellectual Properties)&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In preclinical testing,
certain molecules under Patent 9,611,213 were screened for neuroprotection and may have the potential mechanism of action for reducing
inflammation and neuropathic pain. These molecules indicate that they are more soluble than cannabidiol, also deemed a neuroprotectant
with potential anti-inflammatory properties. A molecule that is potentially more water soluble than cannabidiol in this regard may be
good candidate(s) for use in topical applications.</p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has completed
the following relating to LEA<sup>TM</sup> (formerly, KLS-13022):</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Preclinical screening for consumer OTC cosmetic use under CFR 21.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Application to International Nomenclature of Cosmetic Ingredients (INCI) completed to receive
a compound nomenclature for KLS-13022 - Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (LEA).</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Received a registered trademark from the U.S. Patent and Trademark Office (USPTO)
for LEA<sup>TM</sup>, to be used as a branded product as a relief cream, containing LEA, to treat inflammatory disorders like eczema,
psoriasis, radiation dermatitis and excessive UVB radiation (post sun burn).</td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on preclinical testing
of LEA<sup>TM</sup> versus CBD (cannabidiol) in cultured human epidermal keratinocytes the summary of findings were as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">LEA<sup>TM</sup> provided better anti-inflammatory activity compared to CBD for TNFa, IL-6
and significantly more potent that CBD for IL-1b inhibition in UVB irradiation induced inflammation.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">LEA<sup>TM</sup> decreased CXCL5 levels by 100% after UVB irradiation with IC50 of 0.05 mM.
(CXCL5 is a small cytokine belonging to the chemokine family known as epithelial-derived neutrophil-activating peptide 78 (ENA-78). It
is produced following the stimulation of cells with the inflammatory cytokines TNFa and IL-1b.)</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">LEA<sup>TM</sup> decreases levels of four (4) inflammatory mediators at concentrations &gt;
65 times less than toxic levels.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">LEA<sup>TM</sup> is an antioxidant that does not exhibit cellular irritation and is locally
restricted in its action (antioxidant activity of EC50 at 25 mM).</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">LEA<sup>TM</sup> (3 M) was non-toxic at the highest concentration in culture media after
24 hours incubation.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Alpha-tocopherol produced a modest anti-inflammatory effect (IL-6 inhibition = 46% at 10
M).</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">LEA<sup>TM</sup> provided a maximum 95% IL-6 inhibition with IC<sub>50</sub> = 0.9 M,
suggesting a better UVA anti-inflammatory activity.</td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on these data, it was concluded
that LEA<sup>TM</sup> provided positive photoaging potential.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Franz Cell Dermal Penetration: LEA<sup>TM</sup> penetrated through the viable skin (0.87-1.13%),
the receptor solution (0.26-0.27%) and the stratum corneum (2.50-3.84%).</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Modified Draize Human Repeat Insult Patch Test (HRIPT) In 53 Health Volunteers resulted in:</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">No adverse events or reactions were reported. 4 subjects withdrew for personal reasons.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">Lighter Cream and Heavier Cream elicited no visible erythematous reactions during the induction
phase of the study.</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">There were no questionable reactions during the challenge phase (days 38 and 40), supporting
the assessment that the test articles have low potential for irritation and sensitization.</td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on these data it was
concluded that the test articles can be considered as safe for use under the conditions of the study, and claims such as, Dermatologically
Tested, Clinically Tested, Kind to Skin and Safe for Skin are substantiated.</p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Neuropathic Pain, Anti-Inflammation, Anti-Pruritic
&amp; Skin Ulcers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>Target 1: Anti-Puritics
(Anti-Itch) &nbsp;$3.85 Billion Global Market in 2019</b>&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In 2019 it is estimated
that the top ten product segments for use in U.S. pruritus therapeutics market accounted for USD$448.7 million in sales of products such
as corticosteroids and antihistamines. The global compounded annual growth rate (CAGR) is expected to be 12.5% annually,
which predicts a global market size of USD$10.97 billion by 2030, with U.S. sales estimated at USD$1.295 billion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"><b>Growing
worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast
period. The introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets,
particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to
capitalize on over the forecast period.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Corticosteroids remain
the leading product segment. Topical applications of corticosteroids have been found to be extremely effective in the treatment and maintenance
therapies pertaining to pruritus. However, according to a 2007 article in American Family Physician, <span style="color: #09142A; background-color: white">long-term
topical corticosteroid use is associated with local and systemic adverse effects that may lead to the underutilization of these effective
agents.&nbsp;Common local adverse effects include striae, petechiae, telangiectasia, skin thinning, atrophy, and worsening acne. These
effects are reported infrequently in clinical trials, although trials are primarily designed to assess effectiveness rather than safety
and tolerability. Most clinical trials of topical steroids are of short duration and, therefore, are unable to evaluate long-term toxicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Itching is a sensation that, if sufficiently
strong, will provoke scratching or the desire to scratch. It is a frequent and distressing symptom of various dermatological and systemic
diseases. It can also occur in some patients without any skin symptoms. Knowledge has been accumulated about the initiation of itch by
external stimuli, but the neuronal substrate in the skin has not been completely identified. This has, fortunately, changed to some degree
since a group of histamine-sensitive C-fibers were recently identified, which likely represent the afferent units that mediate itch sensations.
Histamine, derived from mast cells, is the best known pruritogen. It induces different degrees of itching when applied in different concentrations
into the skin. In most dermatological and systemic diseases, except urticaria, histamine is not the main mediator. There are other proinflammatory
mediators to consider, such as substance P, proteases, interleukin-2, acetylcholine, vasoactive intestinal peptide (VIP) and opioid peptides.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Several key characteristics
of the anti-puritics market are set forth below:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Calcineurin inhibitor is identified as the most lucrative segment
of the market on account of high usage rate of these drugs in combination therapy for the treatment of pruritus in patients suffering
from chronic pruritus and growing market penetration rates. Moreover, the introduction of new products such as Pimecrolimus cream and
Tacrolimus ointment is expected to further drive this market.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Anti-histamines owing to its growing use as a first line treatment
and presence of drugs in pipeline with expected commercialization is also expected to grow at a healthy rate during the forecast period.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif"><b>Target 2: Anti Inflammatory<sup>&nbsp;</sup> $74 Billion
Global Market in 2019</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In a research study published
in April 2018  Global Anti-Inflammatory Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth
Trends, Key Players, Competitive Strategies and Forecasts, 2018 to 2026 the Anti-inflammatory therapeutics market projected to
US$ 130.6 Bn by 2026 with CAGR of 8.5% throughout the forecast period from 2018 to 2026. Biologics and immune selective anti-inflammatory
derivatives (ImSAIDs) are the promising drugs classes that will play the main role in the market. Global anti-inflammatory therapeutics
market from 2018-2026 study is based on exhaustive analysis with insights from industry stakeholders. The detailed study incorporates
the market landscape and its growth scenarios for the forecasting period from 2018-2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">According to World Health
Organization (WHO), around 235 million individuals experience the ill effects of asthma around the globe. Symptomatic help amid the inflammation
gives alleviation to the patients suffering from inflammatory diseases. In spite of the fact that there are numerous anti-inflammatory
drugs present in the market, still, there is an essential requirement for better and novel anti-inflammatory therapeutics drugs with slighter
side effects and improved efficacy.</p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Based on the drug types,
the global anti-inflammatory therapeutics market is segmented into biologics, corticosteroids, immune selective anti-inflammatory derivatives
(ImSAIDs), and non-steroidal anti-inflammatory drugs (NSAIDs); additionally, the indication studied in this report are categorized into
COPD, multiple sclerosis, IBD, psoriatic arthritis, gout, and Others (Osteoarthritis, Systemic Lupus, Psoriasis). Rising prevalence of
inflammatory diseases and the strong drug pipeline would additionally boost the anti-inflammatory therapeutics market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In addition, they are
also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by
factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In 2014, AstraZeneca
had five anti-inflammatory drugs in the final stages of drug development. These drugs are lesinurad, sifalimumab, anifrolumab, mavrilimumab
and brodalumab. The companies have filed new patents to overcome the issues of patent expiries of their existing drugs, and to gain a
prominent market share. The key companies profiled in this report include Pfizer, Inc., Abbvie, Inc., Johnson &amp; Johnson, GlaxoSmithKline,
Merck &amp; CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Target 3: Atopic Dermatitis / Eczema &nbsp;$3+
Billion Market in North America in 2020</b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">In a research study published
in February 2020  North America Atopic Dermatitis Treat Market Research Study  the size of the atopic dermatitis treatment
market in North America is valued at USD$2.95 billion in 2020 and is expected to grow at a CAGR of 13.4% to reach USD$5.52 billion by
2025. Atopic dermatitis is an inflammatory skin disease. The degree of its severity varies from patient to patient. It usually begins
in childhood and is mostly confined to flexural surfaces of the body. It is highly prevalent. It is more commonly known as eczema. Itching,
redness of skin, cracking, and weeping are symptoms of it. It is a long term disease. Low humidity, cold weather, seasonal allergies
are the common causes of it. Pattern of the disease and its severity determine the kind of treatment a patient with eczema is to receive.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>The Eczema Therapeutics
Market is Dominated by Topical Corticosteroids (TCSs)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Current competition in
the eczema therapeutics market contains conventional forms of therapy such as topical corticosteroids, topical immunomodulators and emollients
as the most prominent therapies. Among all the available treatment options, topical corticosteroids hold a large share and dominate the
market. Topical corticosteroids are available in various strengths (mild, moderate, potent and very potent) and formulations (ointment,
cream, lotion and many more), so that they can be used according to the severity of eczema. Calceurin inhibitors (Protopic (tacrolimus)
and Elidel (pimecrolimus)) showed higher efficacy in comparison to corticosteroids and these products were widely used after their respective
launches. However, in 2005 the FDA issued black box warnings for the calceurin inhibitors (Protopic and Elidel), which has resulted in
declining sales of these products. Emollients have good efficacy as well as good safety. They hydrate, moisturize and repair the skin.
These products do not offer first line treatment, but they are useful as maintenance therapy in eczema patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>Significant Unmet
Need in Eczema Therapeutics Market Could Drive Market</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Eczema is a chronic condition
characterized by frequent relapses known as flare-ups. The market has various products that are effective, but their safety profile is
not always satisfactory, leaving a significant unmet need in the market. The unmet need is also a result of the lack of effective treatment
options for severe conditions; the need for a controlled and targeted drug delivery system; low patience compliance and the black box
warnings issued to Elidel and Protopic. The unmet need in eczema therapeutics could be filled by a new entrant with a better safety profile,
enhanced patient compliance, and competitive pricing with respect to the available products.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Target 4: Psoriasis &nbsp;$5+ Billion
Market in North America</b>&nbsp;<b>in 2019</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Psoriasis
is a common chronic skin disorder. It is also associated with several comorbidities, such as obesity, hypertension, psoriatic arthritis,
depression, and diabetes. Psoriasis is characterized by skin flares and inflammation that vary in severity, from minor localized patches
to substantial body surface involvement. Around 20% of diagnosed patients have moderate to severe psoriasis. In 2019 in the United States,
psoriasis was a $8.48 billion market, of which 90% are from drugs targeting moderate to severe psoriasis patients where the skin manifestation
affects more than 3% of the body. See&nbsp;<i>Treatment of Psoriasis in Adults</i>&nbsp;&nbsp;Steven R. Feldman, MD, PhD, August
24, 2018. For such patients, psoriasis is often a debilitating condition impacting their quality of life and psychological well-being.
Over the past decade, biologics have altered the landscape in the management of moderate to severe psoriasis by achieving improved skin
clearance, control of symptoms and quality of life for hundreds of thousands of individuals affected.</span></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Psoriasis
is linked to pathogenesis caused by dysregulation of T-cell-dependent immune response, as well as hyperproliferation of keratinocytes,
the predominant cell type on the outer layer of skin. Biologics target the cytokines usually upregulated as a result of the abnormal immune
response. </span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">&nbsp;</span><b>Target
5: Diabetic Foot Ulcers &nbsp;$3+ Billion Market in U.S.</b>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">The market
for Diabetic Foot Ulcers in the U.S. is $3+ billion and growing. There are 29 million people living with diabetes and 86 million pre-diabetics
in the U.S. Approximately 25% of diabetics will acquire a non-healing ulcer in their lifetime, which equates to approximately 3 million
diabetic ulcers annually. Diabetic foot ulcers lead to over 73,000 amputations annually at a cost that is estimated to exceed $5 billion
annually. Hospitalization costs are approximately $20,000 per patient with diabetic foot ulcers and $70,000 for an amputation. The global
numbers are more startling. 400 million people are currently living with diabetes worldwide and that number is expected to increase to
approximately 600 million by 2035.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The current approach to treating diabetic foot
ulcers requires offloading the wound by using appropriate therapeutic footwear,<sup>&nbsp;</sup>daily saline or similar dressings to provide
a moist wound environment,<sup>&nbsp;</sup>debridement when necessary, antibiotic therapy if osteomyelitis or cellulitis is present,<sup>&nbsp;</sup>optimal
control of blood glucose, and evaluation and correction of peripheral arterial insufficiency. Wound coverage by cultured human cells<sup>&nbsp;</sup>or
heterogeneic dressings/grafts, application of recombinant growth factors,<sup>&nbsp;</sup>and hyperbaric oxygen treatments also may be
beneficial at times, but only if arterial insufficiency is not present. Among people with diabetes, most severe foot infections that ultimately
require some part of the toe, foot or lower leg to be amputated start as a foot ulcer. See&nbsp;<i>Diabetic Ulcers Treatment &amp; Management</i>,
V.L. Rowe, MD, R. Khardori MD, PhD, FACP, Medscape, March 12, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white">Foot ulcers are especially common in people
who have one or more of the following health problems:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Peripheral neuropathy.</b>&nbsp;This is nerve damage in
the feet or lower legs. Diabetes is the most common cause of peripheral neuropathy. When nerves in the feet are damaged, they can no
longer warn about pain or discomfort. When this happens, tight-fitting shoes can trigger a foot ulcer by rubbing on a part of the foot
that has become numb. People with peripheral neuropathy may not be able to feel when they've stepped on something sharp or when they
have an irritating pebble in their shoes. They can injure their feet significantly and never know it, unless they examine their feet
routinely for injury.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Many elderly people and
diabetics with vision problems also can't see their feet well enough to examine them for problems.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Circulatory problems.</b>&nbsp;Any illness that decreases
circulation to the feet can cause foot ulcers. Less blood reaches the feet, which deprives cells of oxygen. This makes the skin more
vulnerable to injury, and it slows the foots ability to heal.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Poor circulation in the leg arteries
is called peripheral artery disease. It also causes pain in the leg or buttock during walking. It is caused by atherosclerosis. This
is a disease in which fatty deposits of cholesterol build up inside arteries.&nbsp;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Abnormalities in the bones or muscles of the feet.</b>&nbsp;Any
condition that distorts the normal anatomy of the foot can lead to foot ulcers. This is particularly true if the foot is forced into
shoes that dont fit the foots altered shape. Examples are claw feet, feet with fractures, and cases of severe arthritis.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">More than any other group,
people with diabetes have a particularly high risk of developing foot ulcers. This is because the long-term complications of diabetes
often include neuropathy and circulatory problems. Without prompt and proper treatment, a foot ulcer may require hospital treatment. Or,
it may lead to deep infection or gangrene and amputation.&nbsp;</p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Governmental Regulations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Manufacturing</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Although we would be
reliant upon the manufacturing of our target drug candidates and API from well-established manufacturers, manufacturers of therapeutic
products and their facilities are subject to continual review and periodic inspections by the FDA, the EMA and other comparable foreign
regulatory authorities for compliance with current good manufacturing practices (cGMP) regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Further, manufacturers of controlled
substances must obtain and maintain necessary DEA and state registrations and registrations with applicable foreign regulatory authorities
and must establish and maintain processes to ensure compliance with DEA and state requirements and requirements of applicable foreign
regulatory authorities governing, among other things, the storage, handling, security, recordkeeping and reporting for controlled substances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">If we or a regulatory
agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems
with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility
or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates
or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency
may, among other things:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">issue untitled letters or warning letters;</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">mandate modifications to promotional materials or require us to provide corrective information
to healthcare practitioners;</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">require us to enter into a consent decree, which can include imposition of various fines,
reimbursements for inspection costs, required due dates for specific actions and penalties for non-compliance;</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">seek an injunction or impose civil or criminal penalties or monetary fines;</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">suspend or withdraw regulatory approval;</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">suspend any ongoing clinical trials;</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">refuse to approve pending applications or supplements to applications filed by us;</td>
</tr></tbody></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify">or require us to initiate a product recall.</td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; background-color: white">The occurrence of any event or penalty described
above may inhibit our ability to commercialize our product candidates and may otherwise have a material adverse effect on our business,
financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Regulation of CBD</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">KLS-13023 contains controlled
substances as defined in the CSA. Controlled substances that are pharmaceutical products are subject to a high degree of regulation under
the CSA, which establishes, among other things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import,
export and other requirements administered by the DEA. The DEA classifies controlled substances into five schedules: Schedule I, II, III,
IV or V substances. Schedule I substances, by definition, have a high potential for abuse, have no currently accepted medical use
in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United
States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances
considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among
such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement
quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II drugs is further restricted. For example,
they may not be refilled without a new prescription.</p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">While cannabis is a Schedule
I controlled substance, products approved for medical use in the United States that contain cannabis or cannabis extracts must be placed
in Schedules II - V, since approval by the FDA satisfies the accepted medical use requirement. If and when KLS-13023 receives
FDA approval, the DEA will make a scheduling determination and place it in a schedule other than Schedule I in order for it to be prescribed
to patients in the United States. If approved by the FDA, we expect the finished dosage forms of KLS-13023 to be listed by the DEA as
a Schedule II or III controlled substance. Consequently, their manufacture, importation, exportation, domestic distribution, storage,
sale and legitimate use will be subject to a significant degree of regulation by the DEA. The scheduling process may take one or more
years beyond FDA approval, thereby significantly delaying the launch of KLS-13023. Furthermore, if the FDA, DEA or any foreign regulatory
authority determines that KLS-13023 may have potential for abuse, it may require us to generate more clinical data than that which is
currently anticipated, which could increase the cost and/or delay the launch of KLS-13023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Because KLS-13023 contains
active ingredients of cannabis, which are Schedule I substances, to conduct pre-clinical studies and clinical trials with KLS-13023 in
the United States prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA
researcher registration that will allow those sites to handle and dispense with KLS-13023 and to obtain the product from our manufacturer.
If the DEA delays or denies the grant of a research registration to one or more research sites, the pre-clinical studies or clinical trials
could be significantly delayed, and we could lose and be required to replace clinical trial sites, resulting in additional costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expect that KLS-13023 will be scheduled
as Schedule II or III, as a result of which we will also need to identify wholesale distributors with the appropriate DEA registrations
and authority to distribute the products to pharmacies and other healthcare providers, and these distributors would need to obtain Schedule
II or III distribution registrations. The failure to obtain, or delay in obtaining, or the loss of any of those registrations could result
in increased costs to us. If KLS-13023 is a Schedule II drug, pharmacies would have to maintain enhanced security with alarms and monitoring
systems and they must adhere to recordkeeping and inventory requirements. This may discourage some pharmacies from carrying the product.
Furthermore, state and federal enforcement actions, regulatory requirements, and legislation intended to reduce prescription drug abuse,
such as the requirement that physicians consult a state prescription drug monitoring program, may make physicians less willing to prescribe,
and pharmacies to dispense, Schedule II products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We may manufacture the
commercial supply of KLS-13023 outside of the United States. If KLS-13023 is approved by the FDA and classified as a Schedule II or III
substance, an importer can import for commercial purposes if it obtains from the DEA an importer registration and files an application
with the DEA for an import permit for each import. The DEA provides annual assessments/estimates to the International Narcotics Control
Board, which guides the DEA in the amounts of controlled substances that the DEA authorizes to be imported. The failure to identify an
importer or obtain the necessary import authority, including specific quantities, could affect the availability of KLS-13023 and have
a material adverse effect on our business, results of operations and financial condition. In addition, an application for a Schedule II
importer registration must be published in the Federal Register, and there is a waiting period for third party comments to be submitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Individual states have
also established controlled substance laws and regulations. Though state-controlled substance laws often mirror federal law, because the
states are separate jurisdictions, they may separately schedule our product candidates as well. While some states automatically schedule
a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial
sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the
commercial attractiveness of such product. We or our partners must also obtain separate state registrations, permits or licenses in order
to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable
regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under
federal law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We currently obtain the
API for KLS-13023 from a bulk manufacturer of pharmaceutical grade API in Switzerland. For KLS-13023, we plan to conduct Phase 1 clinical
trials in Australia, subject to applicable regulatory approval. In addition, we may decide to develop, manufacture or commercialize our
product candidates in additional countries. As a result, KLS-13023 will also be subject to controlled substance laws and regulations from
the Therapeutic Goods Administration in Australia, Health Canadas Office of Controlled Substances in Canada, and from other regulatory
agencies in other countries where we may develop, manufacture or commercialize KLS-13023 in the future. We plan to submit NDA for KLS-13023
to the FDA upon completion of all requisite clinical trials and will require additional DEA approvals at such time as well.</p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 27, 2018,&nbsp;<span style="background-color: white">the
DOJ and DEA announced that Epidiolex, the newly approved medication by the Food &amp; Drug Administration, was being placed in Schedule
V of the Controlled Substances Act, the least restrictive schedule of the CSA.</span>&nbsp;On June 26,<span style="background-color: white">&nbsp;2018,
the FDA announced it approved Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut
syndrome and Dravet syndrome, in patients two years of age and older.</span>&nbsp;<span style="background-color: white">Epidiolex contains
CBD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">The CBD
in Epidiolex is extracted from the cannabis plant and is the first FDA-approved drug to contain a purified extract from the plant. Schedule
V drugs represents the least potential for abuse.&nbsp;</span>Schedule V drugs, substances, or chemicals are defined as drugs with lower
potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Schedule V drugs
are generally used for antidiarrheal, antitussive, and analgesic purposes. Some examples of Schedule V drugs are: cough preparations with
less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Despite the approvals by the FDA and DEA for Epidiolex,
any of these foregoing factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and
successfully market KLS-13019 or KLS-13023. Moreover, because our business is almost entirely dependent upon these two product candidates,
any such setback in our pursuit of regulatory approval would have a material adverse effect on our business and prospects.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">KLS-13019 does not contain CBD and is a new chemical
entity that would not fall under the CSA or be deemed a Schedule 1 controlled substance.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">KLS-13023 is a formulation
that does contain CBD. At present, CBD is deemed a Schedule 1 controlled substance by the DEA under the CSA. Like the drug molecule Epidiolex,
which was recently approved by the FDA for marketing and sale for use in treating Dravets Syndrome and Lennox-Gasteau Syndrome
(forms of child epilepsy), KLS-13023 would need to follow the guidance set forth by the CSA, complete a successful human clinical trial
and apply for rescheduling, as was the case with Epidiolex, now a Schedule 5 drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 14, 2019, we received written notice
from the DEA Drug and Chemical Evaluation Section, as follows: Please be advised that your material meets the definition of Hemp
and is not regulated under the CSA, as long as it consists of high purity Cannabidiol (CBD) that contains approximately 0.1% delta-9-
THC. (However, if it contains more than 0.3% delta-9 THC, it is considered Marihuana and would be in Schedule 1 of the CSA).
While this notice is an official notice from the DEA regarding the scheduling of high purity CBD, we will continue to abide by the CSA
in all respects with regards to our treatment and handling of CBD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The active pharmaceutical ingredient (API)
found in KLS-13023 is highly purified pharmaceutical grade synthetic CBD produced by Purisys. Purisys has been manufacturing cannabidiol
since 2016 (DMF33223). Today, through our partnership with Purisys, we have the ability to produce on the largest commercial scale. Purisys
ultra-high purity CBD (Purisys CBD) is attractive for drug development projects and falls significantly below the 0.3% THC
limits set in the 2018 Farm Bill for use in consumer products.&nbsp;Purisys patent-protected manufacturing process produces a consistently
odorless, tasteless white powder highest-purity form of CBD that exhibits:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No heavy metals (e.g. lead) from soil; No pesticide residues;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No environmental influences on quality such as rain, sunlight
&amp; soil nutrients;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No plant impurities to remove; No microbial or mold proliferation;
and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No structural (or stereo chemical) differences exist between
an active cannabinoid ingredient manufactured by Purisys and those that are chemically extracted and isolated from plants. They are,
in effect, nature-identical.;</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif">Purisys currently has a drug master file (DMF) for its
ultra-high purity CBD with the FDA. In November 2019, Purisys received advise notice from the DEA that the Purisys CBD has been removed
from Schedule 1 of the CSA.</p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 11, 2021, the chairman of the House Judiciary
Committee, announced that the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act, introduced in 2019, which passed in the
U.S. House of Representatives in December 2020, will be re-filed in 2021, seeking ratification by the Senate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If passed by the U.S. Senate, the MORE Act would
deschedule cannabis from the Controlled Substances Act and enact various criminal and social justice reforms to cannabis, including the
expungement of prior convictions. The MORE Act also seeks to tax cannabis products at 5% to fund criminal and social reform projects,
including an Office of Cannabis Justice within the Department of Justice Office of Justice Programs responsible for administering grants
to aid communities negatively affected by the war on drugs. (See: Controlled Substances Laws and Regulations<b>)</b>.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><i>Foreign Regulatory Agencies</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>EMA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In order to market and sell our products in jurisdictions
other than the United States and the European Union, we must obtain separate marketing approvals and comply with numerous and varying
regulatory requirements. The regulatory approval process outside the United States and the European Union generally includes all of the
risks associated with obtaining FDA and EMA approval, but can involve additional testing. We may need to partner with third parties in
order to obtain approvals outside the United States and the European Union. In addition, in many countries worldwide, it is required that
the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from
regulatory authorities outside the United States and the European Union on a timely basis, if at all. Even if we were to receive approval
in the United States or the European Union, approval by the FDA or the EMA does not ensure approval by regulatory authorities in other
countries or jurisdictions. Similarly, approval by one regulatory authority outside the United States and the European Union would not
ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA or the EMA. We may not be able to file for
marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval
of our product candidates by regulatory authorities in other foreign jurisdictions, the commercial prospects of those product candidates
may be significantly diminished and our business prospects could decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Therapeutic Goods Administration (TGA)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trials conducted in Australia are subject to various
regulatory controls to ensure the safety of participants. The TGA regulates the use of therapeutic goods supplied in clinical trials
in Australia under the therapeutic goods legislation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trial sponsors must be aware of the requirements
to import, export, manufacture and supply therapeutic goods in Australia. The following avenues provide for the importation into and/or
supply in Australia of unapproved therapeutic goods for use in a clinical trial:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Clinical Trial Notification (CTN) scheme; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Clinical Trial Exemption (CTX) scheme.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">The CTN
Scheme is a notification process involving the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The Australian clinical trial sponsor must notify us of the
intent to sponsor a clinical trial involving an unapproved therapeutic good. This must take place before starting to use
the goods. The notification form must be submitted online and accompanied by the relevant fee.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We may give the sponsor of the trial written notice to provide
specified information relating to goods notified in the CTN form.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We do not evaluate any data relating to the clinical trial
at the time of submission. The Human Research Ethics Committee (HREC) reviews the scientific validity of the trial design,
the balance of risk versus harm of the therapeutic good, the ethical acceptability of the trial process, and approves the trial protocol.
The HREC is also responsible for monitoring the conduct of the trial.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The institution or organization at which the trial will be
conducted, referred to as the Approving Authority, gives the final approval for the conduct of the trial at the site, having
due regard to advice from the HREC</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">It is the responsibility of the sponsor to ensure that all
relevant approvals are in place before supplying the unapproved therapeutic goods in the clinical trial.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The CTX Scheme is an&nbsp;approval&nbsp;process
involving the following:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">A sponsor submits an application to us seeking approval to
supply unapproved therapeutic goods in a clinical trial. The application must be accompanied by the relevant fee.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We evaluate summary information about the product including
relevant, but limited, scientific data (which may be preclinical and early clinical data) prior to the start of a trial.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The HREC is responsible for considering the scientific and
ethical issues of the proposed trial protocol.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The sponsor must notify us of each trial conducted using the
unapproved therapeutic good(s) approved in the CTX application.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trials that do not involve unapproved
therapeutic goods are not subject to requirements of the CTN or CTX schemes. It is the responsibility of the Australian clinical trial
sponsor to determine whether a product is considered an unapproved therapeutic good.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trials that do not involve unapproved
therapeutic goods are not subject to requirements of the CTN or CTX schemes. It is the responsibility of the Australian clinical trial
sponsor to determine whether a product is considered an unapproved therapeutic good.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 27, 2013, the TGA approved Nabiximols
(Sativex<b>&nbsp;</b>), a pharmaceutical manufactured by GW Pharmaceuticals for its collaborator Novartis Pharmaceuticals Australia
Pty Limited, in the treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS)
who have not responded adequately to other anti-spasticity medication and who demonstrated clinically significant improvement in spasticity
related symptoms during the initial trial of therapy.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In Australia, in 2014, the Advisory Council on
Medicines Scheduling recommended rescheduling CBD from a prohibited substance to being a prescription medicine because, according to the
Advisory Council on Medicines Scheduling, there is a low risk of misuse or abuse as cannabidiol does not possess psychoactive properties.
The TGA accepted this recommendation, and the decision took effect in July 2015.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">CBD is one of the cannabinoids which may be extracted
as a therapeutic good from cannabis. From June 1, 2015, cannabidiol has been included under Schedule 4 (S4) Prescription Only Medicine
of the Poisons Standard (/publication/poisonsstandard-susmp) when preparations for therapeutic use contain 2% or less of other cannabinoids
found in cannabis.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In February 2016, the Australian Federal Government passed legislation
that amended the Narcotic Drugs Act, allowing the supply of suitable medicinal cannabis products for the management of painful and chronic
conditions. This legislation does not relate to the decriminalization of cannabis for general cultivation or recreational use and it
does not include the provision of medicinal grade herbal cannabis, only processed, non-smokable medicinal grade products</p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Much of the detail remains unclear. For example,
the legislation does not specify which products will be covered under the amendment, and it does not specify which particular conditions
or symptoms will be eligible for treatment with cannabis-based products. Before products can be prescribed, they must be registered with
the Therapeutic Goods Administration (TGA) or, in rare circumstances, receive special approval from the TGA. The registration process
requires evidence of testing and efficacy and it is therefore unlikely Australia will see a TGA registered medicinal cannabis product
that GPs can prescribe any time soon. Whilst there are currently no cannabis-based products that are lawfully produced in Australia, the
medicinal use of pharmaceutical products containing cannabinoids is not prohibited, as long as authorization for prescribing is granted
from the Commonwealth Therapeutic Goods Administration and at this point in time, NSW Health.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Raw Materials and Product Manufacturing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company does not currently manufacture any
API and relies solely upon third party manufacturers to produce research quantities of its compounds, KLS-13019; KLS-13022; and KLS-13023,
in the 5 gram to 100 gram scale for its preclinical research.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For the KLS-13023 compound, the Company relies
upon Purisys to produce a highly purified synthetic CBD. Purisys has been manufacturing cannabidiol since 2016 (DMF33223). Today, through
our partnership with Purisys, we have the ability to produce on the largest commercial scale. Purisys ultra-high purity CBD (Purisys
CBD) is attractive for drug development projects and falls significantly below the 0.3% THC limits set in the 2018 Farm Bill for
use in consumer products.&nbsp;Purisys patent-protected manufacturing process produces a consistently odorless, tasteless white
powder highest-purity form of CBD that exhibits:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No heavy metals (e.g. lead) from soil;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No pesticide residues;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No environmental influences on quality such as rain, sunlight
&amp; soil nutrients;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No plant impurities to remove;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No microbial or mold proliferation; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">No structural (or stereo chemical) differences exist between
an active cannabinoid ingredient manufactured by Purisys and those that are chemically extracted and isolated from plants. They are,
in effect, nature-identical.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Purisys currently has
a drug master file (DMF) for its ultra-high purity CBD with the FDA. In November 2019, Purisys received advise notice from
the DEA that the Purisys CBD has been removed from Schedule 1 of the CSA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company pursues a strategy to
move KLS-13023 into FDA clinical trials, it has set up a manufacturing process utilizing Purisys as the bulk API producer of ultra-high
purity CBD and Catalent Pharma Solutions (Catalent), a manufacturer of formulated and packaged pharmaceuticals, will enable
us to meet our objectives in the production of target drug candidates that can be used in clinical trials and, beyond successful clinical
trials, meet patient demand in commercial sales for each of our target disease indications. (See: Neuropathix Studies on CBD)</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Environmental Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">No significant pollution or other types of hazardous emission
result from our current operations, and we do not anticipate that our operations will be materially affected by federal, state or local
provisions concerning environmental controls. Our costs of complying with environmental, health and safety requirements have not been
material. Furthermore, compliance with federal, state and local requirements regulating the discharge of materials into the environment,
or otherwise relating to the protection of the environment, have not had, nor are they expected to have, any material effect on the capital
expenditures, earnings or competitive position of the Company. However, we will continue to monitor emerging developments in this area.</p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">There are several companies developing cannabinoid
therapeutics for a range of medical indications. The cannabinoid therapeutic area currently includes formulated extracts of the&nbsp;<i>Cannabis</i>&nbsp;plant
and synthetic formulations. These formulations include CBD or THC, or a combination of CBD and THC as the active pharmaceutical ingredient.
Certain companies such as GW Pharmaceuticals plc have focused on plant-based CBD formulations, while other companies such as Zynerba Pharmaceuticals,
Inc. and Insys Therapeutics, Inc. have focused on synthetic CBD formulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We currently have six full time employees. We
plan to increase the number of employees in the areas of regulatory affairs, clinical research and testing, and marketing in 2021. There
are no collective-bargaining agreements with our employees, and we have not experienced work interruptions or strikes. We believe our
relationship with employees is good and we provide health and life insurance for all employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Company Website</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We maintain a corporate Internet website at: www.neuropathix.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The contents of our website are not incorporated
in or otherwise to be regarded as part of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We file reports with the Securities and Exchange
Commission (SEC), which are available on our website free of charge. These reports include annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K, Section 16 filings on Form 3, Form 4, and Form 5, and other
related filings, each of which is provided on our website as soon as reasonably practical after we electronically file such materials
with or furnish them to the SEC. In addition, the SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements,
and other information regarding issuers that file electronically with the SEC, including the Company.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><span id="ITEM1A"></span>ITEM 1A. RISK FACTORS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Investing in our common stock involves a high
degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form
10-K, including our consolidated financial statements and the related notes and Managements Discussion and Analysis of Financial
Condition and Results of Operations, before deciding whether to invest in our common stock. The occurrence of any of the events
or developments described below could harm our business, financial condition, operating results, and growth prospects. In such an event,
the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties
not presently known to us or that we currently deem immaterial also may impair our business operations.</i>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Summary of Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our business is subject to a number of risks that
could cause actual results to differ materially from those indicated by forward-looking statements made in this Annual Report on Form
10-K or presented elsewhere from time to time. The following is a summary of the principal risk factors associated with an investment
in our securities. Further details regarding each risk included in the summary can be found further below.</p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We have never generated any product revenues, and do not expect
to become profitable in the near future, if ever;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We have incurred significant losses since our inception and
anticipate that we will continue to incur losses in the foreseeable future;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">There is substantial doubt about our ability to continue as
a going concern, and we will require additional capital to fund our operations, including clinical trials for our product candidates,
which may not be available on favorable terms, if at all;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The COVID-19 pandemic and actions taken by governmental authorities
to mitigate its spread has significantly impacted economic conditions, and a future outbreak of COVID-19 or another highly contagious
disease, could adversely affect our business activities, results of operations and financial condition;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We are largely dependent on the success of our product candidates,
KLS-13019 and KLS-13023, which are still in preclinical development and will require significant capital resources and years of clinical
development effort;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to commence clinical trials in 2021, and
even if our product candidates do advance into clinical trials, we may experience difficulties in managing our growth and expanding our
operations;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We are subject to significant regulatory requirements, both
within the United States and in certain foreign jurisdictions, which may result in, amongst other things, significant delays in our ability
to commence clinical trials, if we are ever approved to do so; failure to obtain regulatory approval for our product candidates; difficulties
marketing our products, if we obtain approval to do so; and significant costs;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Cannabis, including derivatives thereof, currently remain illegal
under federal law, and it is unclear when, if ever, that may change;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Our product candidates, if approved, may be unable to achieve
broad market acceptance and, consequently, limit our ability to generate revenue from new products;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Any inability to attract and retain qualified key management
and technical personnel would impair our ability to implement our business plan;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We face significant competition, which may result in other
discovering, developing or commercializing products before us or more successfully than we do;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We rely on third parties to conduct, supervise and monitor
our preclinical and clinical trials, and if those third parties perform in an unsatisfactory manner, we may not be able to obtain regulatory
approval for or commercialize our product candidates;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We rely on third-party manufacturers and suppliers and we intend
to rely on third parties to produce preclinical, clinical and commercial supplies of active pharmaceutical ingredients, or APIs, for
KLS-13019 and KLS-13023;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">If we are unable to protect our intellectual property rights
or if our intellectual property rights are inadequate to protect our technology and product candidates, our competitive position could
be harmed;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We may become involved in lawsuits to protect or enforce our
intellectual property, which could be expensive, time consuming and unsuccessful and have a material adverse effect on the success of
our business;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We may not be able to protect our intellectual property rights
throughout the world, and in developing countries in particular;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We do not know whether an active, liquid and orderly trading
market will develop for our common stock or what the market price of our common stock will be and, as a result, it may be difficult for
you to sell your shares of our common stock;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">The market price of our stock may be volatile, and you could
lose all or part of your investment;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Our common stock is classified as a penny stock
under SEC Rules and Regulations, which means there may be very limited trading market for our shares;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Insiders have substantial influence over us and could delay
or prevent a change in corporate control;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Because we do not anticipate paying any cash dividends on our
capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">We have issued preferred stock with designations, rights and
preferences that are superior to that of our common stock, and we may issue additional shares of preferred stock in the future.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span>&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Risks Related to Our Financial Position
and Capital Needs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>We have incurred significant losses
since our inception and anticipate that we will continue to incur losses in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are a preclinical
stage specialty pharmaceutical company, engaged in developing next-generation synthetic cannabinoid therapeutics. Since our inception
in August 2010, we have devoted substantially all of our resources to the development of our product candidates, KLS-13019 and KLS-13023.
We have generated significant operating losses since our inception. Our losses for the years ended December 31, 2021 and 2020 were approximately
$3.5 million and $4.5 million, respectively. As of December 31, 2021, we had an accumulated deficit of $16,564,350. Substantially all
of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative
costs associated with our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expect to continue
to incur significant expenses and operating losses for the foreseeable future. We anticipate these losses will increase as we continue
the research and development of, and clinical trials for, our product candidates. In addition to budgeted expenses, we may encounter unforeseen
expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If either of our product
candidates fails in clinical trials or does not gain regulatory approval, or even if approved, fails to achieve market acceptance, we
may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent
periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Due to our limited operating
history and history of losses, any predictions about our future success, performance or viability may not be accurate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>We currently have no commercial revenue
and may never become profitable.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">To date, the only revenue
we have generated has been from the receipt of research grants and payments for research services. Our ability to generate revenue and
become profitable depends upon our ability to obtain regulatory approval for, and successfully commercialize, KLS-13019, KLS-13023 or
other product candidates that we may develop, in-license or acquire in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Even if we are able to successfully achieve regulatory
approval for these product candidates, we do not know what the reimbursement status of our product candidates will be or when any of these
products will generate revenue for us, if at all. We have not generated, and do not expect to generate, any product revenue for the foreseeable
future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development,
preclinical studies and clinical trials, and the regulatory approval process for our product candidates. The amount of future losses is
uncertain and will depend, in part, on the rate of growth of our expenses. Our ability to generate revenue from our product candidates
also depends on a number of additional factors, including, without limitation, our ability to:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">successfully complete development activities, including the
remaining preclinical studies and planned clinical trials for our product candidates;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">complete and submit New Drug Applications (NDAs)
to the FDA, and Marketing Authorization Applications (MAAs) to the European Medicines Agency (the EMA), and
obtain regulatory approval for indications for which there is a commercial market;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">complete and submit applications to, and obtain regulatory
approval from, other foreign regulatory authorities;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">manufacture any approved products in commercial quantities
and on commercially reasonable terms;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">develop a commercial organization, or find suitable partners,
to market, sell and distribute approved products in the markets in which we have retained commercialization rights;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">achieve acceptance among patients, clinicians and advocacy
groups for any products we develop;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">obtain coverage and adequate reimbursement from third parties,
including government payors; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">set a commercially viable price for any products for which
we may receive approval.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are unable to predict
the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. Even if we are able to
complete the processes described above, we anticipate incurring significant costs associated with commercializing our product candidates.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>There is substantial doubt about our
ability to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On March 28, 2022, the
report of our independent registered public accounting firm on our December 31, 2021 audited financial statements includes an explanatory
paragraph referring to our ability to continue as a going concern. As of December 31, 2021 and 2020, we had cash balances of $15,677 and
$21,874, respectively. Management plans to raise additional capital through the issuance of common stock shares through the sale of registered
securities and private investment in public equity. We expect that between our existing cash, cash equivalents and cash raised through
our debt offering we will be able to sufficiently fund our operations and capital requirements for the next 12 months. Additional funding
will be required to continue our R&amp;D and other operating activities, as we have not reached successful commercialization of our products.
These circumstances cast significant doubt as to our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We will require
additional capital to fund our operations, and if we fail to obtain necessary financing, we will not be able to complete the development
and commercialization of KLS-13019 or KLS-13023.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our operations have consumed
substantial amounts of cash since inception. We expect to continue to spend substantial and increasing amounts to conduct further research
and development, preclinical testing and clinical trials of our product candidates, to seek regulatory approvals and reimbursement for
our product candidates, and to launch and commercialize any product candidates for which we receive regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2021, we had $15,677 in cash
and cash equivalents. As a result of receiving a $2.97 million NIH-NINDS grant in September 2021, we expect that between our existing
cash, cash equivalents and continuing cash raises through our debt offering we will be able to sufficiently fund our operations and capital
requirements through September 2024. We believe that these available funds will be sufficient to complete a Phase 1 clinical trials for
KLS-13019 for patients with chemotherapy induced peripheral neuropathy. We anticipate, based on current estimates, that costs associated
Phase 1 clinical trials for KLS-13019 will be approximately $2.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our management believes
that we will need to seek additional sources of capital to facilitate and carry out our business plan of proceeding with commencing Phase
1a, Phase 1b and Phase 2a clinical trials for KLS-13019 for patients with chemotherapy induced peripheral neuropathy; and commencing a
Phase 1b clinical trial for KLS-13019 for patients suffering from the effects of mild traumatic brain injury; and commencing a Phase 1b
clinical trial for KLS-13023 for patients suffering with OHE. The cost of commencing and conducting these trials will likely be in the
tens of millions of dollars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The progress of KLS-13019 and KLS-13023 for the target indication is
uncertain due to numerous factors, including, without limitation, the rate of progress of clinical trials, the results of preclinical
studies and clinical trials for such indication, the costs and timing of seeking and obtaining FDA and other regulatory approvals for
clinical trials, and FDA guidance regarding clinical trials for such indication. In addition, it is difficult to predict our spending
for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly
faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.
For these reasons, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization
activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the initiation, progress, timing, costs and results of preclinical
studies and clinical trials for our product candidates;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the clinical development plans we establish for our product
candidates;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the number and characteristics of product candidates that we
develop or may in-license;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the terms of any collaboration agreements we may choose to
execute;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the outcome, timing and cost of meeting regulatory requirements
established by the DEA, the FDA, the EMA or other comparable foreign regulatory authorities;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of filing, prosecuting, defending and enforcing our
patent claims and other intellectual property rights;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of defending intellectual property disputes, including
patent infringement actions brought by third parties against us;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the effect of competing product and market developments;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">costs and timing of the implementation of commercial scale
manufacturing activities; and</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We cannot be certain
that additional funding will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts
or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one
or more of our product candidates or one or more of our other research and development initiatives.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Our federal and
state government grants could subject us to audits and could require us to repay substantial amounts of funds previously awarded to us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">To date, most of our
revenue has been from the receipt of state and federal research grants. In connection with these grants, we may be subject to routine
audits by government agencies. As part of an audit, these agencies may review our performance, cost structures and compliance with applicable
laws, regulations, policies and standards and the terms and conditions of the grant. If any of our expenditures are found to be unallowable
or allocated improperly, or if we have otherwise violated terms of the grant, the expenditures may not be reimbursed and/or we may be
required to repay funds already disbursed. Accordingly, an audit could result in a material adjustment to our results of operations and
financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Raising additional
capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies
or product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We may seek additional
capital through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances, and licensing
arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing ownership
interests will be diluted and the terms of such financings may include liquidation or other preferences that adversely affect the rights
of existing stockholders. Debt financings may be coupled with an equity component, such as warrants to purchase shares, which could also
result in dilution of our existing stockholders ownership. The incurrence of indebtedness would result in increased fixed payment
obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on such indebtedness,
we could lose such assets and intellectual property. If we raise additional funds through strategic partnerships and alliances and licensing
arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that
are not favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Risks Related to our Business and Industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Our business may be subject to risks arising
from pandemic, epidemic, or an outbreak of diseases, such as the outbreak of COVID-19.&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If a pandemic, epidemic or outbreak of an infectious
disease occurs in the United States or elsewhere, our business may be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">COVID-19 has spread worldwide and has resulted
in government authorities implementing numerous measures to try to contain it, such as travel bans and restrictions, quarantines, shelter-in-place
orders and shutdowns. These measures have impacted, and may further impact, our workforce and operations, the operations of our partners,
and those of our respective vendors and suppliers. Our critical business operations, including our headquarters, are located in regions
which have been impacted by COVID-19. Our suppliers and partners worldwide have also been affected and may continue to be affected by
COVID-19 related restrictions and closures.</p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The spread of COVID-19 has caused us to modify
our business practices as we comply with state mandated requirements for safety in the workplace to ensure the health, safety and well-being
of our employees. These measures include personal protective equipment, social distancing, cleanliness of the facilities and daily monitoring
of the health of employees in our facilities, as well as modifying our policies on employee travel and the cancellation of physical participation
in meetings, events and conferences. We may take further actions as required by government authorities or that we determine are in the
best interests of our employees, partners and suppliers. However, we have not developed a specific and comprehensive contingency plan
designed to address the challenges and risks presented by the COVID-19 pandemic and, even if and when we do develop such a plan, there
can be no assurance that such plan will be effective in mitigating the potential adverse effects on our business, financial condition
and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition, while the extent and duration of the COVID-19 pandemic
on the global economy and our business in particular is difficult to assess or predict, the pandemic has resulted in, and may continue
to result in, significant disruption of global financial markets, which may reduce our ability to access capital, which could negatively
affect our liquidity. A recession or financial market correction resulting from the lack of containment and spread of COVID-19 could
impact overall technology spending, adversely affecting demand for our products, our business and the value of our common stock.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The ultimate impact of the COVID-19 pandemic or
a similar health epidemic is highly uncertain and subject to change. The extent of the impact of the COVID-19 pandemic on our operational
and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame, will depend
on future developments, including, but not limited to, the duration and continued spread of the pandemic, its severity, the actions to
contain the disease or treat its impact, further related restrictions on travel, all of which are uncertain and cannot be predicted. An
extended period of economic disruption as a result of the COVID-19 pandemic could have a material negative impact on our business, results
of operations, access to sources of liquidity and financial condition, though the full extent and duration is uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We are largely
dependent on the success of our product candidates, KLS-13019 and KLS-13023, which are still in preclinical development and will require
significant capital resources and years of clinical development effort.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We currently have no
products on the market, and our product candidates, KLS-13019 and KLS-13023, are still in preclinical development. Our business depends
almost entirely on the successful clinical development, regulatory approval and commercialization of KLS-13019 and KLS-13023, and additional
preclinical testing and substantial clinical development and regulatory approval efforts will be required before we are permitted to commence
commercialization, if ever. It will be several years before we can commence and complete a pivotal study for KLS-13019 or KLS-13023, if
ever. For KLS-13019 and KLS-13023, we plan to conduct Phase 1, and possibly Phase 2, clinical trials in Australia, subject to applicable
regulatory approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We plan to submit NDAs
for KLS-13019 and KLS-13023 to the FDA upon completion of all requisite clinical trials. The clinical trials and manufacturing and marketing
of KLS-13019 and KLS-13023 will be subject to extensive and rigorous review and regulation by numerous government authorities in the United
States, Australia, the European Union, Canada, and other jurisdictions where we intend to test and, if approved, market our product candidates.
Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through preclinical testing
and clinical trials that the product candidate is safe and effective for use in each target indication, and potentially in specific patient
populations. This process can take many years and may include post-marketing studies and surveillance, which would require the expenditure
of substantial resources. Of the large number of drugs in development for approval in the United States and the European Union, only a
small percentage successfully complete the FDA or EMA regulatory approval processes, as applicable, and are commercialized. Accordingly,
even if we are able to obtain the requisite financing to continue to fund our research, development and clinical programs, we cannot assure
you that any of our product candidates will be successfully developed or commercialized.&nbsp;</p>

<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Because the results
of preclinical testing are not necessarily predictive of future results, KLS-13019 and KLS-13023 may not have favorable results in our
planned clinical trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Any positive results
from our preclinical testing of KLS-13019 and KLS-13023 may not necessarily be predictive of the results from our planned clinical trials
in humans. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after
achieving positive results in preclinical development, and we cannot be certain that we will not face similar setbacks. These setbacks
have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations
made in clinical trials, including adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations
and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials
nonetheless failed to obtain FDA or EMA approval. If we fail to produce positive results in our clinical trials of KLS-13019 and KLS-13023,
the development timeline and regulatory approval and commercialization prospects for KLS-13019 and KLS-13023, and, correspondingly, our
business and financial prospects, would be materially adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We may not be able
to commence clinical trials in 2021; even if KLS-13019 and KLS-13023 advance into clinical trials, we may experience difficulties in managing
our growth and expanding our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We have not begun clinical trials for
any of our product candidates. While we expect to commence clinical trials in the U.S. or Australia in 2024 and/or 2025 for KLS-13019
and KLS-13023, we have limited resources to carry out these objectives. Our company has no history of conducting clinical trials, which
is a time-consuming, expensive and uncertain process. In addition, while we have experienced management and expect to contract out many
of the activities related to conducting clinical trials, we are a small company with only seven employees and therefore have limited
internal resources both to conduct clinical trials and to monitor third-party providers. As our product candidates enter into and advance
through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing operations,
either by expanding our internal capabilities or contracting with other organizations to provide these capabilities for us. In the future,
we expect to have to manage additional relationships with collaborators or partners, suppliers and other organizations. Our ability to
manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting
systems and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Failures or delays
in the completion of our preclinical studies or the commencement and completion of our planned clinical trials of KLS-13019 or KLS-13023
could result in increased costs to us and could delay, prevent or limit our ability to generate revenue and continue our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">To date, we have not
commenced any clinical trials for KLS-13019 or KLS-13023. Successful completion of such clinical trials is a prerequisite to submitting
an NDA to the FDA or an MAA to the EMA. Clinical trials are expensive, difficult to design and implement, can take many years to complete,
and are uncertain as to outcome. A product candidate can unexpectedly fail at any stage of clinical development. The historic failure
rate for product candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables.
We expect to initiate clinical trials for KLS-13019 and KLS-13023 in 2024 and/or 2025. However, we do not know whether our clinical trials
will begin or be completed on schedule, if at all, as the commencement and completion of clinical trials can be delayed or prevented for
a number of reasons, including, among others:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">delays in reaching or failing to reach agreement on acceptable
terms with prospective clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among
different clinical trial sites;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">delays or inability in manufacturing or obtaining sufficient
quantity or quality of a product candidate or other materials necessary to conduct clinical trials due to regulatory and manufacturing
constraints;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">difficulties obtaining institutional review board, or IRB,
DEA or comparable foreign regulatory authority, or ethics committee approval to conduct a clinical trial at a prospective site or sites;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">challenges in recruiting and enrolling patients to participate
in clinical trials, including the size and nature of the patient population, the proximity of patients to clinical trial sites, eligibility
criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the
relevant indication and competition from other clinical trial programs for similar indications;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">severe or unexpected toxicities or drug-related side effects
experienced by patients in our clinical trials or by individuals using drugs similar to our product candidates;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">DEA or comparable foreign regulatory authority-related recordkeeping,
reporting or security violations at a clinical trial site, leading the DEA, state authorities or comparable foreign regulatory authorities
to suspend or revoke the sites controlled substance license and causing a delay or termination of planned or ongoing clinical
trials;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory concerns with cannabinoid products generally and
the potential for abuse of those products;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">difficulties retaining patients who have enrolled in a clinical
trial who may withdraw due to lack of efficacy, side effects, personal issues or loss of interest;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">ambiguous or negative interim results; or</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">lack of adequate funding to continue the clinical trial.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>

<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In addition, a clinical
trial may be suspended or terminated by us, the FDA, IRBs, ethics committees, data safety monitoring board or other foreign regulatory
authorities overseeing the clinical trial at issue or other regulatory authorities due to a number of factors, including, among others:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">failure to conduct the clinical trial in accordance with regulatory
requirements or our clinical trial protocols;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">inspection of the clinical trial operations or clinical trial
sites by the FDA, the DEA, the EMA or other foreign regulatory authorities that reveals deficiencies or violations that require us to
undertake corrective action, including the imposition of a clinical hold;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">unforeseen safety issues, including any safety issues that
could be identified in our ongoing toxicology studies;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">adverse side effects or lack of effectiveness; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">changes in government regulations or administrative actions.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We intend to expend
our limited resources to pursue KLS-13019 and KLS-13023 for certain indications, and may fail to capitalize on other product candidates
or other indications for KLS-13019 or KLS-13023 that may be more profitable or for which there is a greater likelihood of success.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Because we have limited
financial and managerial resources, we are focusing on research programs relating to KLS-13019 and KLS-13023 for certain indications,
which concentrates the risk of product failure in the event KLS-13019 or KLS-13023 proves to be unsafe or ineffective or inadequate for
clinical development or commercialization. In particular, we intend to study KLS-13019 in patients with chemotherapy induced peripheral
neuropathy, and we intend to study KLS-13023 in patients with mild traumatic brain injury. As a result, we may forego or delay pursuit
of opportunities with other product candidates or for other indications for KLS-13019 or KLS-13023 that could later prove to have greater
commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable
market opportunities. Our spending on proprietary research and development programs relating to KLS-13019 and KLS-13023 may not yield
any commercially viable products. If we do not accurately evaluate the commercial potential or target market for KLS-13019 and KLS-13023,
we may relinquish valuable rights to KLS-13019 or KLS-13023 through collaboration, licensing or other royalty arrangements in cases in
which it would have been more advantageous for us to retain sole development and commercialization rights to KLS-13019 or KLS-13023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>The regulatory
approval processes of the FDA, the EMA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently
unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially
harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are not permitted
to market our product candidates in the United States or the European Union until we receive approval of an NDA from the FDA or an MAA
from the EMA, respectively, or in any foreign countries until we receive the requisite approval from such countries. Prior to submitting
an NDA to the FDA or an MAA to the EMA for approval of our product candidates, we will need to complete our ongoing preclinical studies,
as well as Phase 1, Phase 2 and Phase 3 clinical trials. We are still conducting preclinical studies and have not yet commenced our clinical
program or tested KLS-13019 or KLS-13023 in humans. For KLS-13019, we plan to conduct Phase 1, and possibly Phase 2, clinical in the U.S.
or Australia, subject to applicable regulatory approval. We plan to conduct our Phase 1 clinical trials for KLS-13023 in U.S. or Australia,
subject to applicable regulatory approval. We plan to submit NDAs for KLS-13019 and KLS-13023 to the FDA upon completion of all requisite
clinical trials. Successfully initiating and completing our clinical program and obtaining approval of an NDA or MAA is a complex, lengthy,
expensive and uncertain process, and the FDA or EMA may delay, limit or deny approval of our product candidates for many reasons, including,
among others, because:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">we may not be able to demonstrate that our product candidates
are safe and effective in treating patients to the satisfaction of the FDA or EMA;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the results of our clinical trials may not meet the level of
statistical or clinical significance required by the FDA or EMA for marketing approval;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or EMA may disagree with the number, design, size,
conduct or implementation of our clinical trials;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or EMA may require that we conduct additional clinical
trials;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or EMA or other applicable foreign regulatory authorities
may not approve the formulation, labeling or specifications of our product candidates;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the contract research organizations, or CROs, and other contractors
that we may retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical
trials;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or EMA may find the data from preclinical studies and
clinical trials insufficient to demonstrate that KLS-13019s or KLS-13023s clinical and other benefits outweigh its safety
risks;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or EMA may disagree with our interpretation of data
from our preclinical studies and clinical trials;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or EMA may not accept data generated at our clinical
trial sites or may disagree with us over whether to accept efficacy results from clinical trial sites outside the United States where
the standard of care is potentially different from that in the United States;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">if and when our NDAs or MAAs are submitted to the FDA or EMA,
as applicable, the regulatory agency may have difficulties scheduling the necessary review meetings in a timely manner, may recommend
against approval of our application or may recommend or require, as a condition of approval, additional preclinical studies or clinical
trials, limitations on approved labeling or distribution and use restrictions;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA may require development of a Risk Evaluation and Mitigation
Strategy, or REMS, which would use risk minimization strategies beyond the professional labeling to ensure that the benefits of certain
prescription drugs outweigh their risks, as a condition of approval or post-approval, and the EMA may grant only conditional approval
or impose specific obligations as a condition for marketing authorization, or may require us to conduct post-authorization safety studies;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA, EMA, DEA or other applicable foreign regulatory agencies
may not approve the manufacturing processes or facilities of third-party manufacturers with which we contract or DEA or other applicable
foreign regulatory agency quotas may limit the quantities of controlled substances available to our manufacturers; or</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the FDA or EMA may change their approval policies or adopt
new regulations.</span></td>
</tr></tbody></table>





<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On September 27, 2018, <span style="background-color: white">the DOJ
and DEA announced that Epidiolex, the newly approved medication by the Food &amp; Drug Administration, was being placed in Schedule V
of the Controlled Substances Act, the least restrictive schedule of the </span>federal CSA<span style="background-color: white">. </span>On
June 26, <span style="background-color: white">2018, the FDA announced it approved Epidiolex for the treatment of seizures associated
with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. Epidiolex
contains CBD. The CBD in Epidiolex is extracted from the cannabis plant and is the first FDA-approved drug to contain a purified extract
from the plant. Schedule V drugs represent the least potential for abuse. </span>Schedule V drugs, substances, or chemicals are defined
as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics.
Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes. Some examples of Schedule V drugs are: cough
preparations with less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Despite the approvals
by the FDA and DEA for Epidiolex, any of these foregoing factors, many of which are beyond our control, could jeopardize our ability to
obtain regulatory approval for and successfully market KLS-13019 or KLS-13023. Moreover, because our business is almost entirely dependent
upon these two product candidates, any such setback in our pursuit of regulatory approval would have a material adverse effect on our
business and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><span style="text-decoration: underline">Therapeutic Goods
Administration (TGA)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Clinical trials conducted in Australia are subject
to various regulatory controls to ensure the safety of clinical trial participants. The TGA regulates the use of therapeutic goods supplied
in clinical trials in Australia under the therapeutic goods legislation. Clinical trial sponsors must comply with various import, export,
manufacture and supply requirements promulgated by the TGA, the compliance with which are not always clear and require a significant amount
of subjective interpretation on the part of the Australian clinical trial sponsor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In 2014, the Australian Advisory Council on Medicines
Scheduling recommended rescheduling CBD from a prohibited substance to being a prescription medicine because, according to the Advisory
Council on Medicines Scheduling, there is a low risk of misuse or abuse as cannabidiol does not possess psychoactive properties.
The TGA accepted this recommendation and the decision took effect in July 2015.&nbsp;From 1 July 2015, CBD has been included under Schedule
4 (S4) Prescription Only Medicine of the Poisons Standard when preparations for therapeutic use contain 2% or less of other cannabinoids
found in cannabis.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In February 2016, the
Australian Federal Government passed legislation that amended the Narcotic Drugs Act, allowing the supply of suitable medicinal cannabis
products for the management of painful and chronic conditions. This legislation does not relate to the decriminalization of cannabis for
general cultivation or recreational use and it does not include the provision of medicinal grade herbal cannabis, only processed, non-smokable
medicinal grade products<sup>.</sup>&nbsp;Much of the detail remains unclear. For example, the legislation does not specify which products
will be covered under the amendment, and it does not specify which particular conditions or symptoms will be eligible for treatment with
cannabis-based products. Before products can be prescribed, they must be registered with the TGA or, in rare circumstances, receive special
approval from the TGA. The registration process requires evidence of testing and efficacy, and it is therefore unlikely Australia will
see a TGA registered medicinal cannabis product that GPs can prescribe any time soon.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Whilst there are currently no cannabis-based products
that are lawfully produced in Australia, the medicinal use of pharmaceutical products containing cannabinoids is not prohibited, as long
as authorization for prescribing is granted from the TGA and at this point in time, NSW Health.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">&nbsp;Despite the 2016
legislation discussed above, there are many factors, a significant number of which are beyond our control, that could jeopardize our ability
to obtain regulatory approval to commence our KLS-13019 and KLS-13023 clinical trials in Australia. If we are unable to obtain the necessary
regulatory approvals in Australia, we will have to consider alternative locations for our clinical trials, including the United States,
which may be more costly or have stringent regulatory requirements of their own, and which would likely delay aspects of our development
plan.</p>


<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We plan to conduct
clinical trials for KLS-13019 and KLS-13023 outside the United States and the FDA may not accept data from such trials.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We plan to conduct clinical
trials outside the United States. For KLS-13019, we plan to conduct Phase 1, and possibly Phase 2, clinical trials in Australia, subject
to applicable regulatory approval. We plan to conduct our Phase 1 clinical trials for KLS-13023 in U.S. or Australia, subject to applicable
regulatory approval. We plan to submit NDAs for KLS-13019 or KLS-13023 to the FDA upon completion of all requisite clinical trials. Although
the FDA may accept data from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject
to certain conditions. For example, the clinical trial must be conducted in accordance with Good Clinical Practices (GCP)
requirements, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection
necessary. Where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States,
the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and
U.S. medical practice, the clinical trials were performed by clinical investigators of recognized competence, and the data is considered
valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able
to validate the data through an on-site inspection or other appropriate means. In addition, such clinical trials would be subject to the
applicable local laws of the foreign jurisdictions where the clinical trials are conducted. There can be no assurance the FDA will accept
data from clinical trials conducted outside of the United States. If the FDA does not accept any such data, it would likely result in
the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our development plan. In addition,
the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting international
clinical trials include:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">foreign regulatory requirements that could burden or limit
our ability to conduct our clinical trials;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">administrative burdens of conducting clinical trials under
multiple foreign regulatory schema;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">foreign exchange fluctuations;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">manufacturing, customs, shipment and storage requirements;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">cultural differences in medical practice and clinical research;
and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">diminished protection of intellectual property in some countries.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Even if KLS-13019
or KLS-13023 receive regulatory approval, they may still face future development and regulatory difficulties.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">If we obtain regulatory
approval for KLS-13019 or KLS-13023, such approval would be subject to extensive ongoing requirements by the DEA, FDA, EMA and other foreign
regulatory authorities related to the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety
surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety
profile of any product will continue to be closely monitored by the FDA, EMA and other comparable foreign regulatory authorities. If the
FDA, EMA or any other comparable foreign regulatory authority becomes aware of new safety information after approval of any of our product
candidates, these regulatory authorities may require labeling changes or establishment of a REMS, impose significant restrictions on a
products indicated uses or marketing, impose ongoing requirements for potentially costly post-approval studies or post-market surveillance
or impose a recall.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition, manufacturers of therapeutic products
and their facilities are subject to continual review and periodic inspections by the FDA, the EMA and other comparable foreign regulatory
authorities for compliance with current good manufacturing practices (cGMP) regulations. Further, manufacturers of controlled
substances must obtain and maintain necessary DEA and state registrations and registrations with applicable foreign regulatory authorities,
and must establish and maintain processes to ensure compliance with DEA and state requirements and requirements of applicable foreign
regulatory authorities governing, among other things, the storage, handling, security, recordkeeping and reporting for controlled substances.
If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or
frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product,
the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.
If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements,
a regulatory agency may, among other things:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">issue untitled letters or winning letters;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">mandate modifications to promotional materials or require us
to provide corrective information to healthcare practitioners;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">require us to enter into a consent decree, which can include
imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">seek an injunction or impose civil or criminal penalties or
monetary fines;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">suspend or withdraw regulatory approval;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">suspend any ongoing clinical trials;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">refuse to approve pending applications or supplements to applications
filed by us; or</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">require us to initiate a product recall.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif">&nbsp;</p>

<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The occurrence of any
event or penalty described above may inhibit our ability to commercialize our product candidates and may otherwise have a material adverse
effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>KLS-13023 will
be subject to controlled substance laws and regulations; failure to receive necessary approvals may delay the launch of our products and
failure to comply with these laws and regulations may adversely affect the results of our business operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">KLS-13023 contains controlled
substances as defined in the CSA. Controlled substances that are pharmaceutical products are subject to a high degree of regulation under
the CSA, which establishes, among other things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import,
export and other requirements administered by the DEA. The DEA classifies controlled substances into five schedules: Schedule I, II, III,
IV or V substances. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use
in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United
States. Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances
considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among
such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement
quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II drugs is further restricted. For example,
they may not be refilled without a new prescription.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">While cannabis is a Schedule
I controlled substance, products approved for medical use in the United States that contain cannabis or cannabis extracts must be placed
in Schedules II - V, since approval by the FDA satisfies the accepted medical use requirement. If and when KLS-13023 receives
FDA approval, the DEA will make a scheduling determination and place it in a schedule other than Schedule I in order for it to be prescribed
to patients in the United States. If approved by the FDA, we expect the finished dosage forms of KLS-13023 to be listed by the DEA as
a Schedule II or III controlled substance. Consequently, their manufacture, importation, exportation, domestic distribution, storage,
sale and legitimate use will be subject to a significant degree of regulation by the DEA. The scheduling process may take one or more
years beyond FDA approval, thereby significantly delaying the launch of KLS-13023. Furthermore, if the FDA, DEA or any foreign regulatory
authority determines that KLS-13023 may have potential for abuse, it may require us to generate more clinical data than that which is
currently anticipated, which could increase the cost and/or delay the launch of KLS-13023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Because KLS-13023 contains
active ingredients of cannabis, which are Schedule I substances, to conduct preclinical studies and clinical trials with KLS-13023 in
the United States prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA
researcher registration that will allow those sites to handle and dispense KLS-13023 and to obtain the product from our manufacturer.
If the DEA delays or denies the grant of a research registration to one or more research sites, the preclinical studies or clinical trials
could be significantly delayed, and we could lose and be required to replace clinical trial sites, resulting in additional costs.</p>

<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expect that KLS-13023
will be scheduled as Schedule II or III, as a result of which we will also need to identify wholesale distributors with the appropriate
DEA registrations and authority to distribute the products to pharmacies and other healthcare providers, and these distributors would
need to obtain Schedule II or III distribution registrations. The failure to obtain, or delay in obtaining, or the loss of any of those
registrations could result in increased costs to us. If KLS-13023 is scheduled as a Schedule II drug, pharmacies would have to maintain
enhanced security with alarms and monitoring systems and adhere to recordkeeping and inventory requirements. This may discourage some
pharmacies from carrying the product. Furthermore, state and federal enforcement actions, regulatory requirements, and legislation intended
to reduce prescription drug abuse, such as the requirement that physicians consult a state prescription drug monitoring program, may make
physicians less willing to prescribe, and pharmacies to dispense, Schedule II products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We may manufacture the
commercial supply of KLS-13023 outside of the United States. If KLS-13023 is approved by the FDA and classified as a Schedule II or III
substance, an importer can import for commercial purposes if it obtains from the DEA an importer registration and files an application
with the DEA for an import permit for each import. The DEA provides annual assessments/estimates to the International Narcotics Control
Board, which guides the DEA in the amount of controlled substances that the DEA authorizes to be imported. The failure to identify an
importer or obtain the necessary import authority, including specific quantities, could affect the availability of KLS-13023 and have
a material adverse effect on our business, results of operations and financial condition. In addition, an application for a Schedule II
importer registration must be published in the Federal Register, and there is a waiting period for third party comments to be submitted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Individual states have
also established controlled substance laws and regulations. Though state-controlled substance laws often mirror federal law, because the
states are separate jurisdictions, they may separately schedule our product candidates as well. While some states automatically schedule
a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. State scheduling may delay commercial
sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the
commercial attractiveness of such product. We or our partners must also obtain separate state registrations, permits or licenses in order
to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure to meet applicable
regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under
federal law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We currently obtain the
API for KLS-13023 from a bulk manufacturer of pharmaceutical grade API in Switzerland. For KLS-13023, we plan to conduct Phase 1 clinical
trials in the U.S. or Australia, subject to applicable regulatory approval. In addition, we may decide to develop, manufacture or commercialize
our product candidates in additional countries. As a result, KLS-13023 will also be subject to controlled substance laws and regulations
from the TGA in Australia, Health Canadas Office of Controlled Substances in Canada, and from other regulatory agencies in other
countries where we may develop, manufacture or commercialize KLS-13023 in the future. We plan to submit NDA for KLS-13023 to the FDA upon
completion of all requisite clinical trials and will require additional DEA approvals at such time as well.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">KLS-13023 is a formulation that does contain CBD.
At present, CBD is deemed a Schedule 1 controlled substance by the U.S. Drug Enforcement Agency under the CSA. And like the drug molecule
Epidiolex, which was recently approved by the FDA for marketing and sale for use in treating Dravet Syndrome and Lennox-Gasteau
Syndrome (forms of child epilepsy), KLS-13023 would need to follow the guidance set forth by the CSA, complete a successful human clinical
trial and apply for rescheduling, as was the case with Epidiolex, now a Schedule 5 drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Despite the approvals
by the FDA and DEA for Epidiolex, any of these foregoing factors, many of which are beyond our control, could jeopardize our ability to
obtain regulatory approval for and successfully market KLS-13019 or KLS-13023. Moreover, because our business is almost entirely dependent
upon these two product candidates, any such setback in our pursuit of regulatory approval would have a material adverse effect on our
business and prospects.</p>

<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On January 14, 2019,
the Company received written notice from the Drug Enforcement Administration (DEA) Drug and Chemical Evaluation Section,
as follows: Please be advised that your material meets the definition of Hemp and is not regulated under the CSA,
as long as it consists of high purity Cannabidiol (CBD) that contains approximately 0.1% delta-9- THC. (However, if it contains more than
0.3% delta-9 THC, it is considered Marihuana and would be in Schedule 1 of the CSA). While this notice is an official
notice from the DEA regarding the scheduling of high purity CBD, the Company will continue to abide by the CSA in all respects with regards
to its treatment and handling of CBD.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><i>Cannabis remains illegal under Federal law.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Despite the development of a regulated cannabis industry under
the laws of certain states, these state laws regulating medical and adult cannabis use are in conflict with the CSA, which classifies
cannabis as a Schedule I controlled substance and makes cannabis use and possession illegal on a national level. The United States Supreme
Court has ruled that the Federal government has the right to regulate and criminalize cannabis, even for medical purposes, and thus federal
law criminalizing the use of cannabis preempts state laws that regulate its use.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 29, 2013, United States Deputy Attorney
General James Cole issued the Cole Memo to United States attorneys guiding them to prioritize enforcement of Federal law away from the
cannabis industry operating as permitted under certain state laws, so long as:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">cannabis is not being distributed to minors and dispensaries
are not located around schools and public buildings;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the proceeds from sales are not going to gangs, cartels or
criminal enterprises;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">cannabis grown in states where it is legal is not being diverted
to other states;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">cannabis-related businesses are not being used as a cover for
sales of other illegal drugs or illegal activity;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">there is not any violence or use of firearms in the cultivation
and sale of marijuana;</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">there is strict enforcement of drugged-driving laws and adequate
prevention of adverse health consequences; and</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">cannabis is not grown, used, or possessed on Federal properties.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&nbsp;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Cole Memo was a guide for United States attorneys
and did not alter in any way the DOJs authority to enforce federal law, including federal laws relating to cannabis, regardless
of state law. As described below, as a result of the issuance of the Sessions Memo by the Department of Justice on January 4, 2018, the
Cole memo was rescinded. We cannot provide assurance that our actions are or will be in compliance with the Cole Memo, the Sessions Memo
or any other laws or regulations that currently exist or may be amended or adopted in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 4, 2018, former Attorney General Jefferson
B. Sessions, III issued a memo on federal marijuana enforcement policy announcing a return to the rule of law and the rescission of previous
nationwide guidance by the DOJ (including, but not limited to, the Cole Memo). In the memorandum, Attorney General Jefferson Sessions
directs all U.S. attorneys to enforce the laws enacted by Congress and to follow well established principles when pursuing prosecutions
related to marijuana activities. These principles include weighing all relevant considerations, including federal law enforcement priorities
set by the Attorney General, the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of
particular crimes on the community. The effect of this memo was to shift federal policy from a hands-off approach adopted by the Obama
administration to permitting federal prosecutors across the country to determine how to prioritize resources to regulate marijuana possession,
distribution and cultivation in states where marijuana use is legal.</p>

<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Although the Obama administration determined that
it was not an efficient use of resources to direct Federal law enforcement agencies to prosecute those lawfully abiding by state laws
allowing the use and distribution of medical and recreational cannabis, the last administration issued the Sessions Memo announcing a
return to the rule of law and the rescission of previous guidance documents. The Sessions Memo rescinds the Cole Memo, which was adopted
by the Obama administration as a policy of non-interference with marijuana-friendly state laws. The Sessions Memo shifts federal policy
from a hands-off approach adopted by the Obama administration to permitting federal prosecutors across the country to decide how to prioritize
resources to regulate marijuana possession, distribution and cultivation in states where marijuana use is regulated. The current administration
has not yet weighed in on the issue of enforcement of federal laws related to the use and distribution of medical and recreational cannabis,
and it is currently unknow what their stance is likely to be if and when they do.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">There can be no assurance that federal prosecutors
will not prosecute and dedicate resources to regulate marijuana possession, distribution and cultivation in states where marijuana use
is regulated which may cause states to reconsider their regulation of marijuana which would have a detrimental effect on the marijuana
industry. Any such change in state laws based upon the Sessions Memo and the Federal governments enforcement of Federal laws could
cause significant financial damage to us and our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 11, 2021, the chairman of the House Judiciary
Committee, announced that the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act, introduced in 2019, which passed in the
U.S. House of Representatives in December 2020, will be re-filed in 2021, seeking ratification by the Senate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If passed by the U.S. Senate, the MORE Act would
de-schedule cannabis from the Controlled Substances Act and enact various criminal and social justice reforms to cannabis, including the
expungement of prior convictions. The MORE Act also seeks to tax cannabis products at 5% to fund criminal and social reform projects,
including an Office of Cannabis Justice within the Department of Justice Office of Justice Programs responsible for administering grants
to aid communities negatively affected by the war on drugs. (See: Controlled Substances Laws and Regulations<b>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Product shipment
delays could have a material adverse effect on our business, results of operations and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The shipment, import
and export of KLS-13023 and the API used to manufacture KLS-13023 will require import and export licenses. In the United States, the FDA,
U.S. Customs and Border Protection, and the DEA, and in Canada, where our API is manufactured, the Canada Border Services Agency and Health
Canada, and in Australia, where we intend to commence clinical trials, the Australian Customs and Board Protection Service and the Therapeutic
Goods Administration, and in other countries, similar regulatory authorities, regulate the import and export of pharmaceutical products
that contain controlled substances. Specifically, the import and export process requires the issuance of import and export licenses by
the relevant controlled substance authority in both the importing and exporting country. We may not be granted, or if granted, maintain,
such licenses from the authorities in certain countries. Even if we obtain the relevant licenses, shipments of API and our product candidates
may be held up in transit, which could cause significant delays and may lead to product batches being stored outside required temperature
ranges. Inappropriate storage may damage the product shipment, resulting in delays in clinical trials or, upon commercialization, a partial
or total loss of revenue from one or more shipments of API or KLS-13023. A delay in a clinical trial or, upon commercialization, a partial
or total loss of revenue from one or more shipments of API or KLS-13023 could have a material adverse effect on our business, results
of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Failure to obtain
regulatory approval in jurisdictions outside the United States and the European Union would prevent our product candidates from being
marketed in those jurisdictions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In order to market and
sell our products in jurisdictions other than the United States and the European Union, we must obtain separate marketing approvals and
comply with numerous and varying regulatory requirements. The regulatory approval process outside the United States and the European Union
generally includes all of the risks associated with obtaining FDA and EMA approval, but can involve additional testing. We may need to
partner with third parties in order to obtain approvals outside the United States and the European Union. In addition, in many countries
worldwide, it is required that the product be approved for reimbursement before the product can be approved for sale in that country.
We may not obtain approvals from regulatory authorities outside the United States and the European Union on a timely basis, if at all.
Even if we were to receive approval in the United States or the European Union, approval by the FDA or the EMA does not ensure approval
by regulatory authorities in other countries or jurisdictions. Similarly, approval by one regulatory authority outside the United States
and the European Union would not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA or the EMA.
We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.
If we are unable to obtain approval of our product candidates by regulatory authorities in other foreign jurisdictions, the commercial
prospects of those product candidates may be significantly diminished and our business prospects could decline.&nbsp;</p>

<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Healthcare legislation,
including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for
us to obtain marketing approval of and commercialize our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In the United States
there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent
or delay marketing approval of our product candidates, restrict or regulate post-approval activities, or affect our ability to profitably
sell any product candidates for which we obtain marketing approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The Patient Protection
and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or Affordable Care Act, among other things, imposes
a significant annual fee on companies that manufacture or import branded prescription drug products. It also contains substantial provisions
intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare
fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on pharmaceutical
and medical device manufacturers, and impose additional health policy reforms, any of which could negatively impact our business. Certain
of provisions have only recently become effective, but the Affordable Care Act is likely to continue the downward pressure on pharmaceutical
and medical device pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In addition, other legislative
changes have been proposed and adopted since passage of the Affordable Care Act. The Budget Control Act of 2011, among other things, created
the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee
did not achieve a targeted deficit reduction of an amount greater than $1.2 trillion for the fiscal years 2012 through 2021, triggering
the legislations automatic reduction to several government programs. This included aggregate reductions to Medicare payments to
healthcare providers of up to 2.0% per fiscal year, which went into effect in April 2013. In January 2013, President Obama signed into
law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare
providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
If we ever obtain regulatory approval and successfully commercialize KLS-13019, KLS-13023 or other product candidates that we may develop,
these new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect
on our customers and accordingly, our financial operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expect that the Affordable
Care Act, as well as other healthcare reform measures that have been and may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future
revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from
private payors. The implementation of cost containment measures or other healthcare reforms may compromise our ability to generate revenue,
attain profitability or commercialize our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On December 2, 2017,
the U.S. Senate passed the Tax Cut and Jobs Act of 2017. <span style="background-color: white">The Senate bill repealed the individual
mandate that requires all Americans under 65 to have health insurance or pay a penalty, effective starting in 2019. The CBO initially
estimated that 13 million fewer persons would have health insurance by 2025, including 8 million fewer on the Affordable Care Act exchanges
and 5 million fewer on Medicaid. Fewer persons with healthcare means lower costs for the government, so CBO estimated over $300 billion
in savings. This allowed Republicans to increase the size of the tax cuts in the bill. Health insurance premiums on the exchanges could
rise as much as 10 percentage points more than they would otherwise. CBO later revised this estimate in 2018 to 7 million fewer insured
by 2026. </span></p>

<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><span style="background-color: white">In
addition to these changes, </span>the corporate tax rate was reduced from 35% to 21%, while some related business deductions and credits
were either reduced or eliminated. The Act also changes the U.S. from a global to a territorial tax system with respect to corporate income
tax. Instead of a corporation paying the U.S. tax rate (35%) for income earned in any country (less a credit for taxes paid to that country),
each subsidiary would pay the tax rate of the country in which it is legally established.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Even if we are
able to commercialize KLS-13019 or KLS-13023, the products may not receive coverage and adequate reimbursement from third-party payors,
which could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The availability of reimbursement
by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our product candidates,
if approved, will depend substantially on the extent to which the costs of these product candidates will be paid by health maintenance,
managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities,
private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels,
we may not be able to successfully commercialize KLS-13019 or KLS-13023. Even if coverage is provided, the approved reimbursement amount
may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In the United States,
the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act, established the Medicare Part
D program and provided authority for limiting the number of drugs that will be covered in any therapeutic class thereunder. The Medicare
Modernization Act, including its cost reduction initiatives, could decrease the coverage and reimbursement rate that we receive for any
of our approved products. Furthermore, private payors often follow Medicare coverage policies and payment limitations in setting their
own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar
reduction in payments from private payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">There is significant
uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions
about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within
the U.S. Department of Health and Human Services, or HHS, as CMS decides whether and to what extent a new medicine will be covered and
reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The intended use of a drug product
by a physician can also affect pricing. For example, CMS could initiate a National Coverage Determination administrative procedure, by
which the agency determines which uses of a therapeutic product would and would not be reimbursable under Medicare. This determination
process can be lengthy, thereby creating a long period during which the future reimbursement for a particular product may be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Outside the United States,
particularly in member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries,
pricing negotiations or the successful completion of health technology assessment procedures with governmental authorities can take considerable
time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders
on prices and reimbursement levels, including as part of cost containment measures. Certain countries allow companies to fix their own
prices for medicines, but monitor and control company profits. Political, economic and regulatory developments may further complicate
pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European
Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices.
In some countries, we or our collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness
of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of
discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of
publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or
amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be
adversely affected.</p>

<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Our relationships
with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations,
which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future
earnings.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Healthcare providers,
physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which
we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud
and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through
which we market, sell and distribute our products for which we obtain marketing approval. As a pharmaceutical company, even though we
do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain
federal and state healthcare laws and regulations pertaining to fraud and abuse and patients rights are and will be applicable
to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate
include the following:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the U.S. federal healthcare Anti-Kickback Statute impacts our
marketing practices, educational programs, pricing policies and relationships with healthcare providers or other entities, by prohibiting,
among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly,
in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation
of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">federal civil and criminal false claims laws and civil monetary
penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities
for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims
for payment that are false or fraudulent (including through impermissible promotion of our products for off-label uses) or making a false
statement or record to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the U.S. federal Health Insurance Portability and Accountability
Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also
created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">HIPAA, and the rules and regulations promulgated thereunder,
establish federal standards for maintaining the privacy and security of certain patient health information known as Protected Health
Information, or PHI. As amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, HIPAA establishes
federal standards for administrative, technical and physical safeguards relevant to the electronic transmission of PHI and imposes notification
obligations in the event of a breach of the privacy or security of PHI. In addition to adhering to the requirements of HIPAA, entities
considered covered entities under HIPAA (such as health plans, healthcare clearinghouses, and certain healthcare providers)
are required to obtain assurances in the form of a written contract from certain business associates to which they transmit PHI (or who
create, receive, transmit or maintain PHI on the covered entitys behalf) to ensure that the privacy and security of such information
is maintained in accordance with HIPAA requirements. HITECH made changes to HIPAA including extending the reach of HIPAA beyond HIPAA
covered entities to business associates, increased the maximum civil monetary penalties for violations of HIPAA, and granted enforcement
authority to state attorneys general. Failure to comply with HIPAA/HITECH can result in civil and criminal liability, including civil
monetary penalties, fines and imprisonment;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the U.S. federal physician payment transparency requirements
under the Affordable Care Act require applicable manufacturers of covered drugs, devices, biologics and medical supplies to report annually
to HHS information related to payments and other transfers of value to physicians, certain other healthcare providers, and teaching hospitals,
and ownership and investment interests held by physicians and certain other healthcare providers and their immediate family members and
applicable group purchasing organizations; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">analogous state laws and regulations, such as state anti-kickback
and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industrys
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers
to report information related to payments and other transfers of value to physicians and certain other healthcare providers or marketing
expenditures. Additionally, state and foreign laws govern the privacy and security of health information in certain circumstances, many
of which differ from each other in significant ways and often are not preempted by HIPAA/HITECH, thus complicating compliance efforts.</span></td>
</tr></tbody></table>

<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Comparable laws and regulations exist in the countries
within the European Economic Area (EEA). Although such laws are partially based upon European Union law, they may vary from
country to country. Healthcare specific, as well as general European Union and national laws, regulations and industry codes constrain,
for example, our interactions with government officials and healthcare practitioners, and the handling of healthcare data. Non-compliance
with any of these laws or regulations could lead to criminal or civil liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Efforts to ensure that
our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.
It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes,
regulations or case law involving applicable fraud and abuse, or other healthcare laws and regulations. If our operations are found to
be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare
and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with
whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In addition, the U.S.
Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making
improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures
may not protect us from reckless or negligent acts committed by our employees, future distributors, licensees or agents. Violations of
these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business,
results of operations and reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Our employees may
engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could subject
us to significant liability and harm our reputation.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are exposed to the
risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with DEA, FDA or EMA
regulations or similar regulations of other foreign regulatory authorities, or to provide accurate information to the DEA, FDA, EMA or
other foreign regulatory authorities. In addition, misconduct by employees could include intentional failures to comply with certain manufacturing
standards, to comply with U.S. federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established
and enforced by comparable foreign regulatory authorities, to report financial information or data accurately, or to disclose unauthorized
activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or
prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which
could result in regulatory sanctions and serious harm to our reputation. We plan to adopt, and will implement and enforce, a Code of Business
Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and
prevent this activity, such as employee training on enforcement of the Code of Business Conduct and Ethics, may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations,
including the imposition of significant fines or other sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>If we are unable
to develop sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions on acceptable
terms, we may be unable to generate revenue.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We do not currently have
any sales, marketing or distribution capabilities. If KLS-13019 or KLS-13023 is approved, we will need to develop internal sales, marketing
and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or enter into collaborations
with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial
and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and
compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to co-promote products with
collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no
assurance that we will be able to enter into such arrangements on acceptable terms, or at all. In entering into third-party marketing
or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties, and there can be no assurance
that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any
approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties,
our business, financial condition and results of operations could be materially adversely affected.</p>

<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Our product candidates,
if approved, may be unable to achieve broad market acceptance and, consequently, limit our ability to generate revenue from new products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Even when product development
is successful and regulatory approval has been obtained, our ability to generate significant revenue depends on the acceptance of our
products by physicians and patients. The market acceptance of any product depends on a number of factors, including the indication statement
and warnings approved by regulatory authorities in the product label, continued demonstration of efficacy and safety in commercial use,
physicians willingness to prescribe the product, reimbursement from third-party payors such as government healthcare systems and
insurance companies, the price of the product, the nature of any post-approval risk management plans mandated by regulatory authorities,
competition, and marketing and distribution support. Any factors preventing or limiting the market acceptance of our product candidates
could have a material adverse effect on our business, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>If we receive regulatory
approvals, we intend to market KLS-13019 and KLS-13023 in multiple jurisdictions where we have limited or no operating experience and
may be subject to increased business and economic risks that could affect our financial results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">If we receive regulatory
approvals, we plan to market KLS-13019 and KLS-13023 in jurisdictions where we have limited or no experience in marketing, developing
and distributing our products. Certain markets have substantial legal and regulatory complexities that we may not have experience navigating.
We are subject to a variety of risks inherent in doing business internationally, including risks related to the legal and regulatory environment
in non-U.S. jurisdictions, including with respect to privacy and data security, trade control laws and unexpected changes in laws, regulatory
requirements and enforcement, as well as risks related to fluctuations in currency exchange rates and political, social and economic instability
in foreign countries. If we are unable to manage our international operations successfully, our financial results could be adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In addition, controlled
substance legislation may differ in other jurisdictions and could restrict our ability to market our products internationally. Most countries
are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic control of narcotic substances,
including cannabis extracts. Countries may interpret and implement their treaty obligations in a way that creates a legal obstacle to
us obtaining marketing approval for KLS-13019 or KLS-13023 in those countries. These countries may not be willing or able to amend or
otherwise modify their laws and regulations to permit KLS-13019 or KLS-13023 to be marketed, or achieving such amendments to the laws
and regulations may take a prolonged period of time. We would be unable to market KLS-13019 or KLS-13023 in countries with such obstacles
in the near future or perhaps at all without modification to laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>KLS-13023 contains
a controlled substance, the use of which may generate public controversy.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Since our product candidates
contain controlled substances, their regulatory approval may generate public controversy. Political and social pressures and adverse publicity
could lead to delays in approval of, and increased expenses for, our product candidates. These pressures could also limit or restrict
the introduction and marketing of our product candidates. Adverse publicity from cannabis misuse or adverse side effects from cannabis
or other cannabinoid products may adversely affect the commercial success or market penetration achievable by our product candidates.
The nature of our business attracts a high level of public and media interest, and in the event of any resultant adverse publicity, our
reputation may be harmed.</p>

<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">KLS-13023 is a formulation
that contains CBD. At present, CBD is deemed a Schedule 1 controlled substance by the DEA under the CSA. Like the drug molecule Epidiolex,
which was recently approved by the FDA for marketing and sale for use in treating Dravet Syndrome and Lennox-Gasteau Syndrome (forms of
child epilepsy), KLS-13023 would need to follow the guidance set forth by the CSA, complete a successful human clinical trial and apply
for rescheduling, as was the case with Epidiolex, now a Schedule 5 drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On January 14, 2019,
we received written notice from the DEA Drug and Chemical Evaluation Section, as follows: Please be advised that your material
meets the definition of Hemp and is not regulated under the CSA, as long as it consists of high purity Cannabidiol (CBD)
that contains approximately 0.1% delta-9- THC. (However, if it contains more than 0.3% delta-9 THC, it is considered Marihuana
and would be in Schedule 1 of the CSA). While this notice is an official notice from the DEA regarding the scheduling of high purity
CBD, we will continue to abide by the CSA in all respects with regards to its treatment and handling of CBD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Any inability to
attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our success largely depends
on the continued service of key management and other specialized personnel, including Dean Petkanas, our chairman and chief executive
officer, William A. Kinney, our chief scientific officer, Mark Corrao, our chief financial officer, and Thomas Kikis, our chief communications
officer. The loss of one or more members of our management team or other key employees could delay our research and development programs
and materially harm our business, financial condition, results of operations and prospects. The relationships that our team has cultivated
within the life sciences industry makes us particularly dependent upon their continued employment with us. Because our management team
is not obligated to provide us with continued service, they could terminate their employment or services with us at any time without penalty,
subject to providing any required advance notice. We do not maintain key person life insurance policies for any members of our management
team.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our future success and
growth will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management
personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face
competition for personnel from other companies, universities, public and private research institutions, government entities and other
organizations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We face substantial
competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The development and commercialization
of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies and specialized biotechnology companies,
as well as products and processes being developed at universities and other research institutions. Our competitors have developed, are
developing or will develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments
include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe
that a significant number of products are currently available, under development, and may become commercially available in the future,
for the treatment of indications for which we may try to develop product candidates. If either of our product candidates, KLS-13019 or
KLS-13023, is approved for the indications we are currently pursuing, it will compete with a range of therapeutic treatments that are
either in development or currently marketed.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are aware of multiple
companies that are working in the cannabis therapeutic area, including pharmaceutical companies such as GW Pharmaceuticals PLC (GW),
which markets Sativex, a botanical cannabinoid oral mucosal for the treatment of spasticity due to multiple sclerosis and which is
also in development in neuropathic pain in several foreign countries and is seeking FDA approval in the United States, and is developing
Epidiolex, a liquid formulation of highly purified CBD extract, as a treatment for Dravet Syndrome, Lennox Gastaut Syndrome, and
various childhood epilepsy syndromes; Insys Therapeutics, Inc., which was seeking FDA approval for an orally-administered liquid formulation
of its synthetic CBD molecule as a treatment for Dravets Syndrome, Lennox Gastaut Syndrome, and other childhood epilepsy syndromes
has filed for bankruptcy and sold their assets to Chilion Group Holdings US; and Nemus Bioscience, Inc., which is focused on the discovery,
development and commercialization of cannabi<i>s</i> therapeutics.</p>

<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On September 27, 2018,
<span style="background-color: white">the DOJ and DEA announced that Epidiolex, the recently approved medication by the FDA, is being
placed in Schedule V of the CSA, the least restrictive schedule of the CSA.</span> On June 26, <span style="background-color: white">2018,
the FDA announced it approved Epidiolex for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut
syndrome and Dravet syndrome, in patients two years of age and older. Epidiolex contains CBD. The CBD in Epidiolex is extracted
from the cannabis plant, and is the first FDA-approved drug to contain a purified extract from the plant. Schedule V drugs represents
the least potential for abuse.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are also aware of Zynerba Pharmaceuticals,
Inc. and its patent-protected synthetic transdermal cannabinoid product candidates, ZYN002 and ZYN001. These cannabinoid product candidates
represent cannabinoid therapeutics for several indications, including refractory epilepsy, FXS, OA, fibromyalgia and peripheral neuropathic
pain. According to Zynerba Pharmaceuticals, Inc., ZYN002 is the first and only synthetic CBD formulated as a permeation-enhanced gel
for transdermal delivery, and is patent-protected through 2030.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">More established companies
may have a competitive advantage over us due to their greater size, cash flows and institutional experience. Compared to us, many of our
competitors may have significantly greater financial, technical and human resources. As a result of these factors, our competitors may
have an advantage in marketing their approved products and may obtain regulatory approval of their product candidates before we are able
to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are safer,
more effective, more widely used and less expensive than ours, and may also be more successful than us in manufacturing and marketing
their products. These advantages could materially impact our ability to develop and commercialize KLS-13019 or KLS-13023 successfully</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our product candidates,
most notably KLS-13023, may compete with non-synthetic cannabinoid drugs, including therapies such as GWs Sativex. Our product
candidates may also compete with medical and recreational marijuana, in markets where the recreational and/or medical use of marijuana
is legal. There is support in the United States for further legalization of marijuana. In markets where recreational and/or medical marijuana
is not legal, our product candidates may compete with marijuana purchased in the illegal drug market. We cannot assess the extent to which
patients may utilize marijuana obtained illegally for the treatment of the indications for which we are developing KLS-13019 and KLS-13023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Mergers and acquisitions
in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific,
management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>The market opportunity
for chemotherapy induced peripheral neuropathy will be limited to those patients who are not currently receiving adequate relief from
current treatment regimens, which may reduce our targeted market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Pre-existing treatments
may be adequate to treat certain patients with chemotherapy induced peripheral neuropathy. Whenever the first-line therapy fails or is
unsuccessful, then second-line therapy may be administered. For chemotherapy induced peripheral neuropathy, KLS-13019 is particularly
targeted to provide an additional treatment option for patients not currently receiving adequate relief from current treatment regimens.
If a more successful first-line therapy is developed, it may significantly reduce the patient population to which we can supply, which
may affect our ability to successfully commercialize KLS-13019 for chemotherapy induced peripheral neuropathy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Product liability
lawsuits against us could cause us to incur substantial liabilities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our planned use of KLS-13019
and KLS-13023 in clinical trials and the sale of KLS-13019 and KLS-13023, if approved, exposes us to the risk of product liability claims.
Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact
with KLS-13019 or KLS-13023. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise
unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects
in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with
alcohol or other drugs, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we become subject to product liability claims and cannot successfully defend ourselves against them, we could incur substantial
liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">withdrawal of patients from our clinical trials;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">substantial monetary awards to patients or other claimants;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">decreased demand for KLS-13019 or KLS-13023 following marketing
approval, if obtained;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">damage to our reputation and exposure to adverse publicity;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">increased FDA or EMA warnings on product labels;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">significant litigation costs;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">distraction of managements attention from our primary
business;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">loss of revenue; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the inability to successfully commercialize KLS-13019 or KLS-13023,
if approved.</span></td>
</tr></tbody></table>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We will need to obtain product liability insurance coverage for
our clinical trials. We may not be able to obtain such coverage at a reasonable cost or in sufficient amounts to protect us against losses,
including if insurance coverage becomes increasingly expensive. Large judgments have been awarded in class action lawsuits based on drugs
that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor,
could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or series of
claims brought against us could cause our share price to decline and, if we are unsuccessful in defending such a claim or claims and the
resulting judgments exceed our insurance coverage, our financial condition, results of operations, business and prospects could be materially
adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Our business and
operations would suffer in the event of computer system failures.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Despite the implementation
of security measures, our information technology and other internal infrastructure systems and those of our CROs and other contractors
and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication
and electrical failures. A significant disruption in the availability of our information technology and other internal infrastructure
systems could cause delays in our research and development work. For instance, the loss of preclinical data or data from any future clinical
trial involving our product candidates could result in delays in our development and regulatory filing efforts and significantly increase
our costs. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be
delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Risks Related to Our Dependence on Third
Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We rely on third
parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual
duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We rely on CROs, clinical
data management organizations and consultants to design, conduct, supervise and monitor preclinical studies of our product candidates
and may do the same for our planned clinical trials. We and our prospective CROs are required to comply with various regulations, including
GCP, which are enforced by the FDA, and guidelines of the Competent Authorities of Member States of the EEA and comparable foreign regulatory
authorities to ensure that the health, safety and rights of patients are protected in clinical development and clinical trials, and that
trial data integrity is assured. Regulatory authorities ensure compliance with these requirements through periodic inspections of trial
sponsors, principal investigators and trial sites. Our reliance on third parties that we do not control does not relieve us of these responsibilities
and requirements. If we or any of our prospective CROs fail to comply with applicable requirements, the clinical data generated in our
clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory
authority, such regulatory authority will determine that any of our clinical trials comply with such requirements. In addition, our clinical
trials must be conducted with products produced under cGMP requirements, which mandate the methods, facilities and controls used in manufacturing,
processing and packaging of a drug product to ensure its safety and identity. Failure to comply with these regulations may require us
to repeat preclinical and clinical trials, which would delay the regulatory approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our prospective CROs
are not our employees, and except for remedies available to us under future agreements with such prospective CROs, we cannot control whether
or not they devote sufficient time and resources to our ongoing clinical and preclinical programs. If the prospective CROs do not successfully
carry out their contractual duties or obligations or meet expected deadlines, or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical
trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our
product candidates. As a result, our operations and the commercial prospects for our product candidates would be harmed, our costs could
increase and our ability to generate revenues could be delayed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Because we have relied on third parties,
our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform
to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service
providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will
be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify
and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party
service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our prospective
CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges
will not have a material adverse impact on our business, financial condition and prospects.</p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We rely on third-party
manufacturers and suppliers, and we intend to rely on third parties to produce preclinical, clinical and commercial supplies of active
pharmaceutical ingredients, or APIs, for KLS-13019 and KLS-13023.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We rely on third parties
to supply the materials for, and manufacture, our research and development, preclinical and clinical trial APIs. We do not own manufacturing
facilities or supply sources for such components and materials. There can be no assurance that our supply of research and development,
preclinical and clinical development drugs and other materials will not be limited, interrupted, restricted in certain geographic regions
or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our API manufacturer could
require significant effort and expertise because there may be a limited number of qualified manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The manufacturing process
for our product candidates is subject to FDA, EMA, DEA and other foreign regulatory authority review. Suppliers and manufacturers must
meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities
in order to comply with regulatory standards such as cGMP. In addition, our manufacturers must ensure therapeutic consistency among batches,
including preclinical, clinical and, if approved, marketing batches. Demonstrating such consistency may require typical manufacturing
controls as well as clinical data. Our manufacturers must also ensure that our batches conform to complex release specifications. Further,
manufacturers of controlled substances must obtain and maintain necessary DEA and state registrations and registrations with applicable
foreign regulatory authorities, and must establish and maintain processes to ensure compliance with DEA and state requirements and requirements
of applicable foreign regulatory authorities governing, among other things, the storage, handling, security, recordkeeping and reporting
for controlled substances. In the event that any of our suppliers or manufacturers fails to comply with such requirements or to perform
its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or
interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities
or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some
cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original
manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology
to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require
us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required
to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that
comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new
manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expect to continue
to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing,
or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations
in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance.
If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms,
we may not be able to develop and commercialize our product candidates successfully. Our or a third partys failure to execute on
our manufacturing requirements could adversely affect our business in a number of ways, including:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">an inability to initiate or continue preclinical studies or
clinical trials of product candidates under development;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">delay in submitting regulatory applications, or receiving regulatory
approvals, for product candidates;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">loss of the cooperation of a collaborator;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">subjecting our product candidates to additional inspections
by regulatory authorities; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">in the event of approval to market and commercialize a product
candidate, an inability to meet commercial demands for our products.</span></td>
</tr></tbody></table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>If a collaborative
partner terminates or fails to perform its obligations under an agreement with us, the commercialization of KLS-13019 or KLS-13023, if
approved, could be delayed or terminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are not currently party to any collaborative
arrangements for the commercialization of KLS-13019 or KLS-13023, if approved, or similar arrangements, although we may pursue such arrangements
before any commercialization of KLS-13019 or KLS-13023, if approved. If we enter into future collaborative arrangements for the commercialization
of any product candidate or similar arrangements and any of our collaborative partners does not devote sufficient time and resources
to a collaboration arrangement with us, we may not realize the potential commercial benefits of the arrangement, and our results of operations
may be materially adversely affected. In addition, if any such future collaboration partner were to breach or terminate its arrangements
with us, the commercialization of any product candidate could be delayed, curtailed or terminated.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Much of the potential
revenue from future collaborations may consist of contingent payments, such as payments for achieving regulatory milestones or royalties
payable on sales of drugs. The milestone and royalty revenue that we may receive under these collaborations will depend upon our collaborators
ability to successfully develop, introduce, market and sell new products. In addition, collaborators may decide to enter into arrangements
with third parties to commercialize products developed under collaborations using our technologies, which could reduce the milestone and
royalty revenue that we may receive, if any. Future collaboration partners may fail to develop or effectively commercialize products using
our products or technologies, which could have a material adverse effect on our operating results and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Business disruptions
affecting our third-party suppliers, manufacturers and CROs could harm our future revenues and financial condition and increase our costs
and expenses.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We rely on third parties
to supply the materials for, and manufacture our APIs for, our preclinical and clinical trials. There are only a limited number of suppliers
and manufacturers of our APIs and our ability to obtain these materials could be disrupted if the operations of these manufacturers are
affected by earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather
conditions, medical epidemics and other natural or man-made disasters or business interruptions. We also rely on CROs, clinical data management
organizations and consultants to design, conduct, supervise and monitor preclinical studies of our product candidates and will do the
same for our planned clinical trials. If their facilities are unable to operate because of an accident or incident, even for a short period
of time, some or all of our research and development programs may be harmed or delayed and our operations and financial condition could
suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Our third-party
manufacturers may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could
be time consuming or costly.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our third-party manufacturers
may use hazardous materials, including chemicals and molecules that could be dangerous to human health and safety or the environment.
The operations of our third-party manufacturers may also produce hazardous waste products. Federal, state and local laws and regulations
govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. In the event of contamination or
injury, our third-party manufacturers could be held liable for damages or be penalized with fines in an amount exceeding their resources,
which could result in our clinical trials or regulatory approvals being delayed or suspended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>If we are unable
to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product candidates,
our competitive position could be harmed.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our commercial success
will depend in large part on our ability to obtain and maintain patent and other intellectual property protection in the U.S. and other
countries with respect to our proprietary technology and products. We rely on trade secret, patent, copyright and trademark laws, and
confidentiality and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect
our proprietary position by filing and prosecuting patent applications in the United States and abroad related to our novel technologies
and products that are important to our business.</p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The patent positions of biotechnology
and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been
the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patents are highly
uncertain. The steps we have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary
information or infringement of our intellectual property rights, both inside and outside the United States. Our pending applications
cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from
such applications. Further, the examination process may require us to narrow the claims for our pending patent applications, which may
limit the scope of patent protection that may be obtained if these applications issue. We do not know whether any of the pending patent
applications for any of our product candidates will result in the issuance of patents that protect our technology or products, or if
any of our issued patents will effectively prevent others from commercializing competitive technologies and products. The rights already
granted under any of our currently issued patents and those that may be granted under future issued patents may not provide us with the
proprietary protection or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology
and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology
and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely
affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and
commercialization activities before it is too late to obtain patent protection on them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Because the issuance
of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our issued patents may be challenged in the courts
or patent offices in the U.S. and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such
patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing
similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Publications
of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and
other jurisdictions are typically not published until 18 months after filing. Therefore, we cannot be certain that we were the first to
make the inventions claimed in our owned patents or pending patent applications, or that we were the first to file for patent protection
of such inventions.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Protecting against the
unauthorized use of our patented technology, trademarks and other intellectual property rights is expensive, difficult and may in some
cases not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our
intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Obtaining and maintaining
our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The USPTO, and various
foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process. Periodic maintenance fees on any issued patent are due to be paid to the USPTO and various
foreign national or international patent agencies in several stages over the lifetime of the patent. While an inadvertent lapse can in
many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of patent rights include, but are
not limited to, failure to timely file national and regional stage patent applications based on our international patent application,
failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit
formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitors might be
able to enter the market, which would have a material adverse effect on our business.</p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We may become subject
to claims by third parties asserting that we or our employees have misappropriated their intellectual property, or claiming ownership
of what we regard as our own intellectual property.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our commercial success
depends upon our ability to develop, manufacture, market and sell our product candidates, and to use our related proprietary technologies
without violating the intellectual property rights of others. We may become party to, or threatened with, future adversarial proceedings
or litigation regarding intellectual property rights with respect to our product candidates, including interference or derivation proceedings
before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in
the future. If we are found to infringe a third partys intellectual property rights, we could be required to obtain a license from
such third party to continue commercializing our product candidates. However, we may not be able to obtain any required license on commercially
reasonable terms or at all. Under certain circumstances, we could be forced, including by court order, to cease commercializing the applicable
product candidate. In addition, in any such proceeding or litigation, we could be found liable for monetary damages. A finding of infringement
could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially
harm our business. Any claims by third parties that we have misappropriated their confidential information or trade secrets could have
a similar negative impact on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">While our preclinical
studies and clinical trials are ongoing, we believe that the use of KLS-13019 and KLS-13023 in these preclinical studies and clinical
trials falls within the scope of the exemptions provided by 35 U.S.C. Section 271(e) in the United States, which exempts from patent infringement
liability activities reasonably related to the development and submission of information to the FDA, or the Clinical Development Exemption.
As KLS-13019 and KLS-13023 progress toward commercialization, the possibility of a patent infringement claim against us increases. We
attempt to ensure that our product candidates and the methods we employ to manufacture them, as well as the methods for their uses we
intend to promote, do not infringe other parties patents and other proprietary rights. There can be no assurance they do not, however,
and competitors or other parties may assert that we infringe their proprietary rights in any event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We may become involved
in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful and have a material
adverse effect on the success of our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Competitors may infringe
our patents or misappropriate or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, litigation
may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or to determine the
validity and scope of our own intellectual property rights or the proprietary rights of others. Also, third parties may initiate legal
proceedings against us to challenge the validity or scope of intellectual property rights we own. These proceedings can be expensive and
time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to defend their
intellectual property rights than we can. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing
upon or misappropriating our intellectual property. Litigation could result in substantial costs and diversion of management resources,
which could harm our business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned
by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents
do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of
being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings
or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on
the price of shares of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>If we are not able
to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be
significantly diminished.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We rely on trade secrets
to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade
secrets are difficult to protect. We rely in part on confidentiality agreements with our current and former employees, consultants, outside
scientific collaborators, sponsored researchers, contract manufacturers, vendors and other advisors to protect our trade secrets and other
proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate
remedy in the event of unauthorized disclosure of confidential information. In addition, we cannot guarantee that we have executed these
agreements with each party that may have or have had access to our trade secrets. Any party with whom we or they have executed such an
agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain
adequate remedies for such breaches.</p>

<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Enforcing a claim that
a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.
In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade
secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom
they disclose such trade secrets, from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to or independently developed by a competitor or other third-party, our competitive position would be harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We may not be able
to protect our intellectual property rights throughout the world.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Filing, prosecuting and
defending patents on all of our product candidates throughout the world would be prohibitively expensive. Therefore, we have filed applications
and/or obtained patents only in key markets such as the United States, Canada, Japan and parts of Europe. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and, further, may be able to export otherwise
infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States.
These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual
property rights may not be effective or sufficient to prevent them from so competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Many companies have encountered
significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing
of competing products in violation of our proprietary rights generally. For example, an April 2014 report from the Office of the United
States Trade Representative identified a number of countries, including India and China, where challenges to the procurement and enforcement
of patent rights have been reported. Several countries, including India and China, have been listed in the report every year since 1989.
As a result, proceedings to enforce our patent rights in certain foreign jurisdictions could result in substantial cost and divert our
efforts and attention from other aspects of our business and could be unsuccessful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Patent terms may be inadequate
to protect our competitive position on our product candidates for an adequate amount of time.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire
before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if
available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration
Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved
indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the
FDA and the USPTO, and any equivalent regulatory authorities in other countries, may not agree with our assessment of whether such extensions
are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs,
our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical
data and launch their product earlier than might otherwise be the case.</p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Intellectual property
rights do not necessarily address all potential threats to our competitive advantage.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not
adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">others may be able to make molecules that are the same as or
similar to our product candidates but that are not covered by the claims of the patents that we own;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">we might not have been the first to make the inventions covered
by the issued patents or pending patent applications that we own;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">we might not have been the first to file patent applications
covering certain of our inventions;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">others may independently develop similar or alternative technologies
or duplicate any of our technologies without infringing our intellectual property rights;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">it is possible that our pending patent applications will not
lead to issued patents;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">issued patents that we own may not provide us with any competitive
advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">our competitors might conduct research and development activities
in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development
activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop
competitive products for sale in our major commercial markets;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">we may not develop additional proprietary technologies that
are patentable; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the patents of others may have an adverse effect on our business.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Risks Related to Ownership of Our Common
Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We do not know
whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will
be, and as a result, it may be difficult for you to sell your shares of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Historically, there has
not been an active market for shares of our common stock. An active trading market for our shares may never develop or be sustained in
the future. The lack of an active market may impair the ability of our stockholders to sell their shares at the time and at such price
as they consider reasonable. The lack of an active market may also reduce the fair market value of shares of our common stock. Further,
an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter
into collaborations or acquire companies or products by using our shares of common stock as consideration.</p>

<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>The market price
of our stock may be volatile, and stockholders could lose all or part of their investment.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The trading price of
our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond
our control. In addition to the factors discussed in this Risk Factors section and elsewhere in this annual report, these
factors include, without limitation:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">trading volatility of low-priced stock;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the success of competitive products;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory actions with respect to our product candidates or
our competitors products and product candidates;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated changes in our growth rate relative to
our competitors;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">announcements by us or our competitors of significant acquisitions,
strategic partnerships, joint ventures, collaborations or capital commitments;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">results of clinical trials of KLS-13019, KLS-13023 or product
candidates of our competitors;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">regulatory or legal developments in the United States and other
countries;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">developments or disputes concerning patent applications, issued
patents or other proprietary rights;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the recruitment or departure of key personnel;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the level of expenses related to our preclinical and clinical
development programs;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the results of our efforts to in-license or acquire additional
product candidates or products;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated changes in estimates as to financial
results, development timelines or recommendations by securities analysts;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">variations in our financial results or those of companies that
are perceived to be similar to us;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">fluctuations in the valuation of companies perceived by investors
to be comparable to us;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">share price and volume fluctuations attributable to inconsistent
trading volume levels of our common stock;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">announcement or expectation of additional financing efforts;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">sales of our common stock by us, our insiders or our other
stockholders;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">changes in the structure of healthcare payment systems;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">market conditions in the pharmaceutical sector; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">general economic, industry and market conditions.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In addition, the stock
market in general, and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often
been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect
the market price of our common stock, regardless of our actual operating performance. Moreover, some institutional investors and mutual
funds cannot invest in stocks priced below $5.00 per share. The realization of any of these risks or any of a broad range of other risks,
including those described in these Risk Factors, could have a dramatic and material adverse impact on the market price of
our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>We may be subject
to securities litigation, which is expensive and could divert our managements attention.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The market price of our
common stock may be volatile, and in the past certain companies that have experienced volatility in the market price of their stock have
been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation
against us could result in substantial costs and divert our managements attention from other business concerns, which could seriously
harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Our common stock is classified as a penny
stock under SEC Rules and Regulations, which means there may be very limited trading market for our shares</i>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our common stock is deemed to be penny
stock as that term is defined in Rule 3a51-1 of the Securities Exchange Act of 1934, as amended (the Exchange Act).
Penny stocks are stocks (i) with a price of less than five dollars per share; (ii) that are not traded on a recognized national
exchange; (iii) whose prices are not quoted on an automated quotation system sponsored by a registered national securities association;
or (iv) whose issuer has net tangible assets less than $2,000,000 (if the issuer has been in continuous operation for at least three years);
or $5,000,000 (if in continuous operation for less than three years); or with average revenues of less than $6,000,000 for the last three
years.</p>


<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Section 15(g) of the Exchange Act and Rule
15g-2 promulgated thereunder require broker dealers dealing in penny stocks to provide potential investors with a document disclosing
the risks of penny stocks and to obtain a manually signed and dated written receipt of the document before effecting any transaction in
a penny stock for the investors account. Potential investors in our common stock are urged to obtain and read such disclosure carefully
before purchasing any shares that are deemed to be penny stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Moreover, Rule 15g-9 of the Exchange Act requires
broker dealers in penny stocks to approve the account of any investor for transactions in such stocks before selling any penny stock to
that investor. This procedure requires the broker dealer to (i) obtain from the investor information concerning his, her or its financial
situation, investment experience and investment objectives; (ii) reasonably determine, based on that information, that transactions in
penny stocks are suitable for the investor, and that the investor has sufficient knowledge and experience as to be reasonably capable
of evaluating the risks of penny stock transactions; (iii) provide the investor with a written statement setting forth the basis on which
the broker dealer made the determination in (ii) above; and (iv) receive a signed and dated copy of such statement from the investor,
confirming that it accurately reflects the investors financial situation, investment experience and investment objectives. Compliance
with these requirements may make it more difficult for investors in our common stock to resell their shares to third parties or to otherwise
dispose of such shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Insiders have substantial influence
over us and could delay or prevent a change in corporate control.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">As of April 15, 2022,
our executive officers, directors, and holders of 5.0% or more of our capital stock collectively beneficially owned approximately 65.53%
of our voting stock. This concentration of ownership could harm the market price of our common stock by:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">delaying, deferring or preventing a change in control of our
company;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">impeding a merger, consolidation, takeover or other business
combination involving our company; or</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">discouraging a potential acquirer from making a tender offer
or otherwise attempting to obtain control of our company.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The interests of this
group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner
that advances their best interests and not necessarily those of other stockholders, including by seeking a premium value for their common
stock, and might negatively affect the prevailing market price for our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>If we are unable to maintain effective internal
control over our financial reporting, the reputational effects could materially adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Under
the provisions of Section 404(a) of the Sarbanes-Oxley Act of 2002, as amended by the Dodd Frank Wall Street Reform and Consumer Protection
Act of 2010, the SEC adopted rules requiring public companies to perform an evaluation of Internal Control over Financial Reporting (Internal
Controls) and to report on our evaluation in our Annual Report on Form 10-K. Our Internal Controls constitute a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with
GAAP. If in the future we are unable to maintain effective Internal Controls, additional resulting material restatements could occur, regulatory
actions could be taken, and a resulting loss of investor confidence in the reliability of our financial statements could occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Our disclosure controls and procedures
may not prevent or detect all errors or acts of fraud.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are subject to the
periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information
required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded,
processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure
controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not
absolute, assurance that the objectives of the control system are met.</p>

<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">These inherent limitations
include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized
override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures
due to error or fraud may occur and not be detected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Because we do not
anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source
of gain.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We have never declared
or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and
development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result,
capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>We have issued Preferred Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our Certificate of Incorporation authorizes the
issuance of up to 5,000,000 shares of Preferred Stock with designations, rights and preferences determined from time to time by the Board
of Directors. There are currently 75 shares of Series A Preferred Stock and 75 shares of Series B Preferred Stock outstanding. The holders
of our Preferred Stock have voting control of the Company. Accordingly, our Board of Directors is empowered, without stockholder approval,
to issue Preferred Stock with dividend, liquidation, conversion, voting, or other rights which could adversely affect the voting power
or other rights of the holders of the Common Stock. The issuance of Preferred Stock could be utilized, under certain circumstances, as
a method of discouraging, delaying or preventing a change in control of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><span id="ITEM1B"></span>ITEM 1B. UNRESOLVED STAFF COMMENTS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><span id="ITEM2"></span>ITEM 2. PROPERTIES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We do not own any real estate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our principal executive offices are located at
3805 Old Easton Road, Doylestown, PA 18902. Our telephone number at that address is (858) 883-2642. We have additional offices located
at 4 Knoll Court, Lloyd Harbor, N.Y. 11743. On April 1, 2014, we entered into a one year lease arrangement for office space, with the
option to renew the lease annually, which we have continued to do. The monthly rent payment is currently $5,600, and we provided a security
deposit of $15,000. The lease has been renewed through May 2023 at $5,800 per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 15, 2015, we entered into a one year
lease arrangement with the Bucks County Biotechnology Center, Inc. for additional office space in Doylestown, P.A, which lease is currently
scheduled to expire on September 30, 2021. The monthly rent payment is $359, and we provided a security deposit of $183.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 1, 2018, we entered into a month to
month lease arrangement with the Bucks County Biotechnology Center, Inc. for laboratory space. The monthly rent payment is $500.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On July 1, 2018, we entered into a one year lease
arrangement with the Bucks County Biotechnology Center Inc. for additional office space, with the option to renew the lease annually.
On September 1, 2018, we subleased this office space to a third party. The subleasee will pay 50% of the rent until expiration of lease
on June 30, 2021. The monthly rent payment is $2,723, and we provided a security deposit of $2,121.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On June 30, 2021, we entered into a
third amendment to lease agreement with the Bucks County Biotechnoogy Center, Inc. for additional laboratory and office space. This third
amendment extends our lease in Doylestown, PA through June 30, 2024. The monthly rent payment for all office and laboratory space in Doylestown,
PA is $6,023 per month.</p>

<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We believe that these premises are suitable for
the conduct of our business, and that our existing facilities are sufficient to accommodate our current and future operations, at least
in the near-term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="ITEM3"></span><b>ITEM 3. LEGAL PROCEEDINGS.</b>&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif">There are no pending legal proceeding relating to our company and its
CEO to which we are a party, and to our knowledge there are no material proceedings to which any of our directors, executive officers
or affiliates is a party adverse to us or which have a material interest adverse to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><span id="ITEM4"></span><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">Not applicable.</p>


<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>ITEM 5. MARKET FOR REGISTRANTS COMMON
EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our common stock is quoted on the OTCQB Marketplace
operated by the OTC Markets Group, Inc., under the ticker symbol NPTX. There was no established public trading market in
our securities from the time of our initial public offering went effective on July 15, 2016 until a market established on or about December
5, 2019. Trading of securities on the OTCQB is often sporadic and investors may have difficulty buying and selling or obtaining market
quotations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table sets forth the reported high and low closing
bid prices for our common stock as reported on the OTCQB for the following periods. These market quotations reflect inter-dealer prices,
do not include retail mark-ups, markdowns or commissions, and may not necessarily represent actual transactions.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">High</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">Low</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Fiscal Year Ended December 31, 2021</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">First Quarter</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.35</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.108</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Second Quarter</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.171</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.101</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Third Quarter</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
                                 <p style="margin-top: 0; margin-bottom: 0">$</p></td><td style="text-align: right">0.04</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fourth Quarter</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.038</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.075</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Fiscal Year Ended December 31, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fourth Quarter</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.76</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.14</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Holders of Record</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of April 15, 2022, there were approximately
1,200 holders of record of our common stock. This number was derived from our shareholder records, and does not include beneficial owners
of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have not paid, nor declared, any cash dividends
since our inception and do not intend to declare or pay any such dividends in the foreseeable future. Our ability to pay cash dividends
is subject to limitations imposed by state law.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Equity Compensation Plan Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">See Part III, Item 12. Securities Ownership
of Certain Owners and Management and Related Stockholder Matters for information regarding securities authorized for issuance under
equity compensation plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the fourth quarter
of 2021, the Company issued 598,385 shares of common stock to an investor for the conversion of $16,017 of principal and accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Issuer Repurchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We did not repurchase any shares of our common
stock during the fourth quarter of the fiscal year covered by this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 6. SELECTED FINANCIAL DATA.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">Not applicable to a smaller reporting company as defined
in Item 10(f)(1) of SEC Regulation S-K.</p>


<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>You should read the following discussion and
analysis of our financial condition and operating results together with our consolidated financial statements and related notes included
elsewhere in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain
forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual
results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those
set forth under Risk Factors or in other parts of this annual report. The last day of our fiscal year is December 31. Our
fiscal quarters end on March 31, June 30, September 30, and December 31, and our current fiscal year ended on December 31, 2021.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Business Developments </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company was originally incorporated in the
State of Delaware on March 25, 2013 under the name TYG Solutions Corp. Our original business plan was to develop iPhone and Android smartphone
apps for companies who need an app for their internal and external operations. We subsequently expanded our operations to offering corporate
website design services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On July 25, 2018, the Company entered into a Share
Exchange Agreement with Kannalife Sciences, Inc., a Delaware corporation (Kannalife Sciences), and certain stockholders
of Kannalife Sciences (the Kannalife Sciences Stockholders). Pursuant to the terms of the Share Exchange Agreement, the
Company acquired substantially all of the issued and outstanding shares of Kannalife Sciences by means of a share exchange with the Kannalife
Sciences Stockholders in exchange for newly issued shares of the common stock of the Company (the Share Exchange). As a
result of the Share Exchange, Kannalife Sciences became a 99.7% owned subsidiary of the Company. The business operations of the Company
regarding iPhone and Android smartphone apps was reduced significantly to focus efforts on target therapeutics and drug discovery, and
accordingly, by virtue of the Share Exchange, the Company acquired the business of Kannalife Sciences including all of its assets. The
Share Exchange was accounted for as a reverse acquisition and change in reporting entity, whereby Kannalife Sciences was the accounting
acquirer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kannalife Sciences was incorporated
in the State of Delaware on August 11, 2010. Kannalife Sciences is a developmental stage phyto-medical/pharmaceutical and drug discovery
company that specializes in the research, development of cannabinoid and cannabinoid-based therapeutic products derived from synthetic
and botanical sources, including the Cannabis<i>&nbsp;</i>taxa<i></i>&nbsp;(the word taxa is the plural of
taxon, which defines a group of one or more populations of an organism or organisms to form a unit). On November 9, 2018,
the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State to change its name to Kannalife,
Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change to KLFE,
and such action went effective on January 17, 2019. &nbsp;Kannalife Sciences remains a wholly owned operational subsidiary of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On November 9, 2018,
the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State to change its name to Kannalife,
Inc. The Company concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change to KLFE
and such action went effective on January 17, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On November 4, 2020, the Company filed an amendment
to its certificate of incorporation with the Delaware Secretary of State to change its name to Neuropathix, Inc. The Company
concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change from KLFE to
NPTX. The Companys name change and ticker symbol change was reviewed and processed by FINRA, and went effective November
6, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 16, 2021, the Company
established and incorporated a new wholly owned subsidiary named Dermique Incorporated (Dermique). Dermique was established
by the Company to hold, operate and commercialize all intellectual property associated with Kannalife Sciences previous research
and development efforts to create and commercialize novel therapeutic topical over-the-counter cosmeceutical compounds to treat a variety
of skin disorders, including but not limited to atopic dermatitis.</p>

<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Business Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As a result of the Share Exchange, our core businesses
are comprised of the following:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"></td><td style="width: 5pt"></td><td style="text-align: justify">A drug development company focused on the research and development (R&amp;D) of synthetic
and phyto-medical products from:</td>
</tr></tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify">
naturally recurring sources, including but not limited to cannabis, hemp, and other similar species of plantae;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify">
semi-synthetic sources; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify">
synthetic and bio-synthetic sources.</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Drug discovery platform to evaluate and potentially treat neurological
and oxidative stress related disorders such as OHE, CTE and CIPN with high quality assured, quality controlled cGMP pharmaceutical grade
semi-synthetic and synthetic cannabinoids, CBD, and CBD-like molecules.</span></td>
</tr></tbody></table>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Topical skincare pre-clinical program designed to some of our
patented, proprietary CBD-derived NCEs, for use as topical solutions, ointments, and creams for disorders such as diabetic neuropathies,
diabetic ulcers, and for use as an anti-pruritic. Anti-pruritics are known as anti-itch drugs and medications that inhibit the itching
often associated with a variety of disorders and diseases.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Phyto cannabinoids
are a class of molecules derived from cannabis plants. The two primary cannabinoids contained in Cannabis are CBD and D9-tetrahydrocannabinol,
or THC. Clinical and preclinical data suggest that CBD has positive effects on treating refractory epilepsy, FXS and arthritis, and THC
has positive effects on treating pain. Interest in cannabinoid therapeutics has increased significantly over the past several years as
preclinical and clinical data has emerged highlighting the potential efficacy and safety benefits of cannabinoid therapeutics. The cannabinoid
therapeutics market is expected to grow significantly due to the potential benefits these products may provide over existing therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">KLS-13019s advanced
formulation is designed to improve on some of the limitations associated with CBD, including but not limited to CBDs low bioavailability
and limited drug like properties. However, KLS-13019 has not been reviewed or approved for patient use by the FDA or any other healthcare
authority in the world. Our pre-clinical studies suggest increased bioavailability, consistent plasma levels and the avoidance of first-pass
liver metabolism. In addition, an <i>in vitro </i>study performed by us demonstrated that CBD is degraded to THC in an acidic environment
such as the stomach.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In the past three years,
our most recent research and development efforts have been centered on the use of KLS-13019 as a neuroprotectant and therapeutic agent
to treat chronic and neuropathic pain. There is currently no FDA approved drug to treat CIPN. Our preclinical efforts in the research
and development of treating CIPN with our lead compound KLS-13019 have been fostered by a successful study grant from NIH-NIDA that compared
KLS-13019 to CBD in the prevention and reversal of neuropathic pain in animal models. As a result of the outcome of this and other preclinical
studies, we believe there is strong evidence to support the use of KLS-13019 as a non-opioid solution to chronic and neuropathic pain
in human clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We intend to study KLS-13019
in patients with chemotherapy induced neuropathic pain, and we intend to study KLS-13023 in patients with mild traumatic brain injury.
We believe that the claims made in the Pat. 9,611,213 and Pat. 10,004,722 sufficiently cover the use of the novel molecule KLS-13019 in
the treatment of neuropathic pain, which is broadly defined and includes chemotherapy induced neuropathic pain (a/k/a: chemotherapy induced
peripheral neuropathy).</p>

<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To date, we have synthesized, pre-clinically tested
and patented our proprietary CBD like NCEs, including KLS-13019, and also formulated a new CBD based molecule, KLS-13023. KLS-13023 is
a target drug candidate that includes a synthetic CBD formulated in a gel capsule designed for potential use in humans, which is intended
to enable more effective delivery of CBD. The formulation of this product is proprietary and currently held as a trade secret of the Company.
CBD is the primary non-psychoactive component of cannabis. KLS-13023 has undergone a manufacturing feasibility study to improve some of
the limitations associated with CBD, including but not limited to CBDs low bioavailability and limited drug like properties and
improvement of the delivery of CBD through the first pass in the gut and into the circulatory system. In our preclinical animal studies,
KLS-13023 demonstrated effective intervention of neurodegeneration in the OHE disease state. We intend to study KLS-13023 in patients
with mild traumatic brain injury. In our preclinical animal studies, KLS-13023 demonstrated effective intervention of neurodegeneration
in the OHE disease state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We believe these product
candidates will provide new treatment options for patients, as well as additional treatment options for patients not currently receiving
adequate relief from current treatment regimens.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We are still conducting pre-clinical studies and
have not yet commenced our clinical program or tested KLS-13019 or KLS-13023 in humans. For KLS-13019, we plan to conduct Phase 1, and
possibly Phase 2, clinical trials in either the United States or Australia, subject to applicable regulatory approval. We plan to conduct
our Phase 1 clinical trials for KLS-13023 in either the United States or Australia, subject to applicable regulatory approval. We plan
to submit NDAs for KLS-13019 and KLS-13023 to the FDA upon completion of all requisite clinical trials. We expect to initiate clinical
trials for KLS-13019 and KLS-13023 in the first half of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We plan to conduct our Phase 1, and possibly Phase
2, clinical trials for KLS-13019 in the U.S. or Australia, subject to applicable regulatory approval, and do not expect at this time to
file an investigational new drug application, or IND, with the U.S. Food and Drug Administration, or the FDA, prior to the commencement
of those clinical trials. We must file an IND with the FDA and receive approval from the U.S. Drug Enforcement Agency, or DEA, prior to
commencement of any clinical trials in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;<b>Pharmacokinetic and Pharmacodynamic Comparison
Between KLS-13019 and CBD</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Results from PK and PD studies performed in evaluating CBD versus
KLS-13019 have shown KLS-13019 to be superior in aqueous solubility (potential for drug absorption after oral administration); Log P
(ratio which measures difference in solubility in two phases); bioavailability (proportion of the drug that enters the circulation);
and C max at 10 mg/kg, p.o. (peak serum concentration).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_011.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_011.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Results from our pre-clinical efforts in the potential
treatment of OHE and the potential treatment of CIPN have shown a marked improvement over 99.7% pure pharmaceutical grade synthetic CBD
in side by side pre-clinical comparison. In a pre-clinical comparison for neuroprotection between CBD and KLS-13019, results indicated
increased potency for the new molecule (KLS-13019) as determined by six assays, while both molecules exhibited efficacy in preventing
oxidative stress-related toxicities back to control values.</p>

<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Treatment with KLS-13019 alone, however, was 5-fold less toxic
than CBD. Previous studies suggested that CBD targeted the Na<sup>+&nbsp;</sup>Ca<sup>2+</sup>&nbsp;(sodium-calcium) exchanger in mitochondria
to regulate intracellular calcium levels, an important determinant of neuronal survival. After treatment with an inhibitor, the mNCX
inhibitor (CGP-37157), no detectable neuroprotection from ethanol toxicity was observed for either CBD or KLS-13019. Furthermore,
AM630 (a CB2 antagonist) significantly attenuated CBD-mediated neuroprotection, while having no detectable effect on KLS-13019 neuroprotection.
Our studies indicated KLS-13019 was more potent and less toxic than CBD. Both molecules can act through mNCX. Based on these results,
amongst other things, we believe that KLS-13019 may provide an alternative to CBD as a therapeutic candidate to treat disease associated
with oxidative stress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_012.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_012.jpg"></p>

<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_013.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_013.jpg"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As previously noted, comparisons between CBD and
KLS-13019 have been published in peer reviewed articles in ACS Medicinal Chemistry Letters (2016, 7, 424-428) and Journal of Molecular
Neuroscience (14 August 2018).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additional follow on studies recently published
on May 10, 2019 in the&nbsp;<i>Journal of Molecular Neuroscience</i>&nbsp;have further advanced our studies on the mechanism of action
for CBD and KLS-13019 in pre-clinical testing for the treatment of CIPN.&nbsp;The mechanism of action for CBD-and KLS-13019-mediated protection
now has been explored with dissociated dorsal root ganglion (DRG) cultures using small interfering RNA (siRNA) to the mitochondrial
Na+ Ca2+ exchanger-1 (mNCX-1). Treatment with this siRNA produced a 5055% decrease in the immunoreactive (IR)
area for mNCX-1 in neuronal cell bodies and a 7280% decrease in neuritic IR area as determined with high-content image analysis.
After treatment with 100 nM KLS-13019 and siRNA, DRG cultures exhibited a 75 5% decrease in protection from paclitaxel-induced
toxicity, whereas siRNA studies with 10 M CBD produced a 74 3% decrease in protection. Treatment with mNCX-1 siRNA alone did
not produce toxicity. The protective action of cannabidiol and KLS-13019 against paclitaxel-induced toxicity during a 5-h test period
was significantly attenuated after a 4-day knockdown of mNCX-1 that was not attributable to toxicity. This data indicates that decreases
in neuritic mNCX-1 corresponded closely with decreased protection after siRNA treatment. Pharmacological blockade of mNCX-1 with CGP-37157
produced complete inhibition of cannabinoid-mediated protection from paclitaxel in DRG cultures, supporting the observed siRNA effects
on mechanism.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;<span style="background-color: white">Sodium-Calcium
Exchanger (NCX)&nbsp;</span>(often denoted Na<sup>+</sup>/Ca<sup>2+</sup>&nbsp;exchanger, NCX, or exchange protein) is an
antiporter membrane protein that removes calcium from cells. The exchanger exists in many different cell types and animal species. The
NCX is considered to be one of the most important cellular mechanisms for removing Ca<sup>2+</sup>&nbsp;(calcium ions) from cells. The
exchanger is usually found in the plasma membranes and the mitochondria and endoplasmic reticulum of excitable cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mitochondria&nbsp;<span style="background-color: white">is
a double-</span>membrane<span style="background-color: white">-bound&nbsp;</span>organelle<span style="background-color: white">&nbsp;found
in most&nbsp;</span>eukaryotic<span style="background-color: white">&nbsp;organisms. Mitochondria generate most of the cells supply
of&nbsp;</span>adenosine triphosphate<span style="background-color: white">&nbsp;(ATP), used as a source of&nbsp;</span>chemical
energy<span style="background-color: white">. ATP is a complex organic chemical that provides energy to drive many processes in living
cells, including muscle contractions, nerve impulse propagation and chemical synthesis.&nbsp;</span>&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">According to Fallon,
et al. in the March/April 2006 edition of Clinical Medicine, pain is uncontrolled with opioid treatments in approximately 20% of patients
with advanced cancer, or 420,000 people in the United States. There are currently no FDA approved non-opioid treatments for patients who
do not respond to, or experience negative side effects with, opioid medications. We believe that KLS-13019 has the potential to address
a significant unmet need in this large market by treating patients with a product that employs a differentiated non-opioid mechanism of
action, and offers the prospect of pain relief without increasing opioid-related adverse side effects.&nbsp;</p>

<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition to the ACS publication, our research
and development efforts with KLS-13019 were also the subject of peer reviewed, preclinical studies published in April 2021 in the British
Journal of Pharmacology, Behavioural and Pharmacological Effects of Cannabidiol (CBD) and the Cannabidiol Analogue KLS-13019 in
Mouse Models of Pain and Reinforcement reported the following key results:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">Like CBD, KLS-13019 prevented the development
of mechanical sensitivity associated with paclitaxel administration.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">In contrast to CBD, KLS-13019 was also
effective at reversing established mechanical sensitivity.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">KLS-13019 significantly attenuated
acetic acid-induced stretching and produced modest effects in the hot plate assay.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-family: Arial, Helvetica, Sans-Serif"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="color: #1C1D1E; background-color: white">KLS-13019 was devoid of activity at
-, - or -opioid receptors. Lastly, KLS-13019, but not CBD, attenuated the reinforcing effects of palatable food or
morphine.</span></td>
</tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following chart indicates opioid inhibition percentages
for both CBD and KLS-13019</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_014.jpg" src="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/image_014.jpg">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The study also reported the following conclusions
and Implications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="color: #1C1D1E; background-color: white">KLS-13019
like CBD, prevented the development of CIPN, while KLS-13019 uniquely attenuated established CIPN. Because KLS-13019 binds to fewer biological
targets, this will help to identifying molecular mechanisms shared by these two compounds and those unique to KLS-13019. Lastly, KLS-13019
may possess the ability to attenuate reinforced behaviour, an effect not observed in the present study with CBD.</span> <b>Clinical Timelines</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As a result of the unprecedented
effects of COVID-19, we have updated our clinical timelines to give effect to the significant interruption to business and financial operations
worldwide as a result of the COVID-19 crisis. We will continue to monitor the progress of the shutdowns currently in effect, and revise
our clinical timelines accordingly.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 11%"><p style="font: 10pt Times New Roman, Times, Serif"><b>Product Candidate</b></p></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Target Indication</b></span></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 18%; text-align: center"><span style="font-size: 10pt"><b>Delivery
    Method</b></span></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; width: 13%"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Current Development Status</b></p></td>
    <td style="width: 1%; text-align: center"><b>&nbsp;</b></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 22%; text-align: center"><span style="font-size: 10pt"><b>Expected
    Next Steps</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">KLS-13019</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Chemotherapy Induced</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">2Q24: Initiate Phase 1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Peripheral Neuropathy</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Mild Traumatic Brain Injury</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">1Q25: Initiate Phase 1</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">KLS-13023</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Overt Hepatic Encephalopathy</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">3Q24: Initiate Phase 1</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Mild Traumatic Brain Injury</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">Oral Gel Capsule</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">Preclinical</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-size: 10pt">1Q25: Initiate Phase 1</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">With respect to certain other
proprietary compounds underlying Pat. 9,611,213, we plan on pursuing topical solutions as potential relief creams and/or ointments for
neuropathic pain, anti-inflammation, anti-pruritic and skin ulcers. We are considering commercialization routes that include, but are
not limited to, filing and FDA Monograph and have already pursued and completed a commercialization path to the marketplace having received
INCI certification and registration with the PCPC for LEA<span style="font-family: Symbol"></span>.</p>

<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In preclinical testing, certain
molecules under Pat. 9,611,213 were screened for neuroprotection and may have the potential mechanism of action for reducing inflammation
and neuropathic pain. These molecules indicate that they are more soluble than CBD, also deemed a neuroprotectant with potential anti-inflammatory
properties. A molecule that is potentially more water soluble than CBD in this regard may be good candidate(s) for use in topical applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We believe that we will be
able to raise sufficient capital to proceed forth with a Phase 1a human safety trial for the treatment of Chemotherapy Induced Peripheral
Neuropathy. All preclinical work in this indication, including animal toxicity studies, are expected to be completed before the end of
the third quarter 2023. We plan on entering into clinical trials sometime in the second quarter 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Additionally, we believe that
we will be able to raise sufficient capital to proceed forth with a Phase 1a human safety trial for the treatment of Overt Hepatic Encephalopathy.
All preclinical work in this indication, including animal toxicity studies, are expected to be completed before the end of the first quarter
2024.&nbsp;We plan on entering into clinical trials sometime in the third quarter 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We intend to seek additional
capital to proceed with our business plan regarding additional drug pipeline opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Components of Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">For the year ended December
31, 2021, our loss from operations was $2,940,636 and our net loss was $3,557,786. For the year ended December 31, 2020, our loss from
operations was $4,473,728 and our net loss was $4,537,275. We expect to incur losses for the foreseeable future, and we expect these losses
to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks
and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or
if, we will be able to achieve or maintain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><i>Financial Operations
Overview</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The following discussion
sets forth certain components of our statements of operations as well as factors that impact those items.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><i>Revenues</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our revenues consist
of state and federal research grants and fees received from research services for third-party product development. These revenues are
recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed
or determinable and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our research and development
expenses consist of expenses incurred in development and preclinical studies relating to our product candidates, including:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">expenses associated with preclinical development;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">personnel-related expenses, such as salaries, benefits, travel
and other related expenses, including stock-based compensation;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">payments to third-party contract research organizations, or
CROs, contractor laboratories and independent contractors; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">depreciation, maintenance and other facility-related expenses.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expense all research
and development costs as incurred. Preclinical development expenses for our product candidates are a significant component of our current
research and development expenses. Product candidates in later stage clinical development generally have higher research and development
expenses than those in earlier stages of development, primarily due to increased size and duration of the clinical trials. We track and
record information regarding external research and development expenses for each grant, study or trial that we conduct. From time to time,
we intend to use third-party CROs, and have used contractor laboratories and independent contractors in preclinical studies. We recognize
the expenses associated with third parties performing these services for us in our preclinical studies based on the percentage of each
study completed at the end of each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We incurred research
and development expenses of $451,779 and $1,095,405 for the years ended December 31, 2021 and 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expect that our research
and development expenses in 2022 and for the next several years will be higher than in 2021 as a result of the work needed for our expected
initiation of our Phase 1 clinical trials of KLS-13019 and KLS-13023. These expenditures are subject to numerous uncertainties regarding
timing and cost to completion. Completion of our preclinical development and clinical trials may take several years or more and the length
of time generally varies according to the type, complexity, novelty and intended use of a product candidate. The cost of clinical trials
may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the number of sites included in the clinical trials;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the length of time required to enroll suitable patients;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the size of patient populations participating in the clinical
trials;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the duration of patient follow-ups;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the development stage of the product candidates; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the efficacy and safety profile of the product candidates.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due to the early stages of our research
and development, we are unable to determine the duration or completion costs of our development of KLS-13019 and KLS-13023. As a result
of the difficulties of forecasting research and development costs of KLS-13019 and KLS-13023 as well as the other uncertainties discussed
above, we are unable to determine when and to what extent we will generate revenues from the commercialization and sale of an approved
product candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><i>General and Administrative
Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">General and administrative
expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in
our executive, finance, accounting, legal and human resource functions. Our general and administrative expenses also include facility
and related costs not included in research and development expenses, professional fees for legal services, including patent-related expenses,
consulting, tax and accounting services, insurance and general corporate expenses. We expect that our general and administrative expenses
will increase with the continued development and potential commercialization of our product candidates.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We expect that our general
and administrative expenses in 2022 and for the next several years will be higher than in 2021 as we increase our headcount. We also anticipate
increased expenses relating to our operations as a public company, including increased costs for the hiring of additional personnel, and
for payment to outside consultants, including lawyers and accountants, to comply with additional regulations, corporate governance, internal
control and similar requirements applicable to public companies, as well as increased costs for insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Interest Income (Expense), net</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Interest income consists
primarily of interest earned on our money market bank account. Interest expense consists of interest expense on our notes payable.</p>

<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Income Taxes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">As of December 31, 2021,
we had approximately $8.8 million of federal operating loss carryforwards. These operating loss carryforwards will begin to expire in
2033. The Tax Reform Act of 1986, or the Act, provides for limitation on the use of net operating loss and research and development tax
credit carryforwards following certain ownership changes (as defined by the Act) that could limit our ability to utilize these carryforwards.
We may have experienced various ownership changes, as defined by the Act, as a result of past financings. Accordingly, our ability to
utilize the aforementioned carryforwards may be limited. Additionally, U.S. tax laws limit the time during which these carryforwards may
be applied against future taxes; therefore, we may not be able to take full advantage of these carryforwards for federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The closing of the Share
Exchange transaction, together with private placements and other transactions that have occurred since our inception, may trigger, or
may have already triggered, an ownership change pursuant to Section 382 of the Internal Revenue Code of 1986. If an ownership
change is triggered, it will limit our ability to use some of our net operating loss carryforwards. In addition, since we will need to
raise substantial additional funding to finance our operations, we may undergo further ownership changes in the future, which could further
limit our ability to use net operating loss carryforwards. As a result, if we generate taxable income, our ability to use some of our
net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could result in increased
future tax liability to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Critical Accounting Policies and Use of
Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We have based our managements
discussion and analysis of financial condition and results of operations on our consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements
requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
at the date of the consolidated financial statements as well as the reported revenues and expenses during the reporting periods. On an
ongoing basis, we evaluate our estimates and judgments, including those related to preclinical development expenses, stock-based compensation,
convertible debt and derivative liabilities. We base our estimates on historical experience and on various other factors that we believe
to be appropriate under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">While our significant
accounting policies are more fully discussed in note 2 to our audited consolidated financial statements appearing at the end of this annual
report, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in
the preparation of our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b><i>Research and Development
Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We rely on third parties
to conduct our preclinical studies and to provide services, including data management, statistical analysis and electronic compilation.
Once our clinical trials begin, at the end of each reporting period, we will compare the payments made to each service provider to the
estimated progress towards completion of the related project. Factors that we will consider in preparing these estimates include the number
of patients enrolled in studies, milestones achieved and other criteria related to the efforts of our vendors. These estimates will be
subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided,
we will record net prepaid or accrued expenses related to these costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Fair Value of Common Stock and Stock-Based
Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We account for grants
of stock options and restricted stock to employees based on their grant date fair value and recognize compensation expense over the vesting
periods. We estimate the fair value of stock options as of the date of grant using the Black-Scholes option pricing model, and we estimate
the fair value of restricted stock based on the fair value of the underlying common stock as determined by our board of directors or the
value of the services provided, whichever is more readily determinable. We account for stock options and restricted stock awards to non-employees
using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their
vesting terms.</p>

<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In the absence of a public trading
market for our common stock, on each grant date, we develop an estimate of the fair value of our common stock for the option and restricted
stock grants based in part on input from an independent third-party valuation firm. We determined the fair value of our common stock
using methodologies, approaches and assumptions consistent with the AICPA Practice Guide, Valuation of Privately-Held Company Equity
Securities Issued as Compensation. In addition, our board of directors considered various objective and subjective factors, along with
input from management and an independent third-party valuation firm, to estimate the fair value of our common stock, including external
market conditions affecting the pharmaceutical industry, trends within the pharmaceutical industry, the prices at which we sold shares
of our different series of preferred stock, the superior rights and preferences of each series of preferred stock relative to our common
stock at the time of each grant, our results of operations and financial position, the status of our research and development efforts
and progress of our preclinical programs, our stage of development and business strategy, the lack of an active public market for our
common and our preferred stock, and the likelihood of achieving a liquidity event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Derivative liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">FASB ASC 815, Derivatives
and Hedging, requires all derivatives to be recorded on the consolidated balance sheet at fair value.&nbsp;As a result, certain derivative
warrant liabilities (namely those with a price protection feature) are separately valued and accounted for on our balance sheet, with
any changes in fair value recorded in earnings.&nbsp;On our consolidated balance sheets as of December 31, 2021 and 2020, we engaged
a specialist who used the Monte Carlo model to estimate the fair value of these warrants. Key assumptions of the Monte Carlo model include
the market price of our stock, the exercise price of the warrants, applicable volatility rates, risk-free interest rates, expected dividends
and the instruments remaining term.&nbsp;These assumptions require significant management judgment.&nbsp;In addition, changes
in any of these variables during a period can result in material changes in the fair value (and resultant gains or losses) of this derivative
instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Equity Purchase Agreement
with Cross &amp; Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 18, 2020,
the Company entered into an Equity Purchase Agreement with Cross and Company. We have the right to put, or sell, up to 8,108,108
shares of our common stock to Cross.&nbsp;Unless terminated earlier, Crosss purchase commitment will automatically terminate on
the earlier of the date on which Cross shall have purchased shares pursuant to the Equity Purchase Agreement for an aggregate purchase
price of $6,000,000 or September 18, 2023. The purchase price per share is calculated at a fifteen percent discount of the lowest trading
price of the Companys common stock during the ten days after Cross and Co. receives the shares.</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"></span></p>

<!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Results of Operations </b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><i>Comparison of the Years Ended December 31, 2021 and 2020</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Revenues</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenues for the year ended December 31, 2021,
was $183,477 compared to $0 for the year ended December 31, 2020. <span style="background-color: white">Revenues in 2021 was entirely
related to work performed in connection with grants received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Research and development expenses decreased by
$643,626 or 59%, to $451,779 for the year ended December 31, 2021, from $1,095,405 for the twelve months ended December 31, 2020.
The decrease was primarily due to large stock-based compensation related to option granted in the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">General and administrative
expenses decreased by $705,989 or 21%, to $2,672,334 for the year ended December 31, 2021, from $3,378,323 for the twelve months
ended December 31, 2020. This decrease was primarily due to decrease in funds during the year</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since our inception in 2010, we have devoted most
of our cash resources to research and development and general and administrative activities. We have financed our operations primarily
with the proceeds from the sale of preferred stock and convertible promissory notes, state and federal grants and research services. To
date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of
products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of
December 31, 2021, our principal sources of liquidity were our cash and cash equivalents, which totaled $15,677. Our working capital deficit
was $2,844,637 at December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our sources of liquidity and cash flows are used
to fund ongoing operations and research and development projects for our product candidates. In addition, as part of our business strategy,
we occasionally evaluate potential acquisitions of businesses, products and technologies, and minority equity investments. Accordingly,
a portion of our available cash may be used at any time for the acquisition of complementary products or businesses or minority equity
investments. Such potential transactions may require substantial capital resources, which may require us to seek additional debt or equity
financing. We cannot assure you that we will be able to successfully identify suitable acquisition or investment candidates, complete
acquisitions or investments, integrate acquired businesses into our current operations, or expand into new markets. Furthermore, we cannot
provide assurances that additional financing will be available to us in any required time frame and on commercially reasonable terms,
if at all.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Equity Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For the year ended December 31, 2021, we received net proceeds of $833,727
for the sale of common stock and $125,000 for the sale of convertible notes payable. For the year ended December 31, 2020, we received
net proceeds of $852,150, respectively, from the sale of convertible notes and promissory notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b><i>Debt Financings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On July 26, 2021, the
Company entered into a promissory note purchase agreement, with Cross &amp; Company pursuant to which the purchaser agreed to purchase
a promissory note in the principal amount of $100,000. The note matures on July 26, 2023. The note bears interest at 0.25% per annum.
The note holds a right of offset for the holder of the note, whereby the holder shall have the right to offset any proceeds due to the
Debtor for Puts delivered to Holder pursuant to a Equity Purchase Agreement by and between Holder and Debtor dated September
16, 2020. On July 26, 2021, Cross &amp; Company exercised its right of offset under the promissory note agreement with the Company and
the Company put 250,000 shares of its common stock to Cross &amp; Company with net proceeds of $8,288. On August 10, 2021, Cross &amp;
Company exercised its right of offset under the promissory note agreement with the Company and the Company put 172,701 shares of its common
stock to Cross &amp; Company with net proceeds of $8,803. On October 1, 2021, the Company put&nbsp;598,385&nbsp;shares of common stock
as part of a put agreement. An advance of $25,000&nbsp;was received for the shares to be issued to the put holder Cross &amp; Co.&nbsp;After
the effect on the offsets, the promissory note has a remaining balance of $107,910 as of December 31, 2021.</p>

<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Future Capital Requirements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We have not yet achieved
profitability and anticipate that we will continue to incur net losses for the foreseeable future. As discussed in further detail below,
we expect that our expenses will continue to grow and, as a result, we will need to generate significant product revenues to achieve profitability.
We may never achieve profitability. As such, we are dependent on obtaining, and are continuing to pursue, the necessary funding from outside
sources, including obtaining additional funding from the sale of securities in order to continue our operations. Without adequate funding,
we may not be able to meet our obligations. We believe these conditions raise substantial doubt about our ability to continue as a going
concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We are currently raising capital and
we anticipate raising funds sufficient to commence a Phase 1a and 1b clinical trials for KLS-13019 for patients with chemotherapy induced
peripheral neuropathy. We anticipate, based on current estimates, that costs associated Phase 1a and 1b clinical trials for KLS-13019
will be approximately $2.30 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Management of the Company believes that it will
need to seek additional sources of capital to facilitate and carry out its business plan of proceeding forth with commencing a Phase 2a
clinical trial for KLS-13019 for patients with chemotherapy induced peripheral neuropathy; commencing a Phase 1a clinical trial for KLS-13019
for patients suffering from the effects of mild traumatic brain injury; and commencing a Phase 1a clinical trial for KLS-13023 for patients
suffering with overt hepatic encephalopathy. The cost of commencing and conducting these trials will likely be in the tens of millions
of dollars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Furthermore, it is difficult to predict our spending
for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly
faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our expectations regarding future cash requirements
do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we make in the
future. We have no current understandings, agreements or commitments for any material acquisitions or licenses of any products, businesses
or technologies. We may need to raise substantial additional capital in order to engage in any of these types of transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We expect to continue to incur substantial additional
operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and,
subject to obtaining such approval, the eventual commercialization of our product candidates. If we obtain marketing approval for either
of our product candidates, we will incur significant sales, marketing and outsourced manufacturing expenses. In addition, we expect to
incur additional expenses to add operational, financial and information systems and personnel, including personnel to support our planned
product commercialization efforts. We also expect to incur significant costs to comply with corporate governance, internal controls and
similar requirements applicable to us as a public company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our future use of operating cash and capital requirements
will depend on many forward-looking factors, including, without limitation, the following:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the initiation, progress, timing, costs and results of preclinical
studies and clinical trials for our product candidates;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the clinical development plans we establish for these product
candidates;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the number and characteristics of product candidates that we
develop or may in-license;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the terms of any collaboration agreements we may choose to
execute;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the outcome, timing and cost of meeting regulatory requirements
established by the DEA, the FDA, the EMA or other comparable foreign regulatory authorities;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of filing, prosecuting, defending and enforcing our
patent claims and other intellectual property rights;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of defending intellectual property disputes, including
patent infringement actions brought by third parties against us;</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">costs and timing of the implementation of commercial scale
manufacturing activities; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 15pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the cost of establishing, or outsourcing, sales, marketing
and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize
our products on our own.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">To the extent that our capital resources are insufficient
to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings,
debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds.
Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">If we raise additional funds by issuing equity
securities, our stockholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations
and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such
as liquidation and other preferences that are not favorable to us or our stockholders. If we raise additional funds through collaboration
and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams
or product candidates or to grant licenses on terms that may not be favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Cash Flows</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table summarizes our cash flows
from operating, investing and financing activities for the years ended December 31, 2021, and 2020.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Years Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31,</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Statement of Cash Flows Data:</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total net cash provided by (used in):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Operating activities</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(889,637</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(944,198</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investing activities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(6,522</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Financing activities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">889,962</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">844,617</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Decrease in cash</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,197</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(99,581</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Net cash used in operating activities
for the year ended December 31, 2021 was $889,637, including $1,940,518 of net non-cash expenses and a $727,631 net change in operating
assets and liabilities. The net noncash expenses were predominantly related to the stock-based compensation of $1,351,751, amortization
of debt discount of $279,845 and change in fair value of derivative liabilities of $182,561. The change in operating assets and liabilities
was primarily due to a $253,414 decrease in accounts payable and accrued expenses, a $330,948 increase in payroll and related liabilities
and a $38,687 decrease in due to related party and prepaid expenses.</p>

<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Net cash used in operating
activities for the year ended December 31, 2020 was $944,198, including $2,990,990 of net non-cash expenses and a $602,087 net change
in operating assets and liabilities. The net noncash expenses were predominantly related to the stock-based compensation of $1,722,600,
non-cash interest expense of $432,170, amortization of debt discount of $376,661 and change in fair value of derivative liabilities of
$752,495. The change in operating assets and liabilities was primarily due to a $338,145 increase in accounts payable and accrued expenses,
a $136,033 increase in payroll and related liabilities and a $29,909 increase in due to related party and prepaid expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><i>Investing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><span style="background-color: white">Net
cash used in investing activities for the year ended December 31, 2021 was $6,522. Cash was used for purchase of
equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">There were no investing
activities for the year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><i>Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended December 31, 2021, cash provided
by financing activities was $889,962 compared to $844,617 for the year ended December 31, 2020. This was due to a significant increase
of proceeds from common stock, convertible notes and repayment of convertible notes payable in 2021 from 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Inflation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">We have not been affected materially by inflation during the periods
presented, and no material effect is expected in the near future.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><span style="background-color: white"><b>Known Trends or Uncertainties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">We have
seen some consolidation in our industry during economic downturns. These consolidations have not had a negative effect on us to date;
however, should consolidations and downsizing in the industry continue to occur, those events could adversely impact our future revenues
and earnings, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">As discussed
in this Annual Report on Form 10-K, the world has been affected due to the COVID-19 pandemic. Until the pandemic has passed, there remains
uncertainty as to the effect of COVID-19 on our business in both the short and long-term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We do not have any off-balance sheet arrangements,
except for operating leases, or relationships with unconsolidated entities or financial partnerships, such as entities often referred
to as structured finance or special purpose entities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Recent Accounting Pronouncements	</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">In June 2016, the FASB
issued ASU 2016-13, Financial Instruments  Credit Losses to improve information on credit losses for financial assets
and net investment in leases that are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss
impairment methodology with a methodology that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04,&nbsp;Codification
Improvements to Topic 326, Financial Instruments-Credit Losses,&nbsp;Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&nbsp;and
ASU No. 2019-05,&nbsp;Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief&nbsp;which provided additional
implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit
Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), which defers the effective date for public filers
that are considered small reporting companies (SRC) as defined by the Securities and Exchange Commission to fiscal years
beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is
not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Companys
consolidated financial statements.</p>

<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">Not applicable to a smaller reporting company as defined
in Item 10(f)(1) of SEC Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The full text of the Companys audited consolidated
financial statements for the fiscal years ended December 31, 2021 and 2020, begins on page F-1 of this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have had no changes in and disagreements with
our independent auditors on accounting and financial disclosures in the last two fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>ITEM 9A. CONTROLS AND PROCEDURES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to Rule 13a-15(b) under the Securities
Exchange Act of 1934, as amended (Exchange Act), the Company carried out an evaluation, with the participation of the Companys
management, including the Companys Chief Executive Officer (CEO) (the Companys principal executive officer)
and Chief Financial Officer (CFO) (the Companys principal financial and accounting officer), of the effectiveness
of the Companys disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the
period covered by this report. Based upon that evaluation, the Companys CEO and CFO concluded that the Companys disclosure
controls and procedures are not effective to ensure that information required to be disclosed by the Company in the reports that the Company
files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SECs
rules and forms, and that such information is accumulated and communicated to the Companys management, including the Companys
CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Managements Annual Report on Internal Control Over Financial
Reporting.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The management of the Company is responsible for
establishing and maintaining adequate internal control over financial reporting for the Company. Our internal control system was designed
to, in general, provide reasonable assurance to the Companys management and board regarding the preparation and fair presentation
of published consolidated financial statements, but because of its inherent limitations, internal control over financial reporting may
not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our management assessed the effectiveness of the
Companys internal control over financial reporting as of December 31, 2021. The framework used by management in making that assessment
was the criteria set forth in the document entitled Internal Control  Integrated Framework issued by the Committee
of Sponsoring Organizations of the Treadway Commission. Based on that assessment, our management has determined that as of December 31,
2021, the Companys internal control over financial reporting was ineffective for the purposes for which it is intended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">A material weakness is a deficiency, or a combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of the Companys annual or interim consolidated financial statements will not be prevented or detected on a timely basis. In its
assessment of the effectiveness of internal control over our financial reporting as of December 31, 2021 and 2020, the Company determined
that the following items constituted a material weakness:</p>

<!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company does not have an independent audit committee that
can review and approve significant transactions and the reporting process and provide independent oversight of the Company.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These weaknesses were first identified during
the year ended December 31, 2018. 	</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Attestation Report of the Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This Annual Report on Form 10-K does not include
an attestation report of the Companys registered public accounting firm regarding internal control over financial reporting. Management's
report was not subject to attestation by the Company's registered public accounting firm as we are a smaller reporting company and not
required to provide the report.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Changes in Internal Controls over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">No change in our system of internal control over
financial reporting occurred during the period covered by this report, that has materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 9B. OTHER INFORMATION.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">None.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
INSPECTIONS.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">None.&nbsp;</p>


<!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div><p>&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>PART III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">The following table sets forth the names, ages, and positions of our
executive officers and directors:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 37%"><span style="font-size: 10pt">Dean Petkanas</span></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 30%; text-align: center"><span style="font-size: 10pt">58</span></td>
    <td style="width: 1%; text-align: center">&nbsp;</td>
    <td style="width: 31%"><span style="font-size: 10pt">Chief Executive Officer and Chairman of the Board</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Mark Corrao</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">64</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Thomas Kikis</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">44</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td><span style="font-size: 10pt">Chief Communications Officer and Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Dr. William Kinney</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">64</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td><span style="font-size: 10pt">Chief Scientific Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Robert Malasek</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">54</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-size: 10pt">Blake Schroeder</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">43</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Dr. Timothy R. Scott</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td>
    <td style="text-align: center">&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif"><b>Executive Officers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Dean Petkanas</b> was appointed as our Chief
Executive Officer and Chairman of the Board of Directors on July 25, 2018. Mr. Petkanas is a corporate finance and executive management
professional with over 25 years of investment banking and capital markets experience. In 2010, Mr. Petkanas co-founded Kannalife Sciences,
Inc. and for the past 10 years was principally responsible for the creation and execution of the Companys business model, including
the licensing of US Patent #6630507 from the National Institutes of Health for disease indications HE and CTE. Mr. Petkanas is a co-inventor
of US Patent #9611213 Novel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy.
Mr. Petkanas background in the pharmaceuticals extends to his work as investment banker and subsequently V.P. of Business Development
for Xechem International, Inc., where he was principally responsible for Xechems IPO and EXIM Bank rounds of financing. Mr. Petkanas
was involved with Xechem from 1992 to 2007. While at Xechem, he was involved in the financing of Xechems lead target drug candidate
(generic paclitaxel), and later on from 2003 to 2007, was the lead petitioner for Xechem International in steering their federal anti-trust
lawsuit against Bristol-Myers-Squibb for their illegal monopoly of the drug market for the anti-cancer drug, Taxol. Mr. Petkanas
also was an integral part of the development team that named, trademarked and commercialized Hemoxin (Nicosan), a phyto-pharmaceutical
molecule for the treatment of Sickle Cell disease. Mr. Petkanas brings his extensive business and industry experience to the board of
directors as its chairman.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Mark Corrao </b>was appointed as our Chief
Financial Officer on July 25, 2018. Prior to joining the Company, Mr. Corrao served as the CFO of Kannalife Sciences, Inc. beginning in
January 2012. Mr. Corrao currently serves as the Managing Director of The CFO Squad LLC, a CFO and accounting consulting business, and
as CFO of Generex Biotechnologies, Inc. beginning in January 2017. Mr. Corrao was formerly a founder and CFO of Strikeforce Technologies,
Inc., a publicly traded software development and services company specializing in the development of a suite of integrated computer network
security products. In addition to the ten years of his service at Strikeforce, Mr. Corrao has spent numerous years in the public accounting
arena specializing in certified auditing, SEC accounting, corporate taxation and financial planning. Mr. Corraos background also
includes numerous years on Wall Street with Merrill Lynch, Spear Leeds &amp; Kellogg and Greenfield Arbitrage Partners. While on Wall
Street, Mr. Corrao was involved in several initial public offerings and has been a guiding influence in several startup companies. Prior
to joining StrikeForce, he was the Director of Sales at Applied Digital Solutions from December 2000 through December 2001. Mr. Corrao
was the Vice President of Sales at Advanced Communications Sciences from March 1997 through December 2000. Mr. Corrao has a B.S. in Accounting
from The City University of New York. Mr. Corraos business and public company financial reporting experience is invaluable to the
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Thomas Kikis</b> was appointed as our Chief Communications
Officer and a director on July 25, 2018. Prior to his appointment, Mr. Kikis co-founded Kannalife Sciences, Inc. in August 2010. Since
co-founding Kannalife Sciences, Mr. Kikis has handled all communications and marketing efforts of the Company, serving in various executive
roles and as a member of its board of directors. Mr. Kikis also designed and helped formulate Kannactiv  a skincare product line
designed by the Company on behalf of Kannaway LLC. Mr. Kikis is an entrepreneur who has a passion for great stories, new ideas, groundbreaking
technologies, popular culture and their collective point of impact. Most recently, Mr. Kikis has designed dozens of commercial typographical
software distributed for web, print and mobile applications and has produced several films and documentaries available on movie streaming
platforms. Mr. Kikis holds a Bachelor of Science in Communications Management from New York University. Mr. Kikis broad industry
knowledge and strategic communication experience make him an asset to the board of directors.</p>

<!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Dr. William Kinney</b> was appointed as our
Chief Scientific Officer on July 25, 2018. Mr. Kinney is a medicinal chemist and entrepreneur with more than 25 years of experience in
large pharmaceutical (Wyeth, Johnson &amp; Johnson), biotechnology (Magainin), and non-profit (Blumberg Institute) research and development.
He has demonstrated expertise in drug design; synthesis; lead optimization and development of peptides, small molecules, and natural products;
and is inventor of three molecules that advanced to human clinical trials  Perzinfotel (CNS disorders and pain), Squalamine (oncology,
AMD, Parkinson's Disease), and Trodusquemine (obesity). Currently, Dr. Kinney is Senior VP at Enterin, Inc. (since July 2016) and the
Companys Chief Scientific Officer. His scientific contributions include more than 70 publications and presentations; and inventorship
on 38 issued U.S. patents. Dr. Kinney is a co-inventor of our US Patent #9611213 Novel Functionalized 1,3 Benzene Diols and Their
Method of Use for the Treatment of Hepatic Encephalopathy. Dr. Kinney obtained his B.S. (1979) and Ph.D. (1984) degrees from the
Ohio State University. Dr. Kinneys breadth of scientific research and development work and industry knowledge are a great benefit
to the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Non-Employee Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Robert Malasek</b> has served as a director
of the Company since June 20, 2017 and previously served as its Chief Executive Officer and Chief Financial Officer from June 20, 2017
to July 25, 2018. Mr. Malaseks experience includes serving as the Assistant Controller for Starwood Hotel &amp; Resorts Worldwide,
Inc. and as Chief Financial Officer for NatureWell, Inc. From 2011 to 2015, Mr. Malasek served as the Chief Financial Officer, Secretary,
Treasurer and a Director of Liberty Coal Energy Corp. Since 2015, Mr. Malasek has served as the Chief Financial Officer of Cannalink,
Inc. and currently serves as the Chief Financial Officer of AXIM Biotechnologies, Inc. (OTC:AXIM). Mr. Malasek received his Bachelor of
Science in Accountancy from San Diego State University. Mr. Malaseks public company governance and management experience make him
a great fit to the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Blake Schroeder</b> was appointed as a director
of the Company on July 25, 2018. Mr. Schroeders career began as a litigator at a commercial litigation firm in Salt Lake City,
UT. Beginning in 2008, Mr. Schroeder became involved in the sale and marketing of natural products, and opening international marketplaces
to those products. From 2008 to 2015, Mr. Schroeder served in various capacities at MonaVie LLC developing international business plans
and growing international businesses. From August 2014 to February 2016, Mr. Schroeder served as the Chief Operating Officer of Forevergreen
International, where he was responsible for global operation and sales of the multinational organization, including oversight of a global
supply chain. From 2016 to the present, Mr. Schroeder serves as the Chief Executive Officer of Kannaway, LLC, a wholly-owned subsidiary
of Medical Marijuana, Inc. Mr. Schroeder is the COO for Medical Marijuana, Inc. and has served on the board of directors of Medical Marijuana,
Inc. from March 2016 to the present. Mr. Schroeder holds a B.S. in Finance from Utah State University and a J.D. from Syracuse Universitys
College of Law. Mr. Schroeders blend of industry, legal and business knowledge give him and the board of directors a unique viewpoint
that is invaluable to the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>Dr. Timothy R. Scott</b>
was appointed as a director of the Company on July 25, 2018. Mr. Scott brings years of enterprise board-level management expertise, having
served on the board of directors of NatureWell Inc. from 2001 to 2008. Prior to 2001, Mr. Scott served on the board of directors of ICH
Corporation, which owned 265 restaurants with approximately $265M in revenues and 7,800 employees. Dr. Scott currently serves on the board
of directors of Medical Marijuana, Inc. (OTC:MJNA) and Axim Biotechnologies, Inc. (OTC:AXIM). Dr. Scott received his Ph.D. in theology
from Christian University. Dr. Scott holds decades of experience at senior management and board levels in public and private companies
which is a great benefit to the company and its board of directors.</p>

<!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Scientific Advisory Board </b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Douglas Brenneman, Ph.D  Chief Biologist and Distinguished
Senior Scientist  Scientific Advisory Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">Dr. Brenneman
has over 30 years of research experience as a Section Chief within the intramural program at NICHD and as a Senior Research Fellow at
Johnson &amp; Johnson. He has more than 170 scientific publications and 15 patents focused on both evaluating neurotoxic and neuroprotective
substances with various Central Nervous System preparations. At Johnson &amp; Johnson, he was a team leader of the drug discovery group
that advanced three compounds through discovery and preclinical testing. Two of these compounds are currently in clinical trials. As a
result of his NIH work, a neuroprotective peptide (davunetide) that he co-discovered is currently in phase III clinical trials. Dr. Brenneman
has demonstrated scientific experience to drive an innovative program of drug discovery focused on diseases of the central nervous system.
Dr. Brenneman is the founder and Chief Scientific Officer of Advanced Neural Dynamics which is located at the Pennsylvania Biotechnology
Center in Doylestown, PA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;<b>Tage Honor -	Chairman of Scientific
Advisory Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; color: #2B2B2B">Dr. Honor is an experienced
pharma and biotechnology executive, entrepreneur and pioneer with expert knowledge in the fields of Alzheimers disease, amyotrophic
lateral sclerosis, anxiety, cancer immunotherapy, chronic pain, depression, epilepsy, female hormone replacement therapy, learning disorders,
osteoporosis, Parkinsons disease, stroke and schizophrenia. His greatest scientific achievement was discovering and naming the
AMPA subtype of Excitatory Amino Acid Receptors as well as the AMPA antagonists CNQX and NBQX, which have been key tools for mapping the
excitatory pathways in the central nervous system. Additionally, Dr. Honor has published more than 100 scientific papers, is inventor
on 23 patents and championed 40 drugs to progress from idea to clinical development including three products that entered the prescription
drug market. He has held several positions, including: VP Drug Discovery at Novo Nordisk A/S; Senior Executive VP Nervous System Research,
Novartis Pharma Inc; VP Discovery Research, Purdue Pharma LP and President and CEO, Aestus Therapeutics Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Ryan B. Turner, MD  Scientific Advisory Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dr. Ryan Turner is a board certified dermatologist
practicing general dermatology and has advanced training in Mohs Micrographic Surgery, laser surgery, and light therapies. His clinical
interests include skin cancer surgery and cosmetic treatments that enhance and rejuvenate aging skin. He has extensive training in FRAXEL
laser treatments, which reduce photodamage, wrinkles, and stimulate new collagen growth. His research interests vary from the treatment
and management of skin cancers to the successful placement of injectable dermal fillers. He graduated summa cum laude and valedictorian
of the University of Maryland Baltimore County. He received his Doctor of Medicine from Harvard Medical School and was honored with the
Henry Asbury Christian Award for his research accomplishments. He completed his internship in medicine and his dermatology residency at
the Harvard affiliated Brigham and Womens Hospital and the Massachusetts General Hospital, respectively. He has also completed
an ACGME accredited fellowship in Procedural Dermatology at the Mt. Sinai Medical Center in NY.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Daniel Richman, MD  Scientific Advisory Board</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="color: #2B2B2B">Dr. Daniel Richman
is an attending anesthesiologist and pain management physician at Hospital for Special Surgery in the Department of Anesthesiology, Critical
Care &amp; Pain Management. Dr. Richman is also an assistant attending and clinical instructor within the Tri-Institutional Pain Management
Fellowship in conjunction with New York-Presbyterian Hospital and Memorial Sloan Kettering Cancer Center. He is board certified in anesthesiology
and pain medicine and has been practicing at HSS since 1991. Dr. Richman specializes in orthopedic-related pain management with a specific
interest in managing conditions related to the cervical, thoracic and lumbar spine. He is an expert in interventional treatments such
as epidural steroid injections, diagnostic nerve blocks both under fluoroscopic and ultrasound guidance, radiofrequency denervation, sympathetic
blockade and discography. Dr. Richman has extensive knowledge of managing advanced pain with implantable technology such as intrathecal
pumps and spinal cord stimulators. He frequently works with both the inpatient and outpatient pain divisions within HSS as an expert in
managing difficult perioperative analgesia in the chronic pain patient.</span><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">We believe that Dr. Timothy R. Scott and Blake Schroeder are independent
as that term is defined under Nasdaq Rules.</p>

<!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Committees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Board of Directors has not established any
committees. Our Board of Directors as a whole acts as our audit committee, compensation committee, and nominating committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our board of directors has determined that Mr.
Malasek qualifies as an audit committee financial expert as defined by applicable SEC rules and has the requisite financial
sophistication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><b>Term of Office</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">Our directors are appointed
for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance
with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Code of Ethics </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">We have not adopted a
written code of ethics due to our current limited resources, including human resources. If we expand our operations and hire more employees,
we will consider adopting a written code ethics in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Family Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white">There are no family relationships between
any director or executive officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; background-color: white"><b>Involvement in Certain Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">During the past ten years,
none of our directors and executive officers has been involved in any of the events described in Item 401(f) of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Corporate Governance Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have not adopted any material changes to the
procedures by which security holders may recommend nominees to our Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Compliance with Section 16(A) of the Exchange Act.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Section 16(a) of the Exchange Act requires the
Companys officers and directors, and persons who beneficially own more than 10% of a registered class of the Companys equity
securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission and are required to furnish
copies to the Company. Based solely on our review of copies of such forms that we have received, or written representations from reporting
persons, we believe that during the fiscal year ended December 31, 2020, all executive officers, directors and greater than 10% stockholders
complied with all applicable filing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 11. EXECUTIVE COMPENSATION.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table sets forth, for the fiscal
years ended December 31, 2021 and 2020, the dollar value of all cash and noncash compensation earned by any person that was our principal
executive officer, principal financial officer, and our two most highly compensated executive officers (other than our principal financial
and executive officers), during the preceding fiscal year.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Bonus ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plane Compensation ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Qualified Deferred Compensation Earnings ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Totals ($)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Dean Petkanas,</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">2021</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">240,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right"><span style="font-size: 10pt">144,565 <sup>(1)</sup>&nbsp;</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 4%; text-align: right">384,565</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Chief Executive Officer and Chairman</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2020</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">240,000</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">180,000 <sup></sup></span></td><td style="padding-bottom: 1pt; text-align: left"><sup>(1)</sup></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">420,000</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Thomas Kikis,</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">65,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">79,760&nbsp;</span></td><td style="text-align: left"><sup>(1)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">144,760</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Chief Communications Officer and Director</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2020</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">65,000</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">65,000</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mark Corrao,</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">60,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">79,760&nbsp;</span></td><td style="text-align: left"><sup>(1)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">139,760</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Chief Financial Officer</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2020</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">60,000</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">60,000</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">William Kinney,</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">30,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">89,730</span></td><td style="text-align: left"><sup>(1)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">119,730</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chief Scientific Officer</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2020</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">30,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">30,000</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><sup>(1) </sup>Represents the grant date fair
value of restricted stock and stock options issued during the year ended December 31, 2021, calculated in accordance with ASC Topic 718.
The assumptions used in the calculation of these amounts are included in Note 15 of the notes to the consolidated financial statements
contained in this Annual Report on Form 10-K.</p>

<!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Narrative Disclosure to the Summary Compensation Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Base Salary</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">See below for a detailed explanation of each named
executive officers employment agreements, including the annual base compensation that each of such individuals is entitled to.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Stock Awards</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31,2021, the companys
CEO was issued 2,567,308 of common stock valued at $180,000 in lieu of deferred compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif">On March 12, 2021, the Company granted options to purchase an aggregate
of 7,350,000 shares of common stock at a price of $0.13 per share&nbsp;to our named executive officers and are exercisable for ten years.&nbsp;One
quarter of these options vested on the grant day, and the remainder of the options vest equally over thirty-six (36) months starting March
12, 2021. These options were valued at $732,795 using a Black-Scholes Options Pricing Model.</p>

<p style="font: 10pt Times New Roman, Times, Serif">On May 5, 2021, the Company granted options to purchase an aggregate
of 200,000 shares of common stock at a price of $0.145 per share&nbsp;to one of our directors and are exercisable for ten years.&nbsp;One
quarter of these options vested on the grant day, and the remainder of the options vest equally over thirty-six (36) months starting May
4, 2023. These options were valued at $28,900 using a Black-Scholes Options Pricing Model.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Executive Employment Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with the Share Exchange with Kannalife
Sciences, Inc. on July 25, 2018, the newly-appointed officers entered into executive employment agreements with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Dean Petkanas</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Petkanas will receive an annual base salary
of $240,000 and will be eligible to receive equity awards in the future, as determined by the Board. In addition, Mr. Petkanas will have
severance benefits in the form of salary continuation and health benefits through the employment term remaining on the contract. The employment
agreement has a two-year term, provided, however, after the end of one year, the agreement will automatically renew for successive one
year terms unless terminated by Mr. Petkanas or the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Thomas Kikis</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Kikis will receive an annual base salary of
$60,000 (adjusted from his initial annual base salary of $150,000 as permitted in his agreement) and will be eligible to receive equity
awards in the future, as determined by the Board. In addition, Mr. Kikis will have severance benefits in the form of salary continuation
and health benefits through the employment term remaining on the contract. The employment agreement has a one-year term, provided, however,
after the end of one year, the agreement will automatically renew for successive six month terms unless terminated by Mr. Petkanas or
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Mark Corrao</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Mr. Corrao will receive an annual base salary
of $60,000 (adjusted from his initial annual base salary of $150,000 as permitted in his agreement) and will be eligible to receive equity
awards in the future, as determined by the Board. In addition, Mr. Corrao will have severance benefits in the form of salary continuation
and health benefits through the employment term remaining on the contract. The employment agreement has a one-year term, provided, however,
after the end of one year, the agreement will automatically renew for successive six month terms unless terminated by Mr. Petkanas or
the Company.</p>

<!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>Dr. William Kinney</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dr. Kinney will receive an annual base salary
of $30,000 (adjusted from his initial annual base salary of $150,000 as permitted in his agreement) and will be eligible to receive equity
awards in the future, as determined by the Board. In addition, Dr. Kinney will have severance benefits in the form of salary continuation
and health benefits through the employment term remaining on the contract. The employment agreement has a one-year term, provided, however,
after the end of one year, the agreement will automatically renew for successive six month terms unless terminated by Mr. Petkanas or
the Company.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding Equity Incentive Awards at Fiscal Year-End</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table provides information regarding
the outstanding equity awards held by our named executive officers as of December&nbsp;31, 2021. All awards were granted pursuant to the
Company 2017 Equity Incentive Plan. See below for additional information.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Name and principal position</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Date (1)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting<br> Commencement Date</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br> securities<br> underlying<br> unexercised<br> options (#)<br> (exercisable)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br> securities<br> underlying<br> unexercised<br> options (#) (unexercisable)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br> securities<br> underlying<br> unexercised<br> unearned<br> options (#)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option<br> exercise<br> price ($)</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option<br> expiration<br> date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 11%; text-align: left">Dean Petkanas</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 11%; text-align: center">03/12/21</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 11%; text-align: center">03/12/2021</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">412,500</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">1,037,500</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">0.13</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 10%; text-align: center">03/12/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Executive Officer and Chairman</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Thomas Kikis</td><td>&nbsp;</td>
    <td>03/12 /21</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/2021</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">366,667</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">433,333</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chief Communications Officer and Director</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mark Carrao</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/21</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/2021</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">366,667</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">433,333</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Scientific Officer</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">William Kinney</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/21</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/2021</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">412,500</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">487,500</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.13</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">03/12/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Chief Scientific Officer</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">There were no stock options exercised during the
fiscal year ended December 31, 2021, by the named executive officers named in the Summary Compensation Table.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Equity Incentive Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 14, 2019, the Board approved the Kannalife,
Inc. 2019 Equity Incentive Plan (the 2019 Plan) in order to facilitate the grant of cash and equity incentives to directors,
employees (including our named executive officers) and consultants of our company and certain of our affiliates and to enable us and certain
of our affiliates to obtain and retain services of these individuals, which is essential to our long-term success. Our 2019 Plan allows
for the grant of a variety of equity vehicles to provide flexibility in implementing equity awards, including incentive stock options,
non-qualified stock options, restricted stock grants, unrestricted stock grants and restricted stock units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2021, the Company amended the 2019
Plan to replace all references to Kannalife with Neuropathix and to increase the number of shares of common
stock authorized for issuance under the Plan from 11,250,000 to 20,000,000. The 2019 Plan amendment was approved by the Companys
Board of Directors on March 12, 2021, but remains subject to shareholder approval, which the Company shall undertake to obtain as soon
as reasonably practicable, but in no event later than one year from the amendment date. In the event that the Company does not obtain
the requisite shareholder approval of the 2019 Plan amendment within one year, the 2019 Plan amendment shall not be effective. On March
11, 2022, the majority of shareholders of the Common Stock of the Company voted to ratify the 2019 Plan as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Authorized Shares</i>.&nbsp;As of December
31, 2021, a total of 13,000,000 shares of common stock were authorized under the 2019 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Plan Administration</i>.&nbsp;As used herein
with respect to the 2019 Plan, the Board of Directors refers to any committee the Board of Directors appoints as well as
to the Board of Directors itself. Subject to the provisions of the 2019 Plan, the Board of Directors has the power to construe and interpret
the 2019 Plan and awards granted under it and to determine the persons to whom and the dates on which awards will be granted, the number
of shares of common stock to be subject to each award, the time or times during the term of each award within which all or a portion of
such award may be exercised, the exercise price, the type of consideration and other terms of the award. Subject to the limitations set
forth below, the Board of Directors will also determine the exercise price of options granted under the 2019 Plan and, with the consent
of any adversely affected option holder, may reduce the exercise price of any outstanding option, cancel an outstanding option in exchange
for a new option covering the same or a different number of shares of common stock or another equity award or cash or other consideration,
or any other action that is treated as a repricing under generally accepted accounting principles. All decisions, determinations and interpretations
by the Board of Directors regarding the 2019 Plan shall be final and binding on all participants or other persons claiming rights under
the 2019 Plan or any award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Options</i>.&nbsp; &nbsp;Options granted under
the 2019 Plan may become exercisable in cumulative increments (vest) as determined by the Board of Directors. Such increments
may be based on continued service to the Company over a certain period of time, the occurrence of certain performance milestones, or other
criteria. Options granted under the 2019 Plan may be subject to different vesting terms. The Board of Directors has the power to accelerate
the time during which an option may vest or be exercised. In addition, options granted under the 2019 Plan may permit exercise prior to
vesting, but in such event the participant may be required to enter into an early exercise stock purchase agreement that allows the Company
to repurchase unvested shares, generally at their exercise price, should the participants service terminate before vesting. To
the extent provided by the terms of an option, a participant may satisfy any federal, state or local tax withholding obligation relating
to the exercise of such option by a cash payment upon exercise, by authorizing the Company to withhold a portion of the stock otherwise
issuable to the participant, or by such other method as may be set forth in the option agreement. The maximum term of options under the
2019 Plan is 10 years, except that in certain cases the maximum term of certain incentive stock options is five years. Options under the
2019 Plan generally terminate three months after termination of the participants service. Incentive stock options are not transferable
except by will or by the laws of descent and distribution, provided that a participant may designate a beneficiary who may exercise an
option following the participants death. Nonstatutory stock options are transferable to the extent provided in the option agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Stock Bonuses and Restricted Stock Awards.&nbsp;</i>Subject
to certain limitations, the consideration, if any, for restricted stock unit awards must be at least the par value of our common stock.
The consideration for a stock unit award may be payable in any form acceptable to the Board of Directors and permitted under applicable
law. The Board of Directors may impose any restrictions or conditions upon the vesting of restricted stock unit awards, or that delay
the delivery of the consideration after the vesting of stock unit awards, that it deems appropriate. Restricted stock unit awards are
settled in shares of the Companys common stock. Dividend equivalents may be credited in respect of shares covered by a restricted
stock unit award, as determined by the Board of Directors. At the discretion of the Board of Directors, such dividend equivalents may
be converted into additional shares covered by the restricted stock unit award<i>.&nbsp;</i>If a restricted stock unit award recipients
service relationship with the Company terminates, any unvested portion of the restricted stock unit award is forfeited upon the recipients
termination of service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Certain Adjustments</i>.&nbsp;Transactions not involving
receipt of consideration by the Company, such as a merger, consolidation, reorganization, recapitalization, reincorporation, reclassification,
stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, or
a change in corporate structure may change the type(s), class(es) and number of shares of common stock subject to the 2019 Plan and outstanding
awards. In that event, the 2019 Plan will be appropriately adjusted as to the type(s), class(es) and the maximum number of shares of
common stock subject to the 2019 Plan and the Section&nbsp;162(m) Limitation, and outstanding awards will be adjusted as to the type(s),
class(es), number of shares and price per share of common stock subject to such awards.&nbsp;</p>

<!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Long-Term Incentive Plan (LTIP) Awards Table</b></p>

<p style="font: 10pt Times New Roman, Times, Serif">There were no awards made to a named executive officer in the last
completed fiscal year under any LTIP.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Compensation of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The table below summarizes
all compensation of our directors for the year ended December 31, 2021.</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td colspan="29" style="font-weight: bold; text-align: center">DIRECTOR COMPENSATION</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Name</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Fees Earned or Paid in Cash ($)</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Stock Awards ($)</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Option Awards ($)</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Non-Equity Incentive Plan Compensation ($)</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Non-Qualified Deferred Compensation Earnings ($)</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">All Other Compensation ($)</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Total ($)</span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Robert Malasek</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">59,820</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%; text-align: right">&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">59,820</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dean Petkanas</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">144,565</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">144,565</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Thomas Kikis</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">79,760</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">79,760</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Timothy Scott</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59,820</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59,820</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Blake Schroeder</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">88,720</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">88,720</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Although the Company does not have any current
arrangements with respect to the consistent payment of its Directors, the Directors are permitted to receive fixed fees and other compensation
for their services as directors. The Board of Directors has the authority to fix the compensation of our Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 12, 2021, the Company granted options
to purchase 4,050,000 shares of common stock at a price of $0.13 per share&nbsp;to our Directors, which stock options are exercisable
for ten years.&nbsp;One quarter of these options vested on the grant day, and the remainder of the options vest equally over thirty-six
(36) months starting March 12, 2021. These options were valued at $179,459 using a Black-Scholes Options Pricing Model. Other than as
set forth in the table above, the directors did not receive any other compensation for their services performed by them as directors of
the Company during the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table sets forth certain information
regarding the beneficial ownership of our outstanding common stock, as of April 15, 2021 by: (i) each of our directors, (ii) each of our
named executive officers (as defined by Item 402(a)(3) of Regulation S-K promulgated under the Exchange Act), (iii) all of our directors
and named executive officers as a group, and (iv) each person known to us to beneficially own more than 5% of our outstanding Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Beneficial ownership has been determined in accordance
with Rule 13d-3 under the Exchange Act. The percentages in the table have been calculated on the basis of treating as outstanding for
a particular person, all shares of our common stock outstanding on that date and all shares of our common stock issuable to that holder
in the event of exercise of outstanding options, warrants, rights or conversion privileges owned by that person at that date which are
exercisable within sixty (60) days of that date. Except as otherwise indicated, the persons listed below have sole voting and investment
power with respect to all shares of our Common Stock owned by them, except to the extent that power may be shared with a spouse. The Company
does not know of any arrangements the operation of which may at a subsequent date result in a change of control of the Company.</p>

<!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series A Preferred Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Series B Preferred Stock</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% of Total Voting Power</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font-size: 10pt"><b>Name of Beneficial Owner <sup>(1)</sup></b></span></td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">5% or Greater Stockholders</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left"><span style="font-size: 10pt">Medical Marijuana, Inc.<sup>(2)</sup></span></td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">20,342,076</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">23.31</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 6%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="text-align: right">23.31</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Kettner Investments, LLC <sup>(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,817,067</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7.81</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">7.81</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Naturewell, Incorporated <sup>(11)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">75,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">75</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Directors and Executive Officers</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Dean Petkanas <sup>(4)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">23,060,952</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26.42</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">75</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">26.42</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Thomas Kikis <sup>(5)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,454,125</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6.25</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">6.25</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Mark Corrao <sup>(6)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,546,875</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.77</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">1.77</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">William Kinney <sup>(7)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,526,875</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.75</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">1.75</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Timothy R. Scott <sup>(8)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">250,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Robert Malasek <sup>(9)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">250,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Blake Schroeder <sup>(10)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">250,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">All officers and directors as a group (7 persons) <sup>(12)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">32,338,827</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">37.05</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">37.05</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;______________</p>

<p style="font: 10pt Times New Roman, Times, Serif">* Less than 1%</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">3805 Old Easton Road, Doylestown, PA 18902, is the address
for all stockholders in the table except otherwise stated below. Applicable percentages are based on 87,286,137 shares of our common
stock, issued and outstanding as of April 15, 2021, 75 shares of our Series A Preferred Stock and 75 shares of our Series B Preferred
Stock outstanding as of April 15, 2021, and are calculated as required by rules promulgated by the SEC.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(2)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 20,342,076 shares of common stock owned of record
by Medical Marijuana, Inc. (OTC:MJNA). MJNA is a publicly-traded company. MJNAs Executive Committee has joint voting and investment
control of its portfolio investments, including Kannalife, Inc. The Executive Committee consists of three of MJNAs board members:
Chris Prine, Robert L. Cunningham and Timothy R. Scott, PhD. Each of these committee members disclaims beneficial ownership of MJNAs
portfolio securities, including Kannalife, Inc.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(3)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 6,817,067 shares of common stock owned of record
by Kettner Investments, LLC. Kettner Investments, LLC is managed by its three Managers which share joint voting and investment control
of the entity: John Huemoeller, Stuart W. Titus and Timothy R. Scott, PhD. Each of these managers disclaims beneficial ownership of Kettners
portfolio securities, including Kannalife, Inc.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(4)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of (i) 15,942,857 shares of common stock owned of
record by Mr. Petkanas, (ii) 600,000 shares of common stock owned of record by Powerlife Phytomedical, LLC of which Mr. Petkanas exercises
shared voting and investment control, (iii) 6,518,095 shares of common stock owned of record by Golden Gate Capital Partners, LLC of
which Mr. Petkanas is the Managing Member and shares voting and investment control, and (iv) 75,000 shares of common stock issuable to
Mr. Petkanas on conversion of the 75 shares of Series B Preferred Stock held by Mr. Petkanas individually.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(5)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 5,454,125 shares of common stock owned of record
by Mr. Kikis individually.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(6)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 1,546,875 shares of common stock owned of record
by Mr. Corrao individually.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(7)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 1,526,875 shares of common stock owned of record
by Dr. Kinney individually.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(8)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 250,000 shares of common stock owned of record
by Dr. Scott individually.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(9)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 250,000 shares of common stock owned of record
by Mr. Malasek individually.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(10)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 250,000 shares of common stock owned of record
by Mr. Schroeder individually.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"><sup>(11)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of 75,000 shares of common stock issuable to Naturewell,
Incorporated on conversion of the 75 shares of Series A Preferred Stock held by Naturewell, Incorporated. Robert Plomgren is the Chief
Executive Officer of Naturewell, Incorporated and possesses voting and investment control of the shares.</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt">(12)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">Consists of (i) 31,569,596 shares of common stock, and (ii)
75,000 shares of common stock issuable on conversion of the 75 shares of Series B Preferred Stock within 60 days of March 6, 2020 beneficially
owned by our current directors and executive officers.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We describe below the transactions and series
of similar transactions, since January 1, 2020, to which we were a party or will be a party, in which:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">the amounts involved exceeded or will exceed $120,000; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">any of our directors, executive officers, holders of more than
5% of our capital stock or any member of their immediate family had or will have a direct or indirect material interest, other than equity
and other compensation, termination, change in control and other arrangements with directors and executive officers, which are described
where required under the section above titled Executive Compensation.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2021, the Company owes the
CEO $39,749 for expenses the CEO incurred on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Companys Chief Executive Officer shares
the use of the leased office space for personal living quarters. The CEO reimburses the Company for 50% of the monthly rent, or $2,800
per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Audit Fees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate fees billed during the fiscal years
ended December 31, 2021 and 2020 for professional services rendered by dbb<i>mckennon</i>, with respect to the audits of our 2021 and
2020 financial statements, as well as their quarterly reviews of our interim financial statements and services normally provided by the
independent accountant in connection with statutory and regulatory filings or engagements for these fiscal periods, were as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Year Ended December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>2021</b></p></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2020</b></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Audit Fees and Audit Related Fees</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">46,000</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">43,290</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax Fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">All Other Fees</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,070</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">TOTAL</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">47,070</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">43,290</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the above table, audit fees are
fees billed by our Companys external auditor for services provided in auditing the Companys annual financial statements
for the subject year. Audit-related fees are fees that are not included in audit fees and that are billed by the auditor
for assurance and related services that are reasonably related to the performance of the audit review of the Companys financial
statements. Tax fees are fees billed by the auditor for professional services rendered for tax compliance, tax advice and
tax planning. All other fees are fees billed by the auditor for products and services not included in the foregoing categories.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><b>Pre-Approval Policies and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We do not have a separately designated Audit Committee.
The Board of Directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed
and approved by the Board of Directors either before or after the respective services were rendered.</p>

<!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>(a)</i> &nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">1.&nbsp;Financial Statements.
The consolidated financial statements are included in this Annual Report on Form 10-K beginning on page F-2.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">2.&nbsp;Financial Statement
Schedules. Schedules are not submitted because they are not applicable or not required under Regulation S-X or because the required information
is included in the financial statements or notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">3.&nbsp;Exhibits required
to be filed by Item 601 of Regulation S-K. The information called for by this Item is incorporated by reference from the Index to Exhibits
included in this Annual Report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif"><i>(b) Exhibits</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>EXHIBIT INDEX</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 61%"><span style="font-size: 10pt"><b>Description</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 12%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Incorporated </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>By Reference </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>(Form Type)</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 10%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Filing </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Date</b></p></td>
    <td style="border-bottom: black 1pt solid; width: 7%">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Filed </b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>herewith</b></p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">2.1</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex2z1.htm" tabindex="18"><span style="font-size: 10pt">Share Exchange Agreement, dated as of July 25, 2018 by and among TYG Solutions Corp., Kannalife Sciences, Inc. and its stockholders</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000161599917000003/articles_ex3z1.htm" tabindex="18"><span style="font-size: 10pt">Certificate of Incorporation, as filed with the Delaware Secretary of State on March 25, 2013</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/30/2017</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000505/f8k050418_ex3z2.htm" tabindex="18"><span style="font-size: 10pt">Amended and Restated Certificate of Incorporation of TYG Solutions Corp., as filed with the Delaware Secretary of State on May 1, 2018</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/4/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.3</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000505/f8k050418_ex3z3.htm" tabindex="18"><span style="font-size: 10pt">Certificate of Designation of Series A Preferred Stock of TYG Solutions Corp. as filed with the Delaware Secretary of State on May 3, 2018</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/4/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.4</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000505/f8k050418_ex3z4.htm" tabindex="18"><span style="font-size: 10pt">Certificate of Designation of Series B Preferred Stock of TYG Solutions Corp. as filed with the Delaware Secretary of State on May 3, 2018</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/4/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.5</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000161599917000003/bylaws_ex3z3.htm" tabindex="18"><span style="font-size: 10pt">Bylaws of TYG Solutions Corp.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/30/2017</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.6</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000505/f8k050418_ex3z5.htm" tabindex="18"><span style="font-size: 10pt">Amended and Restated Bylaws of TYG Solution Corp.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5/4/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.7</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218001466/s1a1_ex3z7.htm" tabindex="18"><span style="font-size: 10pt">Amendment to Amended and Restated Certificate of Incorporation, as filed with the Delaware Secretary of State on November 9, 2018</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/28/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000726/f10k123117_ex4z1.htm" tabindex="18"><span style="font-size: 10pt">Convertible Note dated February 16, 2018</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/24/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">4.2</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000726/f10k123117_ex4z2.htm" tabindex="18"><span style="font-size: 10pt">Convertible Note Purchase Agreement dated February 16, 2018</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/24/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.3 </span></td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/ex4_3.htm" tabindex="18">Description of Securities</a></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex10z1.htm" tabindex="18"><span style="font-size: 10pt">Form of Lock-up Agreement (Kannalife Stockholders)</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex10z2.htm" tabindex="18"><span style="font-size: 10pt">Form of Lock-up Agreement (Management Stockholders)</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.3</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex10z3.htm" tabindex="18"><span style="font-size: 10pt">Form of Lock-up Agreement (Dean Petkanas Block)</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.4+</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex10z4.htm" tabindex="18"><span style="font-size: 10pt">Executive Employment Agreement by and between TYG Solutions Corp. and Dean Petkanas</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.5+</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex10z5.htm" tabindex="18"><span style="font-size: 10pt">Executive Employment Agreement by and between TYG Solutions Corp. and Thomas Kikis</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.6+</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex10z6.htm" tabindex="18"><span style="font-size: 10pt">Executive Employment Agreement by and between TYG Solutions Corp. and Mark Corrao</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.7+</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218000764/f8k073118_ex10z7.htm" tabindex="18"><span style="font-size: 10pt">Executive Employment Agreement by and between TYG Solutions Corp. and William Kinney, PhD</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">7/31/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.8</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218001466/s1a1_ex10z8.htm" tabindex="18"><span style="font-size: 10pt">Settlement Agreement by and between TYG Solutions Corp. and Medical Marijuana, Inc.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/28/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.9**</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218001466/s1a1_ex10z9.htm" tabindex="18"><span style="font-size: 10pt">Exclusive Patent License Agreement - Exclusive by and between the National Institutes of Health and Kannalife Sciences, Inc. for Hepatic Encephalopathy (HE).</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/28/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.10**</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218001466/s1a1_ex10z10.htm" tabindex="18"><span style="font-size: 10pt">Nonexclusive Patent License Agreement - Nonexclusive by and between the National Institutes of Health and Kannalife Sciences, Inc. for Chronic Traumatic Encephalopathy (CTE).</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/28/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.11**</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218001466/s1a1_ex10z11.htm" tabindex="18"><span style="font-size: 10pt">Feasibility Study Quotation by and between Kannalife Sciences, Inc. and Catalent Pharma Solutions, LLC.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/28/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.12</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218001466/s1a1_ex10z12.htm" tabindex="18"><span style="font-size: 10pt">Stock Purchase Agreement by and between Cross &amp; Co. and the Company.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/28/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.13**</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878219000208/s1a2_ex10z13.htm" tabindex="18"><span style="font-size: 10pt">Materials Transfer and Testing Agreement by and between Kannalife Sciences, Inc. and the Natural Products Discovery Institute.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/8/2019</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.14</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000083/ex10_14.htm" tabindex="18"><span style="font-size: 10pt">Kannalife, Inc. 2019 Equity Incentive Plan and related form agreements.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/30/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.15</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000083/ex10_15.htm" tabindex="18"><span style="font-size: 10pt">Form of Junior Unsecured Convertible Note.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/30/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.16</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000083/ex10_16.htm" tabindex="18"><span style="font-size: 10pt">Form of Common Stock Purchase Warrant.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/30/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.17</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000065/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Form of Securities Purchase Agreement.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/18/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.18</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000065/ex10_2.htm" tabindex="18"><span style="font-size: 10pt">Form of Convertible Promissory Note.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/18/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.19</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000065/ex10_3.htm" tabindex="18"><span style="font-size: 10pt">Form of Irrevocable Transfer Agent Letter</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/18/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.20</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000152/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Form of Securities Purchase Agreement.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/11/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.21</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000152/ex10_2.htm" tabindex="18"><span style="font-size: 10pt">Form of Convertible Promissory Note.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/11/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.22</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000152/ex10_3.htm" tabindex="18"><span style="font-size: 10pt">Form of Irrevocable Transfer Agent Letter.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/11/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.23</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000152/ex10_4.htm" tabindex="18"><span style="font-size: 10pt">Form of Warrant.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/11/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.24</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000191/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Form of Securities Purchase Agreement.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">10-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/29/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.25</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000191/ex10_2.htm" tabindex="18"><span style="font-size: 10pt">Form of Convertible Promissory Note.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/29/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.26</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000191/ex10_3.htm" tabindex="18"><span style="font-size: 10pt">Form of Irrevocable Transfer Agent Letter.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/29/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.27</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000191/ex10_4.htm" tabindex="18"><span style="font-size: 10pt">Form of Warrant.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6/29/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.28</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000287/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Equity Purchase Agreement by and between the Company and Cross &amp; Company, dated September 22, 2020.</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">9/22/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.29</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000333/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Binding Letter of Intent, dated November 17, 2020</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11/19/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.30</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000354/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Intellectual Property Rights Purchase and Transfer Agreement, dated December 17, 2020</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/21/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.31</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706220000354/ex10_2.htm" tabindex="18"><span style="font-size: 10pt">Pharmaceutical Royalty Agreement, dated December 17, 2020</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/21/2020</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.32</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706221000035/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Common Stock Purchase Agreement, dated February 17, 2020</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">2/23/2021</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.33</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706221000035/ex10_2.htm" tabindex="18"><span style="font-size: 10pt">Warrant No. 1, effective February 10, 2021</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">2/23/2021</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.34</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706221000035/ex10_3.htm" tabindex="18"><span style="font-size: 10pt">Warrant No. 2, effective February 10, 2021</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">2/23/2021</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.35</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000160706221000057/ex10_1.htm" tabindex="18"><span style="font-size: 10pt">Second Amendment to Neuropathix, Inc. (formerly Kannalife, Inc.) 2019 Equity Incentive Plan, effective as of March 12, 2021</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/17/2021</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.36</span></td>
    <td>Form of Convertible Note dated March 21, 2022</td>
    <td style="text-align: center"><span style="font-size: 10pt">8-K</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">3/25/2022</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">21.1</span></td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1615999/000107878218001466/s1a1_ex21z1.htm" tabindex="18"><span style="font-size: 10pt">Schedule of Subsidiaries</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">S-1/A</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">12/28/2018</span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.1 </span></td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/ex23_1.htm" tabindex="18">Consent of dbb<i>mckennon</i>, an independent registered public accounting firm</a></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>X</b></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">31.1*</span></td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/ex31_1.htm" tabindex="18">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">31.2*</span></td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/ex31_2.htm" tabindex="18">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">32.1*</span></td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/ex32_1.htm" tabindex="18">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **</a></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">32.2*</span></td>
    <td><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1615999/000160706222000284/ex32_2.htm" tabindex="18">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **</a></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">101.INS*</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">XBRL Instance Document</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>X</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">101.SCH*</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">XBRL Extension Schema Document</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>X</b></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">101.CAL*</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">XBRL Extension Calculation Linkbase Document</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>X</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">101.DEF*</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">XBRL Extension Definition Linkbase Document</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>X</b></span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">101.LAB*</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">XBRL Extension Labels Linkbase Document</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>X</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">101.PRE*</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">XBRL Extension Presentation Linkbase Document</span></td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>X</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">+&nbsp;Indicates management contract or compensatory
plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">** The XBRL related information in Exhibit 101
shall not be deemed filed for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act
of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>ITEM 16. FORM 10-K SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">None.</p>

<!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NEUROPATHIX, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>DECEMBER 31, 2021 AND 2020</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt">Page</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 90%"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm</span></td>
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Consolidated Statements of Operations for the Years Ended December 31, 2021 and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Consolidated Statement of Stockholders' Deficit for the Years Ended December 31, 2021 and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Notes to Consolidated Financial Statements</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  </tbody></table>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<!-- Field: Page; Sequence: 116; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">To the Board of Directors and<br>
Stockholders of Neuropathix, Inc.,<br>
<br>
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify">We have audited the accompanying consolidated
balance sheets of Neuropathix, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements
of operations, stockholders deficit, and cash flows for the years then ended, and the related notes (collectively referred to as
the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material
respects, the consolidated financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its
cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the consolidated financial statements,
the Company has suffered recurring losses from operations and has not generated revenues from its intended operations, which raises substantial
doubt about its ability to continue as a going concern. Managements plans in regard to these matters are also described in Note
3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify">These consolidated financial statements are the
responsibility of the Companys management. Our responsibility is to express an opinion on the Companys consolidated financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Companys
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide
a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="text-decoration: underline">/s/ dbbmckennon</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i style="font-style: normal; font-weight: normal">&nbsp;<span id="xdx_901_edei--AuditorName_c20210101__20211231_zbdROubcJwfh"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorName" inside-table="false" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">dbbmckennon</ix:nonnumeric></span></span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-left: 0pt; text-align: justify">PCAOB #<span id="xdx_907_edei--AuditorFirmId_c20210101__20211231_zJKRPebmBht5"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorFirmId" inside-table="false" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3501</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have served as the Company's auditor since
2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_905_edei--AuditorLocation_c20210101__20211231_zecegeZEom5g"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorLocation" inside-table="false" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">San Diego, California</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">April 14, 2022</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zR7hqnekLTo4" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_495_20211231" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_494_20201231" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">NEUROPATHIX, INC.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">CONSOLIDATED BALANCE SHEETS</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: center">&nbsp;</td><td style="text-align: center; vertical-align: bottom">&nbsp;</td>
    <td colspan="3" style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>December 31, 2020</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zg7OHL7yQ4Ll" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zT4z6coIxaNa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzbeo_zV5txUt57Tyh" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Cash and cash equivalents</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,677</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,874</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseCurrent_i02I_maCzbeo_zWgGKEBQnxo3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,313</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">161,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherReceivables_i02I_maCzbeo_zKdOPIfOvRf3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other receivables</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherReceivables" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OtherReceivables" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_i02TI_mtCzbeo_maCz8ei_zdFT7f3QG2F3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total Current Assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138,390</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">183,274</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsNoncurrentAbstract_i01B_zrElvmrcuhS" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NON-CURRENT ASSETS:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentNet_i02I_maCz0ZQ_zYsGiPS7Tm75" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69,192</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PropertyPlantAndEquipmentNet" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,266</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--SecurityDeposit_i02I_maCz0ZQ_zbN7ZokswMoa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Security deposits</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,121</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,121</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsNoncurrent_i01TI_mtCz0ZQ_maCz8ei_zhfXXyzPmk3g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total Non-Current Assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">86,313</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AssetsNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76,387</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCz8ei_zeZtKzNqKKEg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">224,703</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">259,661</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z6RDxWGmym95" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' DEFICIT</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_z5UXym84LcZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maCzWSt_zltV0qNAKz36" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">799,903</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">721,308</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredRevenueCurrent_i02I_d0_maCzWSt_zucbTYddSuj9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unearned revenue</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredRevenueCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">112,980</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredRevenueCurrent" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzWSt_zeBpw11tgNVd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payroll and related liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">530,189</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">379,241</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--LoansPayableCurrent_i02I_maCzWSt_zYAfpGiQMmY8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loan payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">900,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">950,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--ShortTermBorrowings_i02I_maCzWSt_zdiCIUJu2z6d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loan payable - related party</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShortTermBorrowings" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,092</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShortTermBorrowings" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,092</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maCzWSt_z853r3mYvNqa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayableCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">305,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleNotesPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">198,127</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleDebt_i02I_d0_maCzWSt_z8pjb5lmsFdk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible notes payable, net of $<span id="xdx_90A_eus-gaap--DebtInstrumentUnamortizedDiscount_c20211231_pp0p0" title="Debt discount related party"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,028</ix:nonfraction></span></span> debt discount - related party</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebt" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,972</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleDebt" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--CapitalLeaseObligationsCurrent_i02I_maCzWSt_zp6kmc45Lotf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital lease obligations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligationsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,860</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligationsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,471</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts_i02I_d0_maCzWSt_zQYKvxasfcF8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patent purchase liability</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,135</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--DueToRelatedPartiesCurrent_i02I_maCzWSt_zlJUfZjOQVh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Due to related party, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DueToRelatedPartiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,860</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DueToRelatedPartiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,258</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maCzWSt_zinm1sULPaBj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,171</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138,046</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_mtCzWSt_maCzWTv_zsqsj5GTTYVg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total Current Liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,983,027</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,545,678</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zBRvx65jLZKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherLoansPayableLongTerm_i02I_d0_maCzpZM_zClDhYrbyqte" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;&nbsp;&nbsp;Loan payable - long term</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherLoansPayableLongTerm" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,910</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherLoansPayableLongTerm" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermLoansPayable_i02I_maCzpZM_zuK4Q0NdFHXl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Convertible notes payable - long term</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermLoansPayable" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,373</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermLoansPayable" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,373</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--ConvertibleLongTermNotesPayable_i02I_pp0p0_d0_maCzpZM_zSoVaI0MKRYd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible notes payable - long term - related party</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleLongTermNotesPayable" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConvertibleLongTermNotesPayable" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--CapitalLeaseObligationsNoncurrent_i02I_pp0p0_maCzpZM_z2vCNIw5uYIl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital lease obligation - long term</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligationsNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,776</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligationsNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,293</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts_i02I_maCzpZM_zaGWvYyhseWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patent purchase liability - long term</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">381,865</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">264,826</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeLiabilitiesNoncurrent_i02I_maCzpZM_z3R2dzxsNcRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Derivative liabilities - long term</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">341,507</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">178,143</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--LiabilitiesNoncurrent_i02TI_mtCzpZM_maCzWTv_zpZOWU5FL789" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total Long Term Liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,228,431</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">908,635</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--Liabilities_i01TI_mtCzWTv_maCzK2y_z6TIOVwcwoI" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,211,458</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,454,313</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_zIfyknBmrxeg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and contingencies (Note 14)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--StockholdersEquityAbstract_i01B_zHlCwdBrvSmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS' DEFICIT:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Preferred stock, $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231_pdd" title="Preferred Stock, Par or Stated Value Per Share"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pdd" title="Preferred Stock, Par or Stated Value Per Share"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value, <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20211231_pdd" title="Preferred Stock, Shares Authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20201231_pdd" title="Preferred Stock, Shares Authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares authorized</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A preferred stock, <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred Stock, Shares Authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred Stock, Shares Authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></ix:nonfraction></span></span></span> shares designated, <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred Stock, Shares Issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding"><span id="xdx_901_eus-gaap--PreferredStockSharesIssued_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred Stock, Shares Issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> issued and outstanding (Liquidation preference of $<span id="xdx_904_eus-gaap--PreferredStockLiquidationPreferenceValue_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pp0p0" title="Liquidation preference"><span id="xdx_905_eus-gaap--PreferredStockLiquidationPreferenceValue_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pp0p0" title="Liquidation preference"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,000</ix:nonfraction></span></ix:nonfraction></span></span></span>)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--PreferredStockValue_i02I_pp0p0_d0_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvugLdrgHeld" title="Preferred Stock, Value, Issued" style="text-align: right"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--PreferredStockValue_i02I_pp0p0_d0_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkRUfz0g116e" title="Preferred Stock, Value, Issued" style="text-align: right"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B preferred stock, <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></ix:nonfraction></span></span></span> shares designated, <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></span></span></span></span> issued and outstanding&nbsp;(Liquidation preference of $<span id="xdx_907_eus-gaap--PreferredStockLiquidationPreferenceValue_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p0" title="Liquidation preference"><span id="xdx_904_eus-gaap--PreferredStockLiquidationPreferenceValue_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pp0p0" title="Liquidation preference"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextref="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,000</ix:nonfraction></span></ix:nonfraction></span></span></span>)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--PreferredStockValue_i02I_pp0p0_d0_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zpWfaXUDgDz8" title="Preferred Stock, Value, Issued" style="text-align: right"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--PreferredStockValue_i02I_pp0p0_d0_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z014OOGL4sV" title="Preferred Stock, Value, Issued" style="text-align: right"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-12-31_us-gaap_SeriesBPreferredStockMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--CommonStockValue_i02I_maCzRqe_zP3M7bpwIoh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Common stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common Stock, Par or Stated Value Per Share"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common Stock, Par or Stated Value Per Share"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common Stock, Shares Authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common Stock, Shares Authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> authorized, <span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common Stock, Shares, Issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common Stock, Shares, Outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,060,559</ix:nonfraction></span></ix:nonfraction></span></span></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common Stock, Shares, Issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common Stock, Shares, Outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,670,908</ix:nonfraction></span></ix:nonfraction></span></span></span> issued and outstanding, respectively</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,106</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,767</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--AdditionalPaidInCapital_i02I_maCzRqe_zAuLN7ng5ith" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,595,288</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,830,944</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzRqe_zZU35IGkXbkh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,591,149</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,033,363</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockholdersEquity_i02TI_mtCzRqe_maCzK2y_zR6n5dLZxeBb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL STOCKHOLDERS' DEFICIT</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,986,755</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,194,652</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzK2y_zfkDLreNawI6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">224,703</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">259,661</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">The accompanying notes are an integral part of these consolidated financial statements</td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_zo816DaHktbl" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49F_20210101_20211231" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49D_20200101_20201231" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">NEUROPATHIX, INC.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_406_eus-gaap--RevenuesAbstract_iB_zXgslZbUKMIi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET REVENUES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_i01_d0_maCzWsW_zo3Rz3qLPKTk" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-bottom: 1pt">Grant revenue</td><td style="width: 8%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">183,477</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="width: 8%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--Revenues_i01T_d0_mtCzWsW_maCzfUS_zp3OKqSkGgo3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL NET REVENUES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">183,477</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB_zIPACpLSxK5a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OPERATING EXPENSES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz9r0_zFcfQReBns98" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-137" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">451,779</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,095,405</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--GeneralAndAdministrativeExpense_i01_maCz9r0_zk74rvCM1tp4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,672,334</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,378,323</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpenses_i01T_mtCz9r0_msCzfUS_zWxXeAVDEGOb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL OPERATING EXPENSES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,124,113</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,473,728</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_i01T_mtCzfUS_maCz6Y3_zrxkOPoAmwIe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,940,636</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,473,728</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherIncomeAndExpensesAbstract_iB_zTO1mWk3FWP5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestExpense_i01N_di_msCzMWB_znHz5qiLDzg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest expense, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">434,589</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">924,227</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherIncome_i01_d0_maCzMWB_z4rTlchwPjH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income, net</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherIncome" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-147" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherIncome" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-148" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,185</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maCzMWB_zC80jb9HjFR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">182,561</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-150" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">752,495</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzMWB_maCz6Y3_zRO4XGL5l2Nb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">TOTAL OTHER INCOME (EXPENSE)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">617,150</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,547</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCz6Y3_maCzrEo_zwqOAAJCKKd6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS BEFORE INCOME TAX</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-153" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,557,786</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-154" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,537,275</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_d0_msCzrEo_z9KfBmsQ4pOf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCzrEo_zWxTjHJbW0ja" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,557,786</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,537,275</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_ecustom--PerCommonShareBasicAndDiluted_zMOq9BGvemI4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Loss attributable to Neuropathix, Inc. per common share  basic and diluted</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="NPTX:PerCommonShareBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.04</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="NPTX:PerCommonShareBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.06</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_ecustom--WeightedAverageCommonSharesOutstandingBasicAndDiluted_zXfMspdeDSv4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average common shares outstanding  basic and diluted</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:WeightedAverageCommonSharesOutstandingBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">87,575,637</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:WeightedAverageCommonSharesOutstandingBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">74,623,944</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">The accompanying notes are an integral part of these consolidated financial statements</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif"></p>


<!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">NEUROPATHIX, INC.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td></tr>
  </tbody></table>
<table cellpadding="0" cellspacing="0" id="xdx_302_114_zoAdasLHmCCh" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY DEFICIT" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--SeriesAPreferredStocksMember_zWx0tB2EPVZc" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--SeriesBPreferredStocksMember_z3J4M6ajR5jl" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zsEBiWMYJ82k" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zSwHIvFDvB9b" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zCIkrvQoGpqj" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B6_zQ5V52QdVGn8" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td colspan="5" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Series A Preferred Stock</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td colspan="5" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Series B Preferred Stock</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td colspan="5" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Common Stock</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td><td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td><td style="vertical-align: bottom; text-align: center"></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"></td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td><td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt"></span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Shares</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Shares</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Shares</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Additional Paid-In Capital</td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Accumulated Deficit</td><td style="vertical-align: bottom; padding-bottom: 1pt; text-align: center">&nbsp;</td><td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Total Stockholders Deficit</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_435_c20200101__20201231_eus-gaap--StockholdersEquity_iS_zalh8Hjdhi64" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">Balance at December 31, 2019</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAPreferredStocksMember_zHsQjJKaspn5" title="Beginning balance, shares" style="width: 4%; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-164" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBPreferredStocksMember_zJ6LSQrdgYid" title="Beginning balance, shares" style="width: 4%; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_custom_SeriesBPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0287"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-166" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9TtPTMaIEql" title="Beginning balance, shares" style="width: 4%; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74,225,141</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,422</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,794,612</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,496,088</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-171" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,694,054</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Stock based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-172" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-01-012020-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-173" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-174" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,722,599</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-176" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,722,599</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issuance of common stock for acquisition of intellectual property</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-178" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-01-012020-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-179" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZsDJknTyxZf" title="Issuance of common stock for acquisition of intellectual property, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-180" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,025,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-181" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">103</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">283,148</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-183" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">283,251</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issuance of common stock for conversion of notes payable and accrued interest</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-185" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2020-01-012020-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-186" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_ecustom--IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestShares_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOcqTPW43vE7" title="Issuance of common stock for conversion of notes payable and accrued interest, shares" style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestShares" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">570,767</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">57</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">119,675</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-190" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">119,732</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issuance of common stock for services</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-192" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-01-012020-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-193" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBZXCmR2Rpab" title="Issuance of common stock for services, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-194" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,850,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-195" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">185</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">844,523</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-197" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">844,708</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_ecustom--ReductionOfDerivativeLiability_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Reduction of derivative liability</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-199" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2020-01-012020-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-200" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-201" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">66,387</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-203" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">66,387</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-205" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-206" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-207" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-208" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,537,275</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,537,275</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zdALIQBnDMu5" style="vertical-align: bottom; background-color: White">
    <td>Balance at December 31, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAPreferredStocksMember_zfvVLHOdSrC" title="Beginning balance, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-212" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBPreferredStocksMember_zVPOnBnKkThe" title="Beginning balance, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_custom_SeriesBPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-214" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBargo2LhUYh" title="Beginning balance, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77,670,908</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,767</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,830,944</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,033,363</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,194,652</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_zfIxKzsuUDZj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Stock based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-220" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-221" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-222" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,351,751</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,351,751</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3us-gaap--AllocatedShareBasedCompensationExpense_zSZR9S7j3qQc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issuance of common stock for cash</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-225" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-226" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znueEYkRg4O1" title="Issuance of common stock for cash, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,768,188</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">778</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">832,949</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-230" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">833,727</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_ecustom--IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount_zAMFWnF8aXtf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issuance of common stock for conversion of notes payable and accrued interest</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0376"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-232" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-233" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_ecustom--IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zymEECgbG7N3" title="Issuance of common stock for conversion of notes payable and accrued interest, shares" style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestShares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,009,155</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">199</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">122,639</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0380"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-237" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForConversionOfNotesPayableAndAccruedInterestAmount" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">122,838</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zaBp6fhyvEqi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issuance of common stock for services</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-239" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-240" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIhD3qyv1xDg" title="Issuance of common stock for services, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">525,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,242</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-244" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,295</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfCommonStockForInLieuOfDeferredCompensation_iP3us-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zN0CMfKxgMwi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Issuance of common stock for in lieu of deferred compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForInLieuOfDeferredCompensation" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-246" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForInLieuOfDeferredCompensation" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-247" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_ecustom--IssuanceOfCommonStockForInLieuOfDeferredCompensationShares_iP3custom--IssuanceOfCommonStockForInLieuOfDeferredCompensation_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zt3tBmVkb75j" title="Issuance of common stock for in lieu of deferred compensation, shares" style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForInLieuOfDeferredCompensationShares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,567,308</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForInLieuOfDeferredCompensation" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">257</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForInLieuOfDeferredCompensation" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">179,743</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForInLieuOfDeferredCompensation" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-251" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForInLieuOfDeferredCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockDueToSettlementOfAccruedExpenses_iP3custom--IssuanceOfCommonStockForInLieuOfDeferredCompensationShares_zgsbIXZ8uvw4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Issuance of common stock due to settlement of accrued expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockDueToSettlementOfAccruedExpenses" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-253" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockDueToSettlementOfAccruedExpenses" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-254" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_ecustom--IssuanceOfCommonStockDueToSettlementOfAccruedExpensesShares_iP3custom--IssuanceOfCommonStockDueToSettlementOfAccruedExpenses_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzfg3P6CYhQe" title="Issuance of common stock due to settlement of accrued expenses, shares" style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockDueToSettlementOfAccruedExpensesShares" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">520,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockDueToSettlementOfAccruedExpenses" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">52</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockDueToSettlementOfAccruedExpenses" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">103,948</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockDueToSettlementOfAccruedExpenses" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-258" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockDueToSettlementOfAccruedExpenses" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">104,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_ecustom--ReductionOfDerivativeLiabilityDueToConversions_iP3custom--IssuanceOfCommonStockDueToSettlementOfAccruedExpensesShares_zhSX1kcXUa2d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Reduction of derivative liability due to conversions</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiabilityDueToConversions" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-260" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiabilityDueToConversions" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-261" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiabilityDueToConversions" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-262" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiabilityDueToConversions" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,072</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiabilityDueToConversions" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-264" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiabilityDueToConversions" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,072</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_z8Z1qdDuDfqa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-266" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-267" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-268" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-269" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,557,786</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,557,786</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zaI1ibuc7zhb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAPreferredStocksMember_zmQK5ubB0qjd" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-273" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesBPreferredStocksMember_zo1yzY6Uv5Le" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_custom_SeriesBPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_custom_SeriesBPreferredStocksMember" id="fact-identifier-275" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW8fINxTlpp1" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,060,559</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,106</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,595,288</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,591,149</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,986,755</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </tbody></table>


<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">The accompanying notes are an integral part of these consolidated financial statements</p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_112_zpk9AMAsACs7" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49A_20210101__20211231_zpiTa10RFHDi" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_496_20200101__20201231_zPxdDoXgH2Hf" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">NEUROPATHIX, INC.</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="9" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zgeq4D6bPyc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_i01_maCzlbX_zQGIkMdjIhBa" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Net loss</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,557,786</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,537,275</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">used in operating activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--Depreciation_i01_maCzlbX_zEYNIDJykufj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,066</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:Depreciation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,135</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_i01_maCzlbX_z3uNsVwkIkij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of debt discount</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">279,845</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,661</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_i01_maCzlbX_zENeHZDsyMuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,351,751</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,722,600</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForServices_i01_maCzlbX_zqkEtmK230Fb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock for services</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForServices" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">105,295</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForServices" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">594,708</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueOther_i01N_di0_msCzlbX_zx3sh0SzrZQc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock and debt for acquisition of intellectual property</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-291" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">601,211</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--NoninterestExpense_i01_d0_maCzlbX_z3wQ4sco4kPf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-cash interest expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:NoninterestExpense" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:NoninterestExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">432,170</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_i01N_di_msCzlbX_zMwA41NG1h82" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of derivative liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">182,561</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">752,495</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zgIe3OlGlh3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInPrepaidExpense_i01N_di0_msCzlbX_zycFZZXQjBWl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,687</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_i01_maCzlbX_zxB7LKEfOMsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts payable and accrued expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">253,414</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">338,145</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccruedSalaries_i01_maCzlbX_zFd6Xox4cP51" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payroll and related liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedSalaries" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">330,948</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccruedSalaries" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">136,033</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInUnearnedPremiums_i01_d0_maCzlbX_zc3zxSJ0MHY6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unearned Revenue</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInUnearnedPremiums" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">112,980</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInUnearnedPremiums" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInDueToRelatedParties_i01_maCzlbX_zctewSrZiWbg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Due to related party, net</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,398</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDueToRelatedParties" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,909</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzlbX_maCzSV4_zAzyucFKWL6f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">NET CASH USED IN OPERATING ACTIVITIES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">889,637</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">944,198</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_z29fzH8Ps7B3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS USED IN INVESTING ACTIVITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di0_msCzXsO_zzHqsLhO1vgb" style="vertical-align: bottom; background-color: White">
    <td>Purchase of equipment</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,522</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_d0_mtCzXsO_maCzSV4_zD9N9tTAqEWe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">NET CASH USED IN INVESTING ACTIVITIES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,522</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zpcIpchDIqr5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_d0_maCzukH_zoOql6t9CV14" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from issuance of common stock</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">833,727</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities_i01_maCzukH_zsbcWjToIr1d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Principal payments toward capital lease obligations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,765</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,533</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfLongTermDebt_i01_d0_maCzukH_zxakoXGTxPmj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from loan payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">330,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_ecustom--ProceedsFromConvertibleNotesPayable_i01_d0_maCzukH_zxKUvYudL6z4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from convertible notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:ProceedsFromConvertibleNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:ProceedsFromConvertibleNotesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">372,150</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--RepaymentsOfConvertibleDebt_i01N_di_msCzukH_zT9dOEsPkhji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Repayment of convertible notes payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:RepaymentsOfConvertibleDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515"><span><ix:nonfraction name="us-gaap:RepaymentsOfConvertibleDebt" contextref="From2020-01-012020-12-31" id="fact-identifier-322" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromNotesPayable_i01_d0_maCzukH_zi8WkEYmTY48" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from convertible notes payable - related party</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromNotesPayable" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromNotesPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromConvertibleDebt_i01_d0_maCzukH_zFgREdSgniy7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Proceeds from convertible notes payable</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzukH_maCzSV4_z8KrhbveeEMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">889,962</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">844,617</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzSV4_zrMegx68njXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net decrease in cash</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,197</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">99,581</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zDU7h0sHVrp2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of year</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,874</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">121,455</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zqKoJbKk1F7j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of year</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,677</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,874</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zu79aoro9Kx9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestPaidNet_i01_zTTF4Fm82ex6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">798</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,262</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--NoncashInvestingAndFinancingItemsAbstract_iB_zYh0p6KK1m1i" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NON-CASH ACTIVITIES:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssued1_i01_ze5KSF2j3cec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Issuance of common stock for conversion of notes payable and accrued interest</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockIssued1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,838</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockIssued1" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,032</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_ecustom--IssuanceOfCommonStockForPrepaidExpenses_i01_z2MHQZJHOp6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Issuance of common stock for prepaid expenses</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0547"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForPrepaidExpenses" contextref="From2021-01-01to2021-12-31" id="fact-identifier-339" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:IssuanceOfCommonStockForPrepaidExpenses" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">250,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_ecustom--SettlementOfAccruedExpensesThroughIssuanceOfCommonStock_i01_d0_z3dVY4e2h7s4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Settlement of accrued expenses through issuance of common stock</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:SettlementOfAccruedExpensesThroughIssuanceOfCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:SettlementOfAccruedExpensesThroughIssuanceOfCommonStock" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_ecustom--PropertyAndEquipmentFinancedThroughCapitalLeases_i01_d0_zwDU6tCUuSF9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Property and equipment financed through capital leases</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:PropertyAndEquipmentFinancedThroughCapitalLeases" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24,637</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:PropertyAndEquipmentFinancedThroughCapitalLeases" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_ecustom--ReductionOfDerivativeLiability_i01_zwKnetv1eOz2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Reduction of derivative liability</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,072</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:ReductionOfDerivativeLiability" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">66,387</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_ecustom--DebtDiscountUponIssuanceOfConvertibleNotePayable_i01_d0_zdlPawTLIf15" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Debt discount upon the issuance of convertible note payable</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:DebtDiscountUponIssuanceOfConvertibleNotePayable" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:DebtDiscountUponIssuanceOfConvertibleNotePayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">372,150</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_ecustom--DebtDiscountUponIssuanceOfConvertibleNotePayableRelatedParty_i01_d0_zrR5Z9Hgh2Cc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Debt discount upon the issuance of convertible note payable - related party</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:DebtDiscountUponIssuanceOfConvertibleNotePayableRelatedParty" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:DebtDiscountUponIssuanceOfConvertibleNotePayableRelatedParty" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_ecustom--SettlementOfAccruedExpensesThroughIssuanceOfCommonStock1_i01_d0_z1fmAwRNlK21" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Settlement of accrued expenses through issuance of common stock</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:SettlementOfAccruedExpensesThroughIssuanceOfCommonStock1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">104,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="NPTX:SettlementOfAccruedExpensesThroughIssuanceOfCommonStock1" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="text-transform: uppercase"><b>&nbsp;</b></span>The
accompanying notes are an integral part of these consolidated financial statements</p>

<!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 100%; text-align: center"><span style="font-size: 10pt"><b>NEUROPATHIX, INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 10pt"><b>DECEMBER 31, 2021 AND 2020</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b></b></span></p>

<span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NatureOfOperations" inside-table="false" id="fact-identifier-353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--NatureOfOperations_zhy2PUaw1R22" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b>Note
1  <span id="xdx_826_zaECzy4wOaHa">Organization and Nature of Operations</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Neuropathix, Inc. (the Company)
was incorporated under the laws of the state of Delaware on <span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20210101__20211231_zcyAdMA8CZAa" title="Date of Incorporation"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation" inside-table="false" id="fact-identifier-354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March 25, 2013</ix:nonnumeric></span></span> under the name TYG Solutions Corp. The Company consummated
a share exchange transaction on July 25, 2018 with Kannalife Sciences, Inc. On November 4, 2020, the Company filed an amendment to its
certificate of incorporation with the Delaware Secretary of State that changed its name to Neuropathix, Inc. Neuropathix is a phytomedical/pharmaceutical
company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources,
including the cannabis taxa.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80F_eus-gaap--SignificantAccountingPoliciesTextBlock_zzTz4ehlNVD4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b>Note
2 - <span id="xdx_825_zUHlTMX6OkWc">Summary of Significant Accounting Policies</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The significant accounting policies used in the
preparation of the consolidated financial statements are as follows:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zMe8HeICxp8f" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_867_zUOQYgS9F9rg">Basis of Presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84B_eus-gaap--ConsolidationPolicyTextBlock_zRNCFg3UKBh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_863_zIBwj0iyRw0b">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company evaluates the need to consolidate
affiliates based on standards set forth in ASC 810 Consolidation (ASC 810).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiary, Kannalife. All significant consolidated transactions and balances have been
eliminated in consolidation.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:SignificantRisksAndUncertaintiesPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_841_ecustom--SignificantRisksAndUncertaintiesPolicyTextBlock_zwxBAeCTgUed" style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zvAi0Cf3HKF1">Significant Risks and Uncertainties</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Companys operations are subject to
a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results
of clinical testing and trial activities of the Companys products, the Companys ability to obtain regulatory approval to
market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for,
Company products, the Companys ability to negotiate favorable licensing or other manufacturing and marketing agreements for its
products, and the Companys ability to raise capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company currently has no commercially approved
products and there can be no assurance that the Companys research and development will be successfully commercialized. Developing
and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition
from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the
continued services of its employees and consultants and obtaining and protecting intellectual property.</p>


<ix:exclude><!-- Field: Page; Sequence: 122 -->
    <div id="xdx_236_zu9YQuJ26eFh" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_zca0TuFjkAO" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_23C_zP4XK8e2yCOg" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23F_zzMU9kar3cJ7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_233_zi4YDLd8uNP4" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In December 2019, a novel strain of coronavirus,
commonly known as COVID-19, surfaced. The spread of COVID-19 around the world in 2020 has caused significant volatility in U.S. and international
markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its
impact on the U.S. and international economies and, as such, the Company is unable to determine if it will have a material impact to its
operations. The Companys operations as of December 31, 2021 have not been significantly affected, but may be affected in the future,
by the ongoing outbreak of COVID-19, which was declared a pandemic by the World Health Organization. The ultimate disruption which may
be caused by the outbreak is uncertain; however, it may result in a material adverse impact on the Companys financial position,
operations and cash flows. Possible areas that may be affected include, but are not limited to, disruption to the Companys labor
workforce, unavailability of products and supplies used in operations, and the decline in value of assets held by the Company.</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_848_eus-gaap--UseOfEstimates_zBw4mp4IECE1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_86D_zayJ4Q699mG3">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The preparation of consolidated financial statements and
accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements,
and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant
matters requiring the use of estimates and assumptions include, but are not necessarily limited to stock-based compensation and
valuation of derivative liabilities. Management believes
that its estimates and assumptions are reasonable, based on information that is available at the time they are made.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zoGUKgh52Njh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_868_zclE7AmvUpXe">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Our cash and cash equivalents include short-term,
highly liquid investments with original maturities of three months or less when purchased. At times throughout the year, the Company may
maintain bank balances that could exceed Federal Deposit Insurance Corporation insured limits. The Company maintains its cash deposit
accounts with high credit quality financial institutions, and therefore believes that its loss exposure is minimal.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ReceivablesPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84D_eus-gaap--ReceivablesPolicyTextBlock_zZdqOSIwAx9f" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_863_zyQ2EtICpCnf">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts receivable are carried at original invoice
amount less an estimate made for doubtful accounts based on a review of all outstanding amounts. Management determines the allowance for
doubtful accounts by regularly evaluating individual customer receivables and considering a customers financial condition, credit
history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers
accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are
recorded as income when received. As of December 31, 2021 and 2020, the Company had <span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20211231_znoZ42cwfgXc" title="Allowance for doubtful account"><span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_do_c20201231_zpO5u47D0tx9" title="Allowance for doubtful account"><span><ix:nonfraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextref="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextref="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></span></span> allowance for doubtful account.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z1aJuggdj3t6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_868_zhA8wxgP6JCk">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Property and equipment are stated at cost, less
accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to expense when incurred, while renewals
and betterments that materially extend the life of an asset are capitalized. When assets are sold, retired or otherwise disposed of, the
cost and accumulated depreciation are removed from the balance sheets and any resulting gain or loss is reflected in the statements of
operations and members deficit in the period realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Depreciation is provided using the straight-line
method over the estimated useful lives of the assets, which are as follows:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellspacing="0" cellpadding="0" id="xdx_89A_eus-gaap--PropertyPlantAndEquipmentTextBlock_zv51ujxOUhUb" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td><span id="xdx_8BF_zesLoxGTPg6h" style="display: none">Schedule of estimated useful lives of the assets</span></td>
    <td style="text-align: justify">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 70%"><span style="font-size: 10pt">Furniture and equipment</span></td>
    <td style="width: 30%; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231_zrUEEEsJu8Zf" title="Furniture and equipment Useful Life"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" inside-table="true" id="fact-identifier-366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonnumeric></span></span> years</span></td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A3_zk8clsjQbBx4" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<ix:exclude><!-- Field: Page; Sequence: 123 -->
    <div id="xdx_23B_zPVmcPsfwq3l" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zB0Pti7Pq5Ch" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_23B_zte7CGMs4XKl" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_230_zfZ4k3ZuYt6a" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_zxr4nDTV7fq4" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zWMsVwgaxii7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>&nbsp;</i></b>&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_845_eus-gaap--RevenueRecognitionPolicyTextBlock_zo4xvM4ldVj" style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_863_zi0F8r6cCAdi">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">It is the Companys
policy that revenues are recognized in accordance with ASC 606 Revenue Recognition. Five basic steps must be followed before
revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying
the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction
price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised
goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the
company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each
distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation
by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance
obligation. Adoption of ASC 606 has not changed the timing and nature of the Companys revenue recognition and there has been no
material effect on the Companys financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenue consists of research funding from the
Companys National Institute of Health (NIH) Grant. Grant revenue is recognized when qualifying costs are
incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to
the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are
performed and the conditions of the award are met. During the year ended December 31, 2021, the Company recognized $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231_pp0p0" title="Grant revenue"><span><ix:nonfraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">183,477</ix:nonfraction></span></span>
in grant revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On September 28, 2021, the Company received a
notice of award for a $<span id="xdx_90D_eus-gaap--RevenueFromRelatedParties_pn6n6_dm_c20210101__20211231__srt--CounterpartyNameAxis__custom--Phase2STTRStudyGrantMember_zgQZhXcfxqUc" title="Revenue"><span><ix:nonfraction name="us-gaap:RevenueFromRelatedParties" contextref="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember" format="ixt:numdotdecimal" decimals="-6" scale="9" unitref="USD" inside-table="false" id="fact-identifier-369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.97</ix:nonfraction></span></span> million Phase 2 STTR Study Grant (the NINDS Study Grant Award) from National Institutes of Health
(NIH)  National Institute of Neurological Disorders and Stroke (NINDS). The NINDS Study Grant Award
is funded through the NIH HEAL Initiative (Helping End Addiction Long-Term) for Development of Therapies and Technologies
Directed at Enhanced Pain Management and will provide funding specifically in the Development of KLS-13019 for Neuropathic Pain. The NINDS
Study Grant Award sets forth the funding allocation of $<span id="xdx_909_eus-gaap--RevenueFromRelatedParties_c20210101__20211231__srt--CounterpartyNameAxis__custom--Phase2STTRStudyGrantMember__us-gaap--AwardTypeAxis__custom--YearOneMember_zams2gk0FOEb" title="Grant revenue"><span><ix:nonfraction name="us-gaap:RevenueFromRelatedParties" contextref="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember_custom_YearOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">977,054</ix:nonfraction></span></span> in year 1; $<span id="xdx_900_eus-gaap--RevenueFromRelatedParties_c20210101__20211231__srt--CounterpartyNameAxis__custom--Phase2STTRStudyGrantMember__us-gaap--AwardTypeAxis__custom--YearTwoMember_zFRamqsbWzF7" title="Grant revenue"><span><ix:nonfraction name="us-gaap:RevenueFromRelatedParties" contextref="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember_custom_YearTwoMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">991,944</ix:nonfraction></span></span> in year 2; and $<span id="xdx_903_eus-gaap--RevenueFromRelatedParties_c20210101__20211231__srt--CounterpartyNameAxis__custom--Phase2STTRStudyGrantMember__us-gaap--AwardTypeAxis__custom--YearThreeMember_z8CeAgu0hLz7" title="Grant revenue"><span><ix:nonfraction name="us-gaap:RevenueFromRelatedParties" contextref="From2021-01-012021-12-31_custom_Phase2STTRStudyGrantMember_custom_YearThreeMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,001,774</ix:nonfraction></span></span> in year 3. The Company is
able to draw down on the grant to reimburse approved research and development activities. Any losses from the contract would have significant
impact on operations. &nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zpExVrEPTBni" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_86F_z4IAepCSuGTh">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company accounts for income taxes under FASB
ASC Topic 740,&nbsp;<i>Income Taxes</i>&nbsp;(ASC 740). Deferred income tax assets and liabilities are determined based
upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates
and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance
to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements
of operations in the period that includes the enactment date.</p>


<ix:exclude><!-- Field: Page; Sequence: 124 -->
    <div id="xdx_235_z6tsGjC2fe5a" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zuJxosIt9K07" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_235_z2g98TeOjkAe" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_239_zh1iNmAjcn8j" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zOP2SdcTObyd" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:ConvertibleInstrumentsPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_84B_ecustom--ConvertibleInstrumentsPoliciesTextBlock_zPApnvIsSlN1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_86D_zZV1PwYFxhD8">Convertible Instruments</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company evaluates and accounts for conversion
options embedded in convertible instruments in accordance with ASC Topic 815,&nbsp;<i>Derivatives and Hedging Activities</i>&nbsp;(ASC
815).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Applicable U.S. GAAP requires companies to bifurcate
conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain
criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument
are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies
both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted
accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms
as the embedded derivative instrument would be considered a derivative instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company accounts for convertible instruments
(when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments) as follows.
The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based
upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective
conversion price embedded in the preferred shares.</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" inside-table="false" id="fact-identifier-375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zkvo5yWLglg8" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_866_zgKhQZiTu9D7">Stock Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company accounts for share-based compensation
in accordance with the fair value recognition provision of FASB ASC 718,&nbsp;<i>Compensation  Stock Compensation&nbsp;</i>(ASC
718), prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired.
Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee
stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are
recognized as compensation expense in the consolidated financial statements based on the estimated grant date fair values. That expense
is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite
service period (usually the vesting period).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company accounts for stock-based compensation
issued to non-employees and consultants in accordance with the provisions of FASB ASC 505,&nbsp;<i>Equitybased Payments to Non-Employees&nbsp;</i>(ASC
505)<i>.</i>&nbsp;Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is
more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based
payment transaction is determined at the earlier of performance commitment date or performance completion date.&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zae4g7Mn4oi1" style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zglOguPLdRaa">Net Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Basic net loss per share is calculated by dividing
the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share
is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased
by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include
stock options and warrants granted, convertible debt, and convertible preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The weighted average number of common stock equivalents
not included in diluted income per share, because the effects are anti-dilutive, was 44,501,798 and <span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_pdd" title="Weighted average number of common stock, anti-dilutive"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,174,152</ix:nonfraction></span></span> &nbsp;for the years ended
December 31, 2021 and 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Details of dilute securities by instrument are
as follows:</p>

<span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:ScheduleOfDiluteSecuritiesInstrument" inside-table="false" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--ScheduleOfDiluteSecuritiesInstrument_zFIGcqijFgm6" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span style="display: none"><span id="xdx_8B8_zEJxI3rAF8Qh">Schedule of dilute securities by instrument</span></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Series A &amp; B preferred stock</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAandBPreferredStockMember_zVMhRI3yWje" title="Dilute securities" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_custom_SeriesAandBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesAandBPreferredStockMember_zQOPUpc5cLyd" style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_custom_SeriesAandBPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Options</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7NdDbrLzPOk" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,550,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWFQOa3L974d" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,125,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants - convertible notes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--WarrantsConvertibleNotesMember_zBMXGPkSslc7" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_custom_WarrantsConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,287,234</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--WarrantsConvertibleNotesMember_z9KipmZGYlnd" style="text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_custom_WarrantsConvertibleNotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,289,343</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Convertible notes payable</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotePayableMember_z8whqnQv0X72" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-012021-12-31_custom_ConvertibleNotePayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,514,564</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotePayableMember_zQmDHGxPbMfg" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31_custom_ConvertibleNotePayableMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,609,809</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zcXNVEOylJmi" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44,501,798</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zOk230vjJP6l" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,174,152</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A4_zS0y4LCK6py3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i></i></b></p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_848_eus-gaap--ResearchAndDevelopmentExpensePolicy_zgzCEf428t19" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i><span id="xdx_863_zv5IwT71r7C3">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In accordance with FASB ASC 730,&nbsp;<i>Research
and Development</i>&nbsp;(ASC 730) research and development (R&amp;D) costs are expensed when incurred. R&amp;D
costs include supplies, clinical trial and related clinical manufacturing costs, contract and other outside service and facilities and
overhead costs. Total R&amp;D costs for the years ended December 31, 2021 and 2020, were $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_pp0p0" title="Research and Development"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">451,779</ix:nonfraction></span></span> and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_pp0p0" title="Research and Development"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,095,405</ix:nonfraction></span></span>, respectively.</p>

<ix:exclude><!-- Field: Page; Sequence: 125 -->
    <div id="xdx_237_zlLR8SZL11v8" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zcdwdGvHD89f" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_23D_z1gUL9z5pt2d" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_237_ziBH1Ac1Ix9k" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_232_zTYlN5oxBh1i" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zVft5WBFgN9" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:RecentlyIssuedAuthoritativeGuidancePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_848_ecustom--RecentlyIssuedAuthoritativeGuidancePolicyTextBlock_zX24Wp4Ce7Y3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;<b><i><span id="xdx_869_z8mWWIqR0Le8">Recently Issued Authoritative Guidance</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In June 2016, the FASB issued ASU 2016-13, Financial
Instruments  Credit Losses to improve information on credit losses for financial assets and net investment in leases that
are not accounted for at fair value through net income. ASU 2016-13 replaces the current incurred loss impairment methodology with a methodology
that reflects expected credit losses. In April 2019 and May 2019, the FASB issued ASU No. 2019-04,&nbsp;Codification Improvements
to Topic 326, Financial Instruments-Credit Losses,&nbsp;Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&nbsp;and
ASU No. 2019-05,&nbsp;Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief&nbsp;which provided additional
implementation guidance on the previously issued ASU. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit
Loss (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), which defers the effective date for public filers
that are considered small reporting companies (SRC) as defined by the Securities and Exchange Commission to fiscal years
beginning after December 15, 2022, including interim periods within those fiscal years. Since the Company is an SRC, implementation is
not needed until January 1, 2023. The Company will continue to evaluate the effect of adopting ASU 2016-13 will have on the Companys
consolidated financial statements&nbsp;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In February 2016, the FASB issued ASU 2016-02,
Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee
should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset
representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted
to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition,
lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective
approach. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including
interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business
entities upon issuance. The Company (as an EGC) that is taking advantage of the extended transition period offered to private entities
would apply this for fiscal years beginning after December 15, 2021. The Company believes that the adoption will have a material effect
on the Companys consolidated financial statements and related disclosures. Accordingly, the Company will record a right of use
asset and operating lease liability in connection with its leases.</p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zMMcosbxmPL1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b>Note
3  <span id="xdx_82A_ziI1YtLusu8f">Going Concern and Managements Liquidity Plans</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Companys consolidated financial statements have
been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and
commitments in the normal course of business. As reflected in our accompanying consolidated financial statements, the Company has
had a loss from operations of $<span id="xdx_90D_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_c20210101__20211231_zTzPzZw1Ohm6" title="Net loss from operations"><span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="false" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,940,636</ix:nonfraction></span></span>
and $<span id="xdx_906_eus-gaap--OperatingIncomeLoss_iN_pp0p0_di_c20200101__20201231_z9s7aFEvWFHi" title="Net loss from operations"><span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="false" id="fact-identifier-395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,473,728</ix:nonfraction></span></span>
for the years ended December 31, 2021 and 2020, respectively. The net cash used in operations were $<span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20210101__20211231_zoIAcvDksloi" title="Net cash used in operating activities"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="false" id="fact-identifier-396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">889,637</ix:nonfraction></span></span>
and $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_di_c20200101__20201231_zjms0GVyFmfk" title="Net cash used in operating activities"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="false" id="fact-identifier-397" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">944,198</ix:nonfraction></span></span>
for the years ended December 31, 2021 and 2020, respectively. Additionally, the Company had a working capital deficit of $2,844,637
and an accumulated deficit of $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_z2oRq5vb9OFd" title="Accumulated deficit"><span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="false" id="fact-identifier-398" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,591,149</ix:nonfraction></span></span>
at December 31, 2021 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and
to allow it to continue as a going concern. These factors raise substantial doubt about its ability to continue as a going
concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In order to continue as a going concern, the Company
will need, among other things, additional capital resources. Management plans to raise additional capital through the sale of convertible
debt securities offering. However, there are no assurances that such additional funding will be achieved or that managements plans
will be successful. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and
classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue
as a going concern.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_805_eus-gaap--FairValueDisclosuresTextBlock_zIzDfwWXBr4a" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b>Note
4  <span id="xdx_828_zqUIUhaiGTT4">Fair Value Measurements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company follows FASB ASC 820,&nbsp;<i>Fair
Value Measurements and Disclosures&nbsp;</i>(ASC 820) to measure and disclosure the fair value of its financial instruments.
ASC 820 establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements and establishes
a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three
levels of fair value hierarchy defined by ASC 820 are described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - Quoted market prices available in active
markets for identical assets or liabilities as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - Pricing inputs other than quoted prices
in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - Pricing inputs that are generally unobservable
inputs and not corroborated by market data.</p>


<ix:exclude><!-- Field: Page; Sequence: 126 -->
    <div id="xdx_236_zC7ymULep4b5" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zy7judey5Qij" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_235_zeZ9GNQ88Dma" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_230_ztlsTmyEGcpa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_z5nurF5S9ezk" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Financial assets are considered Level 3 when their
fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant
model assumption or input is unobservable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The fair value hierarchy gives the highest priority
to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If
the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is
based on the lowest level input that is significant to the fair value measurement of the instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The carrying amounts reported in the Companys
consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate
or short-term nature of these financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Transactions involving related parties cannot
be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist.
Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated
on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following table presents liabilities that
are measured and recognized at fair value as of December 31, 2021 and 2020, on a recurring basis:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zMh5FACXHTB3" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS - Fair Value, liabilities Measured on Recurring Basis (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center"><span id="xdx_8BB_zTiXgZLX2DM" style="display: none">Fair Value, Liabilities Measured on Recurring Basis</span></td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Total Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Value</b></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Derivative liabilities</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iI_pp0p0_d0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zou7YrOGJnnf" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iI_pp0p0_d0_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1WZOstvUq2k" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-403" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">430,678</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel12And3Member_pp0p0" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_FairValueInputsLevel12And3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-404" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">430,678</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  </tbody></table>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Total Carrying </b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>Value</b></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Derivative liabilities</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iI_pp0p0_d0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_ztGkMSarf0v6" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-405" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iI_pp0p0_d0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1lBA0jmAdT7" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-406" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316,189</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 3%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel12And3Member_pp0p0" title="Derivative liabilities" style="width: 10%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_FairValueInputsLevel12And3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-408" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316,189</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A0_zlTu8ASFJ0Yj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-409" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_809_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zqwIPg4bTIUf" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 5  <span id="xdx_82B_zTkXNBbMDOY">ACCOUNTS PAYABLE AND ACCRUED
EXPENSES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts payable and accrued expenses at December
31, 2021 and 2020 consisted of the following:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-410" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zBF9LghHRTSi" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8BC_zhzA5oulQmDd" style="display: none">Accounts payable and accrued expenses</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_498_20211231_zIl722sLCzIf" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_494_20201231_ztWgAwoEgqek" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>2021</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify">Accounts payable and accrued expenses</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">485,628</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">538,527</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Accrued interest</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-413" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">314,275</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">182,781</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">799,903</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">721,308</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 127 -->
    <div id="xdx_23B_zZ3qwhBDAaJ4" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zGp4IAyQ19tg" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_236_zVMUinKJV8x7" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23D_zwsj0mbnJjSi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_232_z7KlqtTRtHw5" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zh0FWCBHdES4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 6  <span id="xdx_826_z7PyxWOx3mv4">PAYROLL AND RELATED LIABILITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Payroll and related liabilities at December 31,
2021 and 2020 consisted of the following:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:ScheduleOfPayrollAndRelatedLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-418" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfPayrollAndRelatedLiabilitiesTableTextBlock_za6mRY1xFZ9g" summary="xdx: Disclosure - PAYROLL AND RELATED LIABILITIES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: justify"><span id="xdx_8B2_zDmKgJgzXutk" style="display: none">Schedule of Payroll and Related Liabilities</span></td><td>&nbsp;</td>
    <td colspan="3" id="xdx_49D_20211231_zuIQYbJZmCih" style="text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" id="xdx_49A_20201231_zhXYCcX0Vw6g" style="font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>2021</b></p></td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td></tr>
  <tr id="xdx_408_ecustom--Payroll_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify">Payroll</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="NPTX:Payroll" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">288,780</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="NPTX:Payroll" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-420" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">149,704</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_zM4SSJlbRvU1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Payroll taxes</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedPayrollTaxesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">241,409</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedPayrollTaxesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-422" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">229,537</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">530,189</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:AccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-424" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">379,241</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has accrued payroll and payroll taxes
in connection with salaries paid and accrued to four officers of the Company, which includes $<span id="xdx_90B_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zSSfcJTJlct6" title="Payroll taxes"><span><ix:nonfraction name="us-gaap:AccruedPayrollTaxesCurrent" contextref="AsOf2021-12-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">190,000</ix:nonfraction></span></span> accrued for the CEO, and $<span id="xdx_906_eus-gaap--AccruedPayrollTaxesCurrent_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_pp0p0" title="Payroll taxes"><span><ix:nonfraction name="us-gaap:AccruedPayrollTaxesCurrent" contextref="AsOf2021-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,000</ix:nonfraction></span></span>
accrued for executive management for the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company has accrued payroll and payroll taxes
in connection with salaries paid and accrued to four officers of the Company, which includes $<span id="xdx_90E_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_zOVzZMCbCfw8" title="Payroll taxes"><span><ix:nonfraction name="us-gaap:AccruedPayrollTaxesCurrent" contextref="AsOf2020-12-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-427" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">130,000</ix:nonfraction></span></span> accrued for the CEO, and $<span id="xdx_90C_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--DirectorMember_zAL1IekiqN3i" title="Payroll taxes"><span><ix:nonfraction name="us-gaap:AccruedPayrollTaxesCurrent" contextref="AsOf2020-12-31_srt_DirectorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,500</ix:nonfraction></span></span>
accrued for executive management for the year ended December 31, 2020.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zb9QUCujeSWb" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 7  <span id="xdx_82E_zM8wDvJnbXMd">LOANS PAYABLE</span></b></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:ScheduleOfLoansPayableTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--ScheduleOfLoansPayableTableTextBlock_z5mxChT7bxId" summary="xdx: Disclosure - LOANS PAYABLE (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8BA_zwBMdjNgq5a5" style="display: none">Schedule of Loans Payable</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="text-align: justify">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Loan payable at <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableOneMember_zLs9MsrU4eh1" title="Debt Instrument, interest rate"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableOneMember_z38JdICuBjMb" title="Debt Instrument, interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2021-01-012021-12-31_custom_LoansPayableOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2020-01-012020-12-31_custom_LoansPayableOneMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-432" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></ix:nonfraction></span></span></span>%, matures <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableOneMember_zISu2hlqaD08" title="Debt instrument, maturity date"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableOneMember_zxUvmigKARvb" title="Debt instrument, maturity date"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_LoansPayableOneMember" format="ixt:datemonthdayyear" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_custom_LoansPayableOneMember" format="ixt:datemonthdayyear" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-434" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12/31/2021</ix:nonnumeric></span></ix:nonnumeric></span></span></span></td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 11%; text-align: right"><span style="font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--LoansPayableToBank_iI_pp0p0_c20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableOneMember_fKg_____zxt2t6oHYMo8" title="Total" style="width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2021-12-31_custom_LoansPayableOneMember" id="fact-identifier-435" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" data-original-id="Fact000719" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">850,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 5%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--LoansPayableToBank_iI_pp0p0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableOneMember_fKg_____zQpnTA5WGdsj" title="Total" style="width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2020-12-31_custom_LoansPayableOneMember" id="fact-identifier-436" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" data-original-id="Fact000721" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">850,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Loan payable at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableTwoMember_zOqur3sjzhA8" title="Debt Instrument, interest rate"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableTwoMember_zOEiORkxmh78" title="Debt Instrument, interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2021-01-012021-12-31_custom_LoansPayableTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-437" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2020-01-012020-12-31_custom_LoansPayableTwoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></ix:nonfraction></span></span></span>%, matures <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableTwoMember_zPsN2cIGrVWe" title="Debt instrument, maturity date"><span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableTwoMember_zHnLEIjwe5Pc" title="Debt instrument, maturity date"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_LoansPayableTwoMember" format="ixt:datemonthdayyear" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-439" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_custom_LoansPayableTwoMember" format="ixt:datemonthdayyear" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6/11/2021</ix:nonnumeric></span></ix:nonnumeric></span></span></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--LoansPayableToBank_iI_pp0p0_c20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableTwoMember_fKg_____zmWlsr9TYSNc" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2021-12-31_custom_LoansPayableTwoMember" id="fact-identifier-441" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" data-original-id="Fact000731" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--LoansPayableToBank_iI_pp0p0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableTwoMember_fKg_____z2t6odTM9fbc" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2020-12-31_custom_LoansPayableTwoMember" id="fact-identifier-442" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" data-original-id="Fact000733" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Loan payable at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableThreeMember_zRB17q7BW4O4" title="Debt Instrument, interest rate"><span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableThreeMember_zOw1dnEUtgX5" title="Debt Instrument, interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2020-01-012020-12-31_custom_LoansPayableThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2021-01-012021-12-31_custom_LoansPayableThreeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span></ix:nonfraction></span></span></span>%, matures <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableThreeMember_zUDnisGBa0C1" title="Debt instrument, maturity date"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableThreeMember_z76stdnjNuZb" title="Debt instrument, maturity date"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_LoansPayableThreeMember" format="ixt:datemonthdayyear" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-445" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="From2020-01-012020-12-31_custom_LoansPayableThreeMember" format="ixt:datemonthdayyear" name="us-gaap:DebtInstrumentMaturityDate" inside-table="true" id="fact-identifier-446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7/26/2023</ix:nonnumeric></span></ix:nonnumeric></span></span></span></td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--LoansPayableToBank_c20211231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableThreeMember_pp0p0" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2021-12-31_custom_LoansPayableThreeMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-447" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,910</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--LoansPayableToBank_iI_pp0p0_d0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--LoansPayableThreeMember_zJw4MFOCPeGj" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2020-12-31_custom_LoansPayableThreeMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--LoansPayableToBank_c20211231_pp0p0" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-449" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,007,910</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--LoansPayableToBank_iI_pp0p0_c20201231_zXlAp3GsBUsj" title="Total" style="text-align: right"><span><ix:nonfraction name="us-gaap:LoansPayableToBank" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">950,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Less: short term loans</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--DebtCurrent_c20211231_pp0p0" title="Less: short term loans" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DebtCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-451" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">900,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--DebtCurrent_iI_pp0p0_d0_c20201231_zppfQySKm9X2" title="Less: short term loans" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DebtCurrent" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-452" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Total long-term loans</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--LongTermDebtNoncurrent_c20211231_pdp0" title="Total long-term loans" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-453" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,910</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--LongTermDebtNoncurrent_iI_pdp0_c20201231_zfYJzTcQq8pk" title="Total long-term loans" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-454" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">950,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
  <td id="xdx_F09_zEIYxlGgsNp1" style="padding-left: 10pt; text-indent: -10pt; width: 3%">*</td>
  <td id="xdx_F12_znDt3IlL1C79" style="padding-left: 10pt; text-indent: -10pt; width: 97%"><ix:footnote id="Footnote000758" xml:lang="en-US">- unsecured note &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</ix:footnote></td></tr>
</tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company received multiple proceeds from an
investor through promissory notes during the years 2017, 2018 and 2020. These note proceeds bear interest rate of <span id="xdx_90D_eus-gaap--AccountsPayableInterestBearingInterestRate_iI_dp_c20211231_zAg5Y35dTbSd" title="Interest rate"><span><ix:nonfraction name="us-gaap:AccountsPayableInterestBearingInterestRate" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-455" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span>% per annum. As of December 31, 2021, $850,000 is due and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 11, 2020, the Company entered into
promissory note agreement with an investor in the principal amount of $100,000. The note matured on June 11, 2021. The Company paid 50%
of the balance on June 1, 2021. The note now has remaining outstanding balance of $50,000 as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On July 26, 2021, the Company entered into a promissory
note purchase agreement, with Cross &amp; Company pursuant to which the purchaser agreed to purchase a promissory note in the principal
amount of $100,000. The note matures on July 26, 2023. The note bears interest at 0.25% per annum. The note holds a right of offset for
the holder of the note, whereby the holder shall have the right to offset any proceeds due to the Debtor for Puts delivered
to Holder pursuant to a Equity Purchase Agreement by and between Holder and Debtor dated September 16, 2020. During the year 2021, Cross
and Company exercised its right to offset under the promissory note agreement with the Company and the Company Put 422,701 shares of its
common stock to Cross and Company with total net proceeds of $17,091. On October 22,2021 the Company received advanced of $25,000 against
future S-1 from Cross &amp; Co. After the effect on the offsets and advances, the promissory note has a remaining balance of $107,910
as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total interest expense on notes payable, amounted to $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20210101__20211231_pp0p0" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,173</ix:nonfraction></span></span>
and $<span id="xdx_904_eus-gaap--InterestExpenseDebt_c20200101__20201231_pp0p0" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-457" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54,444</ix:nonfraction></span></span> for the years ended December 31, 2021 and 2020, respectively. Accrued interest related to these notes was $<span id="xdx_908_eus-gaap--AccountsPayableInterestBearingCurrent_c20211231_pp0p0" title="Accrued interest"><span><ix:nonfraction name="us-gaap:AccountsPayableInterestBearingCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-458" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">194,997</ix:nonfraction></span></span> and $<span id="xdx_90B_eus-gaap--AccountsPayableInterestBearingCurrent_c20201231_pp0p0" title="Accrued interest"><span><ix:nonfraction name="us-gaap:AccountsPayableInterestBearingCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-459" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127,825</ix:nonfraction></span></span>
as of December 31, 2021 and 2020, respectively.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:LoanPayableRelatedPartyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_80D_ecustom--LoanPayableRelatedPartyTextBlock_zxjjQRwKdb14" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 8  <span id="xdx_820_z2K0Q0wAmSA3">LOANS PAYABLE  RELATED
PARTY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prior to the share exchange agreement, the Company
borrowed $<span id="xdx_908_eus-gaap--NotesPayableRelatedPartiesCurrentAndNoncurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--RelatedPartyPromissoryNoteMember_pp0p0" title="Note payable, related party"><span><ix:nonfraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextref="AsOf2021-12-31_custom_RelatedPartyPromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-461" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,822</ix:nonfraction></span></span> and issued a promissory note with a maturity date of March 31, 2020 which was later extended to <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20211231_z6faz1mWKR42" title="Maturity date"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate" inside-table="false" id="fact-identifier-462" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March 31, 2021</ix:nonnumeric></span></span>. Additionally,
the note holder advanced the Company $<span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--RelatedPartyPromissoryNoteMember_pp0p0" title="Advanced from related party"><span><ix:nonfraction name="us-gaap:DueToRelatedPartiesCurrent" contextref="AsOf2021-12-31_custom_RelatedPartyPromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,270</ix:nonfraction></span></span> for working capital, for a total of $<span id="xdx_904_ecustom--WorkingCapital_c20211231__us-gaap--DebtInstrumentAxis__custom--RelatedPartyPromissoryNoteMember_pp0p0" title="Working capital"><span><ix:nonfraction name="NPTX:WorkingCapital" contextref="AsOf2021-12-31_custom_RelatedPartyPromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-464" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">42,092</ix:nonfraction></span></span>  also see Note 16.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The loans represent working capital advances from
shareholders, bear interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20211231_zPH06vUXPIo7" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-465" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span></span>%, and grant a security interest in the Companys assets as collateral. In March 2018, this note
was amended, and the original note holder assigned the note to Kettner Investments, LLC, a significant shareholder. The note is now non-interest
bearing. Accrued interest related to this note is $<span id="xdx_907_ecustom--AccruedInterestRelatedPartyNote_c20211231__us-gaap--DebtInstrumentAxis__custom--RelatedPartyPromissoryNoteMember_pp0p0" title="Accrued interest, related party note"><span id="xdx_908_ecustom--AccruedInterestRelatedPartyNote_c20201231__us-gaap--DebtInstrumentAxis__custom--RelatedPartyPromissoryNoteMember_pp0p0" title="Accrued interest, related party note"><span><ix:nonfraction name="NPTX:AccruedInterestRelatedPartyNote" contextref="AsOf2021-12-31_custom_RelatedPartyPromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-466" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction name="NPTX:AccruedInterestRelatedPartyNote" contextref="AsOf2020-12-31_custom_RelatedPartyPromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">226</ix:nonfraction></span></ix:nonfraction></span></span></span> as of December 31, 2021 and 2020, respectively.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_805_eus-gaap--DebtAndCapitalLeasesDisclosuresTextBlock_z0hB3CiXDfzd" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b>NOTE
9  <span id="xdx_82B_zirHPgHCS0O8">CAPITAL LEASE OBLIGATIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In September 2019, the Company entered into a
lease agreement with Thermo Fisher Scientific to acquire equipment with <span id="xdx_902_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_dtM_c20190901__20190930_zmB9C7MahmH5" title="Frequency period"><span><ix:nonnumeric contextref="From2019-09-012019-09-30" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" inside-table="false" id="fact-identifier-469" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48</ix:nonnumeric></span></span> monthly payments of $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_c20190901__20190930_pp0p0" title="Monthly payment"><span><ix:nonfraction name="us-gaap:DebtInstrumentPeriodicPayment" contextref="From2019-09-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-470" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">941</ix:nonfraction></span></span>, payable through September 1, 2023,
with an effective interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20211231_zempzC72oWvk" title="Effective interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-471" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span></span>% per annum. The outstanding balance of this capital lease was $<span id="xdx_90A_eus-gaap--CapitalLeaseObligations_c20211231_pp0p0" title="Capital Lease Obligations"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligations" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-472" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,294</ix:nonfraction></span></span>, secured by equipment with
carrying value of $<span id="xdx_900_ecustom--EquipmentWithCarryingValue_c20211231_pp0p0" title="Equipment with carrying value"><span><ix:nonfraction name="NPTX:EquipmentWithCarryingValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">36,691</ix:nonfraction></span></span>, as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In March 2021, the Company entered into a new
lease agreement with Thermo Fisher Scientific to acquire another piece of equipment with <span id="xdx_901_eus-gaap--DebtInstrumentFrequencyOfPeriodicPayment_dtM_c20210302__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThermoFisherScientific2Member_zDXsvPhYnAV2" title="Frequency period"><span><ix:nonnumeric contextref="From2021-03-022021-03-31_custom_ThermoFisherScientific2Member" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" inside-table="false" id="fact-identifier-474" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36</ix:nonnumeric></span></span> monthly payments of $<span id="xdx_90F_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20210302__20210331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThermoFisherScientific2Member_zF2Q4wbUrX3d" title="Monthly payment"><span><ix:nonfraction name="us-gaap:DebtInstrumentPeriodicPayment" contextref="From2021-03-022021-03-31_custom_ThermoFisherScientific2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-475" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">699</ix:nonfraction></span></span> (including tax),
payable through March 2024, with an effective interest rate of 13.4% per annum. As of December 31, 2021, the outstanding balance of this
capital lease is $<span id="xdx_90F_eus-gaap--CapitalLeaseObligations_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThermoFisherScientific2Member_zGkP6nZOLGQa" title="Capital Lease Obligations"><span><ix:nonfraction name="us-gaap:CapitalLeaseObligations" contextref="AsOf2021-12-31_custom_ThermoFisherScientific2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-476" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,342</ix:nonfraction></span></span>, with a carrying value of $<span id="xdx_900_ecustom--EquipmentWithCarryingValue_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ThermoFisherScientific2Member_zwjw1hofvrXj" title="Equipment with carrying value"><span><ix:nonfraction name="NPTX:EquipmentWithCarryingValue" contextref="AsOf2021-12-31_custom_ThermoFisherScientific2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-477" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,614</ix:nonfraction></span></span>.</p>


<ix:exclude><!-- Field: Page; Sequence: 128 -->
    <div id="xdx_230_z1jeC7Dd326b" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zo5SisKYRYA1" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_23C_zWe7VE6rlfIi" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23F_zm8iVjraUOw2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zygpUCxisVZ9" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-478" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zcC2fh0cifbg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b>NOTE
10  <span id="xdx_82C_zcC9iibMLW49">CONVERTIBLE NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prior to the Share Exchange, the Company issued
a convertible note to an investor, face value of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_c20150724__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2015-07-24_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span>, in exchange for $<span id="xdx_90F_eus-gaap--ConvertibleDebt_c20150724__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Convertible debt"><span><ix:nonfraction name="us-gaap:ConvertibleDebt" contextref="AsOf2015-07-24_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">500,000</ix:nonfraction></span></span> in cash. The note is unsecured, bears interest at
the rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20150724__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_z6lIpYGk3lFh" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2015-07-24_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-481" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span></span>% per annum and matures on <span id="xdx_90A_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20150724__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_z3tJ1ZR2c8Gj" title="Maturity date"><span><ix:nonnumeric contextref="AsOf2015-07-24_us-gaap_ConvertibleDebtMember" format="ixt:datemonthdayyearen" name="us-gaap:LongTermDebtMaturityDate" inside-table="false" id="fact-identifier-482" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">February 16, 2030</ix:nonnumeric></span></span>. The note is convertible into common stock of the Company at $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20150724__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pdd" title="Convertible price per share"><span><ix:nonfraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextref="AsOf2015-07-24_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.10</ix:nonfraction></span></span> per share
at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock
of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after
giving effect to such conversion. On September 26, 2019, the Company issued <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_c20190926__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pdd" title="Common stock issued"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2019-09-26_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span></span> shares of common stock for the conversion of $<span id="xdx_90E_ecustom--ValueOfNotesConverted_c20190926__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Value of notes converted"><span><ix:nonfraction name="NPTX:ValueOfNotesConverted" contextref="AsOf2019-09-26_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">123,627</ix:nonfraction></span></span>
convertible notes payable and $<span id="xdx_907_eus-gaap--InterestPayableCurrent_c20190926__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2019-09-26_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-486" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,373</ix:nonfraction></span></span> of related accrued interest. The outstanding balance on this convertible note after the conversion
was $<span id="xdx_90D_eus-gaap--ConvertibleDebt_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zYVEZti45Wj9" title="Convertible debt"><span><ix:nonfraction name="us-gaap:ConvertibleDebt" contextref="AsOf2021-12-31_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-487" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,373</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In December 2019, the Company entered into a Securities
Purchase Agreement with an investor pursuant to which the Company agreed to sell to the investor a $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pp0p0" title="Proceeds from sale of warrants"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2019-12-012019-12-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-488" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span> convertible note bearing interest
at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2019-12-012019-12-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Pure" inside-table="false" id="fact-identifier-489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span>% per annum (the Note). The Note matures two years from the date of issuance. The Note is convertible at the option
of the holder at any time into shares of the Companys common stock at an effective conversion price of 75% of the average closing
price of the Companys common stock on the fifteen days prior to conversion. The Company may not prepay this Note within the first
six months. If, after the first six months until the maturity of the Note the Company:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt">(a)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">elects to repay the Note, it must do so at a premium of one
hundred and twenty five percent (125%) of the face amount of the Note, together with all unpaid and accrued interest to the date of repayment.</span></td>
</tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt">(b)</span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">elects to involuntarily exercise conversion of this Note to
the Holder, the Company must provide written notice to the Holder along with an executed copy of the Companys Notice of Conversion,
specifying that the Note shall be converted into shares of the Companys Common Stock based upon at an effective conversion price
of 75% of the average closing price of the Companys common stock on the fifteen days prior to conversion.</span></td>
</tr></tbody></table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The embedded conversion feature of this Note was
deemed to require bifurcation and liability classification, at fair value. Pursuant to the Securities Purchase Agreement, the Company
also sold warrants to the investors to purchase up to an aggregate of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of warrants sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2019-12-012019-12-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span> shares of common stock. The fair value of the derivative
liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the Note.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 12, 2020, the Company entered into securities
purchase agreements with two different accredited investors (each an Investor, and together the Investors)
pursuant to which each Investor purchased an 8% unsecured convertible promissory note (each a 8% Note, and together the
8% Notes) from the Company. The terms and conditions of each of the 8% Notes are substantially the same. Each 8% Note has
a principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20200312__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_pp0p0" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-03-12_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,000</ix:nonfraction></span></span> less a $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_c20200312__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_pp0p0" title="Debt discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-03-12_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span></span> original issue discount for a purchase price of $<span id="xdx_90F_eus-gaap--DebtInstrumentCarryingAmount_c20200312__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_pp0p0" title="Purchase price"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2020-03-12_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span>, with a maturity date of <span id="xdx_90A_eus-gaap--LongTermDebtMaturityDate_c20200312__us-gaap--DebtInstrumentAxis__custom--N8NotesMember" title="Maturity date"><span><ix:nonnumeric contextref="AsOf2020-03-12_custom_N8NotesMember" format="ixt:datemonthdayyearen" name="us-gaap:LongTermDebtMaturityDate" inside-table="false" id="fact-identifier-494" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March 12,
2021</ix:nonnumeric></span></span>. All principal amounts and the interest thereon are convertible into shares of the Companys common stock at the option of
each Investor, after six (6) months from the date of the 8% Notes.&nbsp;These 8% Notes have a variable conversion price and the Company
recorded embedded derivative liabilities. <span id="xdx_908_eus-gaap--DebtConversionDescription_c20200301__20200312__us-gaap--DebtInstrumentAxis__custom--N8NotesMember" title="Debt conversion, description"><span><ix:nonnumeric contextref="From2020-03-012020-03-12_custom_N8NotesMember" name="us-gaap:DebtConversionDescription" inside-table="false" id="fact-identifier-495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Note is convertible at the option of the holder at any time into shares of the Companys
common stock at an effective conversion price of the lesser of (i) $0.75 or (ii) 68% multiplied by the average of the two lowest trading
closing prices of the Companys common stock on the fifteen days before the issue date of this note or (ii) 68% multiplied by the
average of the two lowest trading closing prices of the Companys common stock on the fifteen days prior to conversion.</ix:nonnumeric></span></span> The fair
value of the derivative liability and warrants as of the date of issuance was in excess of the 8% Note (see Note 13) resulting in full
discount of the <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200312__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_zS3hNmvfOHT7" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-03-12_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-496" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span>% Note.&nbsp;During the year ended December 31, 2020, the Company issued <span id="xdx_90E_eus-gaap--CommonStockSharesIssued_c20211231__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_pdd" title="Common stock issued"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-497" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">570,767</ix:nonfraction></span></span> shares of common stock for the conversion
of $<span id="xdx_90A_ecustom--ValueOfNotesConverted_c20211231__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_pp0p0" title="Value of notes converted"><span><ix:nonfraction name="NPTX:ValueOfNotesConverted" contextref="AsOf2021-12-31_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-498" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">111,000</ix:nonfraction></span></span> convertible notes payable and $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_c20211231__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_pp0p0" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2021-12-31_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-499" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,032</ix:nonfraction></span></span> of related accrued interest. The outstanding balance on these convertible notes after
the conversion was $<span id="xdx_90C_eus-gaap--ConvertibleDebt_c20211231__us-gaap--DebtInstrumentAxis__custom--N8NotesMember_pp0p0" title="Convertible debt"><span><ix:nonfraction name="us-gaap:ConvertibleDebt" contextref="AsOf2021-12-31_custom_N8NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On June 8, 2020, the Company entered into a securities
purchase agreement, dated as of June 2, 2020 (the Purchase Agreement), with an accredited investor pursuant to which the
investor purchased a 12% unsecured convertible promissory note (the 12% Note) from the Company. The <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_zZhIzi4Na9W2" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-501" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span></span>% Note has a principal
amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_pp0p0" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-502" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">165,000</ix:nonfraction></span></span> less a $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_c20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_pp0p0" title="Debt discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-503" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,000</ix:nonfraction></span></span> original issue discount (OID) for a purchase price of $<span id="xdx_904_eus-gaap--DebtInstrumentCarryingAmount_c20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_pp0p0" title="Purchase price"><span><ix:nonfraction name="us-gaap:DebtInstrumentCarryingAmount" contextref="AsOf2020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-504" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">156,000</ix:nonfraction></span></span>, of which $<span id="xdx_908_eus-gaap--RepaymentsOfRelatedPartyDebt_c20200601__20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_pp0p0" title="Repayment of related party debt"><span><ix:nonfraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextref="From2020-06-012020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,000</ix:nonfraction></span></span> was paid
on June 8, 2020 less $<span id="xdx_906_eus-gaap--DeferredFinanceCostsNet_c20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_pp0p0" title="Transaction fees"><span><ix:nonfraction name="us-gaap:DeferredFinanceCostsNet" contextref="AsOf2020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-506" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,100</ix:nonfraction></span></span> in transaction fees (the First Tranche). The 12% Note matures 12 months from the effective date
of each tranche. <span id="xdx_90F_eus-gaap--DebtConversionDescription_c20200601__20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember" title="Debt conversion, description"><span><ix:nonnumeric contextref="From2020-06-012020-06-08_custom_N12NotesMember" name="us-gaap:DebtConversionDescription" inside-table="false" id="fact-identifier-507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">All principal amounts and the interest thereon are convertible into shares of the Companys common stock at the
option of the Investor, after six (6) months from the date of the 12% Note. All closings occurred following the satisfaction of customary
closing conditions. The 12% Note is convertible at the option of the holder at any time into shares of the Companys common stock
at an effective conversion price of the lesser of (i) 68% multiplied by the lowest Trading Price (representing a discount rate of 32%)
during the previous fifteen (15) trading day period ending on the latest complete trading day prior to the date of the 12% Note or (ii)
the Variable Conversion Price.</ix:nonnumeric></span></span> In connection with the Purchase Agreement and the 12% Note, the Company issued a common stock purchase
warrant to purchase <span id="xdx_90B_ecustom--WarrantsIssued_c20200601__20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_pdd" title="Warrants issued"><span><ix:nonfraction name="NPTX:WarrantsIssued" contextref="From2020-06-012020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">36,666</ix:nonfraction></span></span> shares of the Companys common stock at $<span id="xdx_907_eus-gaap--TemporaryEquityRedemptionPricePerShare_c20200608__us-gaap--DebtInstrumentAxis__custom--N12NotesMember_pdd" title="Warrants per share value"><span><ix:nonfraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextref="AsOf2020-06-08_custom_N12NotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-509" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.75</ix:nonfraction></span></span> per share (the Warrant) which may be exercised
by cashless exercise, exercisable for a period of three years. The 12% Note has a variable conversion price and the Company recorded embedded
derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance was in excess of the 12% Note
(see Note 13) resulting in full discount of the 12% Note.&nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 129 -->
    <div id="xdx_23D_zbHYV3rN4jXj" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23A_zHTPTbzsu1Pd" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td id="xdx_230_z7ZV2UZMPfal" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_232_zCekTlt9JDV2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23F_z6Omm4LSTlWa" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white"><br>
On June 23, 2020, the Company entered into a securities purchase agreement, dated as of June 19, 2020, with an accredited investor pursuant
to which the investor purchased a&nbsp;<span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200623__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_z4EMfv41Y8H" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextref="AsOf2020-06-23_custom_N12ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span></span>% convertible promissory note in the principal amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20200623__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_pp0p0" title="Principal amount"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2020-06-23_custom_N12ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-511" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span>, less $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_c20200623__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_pp0p0" title="Debt discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-06-23_custom_N12ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-512" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,750</ix:nonfraction></span></span>&nbsp;in transaction-related,
broker, legal and due diligence expenses. The note matures on <span id="xdx_906_eus-gaap--LongTermDebtMaturityDate_iI_dd_c20200623__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_z1qxoslGLJs9" title="Maturity date"><span><ix:nonnumeric contextref="AsOf2020-06-23_custom_N12ConvertiblePromissoryNoteMember" format="ixt:datemonthdayyearen" name="us-gaap:LongTermDebtMaturityDate" inside-table="false" id="fact-identifier-513" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">June 19, 2021</ix:nonnumeric></span></span>. This note is in default as of&nbsp;June 19, 2021, which may
trigger cross defaults on other notes. The Company is in negotiations to extend the maturity date of the Note. Principal payments on the
note shall be made in six (6) installments, each in the amount of $<span id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_c20200601__20200623__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_pp0p0" title="Periodic payment"><span><ix:nonfraction name="us-gaap:DebtInstrumentPeriodicPayment" contextref="From2020-06-012020-06-23_custom_N12ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-514" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span></span>, starting on December 19, 2020, and continuing thereafter each
thirty (30) days for five (5) months. Notwithstanding the foregoing, the final payment of principal, and accrued and unpaid interest shall
be due on the June 19, 2021. The investor is entitled to, at its option, convert all or any amount of the principal amount and any accrued
but unpaid interest of the note into shares of the Companys common stock, at any time upon an event of default, at a conversion
price for each share of common stock equal to the lesser of (i) the lowest trading price during the previous five (5) trading day period
ending on the latest complete trading day prior to the date of the note, or (ii) the Variable Conversion Price, subject to certain equitable
adjustments. Furthermore, in connection with the securities purchase agreement and the note, the Company issued two common stock purchase
warrants each to purchase&nbsp;<span id="xdx_906_ecustom--WarrantsIssued_c20200601__20200623__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_pdd" title="Warrants issued"><span><ix:nonfraction name="NPTX:WarrantsIssued" contextref="From2020-06-012020-06-23_custom_N12ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">115,385</ix:nonfraction></span></span>&nbsp;shares of the Companys common stock at $<span id="xdx_904_eus-gaap--TemporaryEquityRedemptionPricePerShare_c20200623__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_pdd" title="Warrants per share value"><span><ix:nonfraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextref="AsOf2020-06-23_custom_N12ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-516" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.30</ix:nonfraction></span></span>&nbsp;per share which may be exercised
by cashless exercise, exercisable for a period of five years. One of the warrants only becomes exercisable upon default of the note. During the third quarter of 2021, the anti-dilution clause was triggered and the exercise
price was reset to $0.03 resulting in the number of warrants to be increased to <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210101__20210930__us-gaap--DebtInstrumentAxis__custom--N12ConvertiblePromissoryNoteMember_zOyHPtdU6h95"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-01-012021-09-30_custom_N12ConvertiblePromissoryNoteMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-517" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,500,568</ix:nonfraction></span></span>. The note has a variable conversion price and
the Company recorded embedded derivative liabilities. The fair value of the derivative liability and warrants as of the date of issuance
was in excess of the note (see Note 13) resulting in full discount of the note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total interest expense on convertible notes payable,
inclusive of amortization of debt discount of $<span id="xdx_909_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Amortization of debt discount"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2021-01-012021-12-31_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">205,872</ix:nonfraction></span></span> and $<span id="xdx_90B_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Amortization of debt discount"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-01-012020-12-31_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-519" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">306,662</ix:nonfraction></span></span>, amounted to $<span id="xdx_903_eus-gaap--InterestExpenseBorrowings_c20210101__20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseBorrowings" contextref="From2021-01-012021-12-31_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-520" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">264,944</ix:nonfraction></span></span> and $<span id="xdx_901_eus-gaap--InterestExpenseBorrowings_c20200101__20201231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseBorrowings" contextref="From2020-01-012020-12-31_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">349,889</ix:nonfraction></span></span> for the years ended December 31,
2021 and 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total accrued interest on convertible notes payable,
for the years ended December 31, 2021 and 2020, was $<span id="xdx_90A_eus-gaap--InterestPayableCurrent_c20211231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_pp0p0" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2021-12-31_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-522" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">109,102</ix:nonfraction></span></span> and $<span id="xdx_90C_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20201231__us-gaap--DebtInstrumentAxis__us-gaap--ConvertibleDebtMember_zVMPQ0dBVxe6" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2020-12-31_us-gaap_ConvertibleDebtMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-523" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,993</ix:nonfraction></span></span>, respectively.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="srt:SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-524" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_805_esrt--SummaryOfInvestmentsOtherThanInvestmentsInRelatedPartiesTextBlock_zHBNMCFhDeG4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="text-transform: uppercase"><b>NOTE
11  <span id="xdx_822_zx3qIxpJSXE">CONVERTIBLE NOTES PAYABLE  RELATED PARTY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In January 2020, the Company sold an additional $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KettnerInvestmentsMember_pp0p0" title="Proceeds from sale of warrants"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2020-01-012020-01-31_custom_SecuritiesPurchaseAgreementMember_custom_KettnerInvestmentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span>,
to Kettner Investments, LLC, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KettnerInvestmentsMember_pdd" title="Number of warrants sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-01-012020-01-31_custom_SecuritiesPurchaseAgreementMember_custom_KettnerInvestmentsMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span>
shares of common stock under the Securities Purchase Agreement. The loan was due by December 22, 2021 and accrues interest at a rate
of 8% per annum. Although the note has fully matured, no default notice has been received. The Note is convertible at the option of
the holder at any time into shares of the Companys common stock at an effective conversion price of 75% of the average
closing price of the Companys common stock on the fifteen days prior to conversion. The fair value of the derivative
liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount of the
Note.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In February 2020, the Company sold an additional $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Proceeds from sale of warrants"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span>,
to the CEO of MJNA, a significant shareholder, under the Note and sold warrants to purchase up to an aggregate of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Number of warrants sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span>
shares of common stock under the Securities Purchase Agreement. The loan is due by February 2, 2022 and accrues interest at a rate
of 8% per annum. Although the note has fully matured as of the date of this filing, no default notice has been received. The Note is
convertible at the option of the holder at any time into shares of the Companys common stock at an effective conversion price
of 75% of the average closing price of the Companys common stock on the fifteen days prior to conversion. The fair value of
the derivative liability and warrants as of the date of issuance was in excess of the Note (see Note 13) resulting in full discount
of the Note.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total interest expense on convertible notes payable
 related party, inclusive of amortization of debt discount of $<span id="xdx_904_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartyMember_pp0p0" title="Amortization of debt discount"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-529" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,973</ix:nonfraction></span></span> and $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_pp0p0_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartyMember_z52sTMOjsYGd" title="Amortization of debt discount"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-01-012020-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-530" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,000</ix:nonfraction></span></span>, amounted to $<span id="xdx_909_eus-gaap--InterestExpenseBorrowings_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartyMember_pp0p0" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseBorrowings" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85,973</ix:nonfraction></span></span> and $<span id="xdx_90B_eus-gaap--InterestExpenseBorrowings_pp0p0_c20200101__20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartyMember_zABePOe2ayW6" title="Interest expense"><span><ix:nonfraction name="us-gaap:InterestExpenseBorrowings" contextref="From2020-01-012020-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,178</ix:nonfraction></span></span> for the years
ended December 31, 2021 and 2020, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total accrued interest on convertible notes payable
 related party, for the years ended December 31, 2021 and 2020, was $<span id="xdx_90F_eus-gaap--InterestPayableCurrent_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartyMember_pp0p0" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,178</ix:nonfraction></span></span> and $<span id="xdx_909_eus-gaap--InterestPayableCurrent_iI_pp0p0_c20201231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartyMember_z1HroQAIRFj6" title="Accrued interest"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2020-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-534" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,178</ix:nonfraction></span></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following is a schedule by year of future
debt payments at December 31, 2021.</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-535" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zdzZM64vd7S6" summary="xdx: Disclosure - CONVERTIBLE NOTES PAYABLE - RELATED PARTY (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span id="xdx_8BE_zLFVuEvUYd8g" style="display: none">Schedule of future debt payments</span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_496_20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--LoansPayableMember_zrv8cbpbnMwi" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49D_20211231__us-gaap--LongtermDebtTypeAxis__custom--LoanPayableRelatedPartyMember_z3YvnesxQNac" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49E_20211231__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ze1NvzU8p5c9" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_491_20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesPayableRelatedPartyMember_zeSSnFvLN77b" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_494_20211231_zwYwfib64pNi" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Loan payable</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Loan payable - related party</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible notes payable</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Convertible notes payable - related party</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 14%; font-weight: bold; text-align: left">2021</td><td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextref="AsOf2021-12-31_us-gaap_LoansPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-536" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">900,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextref="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-537" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,092</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-538" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">305,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-539" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,347,092</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_d0_zmX0cgoxo4je" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">2022</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextref="AsOf2021-12-31_us-gaap_LoansPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-541" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextref="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-542" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-543" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-544" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,972</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-545" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,972</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_d0_ziWm3pzSrqA9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">2023</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextref="AsOf2021-12-31_us-gaap_LoansPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextref="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-547" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-548" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-549" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-550" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_d0_zkXtVhr3GIv5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">2024</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextref="AsOf2021-12-31_us-gaap_LoansPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-551" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextref="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-552" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-555" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_pp0p0_d0_zJgl9l2jBjM9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">2025</td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextref="AsOf2021-12-31_us-gaap_LoansPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-556" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextref="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-558" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-559" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_iI_pp0p0_d0_zbs0XfRwscO5" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Thereafter</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextref="AsOf2021-12-31_us-gaap_LoansPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,910</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextref="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-562" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,373</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-565" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">484,283</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--LongTermDebt_iI_pp0p0_zBs03CplMxO1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 10pt"><b>Total</b></span></td><td style="font-weight: bold; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebt" contextref="AsOf2021-12-31_us-gaap_LoansPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,007,910</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebt" contextref="AsOf2021-12-31_custom_LoanPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-567" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,092</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebt" contextref="AsOf2021-12-31_us-gaap_ConvertibleNotesPayableMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-568" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">681,373</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebt" contextref="AsOf2021-12-31_custom_ConvertibleNotesPayableRelatedPartyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-569" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">143,972</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:LongTermDebt" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-570" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,875,347</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:PatentPurchaseLiabilityTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-571" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_804_ecustom--PatentPurchaseLiabilityTextBlock_zQrnIeECcBZc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 12  <span id="xdx_827_zoY8YhNsTUvb">PATENT PURCHASE LIABILITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 17, 2020, the Company entered into
an Intellectual Property Rights Purchase and Transfer Agreement (the IP Purchase Agreement) by and between Advanced Neural
Dynamics (AND), Fox Chase, Dr. Douglas Brenneman (Brenneman) and the Company to acquire the IP Rights and
concurrently entered into a Pharmaceutical Royalty Agreement with AND and Fox Chase.</p>


<ix:exclude><!-- Field: Page; Sequence: 130 -->
    <div id="xdx_23D_zHw2ai0bsLk5" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_236_zPWkkmQ64BJa" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td id="xdx_23F_z73tffRG1WId" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_238_zWBmZqoLRfq6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_237_zCOVvFtukrK1" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to the IP Purchase Agreement, the Company
acquired the IP Assets for a $<span id="xdx_906_eus-gaap--BusinessCombinationConsiderationTransferred1_c20201201__20201217__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember_pp0p0" title="Business acquisition, consideration"><span><ix:nonfraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextref="From2020-12-012020-12-17_custom_IPPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">570,000</ix:nonfraction></span></span> aggregate purchase price payable in restricted common stock of the Company to Fox Chase, Brenneman
and AND, payable as follows:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20201201__20201217__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_pdd" title="Business acquisition, shares issued"><span><ix:nonfraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextref="From2020-12-012020-12-17_custom_IPPurchaseAgreementMember_custom_RestrictedCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-573" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,000,000</ix:nonfraction></span></span> shares of restricted common stock of the Company
were issued to Fox Chase at a price per share of $<span id="xdx_906_eus-gaap--SharePrice_c20201217__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_pdd" title="Shares price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-12-17_custom_IPPurchaseAgreementMember_custom_RestrictedCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.27</ix:nonfraction></span></span> for an aggregate of $<span id="xdx_904_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_c20201217__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_pp0p0" title="Business acquisition, shares issued, value"><span><ix:nonfraction name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" contextref="AsOf2020-12-17_custom_IPPurchaseAgreementMember_custom_RestrictedCommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">270,000</ix:nonfraction></span></span>; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">$<span id="xdx_90B_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_c20201217__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_pp0p0" title="Business acquisition, shares issued, value"><span><ix:nonfraction name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" contextref="AsOf2020-12-17_custom_IPPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-576" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300,000</ix:nonfraction></span></span> in common stock will be issued to AND/Brenneman in
five annual installments which shall be calculated as $60,000 divided by the average ten (10) day closing price prior to each installment
date with the initial installment date occurring on January 5, 2021; provided, however, that for the initial installment issuance price
only, the price per share shall not be below $<span id="xdx_902_eus-gaap--SharePrice_c20201217__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Shares price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-12-17_custom_IPPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-577" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.30</ix:nonfraction></span></span> or above $<span id="xdx_900_eus-gaap--SharePrice_c20201217__us-gaap--TypeOfArrangementAxis__custom--IPPurchaseAgreementMember__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Shares price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-12-17_custom_IPPurchaseAgreementMember_us-gaap_CommonStockMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.60</ix:nonfraction></span></span> per share.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In addition, AND/Brenneman shall receive cash
payments of $15,000 annually, payable in quarterly installments to offset against tax payments, netted out against actual tax costs incurred.
In the event such payments are not made, there will be a 10% penalty assessed on said late tax offset payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The liabilities from the IP purchase agreement
are recognized at the commencement date based on the present value of remaining payments over the payment term using the Companys
secured incremental borrowing rates or implicit rates, when readily determinable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Companys IP purchase agreement does not provide an
implicit rate that can readily be determined. Therefore, the Company uses an 8% discount rate based on our incremental borrowing rate,
which is determined using the average interest rate of our long-term debt as of December 17, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 15, 2021, the Company entered into
an amendment agreement with AND/Brenneman that modified the schedule of issuance of shares to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">All future Issuances of Shares under the IP Purchase
and Transfer Agreement shall commence only upon the earlier of (a.) a full sale and acquisition of Neuropathix, Inc. to a third party
acquiror and based upon the price per share of said acquisition of Neuropathix, Inc. by a third party, or (b.) the commencement of a human
clinical trial of one or more of the AND Assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event of the commencement of a human clinical trial,
an installment process will commence with 1/5th of the transaction or $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zXTLT6d9QFff" title="Number of shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_RestrictedCommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-579" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,000</ix:nonfraction></span></span>
will be exchanged for a certain number of shares of restricted common stock of Neuropathix based upon the average five (5) day
closing price of Neuropathix, Inc. common stock prior to December 31st of each year subsequent the commencement of human clinical
trials. Future installment issuance of shares of restricted common stock of Neuropathix, Inc. shall have a floor price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20201217__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zboQDwTkyE5c" title="Shares price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-12-17_custom_RestrictedCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></span>
per share and a ceiling price of $<span id="xdx_90C_ecustom--CeilingPrice_iI_c20201217__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zTxTQBzMsEab" title="Ceiling price"><span><ix:nonfraction name="NPTX:CeilingPrice" contextref="AsOf2020-12-17_custom_RestrictedCommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-581" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.60</ix:nonfraction></span></span>
per share. As a result of the amendment, the shares issued to Brenneman were clawed back in 2021 and amounts originally classified
as short term, were reclassified as long term.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DerivativesAndFairValueTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-582" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--DerivativesAndFairValueTextBlock_zrK23h7jdFDa" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 13  <span id="xdx_82F_zpHW9FtIIjbg">DERIVATIVE LIABILITIES</span>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company issued debts that consist of the issuance
of convertible notes with variable conversion provisions. In addition, the Company issued warrants with variable conversion provisions.
The conversion terms of the convertible notes and warrants are variable based on certain factors, such as the future price of the Companys
common stock. The number of shares of common stock to be issued is based on the future price of the Companys common stock. The
number of shares of common stock issuable upon conversion of the promissory note is indeterminate. Pursuant to ASC 815-15 Embedded Derivatives,
the fair values of the variable conversion option and warrants and shares to be issued were recorded as derivative liabilities on the
issuance date.&nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 131 -->
    <div id="xdx_238_zcilTXVWIl5a" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zIfa5ayywnci" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td id="xdx_23A_zTZKWwZYEBma" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23B_zQVH4dFz2o6e" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zvfGgCaKTkgh" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Based on the various convertible notes described
in Note 10 and 11, the fair value of applicable derivative liabilities on notes, warrants and change in fair value of derivative liability
are as follows for the year ended December 31, 2021:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zkfy30Qtcqe4" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B0_zf6EUKj09NB7" style="display: none">Schedule of Derivative Liabilities</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative Liability - Convertible Notes</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Derivative Liability - Warrants</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2020</td><td style="width: 5%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zpLKZgjGL8vh" title="Balance at beginning" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-584" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">153,140</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="width: 5%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsZs1AwMAVsk" title="Balance at beginning" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-585" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">163,049</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="width: 5%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231_z5Ghyu1Cw9n2" title="Balance at beginning" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-586" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">316,189</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions during the period</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pp0p0_d0_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_z7G0b3j9wvNd" title="Additions during the period" style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pp0p0_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4m7lfk2a9Fe" title="Additions during the period" style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pp0p0_d0_c20210101__20211231_z9oSdIy6Pta3" title="Additions during the period" style="text-align: right"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-589" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--DerivativeGainLossOnDerivativeNet_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_pp0p0" title="Change in fair value" style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-590" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,103</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--DerivativeGainLossOnDerivativeNet_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pp0p0" title="Change in fair value" style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-591" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">178,458</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--DerivativeGainLossOnDerivativeNet_iN_pp0p0_di_c20210101__20211231_zmfnGBjRgRla" title="Change in fair value" style="text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-592" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">182,561</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change due to exercise / redemptions</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98A_ecustom--ChangeDueToExerciseRedemptions_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_pp0p0" title="Change due to exercise / redemptions" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="NPTX:ChangeDueToExerciseRedemptions" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-593" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,072</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_985_ecustom--ChangeDueToExerciseRedemptions_pp0p0_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zU5Ft8CZELi8" title="Change due to exercise / redemptions" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="NPTX:ChangeDueToExerciseRedemptions" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-594" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_981_ecustom--ChangeDueToExerciseRedemptions_c20210101__20211231_pp0p0" title="Change due to exercise / redemptions" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="NPTX:ChangeDueToExerciseRedemptions" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,072</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember_zxMJ6tiWi268" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_custom_ConvertibleNotesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-596" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,171</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfyZK2NaOkt9" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-597" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">341,507</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20210101__20211231_zDpQtg4pZcn2" title="Balance at end" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">430,678</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A4_znXJoSkh6pSj" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The fair value of the derivative liability 
convertible notes is estimated using a Monte Carlo pricing model with the following assumptions:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-599" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 1)" id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDHzs2pHLVu3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8B8_zViozUzgFhxh" style="display: none">Schedule of share-based payment award, stock options, valuation assumptions</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: justify">Market value of common stock</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 43%; text-align: right"><span style="font-size: 10pt">$<span id="xdx_903_ecustom--MarketValueOfCommonStockOnIssuanceDate_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Market value of common stock on issuance date"><span><ix:nonfraction name="NPTX:MarketValueOfCommonStockOnIssuanceDate" contextref="AsOf2021-12-31_custom_ConvertibleNotesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-600" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.14</ix:nonfraction></span></span>  <span id="xdx_90E_ecustom--MarketValueOfCommonStockOnIssuanceDate_c20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Market value of common stock on issuance date"><span><ix:nonfraction name="NPTX:MarketValueOfCommonStockOnIssuanceDate" contextref="AsOf2021-12-31_custom_ConvertibleNotesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-601" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.74</ix:nonfraction></span></span></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_zAXHXfN7V2jd" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59.0</ix:nonfraction></span></span>% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_zE6y09uekkI9" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-603" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65.7</ix:nonfraction></span></span>%</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term (in years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_zLlscBqAgoU3" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-604" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.09</ix:nonnumeric></span></span>  <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_zn8n12i9GSQi" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-605" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.00</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Risk-free interest rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_zAN9DnK8Iga8" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-606" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.06</ix:nonfraction></span></span>% - <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_zo7Lr4mkde96" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_custom_ConvertibleNotesMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-607" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.55</ix:nonfraction></span></span>%</span></td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AA_zWQSzqWV2Koi" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The fair value of the derivative liability 
warrants is estimated using a Monte Carlo pricing model with the following assumptions:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-608" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_ziILBff3ex27" summary="xdx: Disclosure - DERIVATIVE LIABILITIES (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span id="xdx_8BF_zSpMrjx88ltj" style="display: none">Schedule of share-based payment award, stock options, valuation assumptions</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Market value of common stock</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">$<span id="xdx_902_ecustom--MarketValueOfCommonStockOnIssuanceDate_c20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Market value of common stock on issuance date"><span><ix:nonfraction name="NPTX:MarketValueOfCommonStockOnIssuanceDate" contextref="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-609" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.58</ix:nonfraction></span></span> - <span id="xdx_904_ecustom--MarketValueOfCommonStockOnIssuanceDate_c20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Market value of common stock on issuance date"><span><ix:nonfraction name="NPTX:MarketValueOfCommonStockOnIssuanceDate" contextref="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.80</ix:nonfraction></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zeH750ZBF8X3" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72.2</ix:nonfraction></span></span>% - <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5UKVSok2UO4" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">114.3</ix:nonfraction></span></span>%</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term (in years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zRxqtkR5vVi" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-613" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.98</ix:nonnumeric></span></span>  <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zqaRn1kOpUZ4" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-614" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.22</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left">Risk-free interest rate</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zLb7titllz8f" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-615" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.67</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">%</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AB_zoEBmhS5l2Rh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b></b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-616" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zMWORfnm9Kh5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 14  <span id="xdx_82F_zN1ZQpfI8g09">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">From time to time the Company may get involved
in legal proceedings arising in the ordinary course of business. Other than as set forth in Legal Proceedings in Part II
below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect
on its results of operations or financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Occupancy Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On April 1, 2014, the Company entered into a one
year lease arrangement for office space, with the option to renew the lease annually. The lease has been renewed through April 2022. The
monthly rent payment is $<span id="xdx_905_ecustom--MonthlyRent_c20140401__us-gaap--OtherCommitmentsAxis__custom--OfficeSpaceMember_pp0p0" title="Monthly Rent"><span><ix:nonfraction name="NPTX:MonthlyRent" contextref="AsOf2014-04-01_custom_OfficeSpaceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-617" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,600</ix:nonfraction></span></span> and the security deposit is $<span id="xdx_904_eus-gaap--SecurityDeposit_c20140401__us-gaap--OtherCommitmentsAxis__custom--OfficeSpaceMember_pp0p0" title="Security Deposit"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2014-04-01_custom_OfficeSpaceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-618" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,000</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On July 1, 2018, we entered
into a one year lease arrangement for additional office space, with the option to renew the lease annually. On July 1, 2021, the lease
was renewed for two years and the monthly rent payment is $<span id="xdx_90C_eus-gaap--SecurityDeposit_c20180702__us-gaap--OtherCommitmentsAxis__custom--OfficeSpaceMember_pp0p0" title="Security Deposit"><span><ix:nonfraction name="us-gaap:SecurityDeposit" contextref="AsOf2018-07-02_custom_OfficeSpaceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-619" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,203</ix:nonfraction></span></span>.</p>


<ix:exclude><!-- Field: Page; Sequence: 132 -->
    <div id="xdx_23E_zbqltTLJpE6" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zGY0annxsvUj" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td id="xdx_23E_zS4xcWoytaS7" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_239_z6pXrwVnc4I2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_230_zdMcsMBhvFh2" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Royalties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On December 17, 2020, the Company entered into
an Intellectual Property Rights Purchase and Transfer Agreement by and between Advanced Neural Dynamics (AND), Fox Chase,
Dr. Douglas Brenneman (Brenneman) and the Company to acquire the IP Rights and concurrently entered into a Pharmaceutical
Royalty Agreement (the Royalty Agreement) with AND and Fox Chase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to the Royalty Agreement, the following
royalties and license fees are payable to Fox Chase and AND as well:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">1% royalties on net sales up to $500,000 per year per participant
(for an aggregate maximum of 2% and up to $1,000,000);</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">1% upfront sublicense fees per participant; and</span></td>
</tr></tbody></table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: right"><span style="font-size: 10pt"></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-size: 10pt">1% reversion rights to each participant (for 2% aggregate),
which rights include future milestone payments.</span></td>
</tr></tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dr. Allen Reitz and Brenneman, the principals
of AND and Fox Chase, respectively, will also become members of the Companys scientific advisory board (SAB) and will receive options
to acquire 100,000 shares of common stock of the Company for each year of SAB service, which is initially a 2-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Concentrations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="background-color: white">All revenue
recognized in the year ended December 31, 2021 was grant revenue from the NIH. While the Company expects to maintain this contract for
the entire term, loss of the grant would significantly impact its operations.</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-620" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zuVQu86LyMo6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 15  <span id="xdx_825_z0YEPEJK9x86">STOCKHOLDERS DEFICIT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>&nbsp;Series A Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90E_eus-gaap--PreferredStockVotingRights_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2TCF5tX0xM6" title="Preferred stock description"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:PreferredStockVotingRights" inside-table="false" id="fact-identifier-621" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Effective May 3, 2018, the Companys Board
of Directors authorized and designated 75 shares of the Companys Preferred Stock as Series A Preferred Stock. Each share of the
Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Companys
common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Companys
board of directors and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders
of Series A Preferred Stock are entitled to cast 1,000 votes per share.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif"><b><i>Series B Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_901_eus-gaap--PreferredStockVotingRights_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zeICkVPWfu71" title="Preferred stock description"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_SeriesBPreferredStockMember" name="us-gaap:PreferredStockVotingRights" inside-table="false" id="fact-identifier-622" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Effective May 3, 2018, the Companys Board
of Directors authorized and designated 75 shares of the Companys Preferred Stock as Series B Preferred Stock. Each share of the
Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Companys
common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Companys
board of directors and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders
of Series B Preferred Stock are entitled to cast 1,000 votes per share.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company is authorized to issue <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zMgXyM2y4285" title="Common Stock, Shares Authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span></span>
shares of common stock, par value of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zRhfzJkMomwj" title="Common Stock, Par or Stated Value Per Share"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-624" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></span> per share. <span id="xdx_90F_eus-gaap--CommonStockVotingRights_c20210101__20211231" title="Common Stock Description"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="us-gaap:CommonStockVotingRights" inside-table="false" id="fact-identifier-625" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">All common stock shares have equal voting rights, are non-assessable and have
one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose
to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">During the year ended
December 31, 2021, the Company sold <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210101__20211231_zsEAAjyz3e33" title="Number of shares"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-626" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,768,188</ix:nonfraction></span></span> shares of common stock to investors at prices between $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20211231__srt--RangeAxis__srt--MinimumMember_zETLj7OoDHC9" title="Sale of stock"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-12-31_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-627" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.03</ix:nonfraction></span></span> to $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_c20211231__srt--RangeAxis__srt--MaximumMember_zUzkyOgFlWyk"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-12-31_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-628" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.17</ix:nonfraction></span></span> per share, or
$<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zrcGdyKKFG07" title="Number of stock issued"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_CommonStockOneMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-629" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">833,727</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended
December 31, 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20210101__20211231_zUkflei5Blae"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-630" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,009,155</ix:nonfraction></span></span> shares of common stock for the conversion of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20210101__20211231_zbbZHyCb6sQ5"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-631" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">122,838</ix:nonfraction></span></span> of notes payable and accrued interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended
December 31, 2021, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_uShares_c20210101__20211231_zfq4CyBgAweh"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-632" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,612,308</ix:nonfraction></span></span> shares of common stock to consultants for services and officers for deferred compensation
for an aggregate amount of $<span id="xdx_902_ecustom--StockIssuedDuringPeriodValueIssuedForServices1_uUSD_c20210101__20211231_zHtQfT94ZSel"><span><ix:nonfraction name="NPTX:StockIssuedDuringPeriodValueIssuedForServices1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-633" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">389,295</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2020, the Company
granted options to purchase <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20211231_pdd" title="Common stock authorized under plan"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-634" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,025,000</ix:nonfraction></span></span> shares of common stock at price ranges between $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zpVEjoMiFdmh" title="Options granted, exercise price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.18</ix:nonfraction></span></span> and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zwUlTCb4E17b" title="Options granted, exercise price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-636" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.84</ix:nonfraction></span></span> per share&nbsp;to consultants and
certain directors and employees of the Company (including our named executive officers) and are exercisable for ten years.&nbsp;One quarter
of these options vest on the grant day, and the remainder of the options vest equally between twelve (12) and thirty-six (36) months.
These options were valued at $<span id="xdx_904_eus-gaap--ProceedsFromStockOptionsExercised_pp0p0_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYHjHBYd39Ql" title="Value of option"><span><ix:nonfraction name="us-gaap:ProceedsFromStockOptionsExercised" contextref="From2020-01-012020-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-637" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,503,040</ix:nonfraction></span></span> using a Black-Scholes Options Pricing Model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended December 31, 2021, the Company
granted options to purchase <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20201231_zYauF1CjXuLf"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-638" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,425,000</ix:nonfraction></span></span> shares of common stock at price ranges between $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zytNXSjdR5ra"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-639" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span></span> and $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zg2sZ64sltXi"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-640" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.16</ix:nonfraction></span></span> per share&nbsp;to consultants and
certain directors of the and are exercisable for ten years.&nbsp;One quarter of these options vest on the grant day, and the remainder
of the options vest equally between twelve (12) and thirty-six (36) months. These options were valued at $<span id="xdx_900_eus-gaap--ProceedsFromStockOptionsExercised_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFXEKyXSP1k7"><span><ix:nonfraction name="us-gaap:ProceedsFromStockOptionsExercised" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-641" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">846,795</ix:nonfraction></span></span> using a Black-Scholes
Options Pricing Model</p>


<ix:exclude><!-- Field: Page; Sequence: 133 -->
    <div id="xdx_234_zoftD1Np1BI8" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zHLGlImh83V3" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td id="xdx_236_zp5LfQoCu75" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23E_zUkkOe6CMS8j" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zkj7N2KQVomf" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif">For the years ended December 31, 2021 and 2020, the Company recorded
$<span id="xdx_906_ecustom--AdjustmentsToAdditionalPaidInCapitalTaxEffectFromSharesBasedCompensation_pp0p0_c20210101__20211231_zzaDXR2bwoS3" title="Stock based compensation"><span><ix:nonfraction name="NPTX:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromSharesBasedCompensation" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-642" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,218,766</ix:nonfraction></span></span> and $<span id="xdx_902_ecustom--AdjustmentsToAdditionalPaidInCapitalTaxEffectFromSharesBasedCompensation_pp0p0_c20200101__20201231_zfFtgpCc3Qte" title="Stock based compensation"><span><ix:nonfraction name="NPTX:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromSharesBasedCompensation" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-643" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">263,424</ix:nonfraction></span></span>, respectively, as stock-based compensation which is included in the general and administrative expenses in the
consolidated statement of operations and $<span id="xdx_906_eus-gaap--OtherResearchAndDevelopmentExpense_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkShd8ytquM" title="Research and development expense"><span><ix:nonfraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-644" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,985</ix:nonfraction></span></span> and $<span id="xdx_90D_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJCztKNn0W6d"><span><ix:nonfraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-645" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">459,175</ix:nonfraction></span></span>, respectively, as research and development expense. The remaining expense
outstanding beyond December 31, 2022 is $<span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pp0p0_c20211231_zFdRcja9ly1a" title="Unrecognized compensation expense"><span><ix:nonfraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-646" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,059,260</ix:nonfraction></span></span>.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The fair value of the options is estimated using
a Black-Scholes Options Pricing Model with the following assumptions:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-647" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zY4ndplqOD61" summary="xdx: Disclosure - STOCKHOLDERS' DEFICIT (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BA_z7bNY87NLjN2" style="display: none">Schedule of share-based payment award, stock options, valuation assumptions</span></td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Market value of common stock on issuance date</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">$<span id="xdx_90C_ecustom--MarketValueOfCommonStockOnIssuanceDate_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Market value of common stock on issuance date"><span><ix:nonfraction name="NPTX:MarketValueOfCommonStockOnIssuanceDate" contextref="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-648" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.05</ix:nonfraction></span></span> - $<span id="xdx_90E_ecustom--MarketValueOfCommonStockOnIssuanceDate_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Market value of common stock on issuance date"><span><ix:nonfraction name="NPTX:MarketValueOfCommonStockOnIssuanceDate" contextref="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-649" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.74</ix:nonfraction></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise price</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">$<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-650" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.18</ix:nonfraction></span></span> - <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextref="AsOf2021-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-651" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.84</ix:nonfraction></span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_z3V52mTZHVl5" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-652" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">86</ix:nonfraction></span></span>% - <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zBquZlM8H2I2" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-653" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">231</ix:nonfraction></span></span> %</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zYXXBZiTHAY4" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-654" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.5</ix:nonnumeric></span></span>  <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_z2QDlWESxJni" title="Expected term (in years)"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" inside-table="true" id="fact-identifier-655" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.5</ix:nonnumeric></span></span></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Risk-free interest rate</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 18%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zSFuE9RcJN3i"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-656" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.64</ix:nonfraction></span></span>% - <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zWIv6uNgxPF6" title="Risk-free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-657" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.67</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yields</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvW4yVIFJFK2" title="Expected dividend yields" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-012021-12-31_us-gaap_StockOptionMember" format="ixt:zerodash" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-658" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AE_zBMH87sZjmYe" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On May 4, 2020, the Company
amended its 2019 Plan to increase the number of shares of Company common stock authorized for issuance thereunder to 11,500,000 shares.
On March 12, 2021, the Company executed a second amendment to the 2019 Plan to (i) replace all references to Kannalife, Inc.,
the Companys former name, to Neuropathix, Inc., and (ii) increase the number of shares of Company common stock authorized
for issuance thereunder 20,000,000 shares (the Second Plan Amendment).</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">The Second Plan Amendment was approved
by the Companys Board of Directors on March 12, 2021. The Second Plan Amendment remains subject to shareholder approval, which
the Company shall undertake to obtain as soon as reasonably practicable, but in no event later than one year from the amendment date.
In the event that the Company does not obtain the requisite shareholder approval of the Second Plan Amendment within one year, the Second
Plan Amendment shall not be effective.&nbsp;On March 11, 2022, the majority of shareholders of the Common Stock of the Company voted
to ratify the 2019 Plan as amended.</p>


<ix:exclude><!-- Field: Page; Sequence: 134 -->
    <div id="xdx_23B_zProF9qTRALk" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td id="xdx_233_zImFBv5DbGq5" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23B_z0JMyaIleiIl" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_233_zoYPYcQE6K87" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following is a summary of outstanding and
exercisable options:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="NPTX:ScheduleOfOutstandingAndExercisableOptionsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-659" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfOutstandingAndExercisableOptionsTableTextBlock_zfD0c3yCwUk1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span id="xdx_8B2_zWky2CHVeeOe" style="display: none">Schedule of outstanding and exercisable options</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="vertical-align: top; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Numbers of Options</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Avg Remaining Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 21%; text-align: left"><span style="font-size: 10pt">Outstanding as of December 31,2019</span></td><td style="vertical-align: top; width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="width: 5%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_zuQcEuvuvZzc" title="Number of Options Outstanding, Beginning" style="border-bottom: Black 1pt solid; width: 19%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-660" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="width: 5%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zJsd4AuehVr3" title="Weighted Average Exercise Price Outstanding, Beginning" style="border-bottom: Black 1pt solid; width: 19%; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-661" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.00</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="width: 5%; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; width: 19%; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190101__20191231_zQ5l7Focdb96" title="Weighted Average Remaining Years Outstanding"><span><ix:nonnumeric contextref="From2019-01-012019-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-662" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.51</ix:nonnumeric></span></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_pdd" title="Number of Options Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-663" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,025,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-664" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.56</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20200101__20201231_zeIUzyTt9JS5" title="Number of Options Exercised" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-665" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200101__20201231_zm9jmm2l6eEd" title="Weighted Average Exercise Price Exercised" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0_c20200101__20201231_zy1Afr74pKi9" title="Number of Options Forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-667" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200101__20201231_zqOAQZ3dhEve" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-668" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expired</span></td><td style="vertical-align: top; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20200101__20201231_zdtxQsgSJick" title="Number of Options Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-669" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20200101__20201231_z0yBQ6BoYtj1" title="Weighted Average Exercise Price Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-670" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; vertical-align: top; text-align: left"><span style="font-size: 10pt">Outstanding as of December 31,2020</span></td><td style="vertical-align: top; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zKZkrO5MgLMe" title="Number of Options Outstanding, Beginning" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-671" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,125,000</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_z4FM0kro54L6" title="Weighted Average Exercise Price Outstanding, Beginning" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-672" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.58</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zT8LkY4VUBX2" title="Weighted Average Remaining Years Outstanding"><span><ix:nonnumeric contextref="From2020-01-012020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-673" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.90</ix:nonnumeric></span></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_pdd" title="Number of Options Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-674" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,425,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-675" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.13</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z1TZkK0I1H6e" title="Granted"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="NPTX:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingGrantedWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-676" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9.95</ix:nonnumeric></span></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_d0_c20210101__20211231_z4xkCw3F2K85" title="Number of Options Exercised" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-677" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20210101__20211231_zzwF9Yd3pvjg" title="Weighted Average Exercise Price Exercised" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-678" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Forfeited</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0_c20210101__20211231_zfuiXidvbIf" title="Number of Options Forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-679" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20210101__20211231_z74TBuomeWDe" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-680" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expired</span></td><td style="vertical-align: top; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d0_c20210101__20211231_zUFwYIQ7bX63" title="Number of Options Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-681" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20210101__20211231_zUf3mSxxZ9u1" title="Weighted Average Exercise Price Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-682" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; vertical-align: top; text-align: left"><span style="font-size: 10pt">Outstanding as of December 31, 2021</span></td><td style="vertical-align: top; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zupSZQ3jbl9i" title="Number of Options Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-683" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,550,000</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zENRGkX9Mjq8" title="Weighted Average Exercise Price Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-684" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.34</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z4Df8rmjXZll" title="Weighted Average Remaining Years Outstanding"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" inside-table="true" id="fact-identifier-685" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.81</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; vertical-align: top; text-align: left"><span style="font-size: 10pt">Outstanding as of December 31, 2021, vested</span></td><td style="vertical-align: top; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20211231_pdd" title="Number of Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-686" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,204,688</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20211231_pdd" title="Weighted Average Exercise Price Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-687" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.40</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zi37piYxVAg7" title="Weighted Average Remaining Years, Exercisable"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" inside-table="true" id="fact-identifier-688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.66</ix:nonnumeric></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AB_zohNMCZsZaf3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In January and February 2020, the Company entered
into a Securities Purchase Agreement with investors pursuant to which the Company agreed to sell the investors a $<span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of stock sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-01-012020-01-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-689" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span> and $<span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of stock sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-690" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span>
convertible note bearing interest at 8% per annum, respectively. The Company also sold warrants to the investors to purchase up to an
aggregate of <span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pp0p0" title="Proceeds from sale of stock"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2020-01-012020-01-31_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-691" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></span> and <span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pp0p0" title="Proceeds from sale of stock"><span><ix:nonfraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextref="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-692" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span> shares of common stock, respectively, with an exercise term of three (<span id="xdx_90E_ecustom--WarrantTerm_dtY_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zvdRj1OdY9Qh" title="Warrant term"><span><ix:nonnumeric contextref="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember" format="ixt-sec:duryear" name="NPTX:WarrantTerm" inside-table="false" id="fact-identifier-693" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonnumeric></span></span>) years, at a per share purchase
price of one hundred twenty five percent (125%) of the voluntary or involuntary conversion price of the Companys <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200201__20200229__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHGrXxw8TKgb" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2020-02-012020-02-29_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-694" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span></span>% convertible
note. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See Note 10.</p>

<ix:exclude><!-- Field: Page; Sequence: 135 -->
    <div id="xdx_23E_zuK7Vm363U51" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td id="xdx_233_zUyQDLQxiGW8" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_238_zJ9QaQ8xykRa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_z1hqppf8jiQ2" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zB8ofChMPzE2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On June 8, 2020, the Company entered into a Securities
Purchase Agreement, dated as of June 2, 2020 (the Purchase Agreement) with an accredited investor pursuant to which
the investor purchased a 12% unsecured convertible promissory note (the 12% Note) from the Company. In connection with
the Purchase Agreement and the <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200601__20200608__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z8W3Yo5xCpj8" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2020-06-012020-06-08_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-695" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span></span>%
Note, the Company issued a common stock purchase warrant to purchase <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200601__20200608__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of stock sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-06-012020-06-08_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-696" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,666</ix:nonfraction></span></span>
shares of the Companys common stock at $0.75 per share which may be exercised by cashless exercise, exercisable for a period
of <span id="xdx_905_ecustom--WarrantTerm_dtY_c20200601__20200608__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zL5fAVzWQC36" title="Warrant term" style="display: none"><span><ix:nonnumeric contextref="From2020-06-012020-06-08_custom_SecuritiesPurchaseAgreementMember" format="ixt-sec:duryear" name="NPTX:WarrantTerm" inside-table="false" id="fact-identifier-697" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonnumeric></span></span> three years. The warrants were deemed as a derivative liability and was recorded as a debt discount at date of issuance. See
Note 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white">On June 23, 2020, the
Company entered into a Securities Purchase Agreement, dated as of June 19, 2020 with an accredited investor pursuant to which the Investor
purchased a&nbsp;<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200601__20200623__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zRIuRjDr9IE" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2020-06-012020-06-23_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-698" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12</ix:nonfraction></span></span>% convertible promissory note from the Company. In connection with the securities purchase agreement and the note,
the Company issued two common stock purchase warrants each to purchase&nbsp;<span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20200601__20200623__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Number of stock sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2020-06-012020-06-23_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-699" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span>&nbsp;shares of the Companys common stock at
$<span id="xdx_90D_eus-gaap--SharePrice_iI_c20200623__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHpY3dXngEba" title="Share Price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2020-06-23_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-700" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0273</ix:nonfraction></span></span>&nbsp;per share which may be exercised by cashless exercise, exercisable for a period of five years. One of the warrants is to
be issued only in the case of default on the note. During the third quarter of 2021, the anti-dilution clause was triggered and the exercise price was reset to $<span id="xdx_900_eus-gaap--SharePrice_iI_c20211231_zvC7wRAwaUX" title="Share Price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-701" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0273</ix:nonfraction></span></span> resulting
in the number of warrants increasing to <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--N10NotesMember_zdBrOcP23Exk"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-01-012021-12-31_custom_N10NotesMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-702" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,500,568</ix:nonfraction></span></span>. The warrants were deemed as a derivative liability and was recorded as a debt discount
at date of issuance. See Note 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 10, 2021, Neuropathix, Inc. (f/k/a
Kannalife, Inc.), a Delaware corporation (the Company), entered into a letter agreement with Lyons Capital LLC (Lyons
Capital), pursuant to which the Company agreed to issue and sell to Lyons Capital 3,500,000 shares of the Companys common
stock, par value $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20210210__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zUqVJP95ba3h" title="Shares issued price per share"><span><ix:nonfraction name="us-gaap:SharesIssuedPricePerShare" contextref="AsOf2021-02-10_custom_LetterAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-703" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0001</ix:nonfraction></span></span> per share (Common Stock), and two warrants to purchase an aggregate of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210101__20210210__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_pdd" title="Number of stock sold"><span><ix:nonfraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextref="From2021-01-012021-02-10_us-gaap_CommonStockMember_custom_LetterAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-704" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,500,000</ix:nonfraction></span></span> additional shares
of Common Stock, the terms of such warrants are further discussed below, for an aggregate purchase price of $<span id="xdx_900_eus-gaap--ProceedsFromRelatedPartyDebt_c20210101__20210210__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_pp0p0" title="Proceeds from related party debt"><span><ix:nonfraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextref="From2021-01-012021-02-10_custom_LetterAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-705" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,207,500</ix:nonfraction></span></span> (the Transaction).&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On February 17, 2021, the Company and Lyons Capital
executed a Common Stock Purchase Agreement (the SPA) and two warrants (each a Warrant, and together, the Warrants)
memorializing the definitive terms of the Transaction. The effective date of the SPA and Warrants is February 10, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The first warrant (Warrant No. 1) grants
Lyons Capital the right to purchase up to 1,750,000 shares of Common stock at an exercise price of $0.22 per share. The second warrant
(Warrant No. 2, and together with Warrant No. 1, the Warrants) grants Lyons Capital the right to purchase
up to an additional 1,750,000 shares of Common stock at an exercise price of $0.27 per share. The Warrants are exercisable immediately,
will expire five years from the date of issuance, and&nbsp;<span style="background-color: white">contain customary provisions allowing
for adjustment to the exercise price and number of shares of Common Stock issuable upon exercise in the event of any stock dividend, recapitalization,
reorganization, reclassification, or similar transaction.</span>&nbsp;Lyons Capital has the right to exercise the Warrants at any time;
provided, however, that&nbsp;<span style="background-color: white">subject to limited exceptions, Lyons Capital may not exercise any portion
of the Warrants if Lyons Capital, together with any of its affiliates, would beneficially own in excess of 4.99% of the number of shares
of the Companys Common Stock outstanding immediately after giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The following is a summary of outstanding and
exercisable warrants:&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-706" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_z1reOofCxXUg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span id="xdx_8B6_z3RymYUewhS3" style="display: none">Schedule of outstanding and exercisable warrants</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: left; font-weight: bold; vertical-align: top">&nbsp;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; font-weight: bold; padding-bottom: 2.5pt; vertical-align: bottom">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Weighted Average Exercise Price</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 27%; text-align: left"><span style="font-size: 10pt">Balance at December 31, 2019</span></td><td style="vertical-align: top; width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="width: 8%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1F7Omn2Nl4a" title="Number of Warrants Outstanding, Beginning" style="border-bottom: Black 2.5pt double; width: 26%; text-align: right"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextref="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-707" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,000</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="width: 8%; padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&nbsp;$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zy3kLetP3Phd" title="Weighted Average Exercise Price Outstanding, Beginning" style="border-bottom: Black 2.5pt double; width: 26%; text-align: right"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2019-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-708" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.26</ix:nonfraction></span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zZ3kKaycN9L8" title="Number of Warrants Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-709" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,189,343</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zu1Zhi2SKycg" title="Weighted Average Exercise Price Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-710" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.44</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwCUm7cnEPuh" title="Number of Warrants Exercised" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-711" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_d0_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpz7XtVUfq8f" title="Weighted Average Exercise Price Exercised" style="text-align: right"><span><ix:nonfraction name="NPTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-712" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expired&nbsp;</span></td><td style="vertical-align: top; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zYaAMtsT3tjh" title="Number of Warrants Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-713" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zd4CYMFwn3Ek" title="Weighted Average Exercise Price Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="NPTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-714" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 10pt">Balance at December 31, 2020</span></td><td style="vertical-align: top; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGOreslygg3" title="Number of Warrants Outstanding, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextref="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-715" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,289,343</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z1RCmOIih1b1" title="Weighted Average Exercise Price Outstanding, Beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-716" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.18</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Granted</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Number of Warrants Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-717" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,194,161</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Weighted Average Exercise Price Granted" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-718" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.21</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Reset</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Number of Warrants Reset" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-719" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,803,730</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsResetInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" title="Weighted Average Exercise Price Reset" style="text-align: right"><span><ix:nonfraction name="NPTX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsResetInPeriodWeightedAverageGrantDateFairValue" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-720" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.03</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Exercised</span></td><td style="vertical-align: top; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9ZXs9bSbwpa" title="Number of Warrants Exercised" style="text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-721" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zc0IaPb98ICj" title="Weighted Average Exercise Price Exercised" style="text-align: right"><span><ix:nonfraction name="NPTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExercisedInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-722" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; vertical-align: top; text-align: left"><span style="font-size: 10pt">Expired&nbsp;</span></td><td style="vertical-align: top; padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zsU5FJXtqohl" title="Number of Warrants Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-723" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJmX4n8VNuL" title="Weighted Average Exercise Price Expired" style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="NPTX:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextref="From2021-01-012021-12-31_us-gaap_WarrantMember" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-724" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 10pt">Balance at December 31, 2021</span></td><td style="vertical-align: top; padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWIgH1LccOWa" title="Number of Warrants Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextref="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-725" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,287,234</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3QxfffJBWC2" title="Weighted Average Exercise Price Outstanding, Ending" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextref="AsOf2021-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-726" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.11</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A5_z30oqKW6jar8" style="font: 10pt Times New Roman, Times, Serif"></p>

<p style="font: 10pt Times New Roman, Times, Serif">At December 31, 2021, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231_zy7Zlq2SHZ67" title="Warrant Exercisable"><span><ix:nonfraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-727" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,287,234</ix:nonfraction></span></span> warrants for common stock were exercisable
and the intrinsic value of these warrants was $<span id="xdx_901_ecustom--IntrinsicValueOfWarrants_iI_pp0p0_c20211231_z3A3Cw9uQr67" title="Intrinsic value of warrants"><span><ix:nonfraction name="NPTX:IntrinsicValueOfWarrants" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-728" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">97,360</ix:nonfraction></span></span>. The weighted average remaining contractual life for warrants outstanding was <span id="xdx_90B_ecustom--WeightedAverageRemainingContractualLifeOfWarrantsOutstanding_dtY_c20210101__20211231_z9QIN9QjWFF4" title="Weighted average remaining contractual life of warrants outstanding"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:duryear" name="NPTX:WeightedAverageRemainingContractualLifeOfWarrantsOutstanding" inside-table="false" id="fact-identifier-729" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.64</ix:nonnumeric></span></span>
years.</p>


<ix:exclude><!-- Field: Page; Sequence: 136 -->
    <div id="xdx_230_zSKzjOHW7wUa" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td id="xdx_23F_zKjwv0sdhmIl" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_234_zLu1IewwLbR3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_231_z9to6wqRSFeg" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-730" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80F_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zFlvE2CjBcT7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 16  <span id="xdx_823_ztwRWrc1U5fd">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Companys Chief Executive Officer (CEO)
shares the use of the leased office space for personal living quarters. The CEO reimburses the Company for 50% of the monthly rent, or
$<span id="xdx_902_eus-gaap--PaymentsForLeasingCosts_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Monthly rent"><span><ix:nonfraction name="us-gaap:PaymentsForLeasingCosts" contextref="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-731" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,800</ix:nonfraction></span></span>&nbsp;per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2021, the Company owes the CEO $<span id="xdx_903_eus-gaap--AccruedBonusesCurrent_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0"><span><ix:nonfraction name="us-gaap:AccruedBonusesCurrent" contextref="AsOf2021-12-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-732" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">190,000</ix:nonfraction></span></span>&nbsp;&nbsp;&nbsp;for
accrued compensation and $<span id="xdx_902_eus-gaap--RelatedPartyCosts_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0"><span><ix:nonfraction name="us-gaap:RelatedPartyCosts" contextref="From2021-01-012021-12-31_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-733" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,860</ix:nonfraction></span></span>&nbsp;for
expenses incurred on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 12, 2021, the Company issued its CEO&nbsp;<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210228__20210312__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Stock issued for compensation, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextref="From2021-02-282021-03-12_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-734" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">692,308</ix:nonfraction></span></span>&nbsp;shares
of common stock at&nbsp;$<span id="xdx_90B_eus-gaap--SharePrice_c20210312__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Price per share"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-03-12_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-735" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.13</ix:nonfraction></span></span>&nbsp;a share in lieu of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210228__20210312__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Stock issued for compensation, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-02-282021-03-12_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-736" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,000</ix:nonfraction></span></span>&nbsp;of accrued compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On July 28, 2021, the Company issued its CEO&nbsp;<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210715__20210728__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Stock issued for compensation, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextref="From2021-07-152021-07-28_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-737" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,875,000</ix:nonfraction></span></span>&nbsp;shares
of common stock at $<span id="xdx_907_eus-gaap--SharePrice_c20210728__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Price per share"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-07-28_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-738" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.05</ix:nonfraction></span></span>&nbsp;a share in lieu of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_c20210715__20210728__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ChiefExecutiveOfficerMember_pp0p0" title="Stock issued for compensation, value"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextref="From2021-07-152021-07-28_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-739" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,000</ix:nonfraction></span></span>&nbsp;of accrued compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">See Notes 8, 11, 14 and 15 for additional related
party transactions.</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-740" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_z3mLCMFuNHF4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 17  <span id="xdx_82A_zn6lgMTFxNC2">INCOME TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We file income tax returns in the United States
federal jurisdiction and in various state and local jurisdictions. In the normal course of business, we are subject to examination by
taxing authorities. The tax years ending 2018 through 2021 remain subject to examination for federal tax purposes and remain subject to
examination in significant state tax jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of December 31, 2021, and 2020, the Company
had federal and state net operating loss carry forwards of $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_c20211231_pp0p0" title="Operating loss carry forwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-741" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,889,000</ix:nonfraction></span></span> and $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_c20201231_pp0p0" title="Operating loss carry forwards"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-742" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,070,000</ix:nonfraction></span></span>, <span id="xdx_90C_eus-gaap--IncomeTaxExaminationDescription_c20210101__20211231" title="Income tax, description"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="us-gaap:IncomeTaxExaminationDescription" inside-table="false" id="fact-identifier-743" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">respectively, of which $.8 million of the 2020 amount
will expire in 2033 through 2037, and $8 million will not expire but will be limited to 80% of taxable income.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The reconciliation of income tax expense computed
at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2021 and 2020 is as follows:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-744" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zlNxMpACLbcf" summary="xdx: Disclosure - INCOME TAXES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BD_z7TNa3pQTmEc" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_492_20210101__20211231_z74HzAb6YWlb" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49D_20200101__20201231_zIri7Os28yXc" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">%</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">%</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_z835SUeJsTr3" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Statutory federal tax rate</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-745" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-746" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_ziq7lJmsmx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-747" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.3</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-748" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.4</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_zjHOdMAT28wc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation allowance</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-749" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27.4</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-750" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28.2</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_dp_zJ7jI0lstVP3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent items</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-751" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-752" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.4</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_ecustom--OtherNet_dp_z5IrB1Ismw92" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other, net</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="NPTX:OtherNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-753" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.4</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="NPTX:OtherNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-754" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.6</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_z3hYxlyZYiKb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Provision for income taxes</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-755" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-756" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A7_zqWgL5S4PIx5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The change in the Company's net increase in the valuation allowance
was mainly caused by the change in estimation of NOL utilization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Deferred income taxes reflect the net tax effects
of: (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes; and (b) operating loss and tax credit carry-forwards. We record net deferred tax assets to the extent we
believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative
evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies
and recent financial operations. Significant components of deferred tax assets as December 31, 2021 and 2020 were as follows:</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-757" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zjsppUYebLJ7" summary="xdx: Disclosure - INCOME TAXES (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BC_zzoz6N0VF0U9" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_494_20211231_zWbsZZahbTPi" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_499_20201231_zojreYJbTdR5" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsNetAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred Tax Assets:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pp0p0_maDTAGz2Df_zrzfnaVYbVFb" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Federal net operating loss carryforwards</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-758" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,868,814</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-759" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,457,706</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsStockBasedCompensation_i01I_pp0p0_maDTAGz2Df_z3POq3H644ub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsStockBasedCompensation" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-760" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">849,922</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsStockBasedCompensation" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-761" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">476,938</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsNoncashInterest_i01I_pp0p0_maDTAGz2Df_z6nwxyyMaj43" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-cash interest</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsNoncashInterest" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-762" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">106,001</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsNoncashInterest" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-763" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">68,405</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsNoncashAccruedCompensation_i01I_pp0p0_maDTAGz2Df_zMmsLu2Pgp9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-cash accrued compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsNoncashAccruedCompensation" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-764" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">916,099</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsNoncashAccruedCompensation" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-765" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">877,976</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_ecustom--DeferredTaxAssetsFixedAssets_i01I_pp0p0_maDTAGz2Df_zW6jiYn7bNa4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Fixed assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsFixedAssets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-766" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">821</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="NPTX:DeferredTaxAssetsFixedAssets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-767" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,616</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsStateTaxes_i01I_pp0p0_maDTAGz2Df_zp3sRb0wyY21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">State taxes</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-768" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">528,512</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsStateTaxes" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-769" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">408,828</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_i01TI_pp0p0_mtDTAGz2Df_maDTANz81z_zcKk2825nv6b" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net deferred tax assets before valuation allowance</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-770" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,270,169</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-771" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,293,468</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANz81z_zOo5Rkk2VkA4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Valuation Allowance</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-772" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,270,169</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-773" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,293,468</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_d0_mtDTANz81z_zb1VewwjGn47" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Deferred Tax Assets</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-775" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8AB_zxPdv8LxXAZg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Utilization of the net operating losses (NOL)
carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could
occur in the future, as required by Section 382 of the Internal Revenue Code (IRC) of 1986, as amended (the Code), as well as similar
state provisions. These ownership changes may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable
income. In general, an ownership change as defined by Section 382 of the Code results from a transaction or series of transactions
over a three-year period resulting in an ownership change of more than <span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_dp_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StockholdersMember_zsUkm0QE56ok" title="Ownership, percentage">50</span> percentage points of the outstanding stock of a company by certain
stockholders. At the time of closing the books, the Company had not yet completed a study to determine the extent of the limitation.</p>


<ix:exclude><!-- Field: Page; Sequence: 137 -->
    <div id="xdx_23B_zF5nhyOE2Klg" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zG61Bt2jjzqd" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td id="xdx_236_zh5gw9Vwfip8" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_233_zFOBLmK8Mm6f" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zINpsL4pMAo8" style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-776" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zO51vEccOMSg" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>NOTE 18  <span id="xdx_824_zMHyI8zVUqic">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In January and February 2022, the Company, exercised
put options and sold and aggregate of <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20220228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPK1WmQnBuJ" title="Common stock, shares"><span><ix:nonfraction name="us-gaap:SharesIssued" contextref="AsOf2022-02-28_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-777" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,000,000</ix:nonfraction></span></span>, of its commons stock to one of its investors under terms of the Equity Purchase Agreement
for an aggregate of $<span id="xdx_900_ecustom--CustomerAdvancesOrDepositNoncurrent_iI_pp0p0_c20220101__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zX2C5JJN51Ad" title="Advance received"><span><ix:nonfraction name="NPTX:CustomerAdvancesOrDepositNoncurrent" contextref="AsOf2022-01-01_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-778" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">53,609</ix:nonfraction></span></span>, net of fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 11, 2022, the majority of shareholders
of the Common Stock of the Company voted to ratify the 2019 Plan and increased the shares available in the option pool to 20,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On March 21, 2022, the Company issued three convertible
notes (the "Convertible Notes") for cash on identical terms to three private investors having an aggregate face value of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20220321__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQ0THpllEMyb" title="Face value"><span><ix:nonfraction name="us-gaap:DebtInstrumentFaceAmount" contextref="AsOf2022-03-21_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-779" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150,000</ix:nonfraction></span></span>.
These convertible notes are unsecured and bear interest at the rate of 3% per annum. These notes mature on March 21, 2032 and are convertible
into restricted shares of common stock at a conversion price equal to the lesser of $0.01 or 70% of the average of the two lowest closing
prices of the Companys common stock in the ten trading days preceding any particular conversion. The embedded beneficial conversion feature of these notes meets the
definition of a derivative and requires bifurcation and liability classification, at fair value.</p>

</ix:nonnumeric></span><p id="xdx_81F_zSoNDTTosxO4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</p>


<!-- Field: Page; Sequence: 138 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to the requirements of Section 13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized,</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 50%; text-align: justify">&nbsp;</td>
    <td style="width: 5%; text-align: justify">&nbsp;</td>
    <td style="width: 45%; text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">By</span></td>
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font-size: 10pt"><i>/s/ Dean Petkanas</i></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif">Dean Petkanas</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>Chief Executive Officer and Chairman</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&nbsp;</td>
    <td style="text-align: justify">&nbsp;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dated: April 15, 2022</p></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and
on the dates indicated.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 29%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 3%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 46%"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 21%"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">/<i>s/ Dean Petkanas</i></span></p></td>
    <td>&nbsp;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer and Chairman</p></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">April 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>Dean Petkanas</td>
    <td>&nbsp;</td>
    <td>(Principal Executive Officer)</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">/s/ Mark Corrao</span></i></p></td>
    <td>&nbsp;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</p></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">April 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>Mark Corrao</td>
    <td>&nbsp;</td>
    <td>(Principal Financial and Accounting Officer)</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">/s/ Thomas Kikis</span></i></p></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Chief Communications Officer and Director</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">April 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>Thomas Kikis</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">/s/ Dr. William Kinney</span></i></p></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Chief Scientific Officer </span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">April 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>Dr. William Kinney</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">/s/ Robert Malasek</span></i></p></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">April 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>Robert Malasek</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">/s/ Blake Schroeder </span></i></p></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">April 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>Blake Schroeder</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif"><i><span style="text-decoration: underline">/s/ Dr. Timothy R. Scott </span></i></p></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">April 15, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td>Dr. Timothy R. Scott</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  </tbody></table>

<p></p>

<!-- Field: Page; Sequence: 139; Options: NewSection; Value: 139 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p>&nbsp;</p>



































































































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->

</body>
</html>